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Å  Angstrom 
Ac  acetyl 
Ala  alanyl 
All  allyl 
ATP  adenosine triphosphate 




bs  broad singlet 
BSA  bovine serum albumin 
Bt  benzotriazole 
Bz  benzoyl 
CAN  Ceric ammonium nitrate 
Cbz  carboxybenzyl 
CDP  cytidine diphosphate 
CE  2-cyanoethyl 
CFU  colony forming unit 
COD  1,5-cyclooctadiene 
COSY  correlation spectroscopy 
CP  capsular polysaccharide 
CPG  controlled pore glass 
δ  chemical shift 
d  doublet 
DCA  dichloroacetic acid 
dd  doublet of doublets 
ddd  doublet of doublet of doublets 
DDQ 2,3-dichloro-4,5-dicyano-1,4-
benzoquinone 
DBU  1,8-diazabicyclo[5.4.0]undec-7-ene 
DC  dual color 
DCC  N,N’-dicyclohexylcarbodiimide 
DCM  dichloromethane 
DCE  1,2-dichloroethane 
DCI  4,5-dicyanoimidazole 
DIC  N,N’-diisopropylcarbodiimide 
DiPEA N,N-diisopropylethylamine 
DMAP 4-dimethylaminopyridine 
DMF  dimethylformamide 
DMT  4,4’-dimethoxytrityl 
DNA  deoxyribonucleic acid 









ELISA enzyme-linked immunosorbent assay 
ESI  electro spray ionization 
Et  ethyl 






F-Pse perfluorooctylpropylsulfonyl ethyl 
F-SPE fluorous solid phase extraction 
Glc  glucose 
GlcNAc N-acetyl glucosamine 
GTA  glycerol teichoic acid 
h  hour(s) 
HEK  human embryonic kidney 
HiB  Haemophilus influenza type b 
HIC hydrophobic interaction 
chromatography 
HOBt  hydroxybenzotriazole 
HP  high performance 
HPLC high performance liquid 
chromatography 
HRMS high resolution mass spectrometry 
HSQC heteronuclear single quantum 
coherence 
Hz  hertz 
i.v.  intravenously 
Ig  immunoglobulin 




J coupling constant 
kDa kilodalton 
KLH keyhole limpet hemocyanin 
LCMS liquid chromatography – mass 
spectrometry 
LPS lipopolysaccharide 
LTA lipoteichoic acid 
m  multiplet 
m-CPBA meta-chloroperbenzoic acid 
Me  methyl 
min  minutes 
MMT  4-methoxytrityl 
MS  molecular sieves 
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m/z mass-to-charge ratio 
NMI  N-methylimidazole 
NMR nuclear magnetic resonance 
NRS normal rabbit serum 
OPA opsonophagocytic assay 
OPIA opsonophagocytic inhibition assay 
PAB para-azidobenzyl 
PAGE polyacrylamine gel electrophoresis 
PBS phosphate buffer saline 
PE  petroleum ether 
PEG  polyethylene glycol 
Ph  phenyl 
Phth  phthaloyl 
Piv  pivaloyl 
PMB  para-methoxy benzyl 
PPTS  pyridinium para-toluene sulfonate 





q  quartet 
RNA  ribonucleic acid 
RP  reversed phase 
RT  room temperature 
r.t.  room temperature 
s  singlet 
























SDS  sodium dodecyl sulfate 
sn  stereospecific numbering 
t triplet  
TA  teichoic acid 
tBu tert-butyl 
TBAF tetrabutylammonium fluoride 
TBAI tetrabutylammonium iodide 
TBDPS tert-butyl-diphenylsilyl 
TCA trichloroacetic acid 
TES triethylsilane 
TFA trifluoroacetic acid 
TfOH  trifluoromethansulfonic acid 
Tf2O  trifluoromethanesulfonic anhydride 
THF  tetrahydrofuran  
TLC  thin liquid chromatography 
TLR  Toll-like receptor 
TMS  trimethylsilyl 
TNF-α tumor necrosis factor alpha 
TPSNT triisopropylphenylsulfonyl 
nitrotriazolate 
Ts  para-toluenesulfonyl 
TTBP  2,4,6-tris(tert-butyl)pyrimidine 
TTd  tetanus toxoid 
UDP  uridine diphosphate 
UV  ultraviolet  
WBC  white blood cell 












Teichoic acids: An introduction 
Teichoic acids (TAs, see Figure 1), a prominent class of phosphodiester containing 
compounds of bacterial origin are the topic of this thesis. TAs, the name of whom is 
derived from the Greek “Teichos”, or city wall, are important components of the cell 
wall of Gram-positive bacteria. TAs comprise 30-70% of the walls of these bacteria 
and consist mostly of alditol (glycerol, ribitol) phosphates, non-stoichiometrically 
functionalized with D-alanyl and carbohydrate moieties.1-6 TAs are involved in several 
functions necessary for survival of the bacterial species. In addition, TAs are known to 
interact with the host immune system, although the molecular mode of action of this 
process has yet to be established. Structure activity relationship studies could provide 
more insight in the immunological behavior of TAs but remain a difficult undertaking 
as TAs isolated from biological 
sources generally consist of a 
microheterogenous mixture of 
compounds varying in length, 
glycosylation/alanylation pattern, 
fatty esters, linkage units etc. Well-
defined fragments which can be 
obtained by means of chemical 
synthesis can be a valuable tool in the 
elucidation of the immunological 
mode of action of TAs. 
This introductory chapter presents the discovery, the structural classification, as 
well as physiological and immunological aspects of TAs. Additionally, it presents a 
selection of previously reported syntheses of TAs and an outline of the thesis. 
Figure 1. Chemical structure of TAs. 
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Discovery of TA and its subclasses 
The discovery of teichoic acid (TA) can be viewed as a consequence of combined 
evidence that was collected by research performed in the 1950s. In 1951, Leloir and 
coworkers identified uridine diphosphate (UDP) sugars as being the active ingredients 
in the biosynthesis of oligosaccharides.7 With the finding of cytidine diphosphate 
glycerol (CDP-glycerol) and CDP-ribitol in the Gram-positive cell wall, the existence of 
a TA type of polymer was hypothesized.8 Moreover, the total amount of phosphate 
present in the Gram-positive cell wall was much higher than could be attributed to the 
then known phosphate-containing biomolecules (nucleic acids, phospholipids etc.).9 
Finally, a polymer containing both ribitol phosphate and glycerol phosphate was 
isolated by Baddiley and coworkers from the cell wall of Lactobacillus arabinosus.1 
Further studies showed that the cell walls of Gram-positive species Bacillus subtilis, 
Staphylococcus aureus and L. arabinosus contained 30-70% of these polymers, which 
were named teichoic acids. In contrast, it was observed that in the Gram-negative 
Escherichia coli no TA was present at all.10-13 
It was found that some TAs are connected to the peptidoglycan layer via a covalent 
linker that consists of a N-acetyl glucosamine moiety, often in combination with one or 
two other amino sugar residues.10 This subclass of TAs is now known as wall teichoic 
acid (WTA) and an example of such a structure is given in Figure 2 (structure 1). 
Ensuing studies on Lactobacillus casei showed the presence of a substantial amount of 
polyglycerol phosphates that shared many structural similarities with the WTA, 
Figure 2. Examples of 1: WTA (Bacillus subtilis)4 and 2: LTA (Staphylococcus aureus).14 
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Figure 3. Schematic representation of LTA/WTA placed in the Gram-positive cell wall. 
bearing D-alanyl and various glycosyl substituents. On the basis of their discriminative 
lipophilicity these polymers were initially named intracellular teichoic acids.15 Later it 
became clear that the polyglycerol phosphate chain of these TAs is terminated with a 
glycolipid moiety (glycosyl diacylglycerol) that, presumably, intercalates in the lipid 
bilayer.16 Therefore their name was changed into lipoteichoic acid (LTA), of which 
compound 2 is an example (Figure 2). A representation of WTA and LTA in the Gram-
positive cell-envelope is given in Figure 3. 
Over the years, various TA structures have been identified and they have been 
classified by Fischer into four distinctive types, differing in the nature of the repeating 
units.2,17 Examples of type I-IV TA structures are portrayed in Figure 4. Type I TA is 
ubiquitous among Gram-positive species and consists of alditol phosphate repeating 
units; generally poly 1,3-glycerol phosphate or poly 1,5-ribitol phosphate (see also 
Figure 1). The general structure of type II TA consists of poly glycosylalditol 
phosphate.An example is the major TA from Bacillus stearothermophilus, consisting of 
poly α-glucosylglycerol phosphate, in which the glucosyl C-6 and the glycerol C-1 are 
linked via a phosphodiester.18 Type III TA is built up from alternating repeating unit 
consisting of alditol phosphate and glycosyl phosphate, exemplified by the TA from 
Staphylococcus hyicus NCTC 10350.19 Finally, type IV TA is characterized by 
alternating alditol phosphate and glycosylalditol phosphate moieties, such as the TA 
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Figure 4. Examples of Type I-IV TA. Type I: ubiquitous in most Gram-positive species. Type II: 
glucosylglycerol phosphate as present in Bacillus stearothermophilus B65.18 Type III TA from 
Staphylococcus hyicus NCTC 10350.19 Type IV TA from several Nocardiopsis strains.20,21 
TAs in bacterial physiology 
TAs are situated in the Gram-positive cell-envelope, protruding through the 
peptidoglycan layer and are essential components for the well-being of the bacteria as 
explained in the coming section of this introduction.2-6 Studies on LTA-deficient 
Bacillus subtilis and Staphylococcus aureus mutants showed that these bacteria were 
only able to proliferate under a narrow range of conditions. The LTA-deficient 
bacteria became more susceptible to temperature stress and showed significant 
impairment of growth.22,23 A mutant of B. subtilis that was prevented from WTA 
expression showed similar behavior. Additionally, these WTA deficient mutants were 
affected by normal buffer components such as citrate and had the tendency to 
aggregate.24-27 Because species, deficient in both WTA and LTA, showed no viability it 
was suggested that WTA and LTA have overlapping functions and they can 
compensate for each other to some extent. 
TAs have the capability to bind cations, especially bivalent ones (e.g. Mg2+ and Ca2+). 
Upon metal ion binding, the conformation of the TAs changes, leading to an alteration 
of the structure and shape of the peptidoglycan/TA matrix, thereby affecting the 
rigidity and porosity of the cell envelope.28 TAs play a vital role in the bacteria’s cation 
homeostasis. This is illustrated by the finding that Bacillus subtilis boosts up its TA 
production in a low Mg2+ environment. Additionally, when the bacteria are grown 
under phosphate deficient conditions a significant amount of teichuronic acids, a non-
phosphorylated polymer built up from negatively charged sugar uronic acids, is 
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produced.29 It is suggested that TAs control the activity of autolysins, an important 
class of cell-envelope based enzymes, which are responsible for the local break down 
of the peptidoglycan layer to allow the bacteria to grow or divide. It is suggested that 
autolysins are activated by bivalent cations present in the TA.27,30 
Because of their polyanionic character TAs also bind to cationic antimicrobial 
peptides and glycopeptides based antibiotics, thereby playing an important role in 
bacterial defense. TAs are also considered as targets for bacteriophages.31-33 
Most TAs are randomly substituted with D-alanine esters and glycosyl moieties and 
the exact substitution pattern differs per Gram-positive species and can change 
depending on the environment. Whereas the function of glycosyl moieties on the TA 
chain is unknown, the role of the alanine substitution is more clear.5,6 The rate of D-
alanylation strongly affects the ability of TA to bind metal ions. In this respect, the 
group of Baddiley found that non-alanylated TA binds up to 60% more Mg2+ when 
compared to the corresponding alanylated TA.34 The degree of alanylation of the TA 
depends on the species, the growth medium, the pH and the temperature.6 The TA 
chains undergo less electrostatic repulsion when alanylated to a higher degree 
(increased neutrality) and probably by forming stabilizing ion pairs that change the 
structure and porosity of the cell-envelope.35 Mutants that lack alanine moieties on the 
TA and thus have a higher overall negative charge are known to be more susceptible 
to antimicrobial peptides, antibiotics and lytic enzymes.36-40 These mutants are more 
easily targeted by the TLR-2 dependent host defense system and they can be killed 
using a significantly lower amount of vancomycin.38 Additionally, these alanine 
deficient strains show impairment of their ability to bind to hosts or artificial surfaces 
and, surprisingly, a lower autolysine activity. The functions of glycosyl substitutions 
on TAs are poorly understood, but it was observed that a genetically altered 
Staphylococcus aureus mutant, lacking the glycosyl transferase necessary for this 
substitution was significantly less virulent.41 
TAs and the immune system 
Immunological studies have shown that TAs may activate both the innate as the 
adaptive immune system.4-6 The effect on the innate immune system of TA and 
especially LTA has been studied quite extensively. It is thought that in combination 
with peptidoglycan TA is the Gram-positive counterpart of lipopolysaccharide (LPS), 
the most important cause of Gram-negative septic shock. However, whereas LPS 
activates the innate immune system through binding with Toll-like receptor 4 (TLR-
4)42, it is not clear how LTA activates the innate immune system.43 Until recently it 
was presumed that LTA by virtue of its amphiphilic nature was recognized by TLR-
2.44,45 However, a clear connection between the immune response and LTA has not 
been established. This can be explained by the fact that the LTA preparations 
contained immunogenic impurities (lipoproteins, lipids, peptidoglycan) that 
interfered in the experiments, and/or that the LTA structures were (partly) 
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decomposed. The D-alanyl esters present on the TA backbone can be easily lost during 
the purification process. Additionally, TA preparations from biological sources are 
generally microheterogenenous, which makes it difficult, if not impossible, to perform 
structure activity relationship studies on these molecules. In 2002, the 
immunostimulatory activity of LTA was proven when Morath et al. observed and 
quantified the cytokine induction in human whole blood of a fully synthetic 
staphylococcal LTA (the synthesis of which is described later in this chapter).46 The 
question on how the innate immune system is triggered by LTA remains unanswered. 
In 2006 Hashimoto and Götz impugned the hypothesis that LTA is a ligand of TLR-2 by 
the finding that a lipopeptide deficient mutant of S. aureus showed negative results 
when tested on TLR-2 dependent activation.47 These findings were corroborated 
when in 2009 Kang et al. reported on the binding of pneumococcal LTA to TLR-2. 
Although these researchers were able to obtain a crystal structure from an LTA/TLR-2 
complex, binding of LTA to the TLR-2/TLR-6 heterodimer, essential for initiation of 
the intracellular immune response was not observed.48 Schmidt and coworkers 
suggested that innate immune recognition of LTA occurs via the complement system 
and, specifically, binding of the TA to a lectin.43,49 
An effect of TAs on the adaptive immune system can be similar to that of bacterial 
capsular polysaccharides. Opsonophagocytic antibodies directed to these 
polysaccharides are at the basis of protective immunity against various encapsulated 
bacteria.50-56 Like capsular polysaccharides, TAs can be recognized by the immune 
system of the host as they are exposed on the surface of many Gram-positive 
bacteria.52  
Enterococcus faecalis, a normally harmless commensal bacterium has become a 
considerable threat in hospitals as growing antibiotic resistance makes this species 
difficult to treat. Currently, it is ranked second among the most prevalent Gram-
positive nosocomial infection sources and accounts for 10% of all infections in 
intensive care unit patients, causing septic shock, urinary tract infections, peritonitis 
and endocarditis. Because of its reduced susceptibility against antibiotics such as 
vancomycin, the interest in finding alternative remedies is renewed.57 In 1999 Wang 
et al. described that antiserum against a polysaccharide of E. faecalis strain 12030 was 
able to kill a homologous strain. In addition, the serum was capable of killing various 
other heterologous strains, including other E. faecalis strains and also E. faecium 
strains. Notably, also some vancomycin resistant strains were susceptible to killing by 
this serum. It was also shown that the purified capsular polysaccharide of E. faecalis 
could be used as an active vaccine against E. faecalis infections in mice.58 In 2006, 
Theilacker et al. reported that the polysaccharide of E. faecalis 12030 against which 
the opsonic antibodies were directed, actually was a type I LTA structure. Notably, this 
LTA lacked D-alanyl modifications in the backbone.59 In another study the group of 
Huebner reported the cross-reactivity of rabbit antibodies raised against E. faecalis 
12030 LTA. These antibodies were capable of binding heterologous LTA from 
different enterococcal strains as well as the LTA of S. aureus and S. epidermis to some 
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extent. In addition, the antibodies opsonized S. aureus and S. epidermis and passive 
immunization with the rabbit serum led to clearance of E. faecalis and S. epidermis 
from the bloodstream in mice. These studies indicate that the raised opsonic 
antibodies were directed at a common structure in the LTA of all these Gram-positive 
bacteria. Because the LTA structures differ by the nature of the C-2 appendages of 
these species (different carbohydrate substituents are encountered in different 
species) the group of Huebner argued that the antibodies were directed against poly-
1,3-glycerolphosphate, the backbone of all LTA structures.60 
Synthetic strategies to TAs and applications thereof 
This part of the introduction describes a selection of syntheses of TAs reported 
throughout the past 30 years. Since, the crucial linkages in TAs are phosphodiesters, 
the assembly of TAs has benefited from the phosphorylation procedures developed in 
the field of nucleic acid chemistry and the first part of this section will briefly sum up 
the main synthetic approaches to the introduction of phosphodiester bonds (see 
Figure 5).61 
In the mid 1950s and the early 1960s the groups of Todd and Khorana were leading 
in the development of methods for the synthesis of DNA and RNA fragments. Although 
Todd and coworkers were the first to obtain a fully synthetic dinucleotide62, Khorana 
and his coworkers advanced and refined the phosphodiester approach, the first 
common approach to oligo(deoxy)nucleotides.63-65 In the key step of this approach a 
phosphomonoester is made suitable for nucleophilic attack by activation with a 
condensation agent (e.g. N,N-dicyclohexylcarbodiimide, tosyl chloride) to give a 
transient leaving group, which is displaced by a nucleophile (e.g. a nucleoside or an 
 
Figure 5. Synthetic approaches that (ultimately) lead to phosphodiesters. 
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oligonucleotide 5’ hydroxyl). In this way an unprotected, charged phosphodiester is 
immediately obtained. The yields obtained by using this approach were generally 
reasonable (60-70%) in a linear approach, but significantly lower for block-
couplings.66 Several side reactions can occur. The phosphomonoester substrate can be 
activated twice and the resulting phosphodiesters, although less reactive, are still 
vulnerable to the activating agents, resulting in symmetric phosphotriesters and 
pyrophosphates. Notably, an increase in the chain length of the oligonucleotide 
synthesis is accompanied by an increase of the quantity of unwanted side products. 
Another major drawback of the phosphodiester approach is the purification 
procedure to separate the target compound from the often also charged side products. 
The required ion-exchange chromatography step is a slow and labor-intensive 
purification procedure. DNA fragments up to a tetramer have been made via this 
approach before it was abandoned in favor of the development of a more efficient 
method, the phosphotriester approach. The synthesis of TAs has not been explored 
with the aid of the phosphodiester approach.66,67 
The phosphotriester approach is a common term for a wide variety of procedures 
developed throughout the early 1960s to the late 1980s, especially by the groups of 
Letsinger68,69, Reese70, Eckstein71 and van Boom72,73. The conformity of nearly all the 
phosphotriester procedures is the use of a substituted phenol as phosphate protecting 
group. In the classical phosphotriester approach a phosphodiester, consisting of a 
suitably protected nucleoside and a phenol (e.g. 2-chlorophenol) protecting group is 
made suitable for nucleophilic attack by reaction with an activating agent (e.g. 
triisopropylphenylsulfonyl chloride) to give an activated intermediate that rapidly 
reacts with an alcohol of choice (e.g. a second suitably protected nucleoside) under 
basic conditions to produce the target compound as a phenol protected 
phosphotriester. Compared with the phosphodiester method, phosphotriester 
approaches generally have shorter reaction times, result in higher coupling yields 
(especially in block-couplings) and are purified by less laborious chromatographic 
procedures due to the uncharged phosphotriester intermediates. However, also the 
phosphotriester approach suffers from the occurrence of side reactions. For example, 
even the use of sterically compromised activating agents (e.g. triisopropyl-
phenylsulfonyl chloride) does not prevent unwanted sulfonylation of the incoming 
alcohol in the condensation step. In the synthesis of oligonucleotides the reaction time 
increases and the yield decreases with the growing of the oligonucleotide chain. 
Finally, the removal of the phenol protecting groups in the final stage of the synthesis 
can be accompanied by unwanted phosphate cleavage reactions.61 
Todd and co-workers74 already reported on the synthesis of a dinucleotide using a 
H-phosphonate intermediate in the late 1950s and renewed interest in the H-
phosphonate approach was initiated in 1985 by the group of Garegg which was 
continued by this and several other research groups for the next ten years.75 In the 
condensation step of this approach, activation of an H-phosphonate monoester with a 
reagent such as pivaloyl chloride results in an activated intermediate, which reacts 
General Introduction 
~ 15 ~ 
with an alcohol to give a H-phosphonate diester. Oxidation of this H-phosphonate 
diester directly leads to the target phosphodiester. The H-phosphonate approach is 
especially suitable for syntheses on solid support and the elongation sequence of an 
automated DNA synthesis protocol consists of only two steps: coupling and liberation 
of the 5’ hydroxyl. At the final stage of the synthesis, global oxidation and deprotection 
affords the target oligonucleotide. The coupling yields are generally high (>90%) and 
oligonucleotides of a length of more than hundred residues have been successfully 
made.76-78 Shortcomings of this method are that during the coupling step side 
reactions can occur by over-activation of the H-phosphonate mono- and diesters , and 
also that H-phosphonate diesters are prone to transesterification. These drawbacks 
and favorable properties of the phosphoramidite method (see below) are the reason 
for the limited use of the H-phosphonate approach in contemporary oligonucleotide 
synthesis.79,80 
The most effective and widely used method to obtain phosphodiesters is the 
phosphoramidite approach, introduced by Beaucage and Caruthers in the early 
1980s.81 The decisive advantage of this approach is the optimal reactivity of the 
intermediates at room temperature and the selectivity of the reactions, leading to a 
minimum amount of by-products. This method was derived from the earlier 
developed, less widely used, phosphite triester approach, in which chloride is used as 
a leaving group. The main disadvantages of the phosphite triester approach are the 
practical difficulty (reaction temperatures around -80 oC) and the fact that it leads to a 
number of by-products.82 In the phosphoramidite approach the chlorine as leaving 
group is replaced by a dialkyl amino moiety, which can be activated by mild and non-
nucleophilic acids such as tetrazole (pKa 4.9), to allow substitution by an alcohol. In 
the next step the obtained phosphite triester is oxidized to give the more stable 
phosphotriester. Soon after the introduction of this approach, it was found that the 
N,N-diisopropyl phosphoramidites are most suitable for oligonucleotide synthesis as 
these amidites are considerably more stable than the corresponding N,N-dimethyl 
derivatives and have a half-time of ~200 hrs in aqueous acetonitrile (at 25 oC).83-85 
The stability of the phosphoramidites in combination with the short reaction times 
(normally within seconds) with alcohols upon activation with a weak acid as well as 
the fact that no significant side-reactions take place during the elongation sequence 
are the main advantages of this approach.61,86 
The past decades, besides oligo(deoxy)nucleotides, various phosphodiester 
containing (bio)molecules have been synthesized using the approaches described 
above. A salient example is the antigenic capsular polysaccharide from Haemophilus 
influenza.87,88 In the framework of the development of a vaccine, several research 
groups explored the synthesis of functionalized fragments of this polysaccharide (see 
Scheme 1). Oligomers with ribosylribitol phosphate as repeating unit, have been 
prepared via a solution phase modified phosphotriester approach (Van Boom)89,90, an 
automated solid phase H-phosphonate approach (Nilsson)91, solution phase/soluble 
support phase phosphoramidite approaches (Van Boom, Klein)92,93 and a controlled 
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polymerization approach using H-phosphonate chemistry (Verez-Bencomo)94. The 
finding that fragments of the capsular polysaccharide from Haemophilus influenza 
conjugated to an immunogenic protein carrier induce a specific immune response in 
vivo culminated in the world’s first synthetic carbohydrate vaccine. In 2004 Verez-
Bencomo and coworkers developed a tetanus toxoid (TTd) conjugate, which is now 
used in Cuba to prevent H. influenza infections in children (99.7% success rate).94 
Scheme 1. Four synthetic approaches to (oligo) ribosylribitol phosphate, an antigenic capsular 
polysaccharide found in Haemophilus influenza which is structurally closely related to TA. 
 
In 1983 the first successful synthesis of a TA (type I) fragment was reported by Van 
Boeckel et al. A trimer derived from the TA from Bacillus subtilis var. niger was 
assembled in solution using a modified phosphotriester approach.95 Of primary 
concern in the construction of the oligo 1,2-glycerol phosphate backbone was 
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excluding the formation of a cyclic phosphate in the “middle” unit. Therefore, 
phosphodiester (1) was coupled to tribromoethylphosphor anilidate (2) using 
triisopropylphenylsulfonyl nitrotriazolate (TPSNT, 3) as the condensating agent.96 The 
phosphoramidate proved stable under the coupling conditions, the TPSNT reagent 
gave minimal unwanted alcohol sulfonylation and the dimer (4) was obtained in 56%. 
The aniline moiety was cleaved in a Sandmeyer type reaction using amyl nitrite in a 
mixture of AcOH and pyridine to give phosphodiester 5 in 80% yield.97 
Phosphodiester 5 was coupled with 2-O-THP protected glucosyl glycerol building 
block 6 again under influence of TPSNT to give the protected trimer in 79%. A four-
step and two-pot deprotection procedure finally gave the deprotected TA trimer 7 in 
good yield (~75%).95 
Scheme 2. Synthesis (phosphotriester approach) of van Boeckel et al. to a B.subtilis TA trimer. 
In 1982 Oltvoort et al. reported on the synthesis of the gentiobiosyl diacylglycerol 
glycolipid anchor of Staphylococcus aureus LTA.98 Two years later, the same group of 
researchers completed the convergent synthesis of an elongated fragment, consisting 
of the same glycolipid anchor connected to a glycerol phosphate trimer (see Scheme 
3).99 The protected glycerol phosphate trimer (8) was obtained via a multistep 
strategy in which the phosphotriester functions were introduced in high yield by the 
use of the bifunctional phosphorylating agents 2-chlorophenyl-bis-benzotriazole 
phosphate 1073 and the corresponding 2,2,2-tribromoethyl agent (not shown). Block 
coupling of trimer 8 with benzylated gentiobiosyl alcohol 9 using phosphorylating 
agent 10 gave the protected construct 11 in 83% yield. The deprotection procedure 
consisted of the following three steps: 1) removal of the tribromoethyl moiety using 
activated zinc, 2) hydrolysis of the 2-chlorophenylphosphate triesters using 
Chapter 1 
~ 18 ~ 
tetramethylguanidinium 2-pyridinylaldehyde oximate, and 3) hydrogenolysis of the 
benzyl ethers, giving LTA fragment 12. The first two steps proceeded uneventfully in 
~60% while the yield of the latter step is not mentioned.  
Scheme 3. Oltvoort’s synthesis of S. Aureus lipoteichoic acid carrier fragment. 
The third TA fragment synthesized by the group of Van Boom features the type II 
teichoic acid from Bacillus licheniformis ATCC 9945, which consists of a 1-O-(β-D-
galactopyranosyl)glycerol repeating unit (see Scheme 4). A pentameric fragment of 
this TA was synthesized using an automated solid phase procedure in combination 
with phosphoramidite chemistry.100 Immobilized 13 and phosphoramidite 14 were 
both obtained from the same orthogonally protected galactosyl glycerol building 
block. With the aid of a DNA/RNA synthesizer, resin 13 (200 mg, 10 µmol) was 
subjected to the following sequence of reactions: 1) 2% trichloroacetic acid in DCM 
(removal of the DMT ether), 2) phosphoramidite 14 and tetrazole in MeCN 
(elongation step), 3) Ac2O, 2,6-lutidine and N-methylimidazole (capping of remaining 
unreacted alcohols), and 4) I2 in 2,6-lutidine and 1,4-dioxane (oxidation of the 
phosphite intermediate). After a three-fold repetition of this elongation cycle, the 
resin was removed from the synthesizer and treated with methanolic ammonia to 
cleave the base labile acetyl and cyanoethyl groups and to release the TA fragment 
from the resin. Finally, purification using size exclusion chromatography and 
subsequent hydrogenolysis afforded target pentamer 15 in good yield (~25% from 
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immobilized 13). It was described that for efficient couplings 50 equivalents of 
phosphoramidite 14 were needed. Nonetheless, this work presented a significant 
improvement compared to the previously described syntheses in terms of time and 
labour efficiency. Additionally, the chemistry (phosphoramidites) and methodology 
(DNA synthesizer) that were amended were at the time both still in its infancy. 
Surprisingly, no more TA fragments were synthesized in the following years using this 
seemingly suitable technique. 
Scheme 4. Westerduin’s automated solid phase approach to a B. Licheniformis TA pentamer (15). 
In the early 1990s Fukase et al. reported on the syntheses of LTA fragments derived 
from Streptococcus pyogenes and Enterococcus hirae.101,102 The closely related 
structures contain a 1-(diacylglycerol)-α-D-kojibiosyl (2-O-[α-glucosyl]-glucosyl) 
glycolipid with the polyglycerol phosphate backbone linked to the C-6 of the terminal 
glucosyl moiety. The LTA of E. hirae LTA contains an additional phosphatidyl 
diacylglycerol part, which is connected to C6 of the inner glucosyl (see Scheme 5). In 
the synthetic targets of Fukase et al. the naturally occurring oleoyl esters were 
replaced by palmitoyl tails and the glycerol phosphate backbone, normally comprising 
~20 subunits was brought back to a tetrameric unit. As can be seen in Scheme 5 the 
glycerol phosphate part was assembled via a convergent approach. Starting from an 
enantiomerically pure glycerol derivative, two differently and orthogonally protected 
building blocks (16 and 18) were acquired and connected via phosphoramidite 
chemistry comprising phosphitylation, tetrazole mediated coupling and oxidation. The 
resulting dimer (19) was treated with either DDQ or TBAF, resulting in alcohols 20 
and 21, respectively, which were connected using the sequence of reactions 
mentioned above. The TBDMS in the tetrameric fragment was cleaved with TBAF and 
the resulting alcohol was converted into the benzylamidite (22) using benzyl bis-(N,N-
Chapter 1 
~ 20 ~ 
diisopropyl)phosphordiamidite and tetrazole. Finally, the glycolipid anchor (23 or 24) 
was coupled to the TA phosphoramidite (22) under the agency of tetrazole to give, 
after deprotection, the respective target TA fragments 25 and 26. The coupling, 
oxidation and single step deprotection in case of S. pyogenes LTA (25) proceeded 
uneventfully in 48% yield over three steps. In the final coupling and oxidation of 22 
and 24 the initial product was obtained in a significantly lower yield (27%). In the 
latter case a severely lowered reaction concentration (~65 mM for 23 vs ~5 mM for 
24) was employed, suggesting that the bis(diacylglycerol) glycolipid is less soluble. 
The final deprotection of the more complex 26 proceeded in high yield (93%). Both 
fragments were evaluated for their ability to induce cytokine production in muramyl 
dipeptide primed mice, but no activity was detected.103 
Scheme 5. Phosphoramidite approach by Fukase et al. to proposed LTA carrier structures of S. 
pyogenes (25) and E. Hirae (26). 
Poly-(1,5-ribitol phosphate) is ubiquitously found in the WTA of Staphylococci and 
Bacilli. In 2006, the group of Pozsgay reported on the synthesis of an octa- and a 
dodecamer ribitol phosphate (33 and 34) and their subsequent conjugation to bovine 
serum albumin (BSA).104 Their first attempt to make a hexameric fragment of these 
WTA oligomers comprised an automated solid phase approach using 
phosphoramidite 28. However, an intractable mixture, in which a hexamer 
predominated, was obtained and the applied chemistry was reinvestigated in a 
solution phase approach using aminospacer alcohol 27 as starting compound. 
Coupling of 27 with phosphoramidite 28 under influence of tetrazole, subsequent 
oxidation of the phosphite, and detritylation with 2% trichloroacetic acid in DCM, 
reportedly, resulted in loss of the integrity of the phosphotriester moieties. Switching 
to the milder AcOH/water/DCM (85:10:5) detritylation cocktail resulted in selective 
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cleavage of the DMT without loss of the phosphotriesters. However, the prolonged 
reaction time (four hours instead of a few minutes for TCA/DCM) prompted to 
abandon the automated solid phase approach and continue their synthesis in solution 
(see Scheme 6). Using this approach fully protected octamer 29 was obtained in 9.9% 
yield over 8 elongation cycles/24 steps (~75% per cycle consisting of coupling, 
oxidation, detritylation) and dodecamer 30 was obtained in 2.4% yield over 12 
elongation cycles/36 steps (~73 % per cycle). Release of the cyanoethyl groups was 
accomplished by β-elimination using ammonium hydroxide in a mixture of methanol 
and water. The subsequent hydrogenolysis proceeded uneventfully after the 
EtOH/H2O mixture was replaced by tBuOH/H2O as the former combination resulted in 
partial N-ethylation. The fully deprotected oligomers were treated with 5-
ketohexanoic anhydride and the resulting N-acylated octamer 31 (56% over three 
steps) and dodecamer 32 (~60%) reacted with aminooxylated BSA105 forming a 
stable oxime linkage. The evaluation of the immunogenic properties of these 
conjugates, which contained 10-15 WTA fragments per molecule of BSA, has not been 
reported in the literature so far. 
Scheme 6. Pozsgay’s synthesis of two ribitol phosphate-BSA conjugates (33, 34).  
About a decade ago, the group of Hartung developed an improved method for the 
isolation and purification of LTA from Staphylococcus aureus, which involved a 
butanol extraction followed by hydrophobic interaction chromatography (HIC) using a 
slightly acidic buffer (NH4OAc, pH 4.7). With this method it was ensured that the D-
alanine esters present on the polyglycerol phosphate backbone were preserved and 
the structure of the full LTA could be revised: The gentiobiosyl glycerol glycolipid 
anchor, containing a mixture of saturated fatty acid tails (~C16), is linked via the C6 
hydroxyl of the sugar to the glycerol phosphate backbone. The glycerol phosphate 
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part, averaging 45-50 residues in length was found substituted with D-alanine esters 
(~70%) and α-D-N-acetylglucosamine (~15%). A small part of the TA was found 
unsubstituted (~15%).14 
In 2003, the group of Schmidt reported on the synthesis of this revised LTA 
structure. Their first aim was to make an LTA construct, containing a 
glycerolphosphate backbone with a glycerol C-2 substitution pattern similar to the 
native staphylococcal LTA. Target LTA 38 (see Scheme 7) consists of a glycolipid 
moiety connected to a hexaglycerol phosphate provided with four D-alanine esters 
and one N-acetylglucosaminyl residue.106 To postpone the installation of the labile 
alanine esters to the penultimate stage of the synthesis the temporary para-methoxy-
benzyl (PMB) protecting group at the glycerol C-2 was applied. It was reasoned that 
the PMB groups could selectively be cleaved in the fully protected stage of the LTA 
construct, followed by introduction of the alanine esters. Starting from 
dibenzylglycerol the hexaglycerol phosphate backbone (35) was made in a linear, 
step-wise procedure (elongation, oxidation, desilylation) using either the 2-O-PMB or 
2-O-(N-acetyl-α-glucosaminyl) glycerol benzylphosphoramidites. After a block 
coupling of hexameric alcohol (35) and the glycolipid anchor benzylphosphoramidite 
(36) under the agency of tetrazole followed by oxidation, fully protected 37 was 
obtained in 75% yield. The PMB ethers were replaced by protected alanine esters by 
treatment of 37 with cerium ammonium nitrate (67% yield) and esterfication with N-
carbobenzyloxy-D-alanine using PyBOP as the condensing agent (70% yield). Finally, 
the protected precursor was deprotected in a single step (Pd(OH)2/H2) and purified 
with hydrophobic interaction chromatography giving LTA 38 in 47% yield. In 
addition, in an analogous manner LTA 39, equipped with L-alanine esters was 
prepared (62% yield, Scheme 7). The immunostimulatory properties of both LTA 
fragments were assessed by an assay in which the response of human blood 
leukocytes was determined. This assay revealed that LTA 38 has a similar effect on 
cytokine production as the LTA which was isolated by the group of Hartung. Contrary, 
L-alanylated LTA 39 showed a strongly diminished activity (10-100 fold) compared to 
the D-alanylated fragment, indicating that alanine modifications play a critical role in 
recognition by the immune system of hosts.14,46 
With the objective to determine the minimum structural properties required for 
innate immune response the group of Schmidt continued their research by 
synthesizing a number of S. aureus LTA derivatives. A convergent approach was 
devised that made it possible to prepare several constructs by minor alterations of the 
synthetic route. In 2005, the syntheses of fragments 40 and 41 were described (see 
Scheme 8).107 Whereas LTA 40 only lacked the gentiobiosyl moiety, derivative 41 
features more radical changes: both gentiobiosyl and GlcNAc moieties were omitted 
and the D-alanine esters were replaced by the more stable amide analogues on the C-2 
glycerol residues of opposed stereochemistry. The effects of these modifications on 
the immunostimulatory properties were minimal, showing that the gentiobiosyl and 
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Scheme 7. Schmidt’s synthesis of a complete staphylococcal LTA construct (38) and analogon (39). 
GlcNAc were not necessary for cytokine (IL-8, TNF-α) production in human whole 
blood, peritoneal macrophages or TLR-transfected HEK-cells.108 The presence of the 
alanylated glycerol phosphate backbone proved more important. This finding was 
confirmed shortly thereafter by the synthesis and evaluation of TA derivatives 42a-e 
by the same authors. These compounds consist of the complete gentiobiosyl diacyl 
glycerol moiety connected to an oligoglycerol phosphate backbone ranging in length 
between two (42a) and six residues (42e) and containing between one and five 
alanine modifications (Scheme 8).109 Biological evaluation showed that a minimum of 
two alanylated glycerol phosphates in the construct is required for significant activity 
(10-fold increase of cytokine induction compared to one alanylated residue). The 
gentiobiosyl diacyl glycerol anchor (structure not shown) alone did not induce any 
immune response. However, it was suggested that the presence of this moiety in LTA 
derivatives is important for innate immune activity. The group of Schmidt also 
reported the synthesis of a construct that contained all the natural substitutions and a 
second glycolipid moiety (structure 43, Scheme 8).110 It was shown that in an immune 
assay cytokine (IL-8, TNF-α) titers were significantly higher compared to the 
monoglycolipid 38 (see Scheme 7). The presentation of the crucial recognition 
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elements, such as the D-alanyl esters, could possibly be increased by this bis-
amphiphilic construct.43,110 
Scheme 8. Synthetic derivatives of Staphylococcus aureus LTA (40-43) made in the lab of Schmidt.  
The type I LTA from Streptococcus sp DSM 8747, a mutant which is genetically 
related to Streptococcus pneumonia, consists of a galactofuranoside diacyl glycerol 
glycolipid with the oligoglycerol phosphate backbone connected to the C-6 of the 
galactofuranose residue. The backbone is substituted for about 30% at C-2 positions 
with D-alanine esters.111 In 2010, Schmidt and coworkers reported on the synthesis of 
a fragment of this LTA.112 The β-galactofuranoside diacylglycerol phosphoramidite 46 
was constructed via the imidate glycosylation procedure using anchimeric assistance 
of a temporary 2’- benzoyl ester, followed by several consecutive (protecting group) 
manipulations (see Scheme 9). Block coupling of the previously reported PMB-
protected pentamer 47 and glycolipid phosphoramidite 46 using tetrazole followed 
by oxidation yielded the fully protected intermediate in 90%. At this stage the PMB 
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ethers were selectively cleaved (85% yield) and the resulting tetraol was decorated 
with alanyl moieties using Cbz-D-alanine and PyBOP (74% yield). Global deprotection 
of the fully protected 48 (containing four alanine esters) followed by purification 
resulted in the target LTA fragment 49 provided with roughly two alanine esters. It is 
unclear why the alanine esters in this particular molecule were prone to hydrolysis, as 
this phenomenon was not observed in similar syntheses reported earlier by the group 
of Schmidt.106,107,109,110  
Scheme 9. Synthesis of the unusual LTA as found in Streptococcus species DSM 8747. 
The complex structure of the type IV LTA found in Streptococcus pneumonia is 
made up from a glycolipid anchor, that consists of diacylglycerol linked to a 
trisaccharide (glucose-diaminofucose-glucose), connected to a repeating unit (n = 1-8, 
2 on average) pentasaccharide phosphate (glucose-diaminofucose-
[phosphatidylcholine]-galactosamine-[phosphatidylcholine]galactosamine-ribitol) 
(see Scheme 10, structure 50).113 In 2010, Pedersen et al. reported on the synthesis of 
the structural variant 51 in which the diaminofucose moieties were mono-(2’)-N-
acetylated and the ribitol unit was non-substituted.114 The synthesis comprised 88 
steps starting from the protected monosaccharide building-blocks. The 
pentasaccharide repeating unit was constructed by the coupling of trisaccharide ABC 
and disaccharide DE. Ensuing manipulations (reduction of the azides, acetylation and 
HF/pyridine treatment) was followed by decoration of the resulting alcohols on 
subunits C/D in the pentasaccharide with phosphatidylcholines. Next, the terminal 
alcohol of the ribitol (E) was selectively unmasked by isomerization of the allyl ether 
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and cleavage of the resulting 1-propenylether, giving pentasaccharide ABCDE (see 
Scheme 10). The glycolipid phosphoramidite (FGHI) was constructed via a linear 
glycosylation strategy. First alcohol I was glycosylated using imidate H and, 
subsequently, the cyclohexylidene group was removed. The resulting diol was 
myristoylated and after several protecting group manipulations, glycosylations and 
finally phosphitylation, the phosphoramidite was acquired. The crucial step was the 
coupling of pentasaccharide alcohol ABCDE (including zwitterionic 
phosphatidylcholine functionalities) and glycolipid phosphoramidite FGHI. 
Phosphitylation in acetonitrile under influence of the activator tetrazole and oxidation 
under basic conditions, by which the cyanoethyl phosphate protecting groups were  
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concomitantly cleaved, the partially protected pseudononasaccharide triphosphate 
(ABCDEFGHI) was obtained in 68% yield. Finally, global deprotection (Pd(OH)2/H2) 
gave the target LTA construct (51). 
At the same time the separate deprotection of the glycolipid115 and repeating 
unit116 moieties were undertaken. The resulting compounds (51, glycolipid and 
repeating unit) were evaluated on their potency to activate the innate immune system 
in human whole blood cells and isolated human mononuclear cells. It was found that 
both the sole glycolipid and construct 51 stimulated the release of the pro-
inflammatory cytokine IL-8. The repeating unit alone did not result in any innate 
immune response. These results support the hypothesis that LTA fragments are not 
recognized by TLR-2 or 4. According to the authors these molecules most probably 
activate the innate immune system via the complement system and, more specifically, 
are recognized via the lectin pathway of the complement system.114-116 
Conclusion 
TAs are important Gram-positive bacteria cell wall components. Although TAs are 
structurally diverse and microheterogenous, their basic structure consists of alditol 
phosphates, randomly decorated with sugars and alanine esters. TAs are ligands for 
both the innate and the adaptive immune system. In this respect organic synthesis is 
indispensable to obtain well-defined TA fragments of desired length and substitution 
pattern. Subsequent structure activity relationship studies of these fragments may 
provide insights in mechanism of the immune system and help in the development of 
future vaccines. 
Outline of this thesis 
The work described in this thesis involves the development of synthetic 
methodologies that give access to glycerol TAs differing in length and composition. 
Solution, solid phase and fluorous phase chemistry methods are applied to obtain the 
desired (library of) TA structures, which have been evaluated for their ability to 
inhibit opsonic killing of Enterococcus faecalis by antibodies raised in rabbits against 
natural LTA of this species. The most active fragments have been coupled to an 
immunogenic carrier protein and the resulting conjugates evaluated on their 
immunogenicity and their potency to function as a (Gram-positive) vaccine.  
Chapter two describes the solution phase synthesis of a glycerol phosphate 
hexamer, using phosphoramidite chemistry. First, the route towards the suitably 
protected glycerol phosphoramidite building blocks is presented after which the 
construction and deprotection of the target oligomer, containing an α-kojibiosyl (α-D-
glucopyranosyl-(1→2)-D-glucose) substituent, is given. 
Based on the chemistry presented in chapter two, the assembly of a small library of 
TAs is described in chapter three. These molecules were made with the use of an 
automated solid phase strategy and a DNA synthesizer. Four fragments ranging in 
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length from 6<20 glycerol phosphate subunits and two hexamers provided with an α-
glucosyl substitution were synthesized and evaluated on their antigenicity by an 
opsonophagocytic inhibition assay (OPIA).  
Chapter four deals with a fluorous phase protocol for the generation of several 
(aminoglucosylated) TAs that are found in a range of bacterial species. The protocol 
combines the advantages of both solution and solid phase strategies, especially 
through a rapid purification step, using a fluorous solid phase extraction (F-SPE) 
methodology after each elongation cycle. These TA fragments, featuring a terminal 
phosphate moiety are immunologically evaluated. 
In chapter five the use of an alternative base-labile fluorous linker is described. 
The applied succinyl type of linker gives access to non-phosphorylated TA fragments. 
Additionally, an acid-stable tetrabenzylglucosyl glycerol phosphoramidite building 
block, that is suitable for incorporation in an earlier stage of the TA oligomer 
synthesis, is prepared. 
Chapter six covers the conjugation to an immunogenic carrier protein of the most 
antigenic TA fragment, the synthesis and evaluation of which is described in chapter 
three and five. The conjugate is evaluated for its potential to function as a vaccine 
modality against E. faecalis and some other Gram-positive strains. The immunological 
experiments include: opsonophagocytic assays (OPAs) and passive immunization in a 
rat endocarditis model using rabbit anti serum raised against the synthetic conjugate.  
The work described in chapter six has been carried out in cooperation with the 
Division of Infectious Diseases from the Department of Medicine of the University 
Medical Center Freiburg: A. Kropec-Huebner, D. Laverde Gomez, C. Theilacker and J. 
Huebner. 
Chapter seven consists of a summary of the work described in this thesis. Several 
synthetic outlooks are given, including improved automated solid phase protocols 
using a photocleavable linker and a fluorous tag. Other future prospects include the 
synthesis of stable D-alanine ester analogues and the synthesis of an improved, 
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Antibiotic resistance is an emerging problem in society and prevention strategies, 
such as vaccination with (synthetic) cell-wall antigens, have become a promising 
approach. As described in chapter 1 teichoic acids (TAs) are Gram-positive cell wall 
components that modulate the mammalian immune system. In order to understand 
the molecular mode of action of these molecules, well defined fragments could be a 
valuable tool.1-5 Synthetic studies to and biological evaluation of Staphylococcus aureus 
LTA fragments by Schmidt and Hartung led to more insight in the minimal structural 
requirements for cytokine induction.6-12 
Enterococcus faecalis is a commensal bacterium and generally of low virulence. 
However, with the emergence of vancomycin-resistant strains an increasing amount 
of E. faecalis infections is reported.13-15 The TA of E. faecalis is antigenic and built up 
from 1,3-poly(glycerolphosphate), randomly decorated at the C-2 positions with D-
alanine, kojibiose (α-D-glucopyranosyl-(1→2)-α-D-glucose), and 6,6’-di-alanyl-α-
kojibiose, as depicted in Figure 1.16,17  
Figure 1. General structure of E. faecalis GTA and its substituents. 
This chapter deals with the synthesis of a glycerol TA hexamer, containing an α-
kojibiosyl substitution.18 The syntheses of the stereochemically pure (kojibiosyl) 
glycerol synthons and their use in the construction of a hexamer (kojibiosyl)glycerol 
phosphate is described. Installment of the phosphodiester bridges was performed 
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using phosphoramidite chemistry, which has emerged in the past two decades as the 
method of choice for (automated) oligonucleotide synthesis.19-21  
Results and Discussion 
Scheme 1. Target hexamer 1 and the required phosphoramidites 2-5. 
     
As retrosynthetically depicted in Scheme 1, TA hexamer 1 can be assembled from 
four synthons: dibenzyl glycerol 2, the starting building block; glycerol 
phosphoramidite 3 and kojibiosyl glycerol phosphoramidite 4, used for chain 
elongation, and aminohexylphosphoramidite 5, the terminal building block. The 
primary amino group of the hexyl spacer presents a chemoselective ligation handle for 
attachment of, for instance, carrier proteins or fluorescent tags (see chapter 7). The 
2-cyanoethyl (CE) was chosen as a phosphate protecting group because of its 
robustness during the synthesis and ease of removal at the end of the synthesis. The 
hydroxyl functions and the amino group of the aminohexyl spacer were masked with 
benzyl type protecting groups, which facilitated global deprotection in the final stage 
of the hexamer assembly by hydrogenolysis. As a temporary protecting group the 
dimethoxytrityl (DMT) group has been selected because it has proven its merits in 
contemporary DNA and RNA synthesis protocols and can be cleaved under mildly 
acidic conditions.21,22 
The synthesis of the four building blocks is depicted in Scheme 2. Dibenzylglycerol 
2 was synthesized according to literature procedures from solketal 6 (Scheme 
2A).7,10,23,24 Solketal 6 also served as starting compound in the synthesis of 
glycerolphosphoramidite 3. Allylation of the free hydroxyl function, acidic hydrolysis 
of the isopropylidene and subsequent selective silylation of the primary alcohol 
yielded partially protected glycerol 7 (Scheme 2B).7 The remaining hydroxyl in 
compound 7 was benzylated to provide the fully protected glycerol in high yield, 
containing a minor amount (~3%) of 1-O-benzyl-2-O-tert-butyldiphenylsilyl-3-O-allyl- 
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Scheme 2. Synthesis of (phosphoramidite) building-blocks 2-5. 
sn-glycerol, which resulted from silyl migration during the basic etherification, and 
which could not be removed by silica gel chromatography. To liberate the C3 
hydroxyl, the allyl ether was isomerized using Ir(COD)(Ph2MeP)2PF6.25 Subsequent 
enol ether cleavage using iodine and aqueous NaHCO3 afforded glycerol 8 in 71% over 
2 steps. Dimethoxytritylation of the primary alcohol furnished glycerol 9, which was 
desilylated to provide alcohol 10. At this stage the product could be separated by silica 
gel chromatography from its regioisomeric impurity. Finally, installment of the 
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phosphoramidite moiety using 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite 
11 provided building block 3. 
With the first two building blocks in hand the synthesis of α-kojibiosylglycerol 
synthon 4, containing two 1,2-cis glucosidic linkages, was undertaken. Although 
tremendous progress has been made in the stereoselective construction of glycosidic 
bonds, the installment of two 1,2-cis-glucosyl linkages still presents a significant 
challenge. Recently, Boons and co-workers revealed an elegant approach to this long 
standing problem, by installing α-directing ethyl (S)-mandelate or (1S)-
phenyl(thiophenyl)ethyl ethers on the 2’ hydroxyl of glucose donors.26-28 
Unfortunately, the assembly of the kojibiose glycerol pseudotrisaccharide requires the 
glycosylation of the first glucose residue at the C-2 hydroxyl and the latter ether 
protecting groups cannot be removed selectively while keeping the other benzyl 
ethers intact. Alternative methods which have been used to construct 1,2-cis 
glucosidic linkages include Lemieux’s in situ anomerization protocol29,30 and the 
employment of large substituents such as the DMT group at the glucosyl C-6 
hydroxyl.31-33 Given the relatively low reactivity of the secondary alcohol function 
which has to be glucosylated the former approach was deemed unsuitable. The latter 
approach was not pursued at this point because this would exclude the use of trityl-
type groups in the glycerol part of the pseudotrisaccharide, which was a prerequisite 
in the design of our protecting group strategy (vide supra).34 An alternative approach 
to the formation of 1,2-cis glucosidic linkages has been described by Crich and co-
workers, using benzylidene protected thioglucosyl donors.35 Three 4,6-O-benzylidene 
functionalized glucosyl donors, having either a C2 para-methoxybenzyl (PMB, 13a), a 
C2 para-azidobenzyl (PAB, 13b) or a C2 trimethylsilyl (TMS, 13c) protecting group, 
were explored (Scheme 2C). The installment of the para-methoxylbenzyl group in 
construct 1236 led to benzylidene glucoside 13a in 88%. This thioglycoside was then 
condensed with glycerol acceptor 7 using the Ph2SO/Tf2O activator system37 to 
provide the intermediate pseudodisaccharide in good yield and excellent selectivity 
(α/β = 10/1). Subsequent treatment of the fully protected adduct with DDQ gave 
alcohol 14 in moderate yield (56%), resulting in a 37% total yield of α-glucosyl 
glycerol 14 from alcohol 12. A similar series of reactions was employed to prepare 
pseudodisaccharide 14 with the use of the para-azido benzyl ether38 instead of the 
para-methoxy benzyl group as a non-participating group at C-2. In this case (13b), the 
benzylation reaction proceeded uneventfully and the ensuing glycosylation reaction 
provided the cis-coupled product in good selectivity (62%, α/β = 7/1). Unfortunately, 
liberation of the C2 hydroxyl via a reduction-oxidation sequence provided target 
alcohol 14 in only 39%, to complete the four step sequence in a total yield of 22% of 
14 from building block 12. The last non-participating group that was tested was the 
trimethylsilyl ether (TMS). Donor 13c was obtained quantitatively from 12, and used 
in the subsequent glycosylation reaction without purification. The coupling of TMS 
protected thioglucose 13c and glycerol 7 was immediately followed by treatment of 
the resulting pseudodisaccharide (~6:1 mixture of α and β-anomers) with sodium 
Synthesis of an α-Kojibiosyl GTA Hexamer 
~ 37 ~ 
carbonate in methanol to yield 14 in 46% over the three steps, using a single 
chromatographical purification step, making this the most efficient route. 
With the first 1,2-cis glycosidic linkage in place, the synthesis was continued with 
the condensation of dibenzyl benzylidene thioglucoside 15 and alcohol 14. 
Gratifyingly, the pseudotrisaccharide (16) was obtained as a single diastereoisomer in 
82% yield. This trisaccharide was transformed into the phosphoramidite building 
block 4 following the same sequence of reactions as described for the transformation 
of 3-O-allyl-2-O-benzyl-1-O-TBDPS-sn-glycerol into phosphoramidite 3. Briefly, the 
allyl ether in 16 was removed by iridium catalyzed isomerisation and iodine mediated 
cleavage of the intermediate enol ether. The DMT group was installed, after which the 
TBDPS ether was removed by fluoride treatment and the primary alcohol was 
phosphitylated to complete the synthesis of the kojibiosyl glycerol 4. To complete the 
set of target synthons, benzyloxycarbonyl protected aminohexanol 20 was treated 
with DiPEA and chlorophosporamidite 11 to give phosphoramidite 5 (Scheme 2D). 
With all necessary building blocks in hand the assembly of the hexamer was 
undertaken (Scheme 3). In the first step dibenzylglycerol 2 and glycerol 
phosphoramidite 3 were coupled with the use of 4,5-dicyanoimidazole (DCI) in 
acetonitrile. After oxidation of the intermediate phosphite (I2 in THF/pyridine 4/1), 
the crude intermediate was detritylated using dichloroacetic acid and triethylsilane in 
Scheme 3. Synthesis of kojibiosyl GTA hexamer 1. 
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dry DCM, giving dimer 21 in 80% yield. Repetition of this reaction sequence led to the 
consecutive formation of trimer 22 in 82% from 21, tetramer 23 in 81% from 22 and 
pentamer 24 in 62% from 23. Next, kojibiosylglycerol phosphoramidite 4 was 
coupled to the glycerolphosphate chain and, after iodine mediated oxidation, hexamer 
25 was obtained in 86% yield. Apparently, the relatively bulky kojibiosyl substituent 
did not have an adverse effect on the formation of the mixed phosphotriester. To 
avoid unwanted acidolysis of the benzylidene functionalities in 25 the mild 
pyridinium para-toluenesulphonate (PPTS)/MeOH cocktail was employed for the 
cleavage of the DMT group.39 Alcohol 26 was obtained in 70% yield when 1 mg/ml 
PPTS in MeOH/DCM (9/1) was employed. Subsequent coupling of spacer 
phosphoramidite 5 and oxidation gave the fully protected target compound 27 in 77% 
yield. 
The deprotection sequence started with ammonolysis of the cyanoethyl groups in 
27, giving the hexameric phosphodiester quantitatively. Finally, all benzyl ethers, the 
two benzylidene acetals and the benzyloxycarbamate were removed using H2/Pd(0) 
in water/dioxane/AcOH. After size-exclusion chromatography, repeated 
lyophilization, and ion exchange the target E. faecalis TA-hexamer (1) was obtained as 
the per sodium salt in 76% yield. Hexamer 1 was evaluated in an opsonophagocytic 
killing inhibition assay (OPIA), to determine its binding to antibodies raised against 
native (Enterococcal) LTA, showing some inhibitory activity (compound 22, figure 1, 
chapter three). 
 Conclusion 
In summary, this chapter describes the synthesis of a kojibiose containing 
Enterococcus faecalis teichoic acid hexamer (1). The teichoic acid fragment was 
constructed by coupling of suitably protected glycerol and α-kojibiosyl substituted 
glycerol phosphoramidites. The key kojibiosyl synthon was obtained via a sequence of 
reactions involving two successive stereoselective α-glucosylations. The use of a 
benzylidene thioglucose donor, temporarily protected at the C2-hydroxyl with a TMS-
group proved to be the most efficient in the synthesis of the kojibiosyl glycerol 
pseudotrisaccharide. The phosphoramidite chemistry used for the assembly of the 
teichoic acid hexamer is compatible with an automated solid-phase approach, as is 
illustrated in chapter 3.40 
Experimental section 
General Procedures and Material: All chemicals (Acros, Fluka, Merck, Schleicher & Schuell, 
Sigma-Aldrich, Genscript) were used as received and reactions were carried out dry, under an 
argon atmosphere, at ambient temperature, unless stated otherwise. Tf2O was distilled over 
P2O5 using flame-dried glass-ware. Column chromatography was performed on Screening 
Devices silica gel 60 (0.040-0.063 mm). TLC analysis was conducted on HPTLC aluminium 
sheets (Merck, silica gel 60, F245). Compounds were visualized by UV absorption (245 nm), by 
spraying with 20% H2SO4 in EtOH or with a solution of (NH4)6Mo7O24·4H2O 25 g/l and 
(NH4)4Ce(SO4)4·2H2O 10 g/l, in 10% aqueous H2SO4 followed by charring at +/- 140 oC. Some 
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unsaturated compounds were visualized by spraying with a solution of KMnO4 (2%) and K2CO3 
(1%) in H2O. Optical rotation measurements ([α]D20) were performed on a Propol automated 
polarimeter (Sodium D-line, λ = 589 nm) with a concentration of 10 mg/ml (c = 1), unless stated 
otherwise. Infrared spectra were recorded on a Shimadzu FT-IR 8300 and are reported in cm-1. 
31P, 1H, and 13C NMR spectra were recorded with a Bruker AV 400 (161.7, 400 and 100 MHz 
respectively) or a Bruker DMX 600 (600 and 150 MHz respectively). NMR spectra were 
recorded in CDCl3 with chemical shift (δ) relative to tetramethylsilane, unless stated otherwise. 
High resolution mass spectra were recorded by direct injection (2 µl of a 2 µM solution in 
water/acetonitrile; 50/50; v/v and 0.1 % formic acid) on a mass spectrometer (Thermo 
Finnigan LTQ Orbitrap) equipped with an electrospray ion source in positive mode (source 
voltage 3.5 kV, sheath gas flow 10, capillary temperature 250 oC) with resolution R = 60000 at 
m/z 400 (mass range m/z = 150-2000) and dioctylphthalate (m/z = 391.28428) as a lock mass. 
The high resolution mass spectrometer was calibrated prior to measurements with a calibration 
mixture (Thermo Finnigan). TLC-MS (ESI) spectra of phosphoramidites 3, 4 and 5 were 
obtained by analysis of TLC-plates (Schleicher & Schuell, treated with Et3N before applying the 
phosphoramidites) with a CAMAG TLC-MS interface coupled to a Perkin Elmer Sciex API 165 
mass instrument. 
1-O-(tert-Butyldiphenylsilyl)-2-O-benzyl-sn-glycerol (8)  
Silyl ether 7 (22.8 g, 61.5 mmol) was dissolved in DMF (200 ml) and cooled to 
0 oC. After the addition of benzyl bromide (11.1 ml, 92.5 mmol) and heptane 
flushed NaH (60 % dispersion in mineral oil, 3.70 g, 92.5 mmol), the mixture 
was allowed to stir for 1.5 h. H2O (50 ml) was added, and after addition of Et2O 
(1.0 l), the mixture was washed with H2O (2 x 200 ml) and brine (200 ml). The organic layer 
was dried over MgSO4 and concentrated in vacuo. Repeated co-evaporation of the residue with 
H2O (5 x 100 ml) and toluene (5 x 100 ml), followed by column chromatography (toluene/PE) 
resulted in the benzylated adduct (28.3 g, 61.4 mmol, 100%, containing ~3% 1-O-benzyl-2-O-
tert-butyldiphenylsilyl-3-O-allyl-sn-glycerol) as a colourless oil. (analytical data: [α]D20 (CHCl3): -
10.4; IR: 737, 924, 1103, 1427, 2856 cm-1; 1H NMR (400 MHz): δ = 1.05 (s, 9H, t-Bu TBDPS), 3.55 
- 3.71 (m, 3H, CH glycerol, 2 x CHH glycerol), 3.77 - 3.80 (m, 2H, 2 x CHH glycerol), 3.99 (m, 2H, 
CH2 allyl), 4.64 (s, 2H, CH2 Bn), 5.16 (m, 1H, CHH allyl), 5.26 (dd, 1H, 1,7 Hz, 17.3 Hz, CHH allyl), 
5.86 - 5.93 (m, 1H, CH allyl), 7.18 - 7.43 (m, 11H, Harom), 7.66 - 7.71 (m, 4H, Harom); 13C NMR (100 
MHz): δ = 19.2 (Cq t-Bu), 26.8 (3 x CH3 TBDPS), 63.5 (CH2 glycerol), 70.2 (CH2 glycerol), 72.2, 
72.3 (CH2 allyl, CH2 Bn), 78.8 (CH glycerol), 116.8 (CH2 allyl), 127.4, 127.7, 128.2, 129.6 (CHarom), 
133.5 (2 x Cq phenyl), 134.8 (CH allyl), 135.6 (CHarom), 138.8 (Cq Bn).) A solution of the 
intermediate (9.21 g, 20.0 mmol) in freshly distilled THF (125 ml) was stirred under argon 
atmosphere for 30 min. After addition of Ir(COD)(Ph2MeP)2PF6 (423 mg, 0.50 mmol, 2.5 mol %), 
the solution turned red. The solution was then purged with H2 (g) for ~30s, after which it was 
stirred for 2 h under argon atmosphere. The solution was diluted with THF (250 ml) and, after 
addition of sat. aq. NaHCO3 (300 ml) and I2 (7.61 g, 30.0 mmol), the mixture was allowed to stir 
overnight. The mixture was diluted with EtOAc (1.5 l) and washed with sat. aq. Na2S2O3 (2 x 300 
ml) and brine (200 ml). The organic layer was dried over MgSO4 and concentrated in vacuo. 
Purification of the residue by column chromatography (EtOAc/PE), yielded 8 (6.26 g, 14.9 
mmol, 75%, containing ~3% 1-O-benzyl-2-O-tert-butyldiphenylsilyl-sn-glycerol) as slightly 
yellow oil. [α]D20 (CHCl3): -22.0; IR: 739, 824, 1113, 1427, 2361, 2858 cm-1; 1H NMR (400 MHz): 
δ = 1.06 (s, 9H, t-Bu TBDPS), 2.05 (t, 1H, J = 6.2 Hz, OH), 3.60 - 3.82 (m, 5H, CH glycerol, 2 x CH2 
glycerol), 4.51 (d, 1H J = 11.7 Hz, CHH Bn), 4.63 (d, 1H, J = 11.7 Hz, CHH Bn), 7.25 - 7.45 (m, 11H, 
Harom), 7.66 - 7.68 (m, 4H, Harom); 13C NMR (100 MHz): δ = 19.2 (Cq t-Bu), 26.8 (3 x CH3 TBDPS), 
62.8 (CH2 glycerol), 63.5 (CH2 glycerol), 72.1 (CH2 Bn), 79.6 (CH glycerol), 127.7, 128.4, 129.8 
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(CHarom), 133.1, 133.2 (2 x Cq phenyl), 135.6 (CHarom), 138.3 (Cq Bn); HRMS: C26H32O3Si + Na+ 
requires 443.2013, found 443.2013. 
1-O-(tert-Butyldiphenylsilyl)-2-O-benzyl-3-O-(4,4’-dimethoxytrityl)-sn-
glycerol (9) 
Alcohol 8 (6.18 g, 14.7 mmol) in DCM (100 ml) was cooled to 0 oC. Added were 
Et3N (3.05 ml, 22.0 mmol) and 4,4’-dimethoxytrityl chloride (DMT-Cl, 5.47 g, 
16.2 mmol), respectively, and the mixture was allowed to stir overnight at 
room temperature. The reaction was quenched by the addition of H2O (3 ml), and stirred for 15 
min. After washing with H2O (30 ml) and brine (30 ml), the organic layer was dried over Na2SO4 
and concentrated in vacuo. The resulting oil was further purified by column chromatography 
(EtOAc/PE/Et3N), giving 9 (10.3 g, 14.2 mmol, 97%, containing ~3% 1-O-benzyl-2-O-tert-
butyldiphenylsilyl-3-O-(4,4’-dimethoxytrityl)-sn-glycerol) as colourless oil. [α]D20 (MeOH): +2.0; 
IR: 827, 1036, 1113, 1250, 1508, 1609, 2359, 2930 cm-1;  1H NMR (400 MHz): δ = 0.97 (s, 9H, t-
Bu TBDPS), 3.23 - 3.31 (m, 2H, 2 x CHH glycerol), 3.71 - 3.78 (m, 9H, 2 x OMe, 2 x CHH glycerol, 
CH glycerol), 4.66 (2 x d, 2H, J = 12.2 Hz, CH2 Bn), 6.74 - 6.83 (m, 4H, Harom), 7.00 - 7.45 (m, 20H, 
Harom), 7.60 - 7.62 (m, 4H, Harom); 13C NMR (100 MHz): δ = 19.1 (Cq t-Bu), 26.8 (3 x CH3 TBDPS), 
55.1 (2 x OMe) 63.7 (CH2 glycerol), 63.9 (CH2 glycerol), 72.3 (CH2 Bn), 79.3 (CH glycerol), 86.0 
(Cq DMT), 113.0, 113.6 (CHarom), 126.1 - 130.3 (CHarom), 133.4, 133.5 (2 x Cq phenyl), 136.3 
(CHarom), 136.4, 138.9, 145.1, 158.3 (Cq Bn, 5 x Cq DMT); HRMS: C47H50O5Si + Na+ requires 
745.3320, found 745.3322. 
2-O-Benzyl-3-O-(4,4’-dimethoxytrityl)-sn-glycerol (10) 
To a solution of glycerol derivative 9 (25.5 g, 35.3 mmol) in THF (200 ml), was 
added TBAF (1.0 M solution in THF, 53 ml). After stirring for 3 h at room 
temperature, the solvent was removed in vacuo. The residue was purified by 
column chromatography (EtOAc/PE/Et3N), affording primary alcohol 10 (16.4 g, 
33.8 mmol, 96%) as colourless oil. [α]D20 (MeOH): +10.6; IR: 829, 1034, 1177, 1250, 1508, 1607, 
2359 cm-1; 1H NMR (400 MHz): δ = 2.02 (bs, 1H, OH), 3.21 - 3.31 (m, 2H, 2 x CHH glycerol), 3.63 - 
3.67 (m, 2H, CH glycerol, CHH glycerol), 3.70 - 3.74 (m, 7H, 2 x OMe, CHH glycerol), 4.53 (d, 1H, J 
= 11.6 Hz, CHH Bn), 4.66 (d, 1H, J = 12.0 Hz, CHH Bn), 6.80 (ad, 4H, J = 8.8 Hz, Harom), 7.16 - 7.38 
(m, 12H, Harom), 7.44 (d, 2H, J = 7.6, Harom); 13C NMR (100 MHz): δ = 55.0 (2 x OMe), 63.0 (CH2 
glycerol), 63.3 (CH2 glycerol), 72.0 (CH2 Bn), 78.9 (CH glycerol), 86.4 (Cq DMTr), 113.2 
(CHarom),126.7 - 129.9 (CHarom), 135.9, 138.2, 144.7, 158.4 (Cq Bn, 5 x Cq DMTr); HRMS: C31H32O5 
+ Na+ requires 507.3142, found 507.3135. 
1-([N,N-Diisopropylamino]-2-cyanoethylphosphite)-2-O-benzyl-3-O-
(4,4’-dimethoxytrityl)-sn-glycerol (3) 
To a solution of 10 (3.19 g, 6.59 mmol) and DIPEA (1.72 ml, 9.88 mmol) in 
DCM (65 ml) were added activated MS3Å and (N,N-diisopropylamino)-2-
cyanoethyl-chlorophosphite (11, 1.82 g, 7.90 mmol). After stirring for 2 h, 
the reaction was quenched with H2O (5.0 ml) and washed with H2O (50 
ml) and brine (50 ml) respectively. The organic layer was dried over 
Na2SO4 and concentrated in vacuo. Column chromatography (EtOAc/heptane/Et3N) gave 
phosphoramidite 3 (3.74 g, 5.34 mmol, 81%, mixture of diastereoisomers) as colourless oil. 31P 
NMR (161.7 MHz, CD3CN): δ = 149.2; 1H NMR (400 MHz, CD3CN): δ = 1.08 (t, 6H, J = 6.5 Hz, 2 x 
CH3 isopropylamino), 1.14 (dd, 6H, J = 1.8 Hz, 6.8 Hz, 2 x CH3 isopropylamino), 2.51 - 2.56 (m, 
2H, CH2 cyanoethyl), 3.17 - 3.24 (m, 2H, 2 x CH isopropylamino), 3.50 - 3.58 (m, 2H, 2 x CHH 
glycerol), 3.64 - 3.81 (m, 11H, CH glycerol, 2 x CHH glycerol, CH2 cyanoethyl, 2 x OMe), 4.61 - 
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4.68 (m, 2H, CH2 Bn), 6.83 (d, 4H, J = 8.9 Hz, Harom), 7.19 - 7.39 (m, 12H, Harom), 7.45 - 7.47 (m, 
2H, Harom); TLC-MS: C40H49N2O6P + H+ requires 685.34, found 685.5. 
Phenyl 2-O-(4-methoxybenzyl)-3-O-benzyl-4,6-O-benzylidene-1-
thio-β-D-glucopyranoside (13a) 
To a cooled (0 oC) solution of thioglucose 12 (18.3 g, 40.5 mmol) in THF 
(250 ml) were added, respectively, p-methoxybenzyl chloride (6.03 ml, 
44.5 mmol) and NaH (60 % dispersion in mineral oil, 1.78 g, 44.5 mmol). After stirring for 5 h, 
the mixture was quenched with MeOH (5.0 ml), diluted with EtOAc (1.0 l) and washed with, sat. 
aq. NaHCO3 (400 ml) and brine (400 ml). The organic layer was dried with MgSO4 and 
concentrated in vacuo, after which crystallization (EtOAc/PE) yielded fully protected 
thioglucose derivative 13a (20.4 g, 35.8 mmol, 88%) as white solid. M.p.: 146-147 oC; [α]D20 
(CHCl3): -11.2; IR: 748, 818, 1030, 1088, 1250, 1516 cm-1; 1H NMR (400 MHz): δ = 3.45 (m, 1H, 
H-5), 3.50 (dd, 1H, J = 8.4 Hz, 9.7 Hz, H-2), 3.69 (at, 1H, J = 9.4 Hz, H4), 3.76 - 3.84 (m, 5H, OMe, 
H-3, H-6), 4.37 (dd, 1H, J = 5.0 Hz, 10.5 Hz, H-6), 4.73 - 4.81 (m, 4H, 3 x CHH Bn, H-1), 4.94 (d, 
1H, J = 11.2 Hz, CHH Bn), 5.57 (s, 1H, CH benzylidene), 6.85 - 6.88 (m, 2H, Harom), 7.26 - 7.39 (m, 
13H, Harom), 7.46 - 7.54 (m, 4H, Harom); 13C NMR (100 MHz): δ = 55.3 (OMe), 68.7 (C-6), 70.2 (C-
5), 75.3, 75.5 (CH2 Bn, CH2 PMB), 80.1 (C-2), 81.4 (C-4), 83.0 (C-3), 88.3 (C-1), 101.1 (CH 
benzylidene), 113.8 (CHarom), 126.0 - 129.9 (CHarom), 130.2 (Cq S-phenyl), 132.2 (CHarom), 133.2, 
137.2, 138.3 (Cq Bn, Cq PMB, Cq benzylidene), 159.4 (Cq PMB); HRMS: C34H34O6S + H+ requires 
571.2149, found 571.2147. 
Phenyl 2-O-(4-azidobenzyl)-3-O-benzyl-4,6-O-benzylidene-1-thio-β-
D-glucopyranoside (13b) 
To a cooled (0 oC) solution of thioglucose 12 (895 mg, 1.99 mmol) in DMF 
(20 ml) were added p-azidobenzyl bromide (634 mg, 2.99 mmol) and 
NaH (60 % dispersion in mineral oil, 127 mg, 3.18 mmol) respectively. 
After stirring for 1.5 h, MeOH (2.0 ml) was added before the mixture was 
diluted with Et2O (80 ml) and washed with H2O (20 ml) and brine (20 
ml). The organic layer was dried with MgSO4 and concentrated in vacuo. 
The residue was taken up in EtOAc (5 ml) and crystallized upon addition of PE, yielding 13b 
(1.07 g, 1.84 mmol, 93%) as ochreous solid. M.p.: 150-155 oC (decomp.); [α]D20 (CHCl3): +3.0; IR: 
991, 1088, 1508, 2112 cm-1; 1H NMR (400 MHz): δ = 3.44 - 3.51 (m, 2H, H-2, H-5), 3.70 (at, 1H, J 
= 9.4 Hz, H-4), 3.78 - 3.84 (m, 2H, H-3, H-6), 4.39 (dd, 1H, J = 5.2 Hz, 10.4 Hz, H-6), 4.73 - 4.82 (m, 
4H, 3 x CHH Bn, H-1), 4.95 (d, 1H, J = 11.2 Hz, CHH Bn), 5.59 (s, 1H, CH benzylidene), 6.96 - 7.00 
(m, 2H, Harom), 7.26 - 7.40 (m, 13H, Harom), 7.45 - 7.53 (m, 4H, Harom); 13C NMR (100 MHz): δ = 
68.7 (C-6), 70.2 (C-5), 75.1, 75.3 (CH2 Bn, CH2 p-N3Bn), 80.3 (C-2), 81.5 (C-4), 82.9 (C-3), 88.2 (C-
1), 101.1 (CH benzylidene), 118.9 (CHarom), 126.0 - 132.2 (CHarom), 133.0, 134.8, 137.2, 138.2, 
139.5 (Cq S-phenyl, Cq Bn, 2 x Cq p-N3Bn, Cq benzylidene); HRMS: C34H31N3O5S + H+ requires 
582.2057, found 582.2056. 
1-O-(tert-Butyldiphenylsilyl)-2-O-(3-O-benzyl-4,6-O-
benzylidene-α-D-glucopyranosyl)-3-O-allyl-sn-glycerol (14) 
From 13a:  
A solution of donor 13a (2.85 g, 4.99 mmol), TTBP (2.86 g, 11.5 
mmol) and Ph2SO (1.11 g, 5.50 mmol) in freshly distilled DCM (100 
ml), together with activated MS3Å, was stirred under argon at RT 
for 30 min. Subsequently, the mixture was cooled to -75 oC and stirred for another 15 min. After 
the addition of Tf2O (0.93 ml, 5.5 mmol), the mixture was stirred for 45 min at -75 oC and, 
Chapter 2 
~ 42 ~ 
subsequently, glycerol acceptor 7 (2.22 g, 5.99 mmol) in DCM (10 ml) was added. After stirring 
for 60 minutes at -75 oC, the mixture was allowed to, gradually, warm to room temperature (~3 
h). The reaction was quenched upon addition of Et3N (2.0 ml, 14 mmol) and stirred for 30 min. 
After washing the mixture with sat. aq. NaHCO3 (30 ml) and brine (30 ml), the organic layer was 
dried over MgSO4 and concentrated in vacuo. The resulting oil was dissolved in pyridine (30 ml) 
and, after the addition of Ac2O (7 ml), stirred for 2 h. After removal of the solvents in vacuo, the 
residue was dissolved in EtOAc (200 ml) and washed with sat. aq. NaHCO3 (2 x 60 ml) and brine 
(60 ml). The organic layer was dried over MgSO4 and the solvent removed under reduced 
pressure. Purification of the resulting oil by column chromatography (EtOAc/PE) gave the fully 
protected product (3.16 g, 3.80 mmol, 76%, α/β mixture, ~10/1), as colourless oil. IR: 737, 
1088, 1369, 1454, 1751, 2855, 2924 cm-1; 1H NMR α-product (400 MHz): δ = 1.05 (s, 9H, t-Bu), 
3.51 - 3.65 (m, 4H, CH glycerol, CHH glycerol, H-2, H-6), 3.69 - 3.80 (m, 6H, OMe, 3 x CHH 
glycerol), 3.89 (m, 1H, H-5), 3.96 - 4.03 (m, 5H, CH2 allyl, H-3, H-4, H-6), 4.66 (d, 1H, J = 11.7 Hz, 
CHH Bn), 4.71 (d, 1H, J = 11.7 Hz, CHH Bn), 4.79 (d, 1H, J = 11.2 Hz, CHH Bn), 4.85 (d, 1H, J = 11.3 
Hz, CHH Bn), 5.17 (dd, 1H, J = 1.6 Hz, 10.4 Hz, CHH allyl), 5.20 (d, 1H, J = 3.8 Hz, H-1), 5.26 (dd, 
1H, J = 1.7 Hz, 17.2 Hz, CHH allyl), 5.49 (s, 1H, CH benzylidene), 5.89 (ddd, 1H, J = 5.5 Hz, 10.7 
Hz, 22.7 Hz, CH allyl), 6.83 (d, 2H, J = 8.6 Hz, Harom),  7.24 - 7.47 (m, 18H, Harom), 7.65 - 7.68 (m, 
4H, Harom); 13C NMR α-product (100 MHz): δ = 19.2 (Cq t-Bu), 26.8 (3 x CH3 TBDPS), 55.2 (OMe), 
62.4 (C-5), 63.8 (CH2 glycerol), 68.9 (C-6), 70.7 (CH2 glycerol), 72.3 (CH2 allyl), 72.3, 75.2 (CH2 
Bn, CH2 PMB), 76.6, 78.2 (C-3, C-4), 78.6 (CH glycerol), 82.1 (C-2), 97.2 (C-1), 101.2 (CH 
benzylidene), 113.7 (CHarom), 116.9 (CH2 allyl), 126.1 - 129.7 (CHarom),130.4, 133.2, 133.2, 134.7, 
135.5, 137.5, 138.9 (CHarom, CH allyl, 2 x Cq phenyl, Cq PMB, Cq Bn, Cq benzylidene), 159.2 (Cq 
PMB); HRMS: C50H58O9Si + Na+ requires 853.3742, found 853.3745.) A combination of batches 
of the fully protected pesudodisaccharide (8.81 g, 10.6 mmol) was dissolved in DCM (100 ml) 
and cooled to 0 oC. After adding H2O (5.0 ml) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
(DDQ, 2.88 g, 12.7 mmol), respectively, the mixture was stirred vigorously for 4 h, before it was 
quenched by the addition of sat. aq. NaHCO3 (25 ml). The mixture was diluted with EtOAc (500 
ml) and washed with sat. aq. NaHCO3 (3 x 200 ml) and brine (3 x 150 ml), respectively, in order 
to remove the bulk of DDQH2. The organic layer was dried over MgSO4 and concentrated in 
vacuo. The crude product was purified by column chromatography (EtOAc/PE). Alcohol 14 
(4.23 g, 5.95 mmol, 56%) was obtained as pale yellow oil.  
 
From 13b:  
A solution of donor 13b (145 mg, 0.250 mmol), TTBP (155 mg, 0.625 mmol) and Ph2SO (60.7 
mg, 0.300 mmol) in freshly distilled DCM (8.0 ml), together with activated MS 3Å, was stirred 
under argon at RT for 30 min. Subsequently, the mixture was cooled to -78 oC and stirred for 
another 15 min. After the addition of Tf2O (50.5 µl, 0.300 mmol), the mixture was stirred for 45 
min at -50 oC before it was cooled down to -78 oC. After the addition of a solution of glycerol 
acceptor 7 (111 mg, 0.300 mmol) in DCM (2.5 ml), the mixture was stirred at -75 oC for 1h, 
before it was allowed to gradually (~3 h) warm to room temperature. The reaction was 
quenched by the addition of Et3N (0.2 ml, 1.4 mmol) and stirred for 30 min. The mixture was 
diluted with DCM (30 ml) and after washing with sat. aq. NaHCO3 (15 ml) and brine (15 ml), the 
organic layer was dried over MgSO4 and concentrated in vacuo. Purification of the resulting oil 
by size-exclusion chromatography (sephadex LH-20, MeOH/DCM 1/1), followed by column 
chromatography (EtOAc/PE) gave the fully protected intermediate (131 mg, 0.156 mmol, 62%, 
α/β mixture, ~7/1), as pale yellow oil. (Analytical data: 1H NMR α-product (400 MHz): δ = 1.06 
(s, 9H, t-Bu), 3.49 - 4.04 (m, 13H, CH glycerol, 2 x CH2 glycerol, H-2, H-3, H-4, H-5, 2 x H-6, CH2 
allyl), 4.68 (d, 1H, J = 12.0 Hz, CHH Bn), 4.74 (d, 1H, J = 12.0 Hz, CHH Bn), 4.80 (d, 1H, J = 12.0 Hz, 
CHH Bn), 4.88 (d, 1H, J = 11.6 Hz, CHH Bn), 5.17 (dd, 1H, J = 1.2 Hz, 10.4 Hz, CHH allyl), 5.23 - 
5.28 (m, 2H, H-1, CHH allyl), 5.50 (s, 1H, CH benzylidene), 5.88 (ddd, 1H, J = 5.6 Hz, 10.6 Hz, 22.8 
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Hz, CH allyl), 6.93 (d, 2H, J = 8.4 Hz, Harom), 7.22 - 7.46 (m, 18H, Harom), 7.64 - 7.68 (m, 4H, Harom); 
13C NMR α-product (100 MHz): δ = 19.2 (Cq t-Bu, 26.8 (3 x CH3 TBDPS), 62.4 (C-5), 63.9 (CH2 
glycerol), 68.8 (C-6), 70.9 (CH2 glycerol), 71.8, 72.3, 75.2 (CH2 allyl, CH2 p-N3Bn, CH2 Bn), 76.7, 
78.2 (C-3, C-4), 79.0 (CH glycerol), 82.2 (C-2), 97.2 (C-1), 101.2 (CH benzylidene), 116.9 (CH2 
allyl), 118.8 (CHarom) 126.1 - 129.7 (CHarom), 133.1, 133.2 (2 x Cq phenyl), 134.6 (CH allyl), 135.1 
(Cq p-N3Bn), 135.5 (CHarom), 137.5, 138.8, 139.3 (Cq Bn, Cq benzylidene Cq p-N3Bn)). A part of the 
intermediate (58 mg, 0.069 mmol) was dissolved in a mixture of dioxane/water (9/1, 10 ml) 
and treated with PMe3 (1M solution in toluene, 0.34 ml). After stirring for 1h, the mixture was 
concentrated in vacuo and coevaporated three times with dioxane (portions of 5 ml) before the 
mixture was redissolved in moist DCM (10 ml) and DDQ (24 mg, 0.10 mmol) was added. After 
stirring vigorously for 4 h, the reaction was quenched by the addition of sat. aq. NaHCO3 (2.5 
ml). The mixture was then diluted with EtOAc (40 ml) and washed with, respectively, sat. aq. 
NaHCO3 (3 x 15 ml) and brine (3 x 15 ml) in order to remove the bulk of DDQH2. The organic 
layer was dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
column chromatography (EtOAc/PE), giving alcohol 14 (19.0 mg, 26.7 µmol, 39%) as pale 
yellow oil.  
 
From 12 (via 13c):  
To a solution of thioglucose 12 (225 mg, 0.500 mmol) in DCM (5.0 ml) were added Et3N (0.69 
ml, 5.0 mmol), TMS-Cl (0.32 ml, 2.50 mmol) and a drop of pyridine. After stirring for 2 h, the 
reaction was diluted with EtOAc (40 ml) and washed with H2O (15 ml) and brine (15 ml) 
respectively. The organic layer was dried with MgSO4 and concentrated in vacuo. Crude 13c, 
together with Ph2SO (121 mg, 0.600 mmol) and TTBP (323 mg, 1.30 mmol) were coevaporated 
with toluene (3 x 5 ml) and together with activated MS3Å dissolved in dry DCM (10 ml). After 
stirring for 15 min, the mixture was cooled to -78 oC and stirred for 5 min. After the addition of 
Tf2O (101 µl, 0.600 mmol), the mixture was allowed to slowly warm up to -60 oC (~ 30 min), 
after which the mixture was cooled down to -78 oC and glycerol acceptor 7 (278 mg, 0.750 
mmol, dissolved in 2.0 ml DCM) was added. After stirring for 1 h at -78 oC, the mixture was 
allowed to warm up to RT overnight. After the addition of a few drops of H2O the mixture was 
diluted with MeOH (20 ml). K2CO3 (10 g) was subsequently added and, after stirring for 5 hrs, 
the mixture was diluted with EtOAc (100 ml). The organic layer was washed with H2O (40 ml) 
and brine (40 ml) and dried with MgSO4. After removal of the solvents in vacuo, the residue was 
purified by column chromatography (EtOAc/PE), affording 14 (165 mg, 0.232 mmol, 46%, only 
α) as pale yellow oil. [α]D20 (CHCl3): +33.6; IR: 741, 1040, 1072, 2343, 2361 cm-1; 1H NMR (400 
MHz): δ = 1.06 (s, 9H, t-Bu), 2.92 (bs, 1H, OH), 3.54 - 3.79 (m, 8H, 2 x CH2 glycerol, H-2, H-3, H-4, 
H-6), 3.85 - 3.95 (m, 2H, H-5, CH glycerol), 4.00 (ad, 2H, J = 5.6 Hz, CH2 allyl), 4.05 (dd, 1H, J = 4.9 
Hz, 10.2 Hz, H-6), 4.85 (d, 1H, J = 11.8 Hz, CHH Bn), 4.91 (d, 1H, J = 11.8 Hz, CHH Bn), 5.06 (d, 1H, 
J = 3.8 Hz, H-1), 5.20 (dd, 1H, J = 1.1 Hz, 10.4 Hz, CHH allyl), 5.28 (dd, 1H, J = 1.5 Hz, 17.2 Hz, CHH 
allyl), 5.51 (s, 1H, CH benzylidene), 5.88 (ddd, 1H, J = 5.5 Hz, 10.8 Hz, 22.8 Hz, CH allyl), 7.23 - 
7.47 (m, 16H, Harom), 7.64 - 7.68 (m, 4H, Harom); 13C NMR (100 MHz): δ = 19.2 (Cq t-Bu), 26.8 (3 x 
CH3 TBDPS), 63.0 (C-5), 63.8 (CH2 glycerol), 68.8 (C-6), 69.8 (CH2 glycerol), 72.3 (CH2 allyl), 73.1 
(C-2), 74.6 (CH2 Bn), 79.0 (CH glycerol), 79.1, 81.5 (C-3, C-4),  99.8 (C-1), 101.2 (CH 
benzylidene), 117.5 (CH2 allyl), 126.1 - 129.8 (CHarom), 133.0, 133.1 (2 x Cq phenyl), 134.2 (CH 
allyl), 135.5 (CHarom), 137.5, 138.8 (Cq Bn, Cq benzylidene); HRMS: C42H50O8Si + Na+ requires 
734.3201, found 734.3203. 
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A solution of glucose donor 15 (130 mg, 0.240 mmol), TTBP (149 
mg, 0.600 mmol) and Ph2SO (57 mg, 0.28 mmol) in freshly distilled 
DCM (5.0 ml), together with activated MS3Å, was stirred under 
argon at RT for 30 min. The mixture was cooled to -78 oC and stirred for another 15 min before 
Tf2O (47 µl, 0.28 mmol) was added and the mixture stirred for another 45 min at -70 oC. 
Subsequently, alcohol 14 (142 mg, 0.200 mmol, dissolved in 2.5 ml DCM) was added and after 
stirring for 60 min at -75 oC, the mixture was allowed to, gradually, warm to room temperature 
(~3 h). The reaction was quenched by the addition of Et3N (0.14 ml, 1.0 mmol) and stirred for 
30 min. The mixture was diluted with EtOAc (30 ml) and washed with sat. aq. NaHCO3 (10 ml) 
and brine (10 ml). The organic layer was dried over MgSO4 and concentrated in vacuo. The 
resulting oil was purified by size-exclusion chromatography (sephadex LH-20, MeOH/DCM 1/1) 
and, subsequently, column chromatography (EtOAc/pentane). Kojibiose derivative 16 (187 mg, 
0.164 mmol, 82%, pure α) was obtained as white foam. [α]D20 (CHCl3): +34.4; IR: 746, 997, 
1028, 1074, 1369, 1454, 2860 cm-1; 1H NMR (400 MHz): δ = 1.05 (s, 9H, t-Bu), 3.54 (dd, 1H, J = 
5.9 Hz, 10.5 Hz, CHH glycerol), 3.57 - 3.69 (m, 7H, 2 x CHH glycerol, H-2, 2 x H-4, 2 x H-6), 3.74 
(dd, 1H, J = 5.3 Hz, 10.4 Hz, CHH glycerol), 3.80 (dd, 1H, J = 3.7 Hz, 9.4 Hz, H-2), 3.88 (m, 2H, CH2 
allyl), 3.91 - 4.00 (m, 2H, CH glycerol, H-5), 4.04 - 4.21 (m, 5H, 2 x H-3, H-5, 2 x H-6), 4.70 (d, 1H, 
J = 11.8 Hz, CHH Bn), 4.74 - 4.83 (m, 4H, CH2 Bn), 4.90 (d, 1H, J = 11.8 Hz, CHH Bn), 5.12 (dd, 1H, 
J = 1.1 Hz, 10.4 Hz, CHH allyl), 5.19 (dd, 1H, J = 1.6 Hz, 17.3 Hz, CHH allyl), 5.27 (d, 1H, J = 3.5 Hz, 
H-1), 5.40 (d, 1H, J = 3.6 Hz, H-1), 5.52 (s, 1H, CH benzylidene), 5.54 (s, 1H, CH benzylidene), 
5.82 (ddd, 1H, J = 5.6 Hz, 10.7 Hz, 22.7 Hz, CH allyl), 7.06 - 7.11 (m, 2H, Harom), 7.19 - 7.39 (m, 
25H, Harom), 7.44 - 7.48 (m, 4H, Harom), 7.64 - 7.68 (m, 4H, Harom); 13C NMR (100 MHz): δ = 19.1 
(Cq t-Bu), 26.8 (3 x CH3 TBDPS), 62.5 (C-5), 62.8 (C-5), 63.5 (CH2 glycerol), 68.8 (C-6), 68.9 (C-6), 
69.7 (CH2 glycerol), 72.1 (CH2 allyl), 72.4 (CH2 Bn), 75.0 (CH2 Bn), 75.3 (C-2), 75.3 (CH2 Bn), 75.9 
(CH glycerol), 76.7 (C-3), 78.1 (C-3), 79.0 (C-2), 82.2 (2 x C-4), 95.4 (C-1), 95.5 (C-1), 101.2 (2 x 
CH benzylidene), 117.0 (CH2 allyl), 126.1 - 129.7 (CHarom), 133.2 (2 x Cq phenyl), 134.5 (CH 
allyl), 135.5 (CHarom), 137.5, 137.6, 138.3, 138.6 (3 x Cq Bn, 2 x Cq benzylidene); HRMS: 




A solution of 16 (3.18 g, 2.79 mmol) and freshly activated MS3Å in 
freshly distilled THF (35 ml) was stirred under argon for 30 min. 
After the addition of Ir(COD)(Ph2MeP)2PF6 (236 mg, 10 mol %) the 
solution turned red and the mixture was purged with H2 (g) for ~ 1 min. After stirring under 
argon for 4 h, the solution was diluted with THF (30 ml) and sat. aq. NaHCO3 (100 ml). After the 
addition of I2 (1.06 g, 4.19 mmol), the mixture was allowed to stir overnight at room 
temperature. The mixture was diluted with EtOAc (250 ml) and washed with sat. aq. Na2S2O3 (2 
x 80 ml) and brine (80 ml), respectively. The organic layer was dried over MgSO4 and 
concentrated in vacuo. Column chromatography (EtOAc/toluene) afforded 17 (2.05 g, 1.86 
mmol, 67%) as pale yellow foam. [α]D20 (CHCl3): +29.4; IR: 748, 997, 1028, 1074, 1371, 2360, 
2858 cm-1; 1H NMR (400 MHz): δ = 1.07 (s, 9H, t-Bu), 3.44 (dd, 1H, J = 5.3 Hz, 8.1 Hz, OH), 3.50 - 
3.68 (m, 8H, 2 x CHH glycerol, 2 x H-2, 2 x H-4, 2 x H-6), 3.76 - 3.91 (m, 5H, 2 x CHH glycerol, CH 
glycerol, H-5, H-6), 3.96 (dd, 1H, J = 4.9 Hz, 10.2 Hz, H-6), 4.02 (at, 1H, J = 9.3 Hz, H-3), 4.16 (at, 
1H, J = 9.3 Hz, H-3), 4.13 - 4.22 (m, 1H, H-5), 4.73 - 4.86 (m, 5H, H-1, 2 x CH2 Bn), 4.94 (d, 1H, J = 
11.1 Hz, CHH Bn), 4.97 (d, 1H, J = 10.7 Hz, CHH Bn), 5.09 (d, 1H, J = 3.6 Hz, H-1), 5.48 (s, 1H, CH 
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benzylidene), 5.50 (s, 1H, CH benzylidene), 7.12 - 7.15 (m, 3H, Harom), 7.27 - 7.47 (m, 28H, Harom), 
7.66 - 7.68 (m, 4H, Harom); 13C NMR (100 MHz): δ = 19.1 (Cq t-Bu), 26.8 (3 x CH3 TBDPS), 62.4 
(CH2 glycerol), 62.5 (C-5), 62.8 (C-5), 63.7 (CH2 glycerol), 68.7 (2 x C-6), 74.0 (CH2 Bn), 75.1 
(CH2 Bn), 75.2 (CH2 Bn), 76.4 (C-3), 77.2 (C-2), 77.7 (C-2), 78.8 (C-3), 80.7 (CH glycerol), 78.1 (C-
3), 79.0 (C-2), 82.5 (C-4), 82.8 (C-4), 97.6 (C-1), 98.6 (C-1), 101.2 (CH benzylidene), 101.3 (CH 
benzylidene), 126.0 - 129.8 (CHarom), 133.0, 133.1 (2 x Cq phenyl), 135.5 (CHarom), 137.2, 137.5, 
137.6, 138.0, 138.5 (3 x Cq Bn, 2 x Cq benzylidene); HRMS: C66H72O13Si + Na+ requires 





Alcohol 17 (480 mg, 0.436 mmol) was dissolved in DCM (20 ml) 
and cooled to 0 oC. After the addition of DIPEA (0.23 ml, 1.3 mmol) 
and DMT-Cl (295 mg, 0.872 mmol) respectively, the mixture was allowed to stir at room 
temperature overnight. The reaction was quenched upon addition of H2O (0.2 ml), and stirred 
for 15 min. The mixture was diluted with DCM (20 ml) and, after washing with H2O (10 ml) and 
brine (10 ml), the organic layer was dried over Na2SO4 and concentrated in vacuo. The resulting 
oil was purified by size-exclusion chromatography (sephadex LH-20, MeOH/DCM 1/1) and, 
subsequently, column chromatography (EtOAc/pentane/Et3N), giving DMTr-ether 18 (601 mg, 
0.428 mmol, 98%) as white foam. [α]D20 (CHCl3): + 35.6; IR: 752, 1030, 1074, 1250, 1508, 2361, 
2858 cm-1; 1H NMR (400 MHz): δ = 0.97 (s, 9H, t-Bu), 3.08 (dd, 1H, J = 5.7 Hz, 10.1 Hz, CHH 
glycerol), 3.44 (dd, 1H, J = 3.4 Hz, 9.2 Hz, H-2), 3.51 (dd, 1H, J = 2.9 Hz, 10.1 Hz, CHH glycerol), 
3.55 - 3.71 (m, 12H, 2 x OMe, 2 x CHH glycerol, 2 x H-4, 2 x H-6), 3.77 (dd, 1H, J = 3.4 Hz, 9.4 Hz, 
H-2), 3.93 - 4.02 (m, 3H, CH glycerol, H-3, H-5), 4.07 - 4.17 (m, 4H, H-3, H-5, 2 x H-6), 4.30 (d, 1H, 
J = 11.5 Hz, CHH Bn), 4.36 (d, 1H, J = 11.4 Hz, CHH Bn), 4.56 (d, 1H, J = 11.4 Hz, CHH Bn), 4.72 (d, 
1H, J = 11.4 Hz, CHH Bn), 4.78 (d, 1H, J = 11.0 Hz, CHH Bn), 4.88 (d, 1H, J = 11.0 Hz, CHH Bn), 4.98 
(d, 1H, J = 3.4 Hz, H-1), 5.39 (d, 1H, J = 3.4 Hz, H-1), 5.53 (s, 1H, CH benzylidene), 5.55 (s, 1H, CH 
benzylidene), 6.74 (d, 4H, J = 8.7 Hz, Harom), 7.08 - 7.48 (m, 40H, Harom), 7.55 (d, 2H, J = 7.1 Hz, 
Harom), 7.59 (d, 2H, J = 6.7 Hz, Harom); 13C NMR (100 MHz): δ = 19.1 (Cq t-Bu), 26.8 (3 x CH3 
TBDPS), 55.1 (2 x OMe), 62.5 (C-5), 62.8 (C-5), 63.3 (CH2 glycerol), 64.3 (CH2 glycerol), 68.8 (C-
6), 68.9 (C-6), 72.4 (CH2 Bn), 75.0 (CH2 Bn), 75.4 (CH2 Bn), 75.7 (C-2), 76.8, 76.9 (C-3, CH 
glycerol), 78.1 (C-3), 79.4 (C-2), 82.1 (C-4), 82.3 (C-4), 86.4 (Cq DMT), 95.2 (C-1), 95.6 (C-1), 
101.2 (CH benzylidene), 101.3 (CH benzylidene), 113.1 (CHarom), 126.1 - 130.0 (CHarom), 133.1, 
133.2 (2 x Cq phenyl), 135.5 (CHarom), 137.5, 137.7, 138.1, 138.2, 138.7, 144.9, 158.4 (3 x Cq Bn, 2 




To a solution of kojibiose derivative 18 (575 mg, 0.410 mmol) in 
THF (10 ml), was added TBAF (1.00 M solution in THF, 1.20 ml). 
After stirring for 48 h at RT, the solvent was removed in vacuo. The 
residue was purified by column chromatography (EtOAc/pentane/Et3N), affording compound 
19 (435 mg, 0.373 mmol, 91%) as white foam. [α]D20 (CHCl3): + 38.0; IR: 1030, 1074, 1508, 
2341, 2361 cm-1; 1H NMR (400 MHz): δ = 2.52 (bs, 1H, OH), 3.02 (dd, 1H, J = 4.1 Hz, 9.9 Hz, CHH 
glycerol), 3.44 - 3.49 (m, 2H, CHH glycerol, H-2), 3.55 - 3.78 (m, 14H, 2 x OMe, 2 x CHH glycerol, 
CH glycerol, H-2, 2 x H-4, 2 x H-6), 3.96 (at, 1H, J = 9.3 Hz, H-3), 4.04 - 4.16 (m, 4H, H-3, 2 x H-5, 
H-6), 4.31 (dd, 1H, J = 4.8 Hz, 10.2 Hz, H-6), 4.49 - 4.55 (m, 3H, 3 x CHH Bn), 4.73 (d, 1H, J = 11.4 
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Hz, CHH Bn), 4.83 (d, 1H, J = 11.0 Hz, CHH Bn), 4.90 (d, 1H, J = 3.3 Hz, H-1), 4.93 (d, 1H, J = 11.0 
Hz, CHH Bn), 5.17 (d, 1H, J = 3.5 Hz, H-1), 5.52 (s, 1H, CH benzylidene), 5.58 (s, 1H, CH 
benzylidene), 6.75 (d, 2H, J = 8.8 Hz, Harom), 6.76 (d, 2H, J = 8.8 Hz, Harom), 7.16 - 7.50 (m, 34H, 
Harom); 13C NMR (100 MHz): δ = 55.1 (2 x OMe), 63.0 (2 x C-5), 63.8 (CH2 glycerol), 64.3 (CH2 
glycerol), 68.7 (C-6), 68.9 (C-6), 73.5 (CH2 Bn), 75.0 (CH2 Bn), 75.4 (CH2 Bn), 76.9 (C-3), 77.0 (C-
2), 78.4 (C-3), 79.0 (C-2), 79.8 (CH glycerol), 82.3 (C-4), 82.5 (C-4), 86.3 (Cq DMTr), 97.1 (C-1), 
97.2 (C-1), 101.2 (CH benzylidene), 101.3 (CH benzylidene), 113.1 (CHarom), 126.0 - 129.9 
(CHarom), 135.7, 135.9, 137.2, 137.6, 137.8, 138.1, 138.6, 144.7, 158.4 (3 x Cq Bn, 2 x Cq 





To a cooled (0 oC) solution of alcohol 19 (1.37 g, 1.17 mmol) 
and DIPEA (0.31 ml, 1.75 mmol) in freshly distilled DCM (12 
ml) was added chlorophosphite 11 (333 mg, 1.41 mmol). After 
stirring for 4 h, the reaction was quenched with H2O (1.0 ml), 
diluted with DCM (50 ml) and washed with H2O (20 ml) and brine (20 ml) respectively. The 
organic layer was dried over Na2SO4 and concentrated in vacuo. After purification of the residue 
by column chromatography (EtOAc/pentane/Et3N), phosphoramidite 4 (1.15 g, 0.842 mmol, 
72%) was obtained as colourless oil. 31P NMR (161.7 MHz, CD3CN): δ = 148.5, 148.7 
(diastereoisomers); 1H NMR (400 MHz, CD3CN): δ = 1.10 - 1.17 (m, 12H, CH3 isopropylamino), 
2.46 - 2.52 (m, 2H, CH2 cyanoethyl), 3.12 - 3.16 (m, 1H, CH isopropylamino), 3.32 - 3.39 (m, 1H, 
CH isopropylamino), 3.51 - 4.15 (m, 24H, 2 x OMe, 2 x CH2 glycerol, CH glycerol, 2 x H-2, 2 x H-3, 
2 x H-4, 2 x H-5, 3 x H-6, CH2 cyanoethyl), 4.29 (dd, 1H, J = 4.2 Hz, 10.0 Hz, H-6), 4.39 (d, 1H, J = 
11.4 Hz, CHH Bn), 4.46 (d, 1H, J = 11.3 Hz, CHH Bn), 4.60 - 4.70 (m, 2H, 2 x CHH Bn), 4.81 (s, 2H, 
2 x CHH Bn), 5.12 (d, 1H, J = 3.3 Hz, H-1), 5.30 (d, 0.5H, J = 3.3 Hz, H-1 diastereomer 1), 5.34 (d, 
0.5H, J = 3.3 Hz, H-1 diastereomer 2), 5.60 (s, 1H, CH benzylidene), 5.66 (s, 1H, CH benzylidene), 
6.82 (d, 4H, J = 8.6 Hz, Harom), 7.16 - 7.50 (m, 34H, Harom); TLC-MS: C80H89N2O16P + H+ requires 
1365.60, found 1365.6. 
benzyl 6-([N,N-diisopropylamino]-2-cyanoethyl-
phosphite)-hexyl-1-carbamate (5) 
To a cooled (0 oC) solution of 6-(benzyloxycarbonylamino)-1-
hexanol41 (3.02 g, 12.0 mmol) and DiPEA (2.51 ml, 14.4 mmol) 
in DCM (60 ml) was added chlorophosphite 11 (2.90 g, 12.2 
mmol). After stirring for 4 h, the reaction was washed with H2O 
(20 ml) and brine (20 ml), respectively. The organic layer was dried over Na2SO4 and 
concentrated in vacuo. After purification of the residue by column chromatography 
(EtOAc/PE/Et3N), phosphoramidite 5 (3.97 g, 8.79 mmol, 73%) was obtained as colourless oil. 
31P NMR (161.7 MHz, CD3CN): δ = 148.2; 1H NMR (400 MHz, CD3CN): δ = 1.18 (d, 6H, J = 2.7 Hz, 2 
x CH3 isopropylamino), 1.19 (d, 6H, J = 2.7 Hz, 2 x CH3 isopropylamino), 1.30 - 1.43 (m, 4H, 2 x 
CH2 aminohexanol), 1.48 (m, 2H, CH2 aminohexanol), 1.59 (m, 2H, CH2 aminohexanol), 2.65 (t, 
2H, J = 6.0 Hz, CH2 cyanoethyl), 3.10 (dd, 2H, J = 6.7 Hz, 13.2 Hz, CH2-N aminohexanol), 3.57 - 
3.68 (m, 4H, CH2-O aminohexanol), 2 x CH isopropylamino), 3.73 - 3.85 (m, 2H, CH2 cyanoethyl), 
5.06 (bs, 2H, CH2 benzylcarbamate), 5.64 (bs, 1H, NH), 7.31 - 7.42 (m, 5H, Harom); TLC-MS: 
C23H38N3O4P + H+ requires 452.27, found 452.1. 
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Glycerol phosphate dimer (21) 
To a solution of dibenzylglycerol 2 (163 mg, 0.600 mmol) in 
acetonitrile (4.0 ml), containing freshly activated MS3Å, were 
added DCI (0.25 M in acetonitrile, 9.6 ml) and phosphoramidite 3 
(0.2 M in acetonitrile, 3.9 ml). After stirring for 2 h, I2 (0.2 M in 
THF/pyridine 4/1, 9.0 ml) and H2O (1.0 ml) were added and the 
mixture was allowed to stir for 1 h. EtOAc (80 ml) was added and the mixture was washed with 
sat. aq. Na2S2O3 (30 ml), aqueous KHSO4 (0.5 M, 30 ml), sat. aq. NaHCO3 (30 ml) and brine (30 
ml) respectively. The organic layer was dried with Na2SO4 and concentrated in vacuo, after 
which the residue was redissolved in DCM (30 ml), containing freshly activated MS3Å. Et3SiH 
(0.97 ml, 6.0 mmol) and dichloroacetic acid (0.49 ml, 6.0 mmol) were added and the mixture 
stirred until the orange colour disappeared (~1 h), after which the mixture was diluted with 
DCM (20 ml) and washed with sat. aq. NaHCO3 (20 ml) and brine (20 ml), respectively. The 
organic layer was dried with Na2SO4, concentrated in vacuo and subsequently purified by 
column chromatography (MeOH/DCM), yielding dimer 21 (272 mg, 0.478 mmol, 80%, mixture 
of diastereoisomers) as colourless oil. 31P NMR (161.7 MHz): δ = -0.6, -0.7; 1H NMR (400 MHz): δ 
= 2.50 (t, 1H, J = 6.2 Hz, CH2 cyanoethyl), 2.54 (t, 1H, J = 6.2 Hz, CH2 cyanoethyl), 2.66 (bs, 1H, 
OH), 3.54 - 3.73 (m, 5H, CH glycerol, 2 x CH2 glycerol), 3.77 - 3.82 (m, 1H, CH glycerol), 4.03 - 
4.32 (m, 6H, CH2 cyanoethyl, 2 x CH2 glycerol), 4.51 - 4.66 (m, 6H, 3 x CH2 Bn), 7.25 - 7.35 (m, 
15H, Harom); 13C NMR (100 MHz): δ = 19.2, 19.3, 19.3 (CH2 cyanoethyl), 60.6, 60.7 (CH2 glycerol), 
61.9 (CH2 cyanoethyl), 66.3, 66.4 (CH2 glycerol), 67.4, 67.5, 67.6 (CH2 glycerol), 68.6 (CH2 
glycerol), 71.9, 72.0 (CH2 Bn), 72.1 (CH2 Bn), 73.4 (CH2 Bn), 76.2, 76.3 (CH glycerol), 77.3, 77.4, 
77.5 (CH glycerol), 116.4 (Cq cyanoethyl), 127.6 - 128.4 (CHarom), 137.7, 137.8, 137.8 (Cq Bn); 
HRMS: C30H37NO8P + Na+ requires 592.2071, found 592.2070. 
Glycerol phosphate trimer (22) 
To a solution of dimer 21 (229 mg, 0.402 mmol) in acetonitrile 
(4.0 ml), containing freshly activated MS3Å, were added DCI 
(0.25 M in acetonitrile, 6.4 ml) and phosphoramidite 3 (0.2 M in 
acetonitrile, 2.6 ml). After stirring for 2 h, more 3 (0.2 M in 
acetonitrile, 0.8 ml) was added and the mixture was allowed to 
react for another 2 hrs. I2 (0.2 M in THF/pyridine 4/1, 6.0 ml) and H2O (1.0 ml) were added and 
the mixture was stirred for 1 h. EtOAc (50 ml) was added and the mixture was washed with sat. 
aq. Na2S2O3 (20 ml), aqueous KHSO4 (0.5 M, 20 ml), sat. aq. NaHCO3 (20 ml) and brine (20 ml) 
respectively. The organic layer was dried with Na2SO4 and concentrated in vacuo, after which 
the residue was redissolved in DCM (20 ml), containing freshly activated MS3Å. Et3SiH (0.65 ml, 
4.0 mmol) and dichloroacetic acid (0.32 ml, 4.0 mmol) were added and the mixture stirred until 
the orange colour disappeared (~1.5 h), after which the mixture was diluted with DCM (30 ml) 
and washed with sat. aq. NaHCO3 (20 ml) and brine (20 ml) respectively. The organic layer was 
dried with Na2SO4, concentrated in vacuo and the residue purified by column chromatography 
(MeOH/DCM), yielding trimer 22 (286 mg, 0.330 mmol, 82%) as colourless oil. 31P NMR (161.7 
MHz): δ = -1.2, -1.2, -1.1, -1.0, -0.8, -0.8; 1H NMR (400 MHz): δ = 2.47 - 2.58 (m, 4H, 2 x CH2 
cyanoethyl), 2.97 (bs, 1H, OH), 3.53 - 3.80 (m, 7H, 3 x CH glycerol, 2 x CH2 glycerol), 4.03 - 4.32 
(m, 12H, 2 x CH2 cyanoethyl, 4 x CH2 glycerol), 4.48 - 4.66 (m, 8H, 4 x CH2 Bn), 7.25 - 7.33 (m, 
20H, Harom); 13C NMR (100 MHz): δ = 19.2 - 19.4 (CH2 cyanoethyl), 60.5, 60.6 (CH2 glycerol), 61.8 
- 62.1 (2 x CH2 cyanoethyl), 65.5 - 65.9 (2 x CH2 glycerol), 66.5 - 66.7 (CH2 glycerol), 67.4 - 67.7 
(CH2 glycerol), 68.6 - 68.7 (CH2 glycerol), 71.9 - 72.1 (3 x CH2 Bn), 73.4 (CH2 Bn), 75.3 - 75.5 (CH 
glycerol), 76.3 - 76.4 (CH glycerol), 77.4 - 77.6 (CH glycerol), 116.4 - 116.5 (2 x Cq cyanoethyl), 
127.6 - 128.4 (CHarom), 137.2, 137.7 - 137.8 (4 x Cq Bn); HRMS: C43H52N2O13P2 + Na+ requires 
889.2837, found 889.2843. 
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Glycerol phosphate tetramer (23) 
To a solution of trimer 22 (280 mg, 0.323 mmol) in acetonitrile 
(3.0 ml), containing freshly activated MS3Å, were added DCI 
(0.25 M in acetonitrile, 5.2 ml) and phosphoramidite 3 (0.2 M in 
acetonitrile, 2.6 ml). After stirring for 2 h, more 3 (0.2 M in 
acetonitrile, 1.3 ml) was added and the mixture was allowed to 
react for another 2 h. I2 (0.2 M in THF/pyridine 4/1, 6.5 ml) and H2O (1.0 ml) were added and 
the mixture was stirred for 1 h. EtOAc (50 ml) was added and the mixture was washed with sat. 
aq. Na2S2O3 (20 ml), aqueous KHSO4 (0.5 M, 20 ml), sat. aq. NaHCO3 (20 ml) and brine (20 ml) 
respectively. The organic layer was dried with Na2SO4 and concentrated in vacuo, after which 
the residue was redissolved in DCM (15 ml), containing freshly activated MS3Å. Et3SiH (0.52 ml, 
3.23 mmol) and dichloroacetic acid (0.27 ml, 3.23 mmol) were added and the mixture stirred 
until the orange colour disappeared (~2 h), after which the mixture was diluted with DCM (20 
ml) and washed with sat. aq. NaHCO3 (15 ml) and brine (15 ml) respectively. The organic layer 
was dried with Na2SO4, concentrated in vacuo and, subsequently, purified by column 
chromatography (MeOH/DCM), yielding tetramer 23 (305 mg, 0.262 mmol, 81%) as colourless 
oil. 31P NMR (161.7 MHz): δ = -1.3 - -0.8; 1H NMR (400 MHz): δ = 2.47 - 2.61 (m, 6H, 3 x CH2 
cyanoethyl), 3.20 (bs, 1H, OH), 3.56 - 3.58 (m, 2H, CH2 glycerol) 3.62 - 3.71 (m, 3H, CH glycerol, 
CH2 glycerol), 3.78 - 3.81 (m, 3H, 3 x CH glycerol), 4.03 - 4.30 (m, 18H, 3 x CH2 cyanoethyl, 6 x 
CH2 glycerol), 4.50 - 4.65 (m, 10H, 5 x CH2 Bn), 7.26 - 7.34 (m, 25H, Harom); 13C NMR (100 MHz): 
δ = 19.2 - 19.4 (3 x CH2 cyanoethyl), 60.4, 60.5 (CH2 glycerol), 61.8 - 62.2 (3 x CH2 cyanoethyl), 
65.5 - 66.0 (4 x CH2 glycerol), 66.5 - 66.7 (CH2 glycerol), 67.4 - 67.7 (CH2 glycerol), 68.6 (CH2 
glycerol), 71.9 - 72.1 (4 x CH2 Bn), 73.4 (CH2 Bn), 75.2 - 75.5 (2 x CH glycerol), 76.2 - 76.4 (CH 
glycerol), 77.4 - 77.6 (CH glycerol), 116.5 (3 x Cq cyanoethyl), 127.6 - 128.4 (CHarom), 137.2, 
137.7 - 137.9 (5 x Cq Bn); HRMS: C56H68N3O18P3 + Na+ requires 1186.3603, found 1186.3614. 
Glycerol phosphate pentamer (24) 
To a solution of tetramer 23 (283 mg, 0.243 mmol) in 
acetonitrile (3.0 ml), containing freshly activated MS3Å, were 
added DCI (0.25 M in acetonitrile, 4.0 ml) and phosphoramidite 
3 (0.2 M in acetonitrile, 2.5 ml). After stirring for 4 h, more 3 
(0.2 M in acetonitrile, 1.2 ml) was added and the mixture was 
allowed to react overnight. I2 (0.2 M in THF/pyridine 4/1, 5.0 ml) and H2O (1.0 ml) were added 
and the mixture was stirred for 1 h. EtOAc (30 ml) was added and the mixture was washed with 
sat. aq. Na2S2O3 (15 ml), aqueous KHSO4 (0.5 M, 15 ml), sat. aq. NaHCO3 (15 ml) and brine (15 
ml) respectively. The organic layer was dried with Na2SO4 and concentrated in vacuo, after 
which the residue was redissolved in DCM (15 ml), containing freshly activated MS3Å. Et3SiH 
(0.39 ml, 2.4 mmol) and dichloroacetic acid (0.20 ml, 2.4 mmol) were added and the mixture 
stirred until the orange colour disappeared (~3 h), after which the mixture was diluted with 
DCM (20 ml) and washed with, respectively, sat. aq. NaHCO3 (15 ml) and brine (15 ml). The 
organic layer was dried with Na2SO4, concentrated in vacuo and, subsequently, purified by 
column chromatography (MeOH/DCM), yielding pentamer 24 (221 mg, 0.151 mmol, 62%) as 
colourless oil. 31P NMR (161.7 MHz): δ = -1.3 - -0.8; 1H NMR (400 MHz): δ = 1.67 (bs, 1H, OH), 
2.45 - 2.64 (m, 8H, 4 x CH2 cyanoethyl), 3.55 - 3.58 (m, 2H, CH2 glycerol) 3.62 - 3.71 (m, 3H, CH 
glycerol, CH2 glycerol), 3.75 - 3.80 (m, 4H, 4 x CH glycerol), 4.04 - 4.28 (m, 24H, 4 x CH2 
cyanoethyl, 8 x CH2 glycerol), 4.49 - 4.51 (m, 2H, CH2 Bn), 4.56 - 4.66 (m, 10H, 5 x CH2 Bn), 7.26 - 
7.35 (m, 30H, Harom); 13C NMR (100 MHz): δ = 19.2 - 19.4 (4 x CH2 cyanoethyl), 60.2 - 60.4 (CH2 
glycerol), 62.0 - 62.5 (4 x CH2 cyanoethyl), 65.6 - 66.1 (6 x CH2 glycerol), 66.7 - 66.9 (CH2 
glycerol), 67.6 - 67.9 (CH2 glycerol), 68.5 (CH2 glycerol), 71.9 - 72.2 (5 x CH2 Bn), 73.4 (CH2 Bn), 
75.2 - 75.4 (3 x CH glycerol), 76.3 - 76.4 (CH glycerol), 77.4 - 77.5 (CH glycerol), 116.6 - 116.8 (4 
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x Cq cyanoethyl), 127.6 - 128.5 (CHarom), 137.2 - 137.3, 137.7 - 137.8 (6 x Cq Bn); HRMS: 
C69H84N4O23P4 + Na+ requires 1483.4369, found 1483.4377. 
Hexamer (25) 
To a solution of pentamer 24 (150 mg, 0.103 mmol) and 
kojibiose-glycerol phosphoramidite 5 (350 mg, 0.257 mmol) 
in acetonitrile (3.0 ml), containing freshly activated MS3Å, 
was added DCI (0.25 M in acetonitrile, 2.0 ml). After stirring 
the mixture overnight at room temperature, I2 (0.2 M in 
THF/pyridine 4/1, 2.5 ml) and H2O (1.0 ml) were added and 
the mixture was stirred for 1 h. The mixture was diluted with 
EtOAc (30 ml) and subsequently washed with sat. aq. Na2S2O3 
(10 ml), aqueous KHSO4 (0.5 M, 10 ml), sat. aq. NaHCO3 (10 
ml) and brine (10 ml). The organic layer was dried with Na2SO4 and concentrated in vacuo, after 
which the residue was purified by size-exclusion chromatography (sephadex LH-20, THF), 
followed by column chromatography (MeOH/DCM), yielding dimethoxytritylated intermediate 
25 (243 mg, 88.6 µmol, 86%) as white foam. 31P NMR (161.7 MHz): δ = -1.3 - -0.9; 1H NMR (400 
MHz): δ = 2.29 - 2.56 (m, 10H, 5 x CH2 cyanoethyl), 3.10 - 4.36 (m, 58H, 5 x CH2 cyanoethyl, 6 x 
CH glycerol, 12 x CH2 glycerol, 2 x OMe, 2 x H-2, 2 x H-3, 2 x H-4, 2 x H-5, 4 x H-6), 4.45 - 4.89 (m, 
18H, 9 x CH2 Bn), 4.92 - 4.94 (m, 1H, H-1), 5.10 - 5.13 (m, 1H, H-1), 5.52 (s, 1H, CH benzylidene), 
5.56 (s, 1H, CH benzylidene), 6.74 (d, 4H, J = 8.6 Hz, Harom), 7.14 - 7.48 (m, 64H, Harom); HRMS: 
[C143H158N5O40P5 + Na]2+ requires 1392.9478, found 1392.9489. 
Hexamer (26) 
Intermediate 25 (122 mg, 44.5 µmol) was dissolved in a 
mixture of DCM (2.5 ml) and MeOH (25 ml). After the addition 
of pyridinium para-toluenesulphonate (PPTS, 25 mg, 0.099 
mmol), the solution was allowed to stir overnight. Toluene (50 
ml) was added and the mixture was concentrated partially 
(leaving ~30 ml) under reduced pressure. Column 
chromatography of the solution (MeOH/DCM) yielded hexamer 
26 (76.0 mg, 31.1 µmol, 70%) as colourless oil. 31P NMR (161.7 
MHz): δ = -1.3 - -0.8; 1H NMR (400 MHz): δ = 1.79 (bs, 1H, OH), 
2.44 - 2.57 (m, 10H, 5 x CH2 cyanoethyl), 3.38 - 4.34 (m, 52H, 5 x CH2 cyanoethyl, 6 x CH glycerol, 
12 x CH2 glycerol, 2 x H-2, 2 x H-3, 2 x H-4, 2 x H-5, 4 x H-6), 4.51 - 4.65 (m, 12H, 6 x CH2 Bn), 
4.76 - 4.99 (m, 7H, 3 x CH2 Bn, H-1), 5.11 - 5.13 (m, 1H, H-1), 5.50 (s, 1H, CH benzylidene), 5.55 
(s, 1H, CH benzylidene), 7.15 - 7.17 (m, 3H, Harom), 7.26 - 7.40 (m, 48H, Harom), 7.42 - 7.47 (m, 4H, 
Harom); HRMS: [C122H140N5O38P5 + Na]2+ requires 1241.8824, found 1241.8837. 
Hexamer-spacer (27) 
To a solution of kojibiose substituted hexamer 26 
(124 mg, 51.0 µmol) and Z-
aminohexylphosphoramidite 5 (184 mg, 0.408 
mmol) in acetonitrile (3.0 ml), containing freshly 
activated MS3Å, was added DCI (0.25 M in 
acetonitrile, 2.0 ml). After stirring the mixture for 4 
h, acetonitrile (5.0 ml), I2 (0.2 M in THF/pyridine 
4/1, 3.1 ml) and H2O (1.0 ml) were added and the 
mixture stirred for 1 h. The mixture was diluted 
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with EtOAc (30 ml) and subsequently washed with sat. aq. Na2S2O3 (10 ml), aqueous KHSO4 (0.5 
M, 10 ml), sat. aq. NaHCO3 (10 ml) and brine (10 ml).  The organic layer was dried with Na2SO4 
and concentrated in vacuo, after which the residue was purified by size-exclusion 
chromatography (sephadex LH-20, MeOH/DCM), followed by column chromatography 
(MeOH/DCM), yielding compound 27 (111 mg, 39.5 µmol, 77%) as colourless oil. 31P NMR 
(161.7 MHz): δ = -1.3 - -0.9; 1H NMR (400 MHz): δ = 1.18 - 1.32 (m, 4H, 2 x CH2 hexylspacer), 
1.35 - 1.44 (m, 2H, CH2 hexylspacer), 1.53 - 1.62 (m, 2H, CH2 hexylspacer), 2.44 - 2.58 (m, 12H, 6 
x CH2 cyanoethyl), 3.05 - 3.13 (m, 2H, CH2-N hexylspacer), 3.56 - 4.33 (m, 56H, 6 x CH2 
cyanoethyl, 6 x CH glycerol, 12 x CH2 glycerol, CH2-O hexylspacer, 2 x H-2, 2 x H-3, 2 x H-4, 2 x H-
5, 4 x H-6), 4.50 - 4.59 (m, 12H, 6 x CH2 Bn), 4.74 - 5.15 (m, 10H, 4 x CH2 Bn, 2 x H-1), 5.53 (s, 1H, 
CH benzylidene), 5.55 (s, 1H, CH benzylidene), 7.16 - 7.18 (m, 3H, Harom), 7.26 - 7.39 (m, 53H, 
Harom), 7.43 - 7.48 (m, 4H, Harom); HRMS: [C139H163N7O43P6 + Na]2+ requires 1424.9497 found 
1424.9512. 
Teichoic acid (1) 
A solution of protected hexamer 27 (51.0 mg, 18.2 
µmol) in dioxane (5.0 ml) was diluted with ammonia 
(25% in H2O, 5.0 ml) and stirred overnight. The 
solution was concentrated in vacuo and the residue 
redissolved in H2O (2.0 ml). The solution was then 
eluted through a small column containing Amberlite 
Na+ resin. The volatiles were removed under reduced 
pressure and the residue lyophilized, yielding the partially protected intermediate (47.6 mg, 
100%) as amorphous white solid. A part of the intermediate (23.6 mg, 9.01 µmol) was dissolved 
in a mixture of dioxane (2.0 ml), H2O (2.0 ml) and AcOH (three drops). After the addition of 
Palladium black (~50 mg, 0.5 mmol), the mixture was allowed to stir for 5 days under a 
hydrogen atmosphere. The mixture was filtered, concentrated in vacuo, and purified by size 
exclusion chromatography (Sephadex HW40, 0.15M NH4HCO3). The purified residue was 
lyophilized twice before it was dissolved in H2O (2.0 ml) and eluted through a small column 
containing Amberlite Na+ resin. Cryodesiccation of the filtrate yielded deprotected teichoic acid 
1 (10.6 mg, 6.81 µmol, 76%) as amorphous white solid. 31P NMR (161.7 MHz, D2O): δ = 0.9 (1P), 
1.1 (1P), 1.2 (3P), 1.3 (1P); 1H NMR (600 MHz, D2O): δ = 1.36 - 1.40 (m, 4H, 2 x CH2 hexylspacer), 
1.59 - 1.66 (m, 4H, 2 x CH2 hexylspacer), 2.95 (t, 2H, J = 7.5 Hz, CH2-N hexylspacer), 3.37 - 3.41 
(m, 2H, 2 x H-5), 3.51 - 3.56 (m, 2H, CHH glycerol, H-2), 3.61 - 3.64 (m, 2H, CHH glycerol, H-2), 
3.70 - 4.01 (m, 37H, 5 x CH glycerol, 11 x CH2 glycerol, CH2-O hexylspacer, 2 x H-3, 2 x H-4, 4 x H-
6), 4.11 - 4.14 (m, 1H, CH glycerol), 5.11 (d, 1H, J = 3.7 Hz, H-1), 5.39 (d, 1H, J = 3.5 Hz, H-1); 13C 
NMR (150 MHz, D2O): δ = 25.4, 26.1, 27.6 (3 x CH2 hexylspacer), 30.4 (d, J = 6.7 Hz, CH2 
hexylspacer), 40.4 (CH2-N hexylspacer), 61.4, 61.4 (2 x C-6), 63.0 (CH2 glycerol), 65.5 (d, J = 5.1 
Hz, CH2 glycerol), 66.0 (d, J = 4.4 Hz, CH2 glycerol), 67.0 - 67.3 (9 x CH2 glycerol, CH2-O 
hexylspacer), 70.4 - 70.6 (4 x CH glycerol, 2 x C-5), 71.7 (d, J = 7.8 Hz, CH glycerol), 72.1 (C-2, C-
3), 72.7 (2 x C-4), 73.3 (C-3), 75.1 (C-2), 76.0 (t, J = 8.3 Hz, CH glycerol), 95.6 (C-1), 96.4 (C-1). 
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Teichoic acids (TAs) have been implied as antigenic structures1,2 and are therefore 
interesting targets for the development of (synthetic) vaccines against increasingly 
resistant Gram-positive species, such as E. faecalis3,4 and S. aureus.5,6 Because of the 
microheterogeneity of the TA in biological preparations, the establishment of 
structure activity relations has been troublesome and the biological activity of TA 
preparations from biological sources has been subject of debate.7-9 Therefore, a library 
of synthetic TA structures would be a powerful means to find the optimal length and 
substitution pattern of an antigen. In chapter two the solution phase synthesis of a 
(kojibiosyl) GTA hexamer is described.10 Although this approach can be used for a 
large scale synthesis of a single target compound, it is too labor intensive to generate a 
library of compounds. 
Automated solid phase synthesis is a well established methodology in oligonucleic 
acid synthesis, giving rapid access to (a library of) oligomers of desired length and 
composition.11-13 Because of their repetitive nature and connection through 
phosphodiester linkages, TAs resemble oligonucleic acids. Therefore, an automated 
solid phase approach, in combination with the chemistry described in chapter two, 
was deemed suitable to obtain a set of synthetic TA fragments. 
This chapter describes the synthesis of GTA oligomers up to a length of a 20-mer, 
using a commercial DNA synthesizer. Glucosylated fragments, a substitution that is 
found in several species of Staphylococcus and Bacillus,14,15 have been obtained using 
tailor-made glucosyl glycerol phosphoramidite. The library of synthetic TAs has been 
evaluated on their antigenicity in an opsonophagocytic inhibition assay (OPIA), 
revealing a length-activity relationship and a high inhibitory potential of two 
glucosylated hexaglycerol phosphates.16 
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Scheme 1. Building blocks for the automated solid phase TA synthesis. 
 
Results and Discussion 
Based on the state-of-the-art in nucleic acid synthesis, and as described in chapter 
two, cyanoethyl (CE) protected glycerol phosphoramidite building blocks were 
employed (see scheme 1).13 The alcohol functions of the building blocks, that were 
used for elongation, mediated glycosylation of glycerol alcohol 5.18-21 The resulting 
glucosylglycerol 6 was transformed into 2a/b as follows: iridium catalyzed 
isomerization of the allyl ether22 and subsequent cleavage of the resulting enol ether 
using iodine under basic conditions liberated the primary alcohol (7), which was 
capped with a DMT group to give compound 8. Next the silyl group was removed to 
provide alcohol 9, which was either phosphitylated to provide the phosphoramidite 
building block 2a, or treated with succinic anhydride to give the glucosylglycerol 
linker 2b.  
With the required building blocks in hand the next goal was to explore the 
automated solid phase TA oligomer synthesis (Scheme 2). As a first objective the 
assembly of spacer containing TA-hexamer 10 was investigated. To this end 
aminopropyl CPG was functionalized with succinyl glycerol 1b. Cleavage of the DMT 
group with 3% dichloroacetic acid (DCA) in toluene and concomitant determination of 
the loading led to a CPG with a loading of 100 µmol/g. At this point, the CPG-glycerol 
was installed into the ÄKTA™ oligopilot™ DNA/RNA synthesizer. For the coupling step 
the resin was treated with 5 equiv. of phosphoramidite 1a and 5-benzylthiotetrazole23 
(5-BTT, 22.5 equiv.) as activator in acetonitrile for 5 minutes. Oxidation of the 
intermediate phosphites was achieved with I2 in pyridine/H2O (1 min.), after which a 
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Scheme 2. Automated solid phase TA synthesis. 
 
capping step (N-methylimidazole/acetic anhydride (Ac2O)/2,6-lutidine) was 
introduced to cap any unreacted alcohol functionalities. To complete the elongation 
cycle the DMT-groups were removed with 3% DCA in toluene. The coupling efficiency 
using this protocol was generally > 98% as judged from the automatic DMT-count. In 
the 6th cycle of the hexamer assembly, the glycerol phosphoramidite 1a was replaced 
by benzyloxy-carbonyl aminohexanol phosphoramidite 3 to terminate the sequence.24 
Cleavage of the hexamer from the CPG using aqueous ammonia, and concomitant 
cyanoethyl removal liberated the partially protected TA-hexamer 10. Two different 
protocols for the purification of the partially protected oligomers were examined: RP-
HPLC purification and anion exchange chromatography followed by desalination. In 
the case of hexamer 10, the former protocol provided the desired oligomer in the 
highest yield (18% overall from aminopropyl CPG).  
There was a possibility that the phosphodiester linkages in the synthetic targets 
would be labile to base treatment, in analogy to the lability of RNA fragments.13 To 
investigate the base lability of the partially protected TA oligomer, hexamer 10 was 
subjected to a treatment with 25% aqueous ammonia for a prolonged period of time 
at room temperature and at 40 oC. No degradation of the hexamer could be detected 
by LCMS analysis after 24h at 40 oC, indicating that transesterification of the 
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phosphodiesters is not a significant risk under the reaction conditions used. Using the 
conditions described above, the following TA-oligomers were assembled: 
unsubstituted 10-mer 11, unsubstituted 14-mer 12, unsubstituted 20-mer 13 and 
mono glucosyl substituted 6-mers 14 and 15. TA-fragment 15 was assembled on CPG 
resin functionalized with glucosyl glycerol succinate 2b (loading 100 µmol/g). The 
results of the syntheses are summarized in Table 1, from which it becomes clear that 
the syntheses of the longer and substituted fragments proceeded with even greater 
efficiency than the assembly of hexamer 10. With increasing size of the oligomers, 
purification by ion exchange chromatography became more efficient than RP-HPLC 
purification. For TA 20-mer 13 and the glucosyl substituted hexamers 14 and 15 
LCMS analysis of the crude reaction products showed significant peak broadening and 
therefore these compounds were solely purified using the ion-exchange protocol. 
From the excellent yields of glucosyl substituted hexamers 14 and 15 it becomes clear 
that the glycerol C-2 glucose substitution had no adverse effect on the coupling 
efficiency of the building blocks used. Notably, the benzylidene functionality on the 
glucosyl moiety in 15 proved to be stable to the repeated detritylation steps. Global 
deprotection of the partially protected TA-fragments was achieved by hydrogenolysis 
of the benzyl ethers, Cbz-group and benzylidene functionality over palladium black 
followed by desalination (Scheme 2), uneventfully leading to TA-target structures 16-
21, as summarized in Table 1. The structure of the final products was confirmed by 
NMR spectroscopy and high resolution mass spectrometry. In the NMR spectra the 
relative ratio of the integrals of the peaks belonging to the spacer CH2 groups, the 
spacer CH2-N group and the terminal glycerol CH2-O moiety with respect to the bulk 
signal originating from of all other glycerol protons, provided proof for the integrity of 
the structures. 
To establish their antigenic activity, the prepared TA fragments (16-21) were 
tested in an opsonophagocytic inhibition assay, as described by Theilacker et al.3,4,16 
Also, kojibiosyl GTA hexamer 22 (figure 1), of which the synthesis is described in 
chapter two was taken along in this biological evaluation. In this assay, rabbit serum 
raised against purified E. faecalis LTA is used to kill E. faecalis bacteria. Blocking the 








1 10 18% 10% 16 (65%) 
2 11 29% 16% 17 (78%) 
3 12 8% 21% 18 (84%) 
4 13  24% 19 (95%) 
5 14  32% 20 (68%) 
6 15  36% 21 (86%) 
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opsonic antibodies in the serum with 
an inhibitor will lead to reduced 
killing. The inhibitory potential of the 
synthesized TA fragments at a 
concentration of 100 µg/mL is 
displayed in Figure 2, which shows 
that the smallest fragment tested, 
hexamer 16, is capable of inhibiting 
the opsonophagocytic killing. For the 
10-, 14- and 20-mer a length-
dependence is observed for the 
inhibitory potential. The longer the 
fragments are the better the binding is 
to the opsonic antibodies, resulting in 
reduced killing. Interestingly, the 
glucose substituted TA fragments 20 
and 21 were found to be relatively 
very potent inhibitors. This is striking 
since the α-glucosyl substituent is 
known from the TA from several 
Staphylococcus and Bacillus strains, 
but has not been found in E. faecalis 
TA.14,15 In contrast, hexamer 22, 
bearing the kojibiosyl substitution 
naturally occurring in E. faecalis TA, 
showed a significantly lower 
inhibition. Compound 21 proved to be 
the most active compound of the 
series, showing already some 
inhibition at a concentration of 0.8 
µg/ml. Furthermore, compound 21 
showed a comparable concentration-
inhibition relation as native LTA (see 
figure 3), which makes this a 
promising candidate for the future 
development of a vaccine comprising 




Figure 2. Results OPIA. α-LTA 12030 represents the 
killing of the serum at 1:200 dilution. LTA is used as 
a positive control. Compounds 16-22 are used in a 
concentration of 100 µg/ml. 
Figure 1. Hexamer 22. 
Figure 3. OPIA of LTA and compound 21 at different 
concentrations. 
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Conclusion 
This chapter describes the development of automated solid phase methodology to 
synthesize glycerol phosphate teichoic acid fragments. Tailor made glycerol 
phosphoramidite building blocks were used as building blocks in combination with a 
commercially available synthesizer, to produce partially protected TA fragments. With 
a full coupling cycle, taking approximately 15 minutes, a TA 20-mer was produced in 5 
hours. Functionalized glycerol phosphate building blocks could also be used in the 
synthesis to allow the assembly of substituted TA fragments. Employing the solid 
phase methodology, a small library of TA fragments was generated which was tested 
for activity in an opsonophagocytic inhibition assay, revealing a clear TA-length-
activity relationship. The assay also revealed glucosyl substituted TA-hexamers 20 
and 21 as promising lead candidates for future vaccine development. Interestingly, 
hexamer 22,containing the kojibiosyl substitution as found in E. Faecalis LTA, did not 
show any opsonophagocytic inhibition. Hexamer 21 can also be synthesized in a light 
fluorous fashion (see chapter five) and conjugated to several immunogenic carrier 
proteins (see chapter seven). 
Experimental section 
General Procedures and Material: All chemicals (Acros, Fluka, Merck, Schleicher & Schuell, 
Sigma-Aldrich, Genscript) were used as received and reactions were carried out dry, under an 
argon atmosphere, at ambient temperature, unless stated otherwise. Column chromatography 
was performed on Screening Devices silica gel 60 (0.040-0.063 mm). TLC analysis was 
conducted on HPTLC aluminium sheets (Merck, silica gel 60, F245). Compounds were visualized 
by UV absorption (245 nm), by spraying with 20% H2SO4 in ethanol or with a solution of 
(NH4)4Ce(SO4)4·2H2O 10 g/l, in 10% aqueous H2SO4 followed by charring at +/- 140 oC. Some 
unsaturated compounds were visualized b y spraying with a solution of KMnO4 (2%) and K2CO3 
(1%) in H2O. Optical rotation measurements ([α]D20) were performed on a Propol automated 
polarimeter (Sodium D-line, λ = 589 nm) with a concentration of 10 mg/ml (c = 1), unless stated 
otherwise. Infrared spectra were recorded on a Shimadzu FT-IR 8300 and are reported in cm-1. 
31P, 1H, and 13C NMR spectra were recorded with a Bruker AV 400 (161.7, 400 and 100 MHz 
respectively) or a Bruker DMX 600 (600 and 150 MHz respectively). NMR spectra were 
recorded in CDCl3 with chemical shift (δ) relative to tetramethylsilane, unless stated otherwise. 
High resolution mass spectra were recorded by direct injection (2 µl of a 2 µM solution in 
water/acetonitrile; 50/50; v/v and 0.1% formic acid) on a mass spectrometer (Thermo 
Finnigan LTQ Orbitrap) equipped with an electrospray ion source in positive mode (source 
voltage 3.5 kV, sheath gas flow 10, capillary temperature 250 oC) with resolution R = 60000 at 
m/z 400 (mass range m/z = 150-2000) and dioctylphthalate (m/z = 391.28428) as a lock mass. 
The high resolution mass spectrometer was calibrated prior to measurements with a calibration 
mixture (Thermo Finnigan). LC-MS analysis was conducted on a JASCO system using an Alltima 
C18 analytical column (5 µm particle size, flow:1.0 ml/min). Absorbance was measured at 214 
nm. Solvent system: A: water, B: MeCN, C:0.15 M NH4OAc in H2O , gradient (13.5 min): 80% A, 
10% B, 10% C → 0% A, 90% B, 10% C. This system was coupled to a PE/SCIEX API165 (Perkin-
Elmer) mass spectrometer.  
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Procedure for automated solid-phase synthesis, purification and global deprotection of 
TA oligomers: Aminopropyl modified controlled pore glass support (CPG, Fluka) was loaded 
with (glucosyl)glycerol succinates 1b or 2b and the loading was determined (loading: 100 
µmol/g CPG) using the method described by Pon.25 The automated syntheses were performed 
on a synthesizer (ӒKTA oligopilot plus, GE Healthcare) on a scale of 100-150 mg 
functionalized CPG (10-15 µmol glycerol derivative) and started off with acidolysis of the 
dimethoxytrityl ether using 3% dichloroacetic acid in toluene (15 ml, 3 min). After flushing with 
acetonitrile (5ml, 1 min), the resulting alcohol was reacted with phosphoramidites 1a or 2a (0.1 
M in MeCN, 5 eq) and 5-benzylthiotetrazole (BTT, 0.3M in MeCN, 22.5 eq) for 5 min using a 
cycled flow. After flushing with MeCN (5ml, 1 min), oxidation of the intermediate phosphite was 
performed using I2 (0.05 M in pyridine/H2O 9/1, 2ml, 1 min). A flushing step with MeCN (5ml, 1 
min) was followed by a capping step (1 ml of a 1/1 mixture of capping solution A (20 v/v% N-
methylimidazole in MeCN) and capping solution B (20 v/v% Ac2O, 15 v/v% 2,6-lutidine in 
MeCN for 12s). After flushing with MeCN (5ml, 1 min), a detritylation step was performed using 
the before mentioned cocktail and the molecule was elongated using phosphoramidites 1a or 
2a using the same set of reactions (coupling, oxidation, capping, detritylation). The average 
coupling efficiency was measured by quantitative UV-detection (400 nm) of the dimethoxytrityl 
cation during each detritylation step. When the desired length was obtained, spacer 
phosphoramidite 3 (0.1 M in MeCN, 2 x 5 eq, 2 x 5 min) was coupled to the CPG-TA-oligomer 
using 5-BTT (0.3M in MeCN, 2 x 22.5 eq) and, subsequently treated with I2 (0.05 M in 
pyridine/H2O 9/1, 2ml, 1 min), before it was released from the solid support using 25% NH4OH 
(10ml, 1h, the cyanoethyl groups are concomitantly released at this stage). The solvents were 
then removed in vacuo before the crude oligomer was purified using method A or B.  
Purification method A: RP-HPLC (Gilson preparative HPLC system; column: Alltima C18, 
particle size: 5 µm, dimensions: 10/250 mm; eluent: (10 mM NH4OAc in H2O)/MeCN, 9/1 → 
1/9, detection: UV (215 and 254 nm), the fractions containing product were collected and the 
solvents were removed under reduced pressure. Repeated lyophilization (twice) of the residue 
was followed by eluting the purified oligomer through a small column containing Dowex Na+ 
cation-exchange resin (type: 50WX4-200, stored on 0.5 M NaOH in H2O, flushed with H2O and 
MeOH before use). Lyophilization gave the partially protected oligomer of which the integrity 
and purity was confirmed by LC-MS, HRMS and NMR (1H, 13C, 31P) analysis. 
Purification method B: Anion-exchange chromatography (device: ӒKTA Explorer, GE 
Healthcare; column: Q-sepharose HR16/10, GE Healthcare; eluent: buffer A (50 mM NaOAc, 50 
mM NaClO4), buffer B (50mM NaOAc, 500mM NaClO4), gradient 1/0 → 0/1) followed by 
desalination using size-exclusion chromatography (Sephadex G10 (hexamer 10) or Sephadex 
G25 (all other oligomers), GE Healthcare, dimensions: 26/60 mm, eluent: 0.15 M NH4HCO3). The 
purified oligomer was lyophilized twice before it was eluted through a small column containing 
Dowex Na+ cation-exchange resin (type: 50WX4-200, stored on 0.5 M NaOH in H2O, flushed with 
H2O and MeOH before use). Lyophilization gave the partially protected oligomer of which the 
integrity and purity was confirmed by LC-MS, HRMS and NMR (1H, 13C, 31P) analysis. 
Deprotection: The oligomers (1-5 µmol) were dissolved in H2O (3-6 ml) together with AcOH 
(3-6 drops) and treated for 3 days with Palladium black (20-40 mg)/H2. Subsequently, the 
mixture was filtered and the solvents removed under reduced pressure before the residue was 
purified by size-exclusion chromatography (Sephadex HW40, Toyopearl, dimensions: 16/60 
mm, eluent: 0.15 M Et3NHOAc or 0.15 M NH4OAc). After repeated lyophilization, the purified 
product was eluted through a small column containing Dowex Na+ cation-exchange resin (type: 
50WX4-200, stored on 0.5 M NaOH in H2O, flushed with H2O and MeOH before use). 
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Lyophilization gave the partially protected oligomer of which the integrity and purity was 
confirmed by HRMS and NMR (1H, 13C, 31P) analysis. 
1-O-(Triethylammonium succinate)-2-O-benzyl-3-O-(4,4’-dimethoxytrit-
yl)-sn-glycerol (1b) 
To a solution of 2-O-benzyl-3-O-(4,4’-dimethoxytrityl)-sn-glycerol (2.50 g, 
5.16 mmol) and Et3N (7.87 ml, 56.8 mmol) in DCM (35 ml) was added succinic 
anhydride (2.58 g, 25.8 mmol). The mixture was stirred for 10 min at 0 oC, 
followed by the addition of a catalytic amount of DMAP. After stirring 2h at 
RT, the mixture was diluted with DCM (80 ml) and washed with 0.5 M HCl (50 
ml), sat. aq. NaHCO3 (40 ml) and brine (40 ml). The organic layer was dried 
over Na2SO4 and concentrated under reduced pressure. Purification of the 
residue by column chromatography (MeOH/DCM/Et3N), afforded glycerol succinate 1b (3.26 g, 
4.75 mmol, 92%) as white foam. [α]D20 (MeOH): +8.2; IR: 829, 1034, 1177, 1250, 1609, 1736, 
2343, 2359; 1H NMR (400 MHz, CD3CN): δ = 1.11 (t, 9H, J = 7.3 Hz, 3 x CH3 Et3N), 2.35 - 2.45 (m, 
4H, 2 x CH2 succinyl), 2.85 (q, 6H, J = 7.3 Hz, 14.6 Hz, 3 x CH2 Et3N), 3.14 - 3.22 (m, 2H, 2 x CHH 
glycerol), 3.72 - 3.74 (m, 7H, 2 x OMe, CH glycerol), 4.15 - 4.23 (m, 2H, 2 x CHH glycerol), 4.57 (s, 
2H, CH2 Bn), 6.83 (d, 4H, J = 8.8 Hz, Harom), 7.17 - 7.33 (m, 12H, Harom), 7.44 (d, 2H, J = 7.6 Hz, 
Harom); 13C NMR (100 MHz, CD3CN): δ = 9.2 (3 x CH3 Et3N), 30.9 (CH2 succinyl), 31.7 (CH2 
succinyl), 45.9 (3 x CH2 Et3N), 55.8 (2 x OMe), 63.7 (CH2 glycerol), 64.4 (CH2 glycerol), 72.6 (CH2 
Bn), 77.2 (CH glycerol), 86.8 (Cq DMT), 113.9 (CHarom), 127.6, 128.4, 128.6, 128.7, 128.8, 129.1, 
130.8 (CHarom), 136.9, 139.7, 146.1, 159.5 (Cq Bn, 4 x Cq DMT), 173.8, 176.9 (2 x CO succinate); 
HRMS (free acid): C35H36O8 + Na+ requires 607.2302, found 607.2298.  
1-O-(tert-Butyldiphenylsilyl)-2-O-(2,3-di-O-benzyl-4,6-O-
benzylidene-α-D-glucopyranosyl)-3-O-allyl-sn-glycerol (6) 
A solution of glucose donor 4 (2.70 g, 5.00 mmol), TTBP (2.86 g, 
11.5 mmol) and Ph2SO (1.11 g, 5.50 mmol) in freshly distilled DCM 
(100 ml), together with activated MS 3Å, was stirred under argon at 
RT for 30 min. The mixture was then cooled to -75 oC and stirred 
for another 15 min. After the addition of Tf2O (0.93 ml, 5.5 mmol) the mixture was stirred for 45 
min at -75 oC and, subsequently, glycerol acceptor 5 (2.22 g, 5.99 mmol) was added. After 
stirring for 2 hrs at -75 oC, the mixture was allowed to warm to room temperature overnight. 
The reaction was by the addition of moist Et3N (3.4 ml, 25 mmol) and stirred for 30 min. After 
washing with sat. aq. NaHCO3 (30 ml) and brine (30 ml), the organic layer was dried over MgSO4 
and concentrated in vacuo. The resulting oil was dissolved in pyridine (50 ml) and Ac2O (10 ml) 
and stirred for 2 hrs. The solvents were removed in vacuo before the residue was redissolved in 
Et2O (125 ml) and washed with H2O (2 x 40 ml) and brine (40 ml). The organic layer was dried 
over MgSO4 and the solvent removed under reduced pressure. Column chromatography 
(EtOAc/PE) of the residue gave α-glucoside 6 (3.10 g, 3.87 mmol, 78%), as a colourless oil with 
a minor amount (< 7%, based on 1H-NMR analysis) of the β-product. [α]D20 (CHCl3): +4.2; IR: 
737, 1088, 1369, 1454, 1751, 2855, 2924; 1H NMR (400 MHz, α-anomer): δ = 1.05 (s, 9H, t-Bu 
TBDPS), 3.53 - 3.69 (m, 4H, CH glycerol, CHH glycerol, H-2, H-6), 3.71 - 3.81 (m, 3H, 3 x CHH 
glycerol), 3.86 - 3.92 (m, 1H, H-5), 3.99 - 4.04 (m, 5H, CH2 allyl, H-3, H-4, H-6), 4.74 (d, 1H, J = 
12.0 Hz, CHH Bn), 4.78 (d, 1H, J = 11.8 Hz, CHH Bn), 4.80 (d, 1H, J = 11.2 Hz, CHH Bn), 4.87 (d, 
1H, J = 11.3 Hz, CHH Bn), 5.16 (dd, 1H, J = 1.3 Hz, 10.4 Hz, CHH allyl), 5.26 (dd, 1H, J = 1.6 Hz, 
17.2 Hz, CHH allyl), 5.26 (d, 1H, J = 3.8 Hz, H-1), 5.50 (s, 1H, CH benzylidene), 5.88 (ddd, 1H, J = 
5.2 Hz, 10.4 Hz, 22.4 Hz, CH allyl), 7.24 - 7.46 (m, 21H, Harom), 7.65 - 7.68 (m, 4H, Harom); 13C NMR 
(100 MHz, α-anomer): δ = 19.2 (Cq t-Bu, 26.8 (3 x CH3 TBDPS), 62.4 (C-5), 63.9 (CH2 glycerol), 
68.8 (C-6), 70.8 (CH2 glycerol), 72.3 (CH2 allyl), 72.5 (CH2 Bn), 75.2 (CH2 Bn), 76.7, 78.2 (C-3, C-
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4), 79.0 (CH glycerol), 82.1 (C-2), 97.2 (C-1), 101.2 (CH benzylidene), 116.9 (CH2 allyl), 126.0 - 
129.7 (CHarom), 133.1, 133.2 (2 x Cq phenyl), 134.6 (CH allyl), 135.5 (CHarom), 137.5, 138.3, 138.8 
(2 x Cq Bn, Cq benzylidene); HRMS: C49H56O8Si + Na+ requires 823.3637, found 823.3631. 
1-O-(tert-Butyldiphenylsilyl)-2-O-(2,3-di-O-benzyl-4,6-O-
benzylidene-α-D-glucopyranosyl)-sn-glycerol (7) 
A solution of glycoside 6 (0.400 g, 0.499 mmol) in freshly distilled 
THF (3.0 ml) was stirred under argon for 30 min. After the addition 
of Ir(COD)(Ph2MeP)2PF6 (0.042 g, 10 mol%) the solution turned red 
and the mixture was purged with H2 (g) until the solution turned 
colourless again (~30s). After stirring under argon for 2 h, the mixture was diluted with THF 
(7.0 ml) and sat. aq. NaHCO3 (25 ml). Upon addition of I2 (0.190 g, 0.75 mmol), the mixture was 
allowed to stir for 1.5 h at room temperature. The mixture was then diluted with EtOAc (100 
ml) and washed with, respectively, sat. aq. NaS2O3 (2 x 20 ml) and brine (20 ml). The organic 
layer was dried over MgSO4 and concentrated in vacuo. Column chromatography 
(EtOAc/toluene/PE) afforded 7 (281 mg, 0.369 mmol, 74%) as a colourless oil. [α]D20 (CHCl3): 
+3.2; IR: 737, 995, 1030, 1076, 1369, 1736, 2858, 2932; 1H NMR (400 MHz): δ = 1.05 (s, 9H, t-Bu 
TBDPS), 3.17 (bs, 1H, OH), 3.53 - 3.68 (m, 5H, 2 x CHH glycerol, H-2, H-4, H-6), 3.72 - 3.90 (m, 
4H, 2 x CHH glycerol, CH glycerol, H-5), 3.99 (dd, 1H, J = 4.9 Hz, 10.1 Hz, H-6), 4.04 (at, 1H, J = 9.3 
Hz, H-3), 4.70 (d, 1H, J = 11.6 Hz, CHH Bn), 4.78 (d, 1H, J = 11.2 Hz, CHH Bn), 4.86 (d, 1H, J = 3.9 
Hz, H-1), 4.88 (d, 1H, J = 11.7 Hz, CHH Bn), 4.93 (d, 1H, J = 11.2 Hz, CHH Bn), 5.50 (s, 1H, CH 
benzylidene), 7.25 - 7.46 (m, 21H, Harom), 7.63 - 7.66 (m, 4H, Harom); 13C NMR (100 MHz): δ = 
19.1 (Cq t-Bu, 26.8 (3 x CH3 TBDPS), 62.7 (C-5), 62.9 (CH2 glycerol), 63.9 (CH2 glycerol), 68.8 (C-
6), 74.5 (CH2 Bn), 75.2 (CH2 Bn), 78.9 (C-2, C-3), 81.8 (CH glycerol), 82.3 (C-4), 99.6 (C-1), 101.2 
(CH benzylidene), 126.0 - 129.8 (CHarom), 133.0, 133.1 (2 x Cq phenyl), 135.5 (CHarom), 137.3, 





To a solution of alcohol 7 (4.68 g, 6.14 mmol) in DCM (50 ml) were 
added, respectively, DiPEA (1.61 ml, 9.22 mmol) and DMT-Cl (2.50 
g, 7.37 mmol). The mixture was allowed to stir overnight after 
which it was quenched by the addition of MeOH (5.0 ml). After stirring 15 min the mixture was 
washed with H2O (20 ml) and brine (20 ml) and the organic layer was dried (Na2SO4) and 
concentrated in vacuo. Purification of the residue by column chromatography (EtOAc/PE/Et3N) 
yielded 8 (6.51 g, 6.12 mmol, 100%) as white foam. [α]D20 (MeOH): +17.2; IR: 1034, 1088, 1250, 
1508, 2343, 2361; 1H NMR (400 MHz): δ = 0.97 (s, 9H, t-Bu TBDPS), 3.30 (dd, 1H, J = 6.2 Hz, 9.8 
Hz, CHH glycerol), 3.46 (dd, 1H, J = 4.4 Hz, 10.0 Hz), 3.52 - 3.64 (m, 3H, H-2, H-4, H-6), 3.72 - 3.80 
(m, 8H, 2 x CHH glycerol, 2 x OMe), 3.90 - 3.97 (m, 1H, H-5), 4.00 - 4.07 (m, 3H, CH glycerol, H-3, 
H-6), 4.59 (d, 1H, J = 12.4 Hz, CHH Bn), 4.64 (d, 1H, J = 12.0 Hz, CHH Bn), 4.79 (d, 1H, J = 11.6 Hz, 
CHH Bn), 4.87 (d, 1H, J = 11.2 Hz, CHH Bn), 5.21 (d, 1H, J = 3.6 Hz, H-1), 5.50 (s, 1H, CH 
benzylidene), 6.74 - 6.76 (m, 4H, Harom), 7.12 - 7.46 (m, 30H, Harom), 7.58 - 7.62 (m, 4H, Harom); 
13C NMR (100 MHz): δ = 19.1 (Cq t-Bu, 26.8 (3 x CH3 TBDPS), 55.1 (2 x OMe), 62.6 (C-5), 64.1 (2 
x CH2 glycerol), 68.9 (C-6), 72.5 (CH2 Bn), 75.2 (CH2 Bn), 77.5, 78.3 (CH glycerol, C-3), 78.9 (C-2), 
82.2 (C-4), 86.5 (Cq DMT), 97.2 (C-1), 101.3 (CH benzylidene), 113.1 (CHarom), 126.1 - 130.1 
(CHarom), 133.2, 133.3 (2 x Cq phenyl), 135.5 (CHarom), 136.0, 136.0, 137.6, 138.1, 138.8 (2 x Cq 
Bn, Cq benzylidene, 5 x Cq DMT); HRMS: C67H70O10Si + H+ requires 1063.4811, found 1063.4804. 
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2-O-(2,3-di-O-Benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-3-
O-(4,4’-dimethoxytrityl)-sn-glycerol (9) 
Compound 8 (6.33 g, 5.95 mmol) was dissolved in THF (60 ml) and 
after addition of TBAF (1M in THF, 10.7 ml) stirred overnight. After 
evaporation of the solvents under reduced pressure the resulting oil 
was purified by column chromatography (EtOAc/PE/Et3N), giving 
alcohol 9 (4.37 g, 5.30 mmol, 89%) as a white foam. [α]D20 (MeOH): +29.2; IR: 1032, 1076, 1250, 
1508, 1609, 2343, 2361; 1H NMR (400 MHz): δ = 2.40 (bs, 1H, OH), 3.28 (dd, 1H, J = 6.3 Hz, 9.8 
Hz, CH2 glycerol), 3.34 (dd, 1H, J = 5.4 Hz, 9.9 Hz, CH2 glycerol), 3.54 (dd, 1H, J = 3.8 Hz, 9.4 Hz, 
H-2), 3.61 (at, 1H, J = 9.5 Hz, H-4), 3.66 - 3.77 (m, 9H, CH2 glycerol, H-6, 2 x OMe), 3.87 (ddd, 1H, 
J = 3.5 Hz, 6.1 Hz, 11.8 Hz, CH glycerol), 3.98 (dd, 1H, J = 4.8 Hz, 10.0 Hz, H-5), 4.02 (at, 1H, J = 9.3 
Hz, H-3), 4.25 (dd, 1H, J = 4.9 Hz, 10.2 Hz, H-6), 4.59 (d, 1H, J = 12.1 Hz, CH2 Bn), 4.68 (d, 1H, J = 
12.1 Hz, CH2 Bn), 4.80 (d, 1H, J = 11.3 Hz, CH2 Bn), 4.90 (d, 1H, J = 11.3 Hz, CH2 Bn), 4.97 (d, 1H, J 
= 3.9 Hz, H-1), 5.54 (s, 1H, CH benzylidene), 6.80 (4, 4H, J = 8.9 Hz, Harom), 7.16 - 7.36 (m, 20H, 
Harom), 7.43 - 7.49 (m, 4H, Harom); 13C NMR (100 MHz): δ = 55.1 (2 x OMe), 62.9 (C-5), 63.3 (CH2 
glycerol), 63.9 (CH2 glycerol), 68.9 (C-6), 73.2 (CH2 Bn), 75.3 (CH2 Bn), 78.4 (C-3), 78.8 (C-2), 
78.8 (CH glycerol), 82.0 (C-4), 86.6 (Cq DMT), 97.4 (C-1), 101.2 (CH benzylidene), 113.1 
(CHarom), 126.0 - 130.0 (CHarom), 133.0 (2 x Cq phenyl), 135.8, 137.3, 137.9, 138.7, 144.6, 158.5 (2 





To a cooled (0 oC) solution of 9 (1.24 g, 1.50 mmol) and DiPEA 
(0.42 ml, 2.4 mmol) in freshly distilled DCM (30 ml) was added 
2-cyanoethyl-N,N-diisopropylchlorophosphoramidite (0.462 g, 
1.95 mmol). After stirring overnight, the reaction was quenched 
by the addition of H2O (2.0 ml) and washed with H2O (10 ml) 
and brine (10 ml), respectively. The organic layer was dried over Na2SO4 and concentrated in 
vacuo. Purification of the residue by column chromatography (EtOAc/PE/Et3N) gave 
phosphoramidite 2a (1.50 g, 1.46 mmol, 98%) as white foam. 31P NMR (161.7 MHz, CD3CN): δ = 
149.0, 149.3 (diastereoisomers); 1H NMR (400 MHz, CD3CN): δ = 1.07 - 1.15 (m, 12H, 4 x CH3 
isopropylamino), 2.46 - 2.50 (m, 2H, CH2 cyanoethyl), 3.11 - 3.29 (m, 2H, 2 x CH 
isopropylamino), 3.51 - 4.27 (m, 19H, CH2 cyanoethyl, 2 x OMe, 2 x CH2 glycerol, CH glycerol, H-
2, H-3, H-4, H-5, H-6, H-6), 4.57 - 4.62 (m, 2H, CH2 Bn), 4.79 (m, 2H, CH2 Bn), 5.15 (m, 1H, H-1), 
5.60 (s, 1H, CH benzylidene), 6.80 (d, 4H, J = 8.1 Hz, Harom), 7.11 - 7.47 (m, 24H, Harom); HRMS: 




To a solution of 9 (3.21 g, 3.89 mmol) and Et3N (5.93 ml, 42.8 
mmol) in DCM (40 ml) was added succinic anhydride (1.95 g, 
19.45 mmol). A catalytic amount of DMAP was added and the 
reaction was stirred for 100 min. The mixture was diluted with 
DCM (50 ml) and washed with H2O (2 x 50 ml) after which the 
organic layer was concentrated under reduced pressure. The 
triethylammonium salt of succinyl ester 2b (3.93 g, 3.83 mmol, 
99%) was obtained as white foam. [α]D20 (MeOH): +31.6 o; IR: 829, 1034, 1250, 1508, 1738, 
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2343, 2361; 1H NMR (400 MHz, CD3CN): δ = 1.11 (t, 9H, J = 7.3 Hz, 3 x CH3 Et3NH), 2.36 - 2.39 
(m, 2H, CH2 succinyl), 2.47 - 2.50 (m, 2H, CH2 succinyl), 2.82 (q, 6H, J = 7.3 Hz, 14.6 Hz, 3 x CH2 
Et3N), 3.21 (m, 2H, CH2 glycerol), 3.56 (dd, 1H, J = 3.7 Hz, 9.3 Hz, H-2), 3.64 (at, 1H, J = 9.5 Hz, H-
4), 3.69 - 3.75 (m, 7H, 2 x OMe, H-6), 3.87 (at, 1H, J = 9.3 Hz, H-3), 3.94 - 4.00 (m, 2H, CH glycerol, 
H-5), 4.15 (dd, 1H, J = 6.4 Hz, 11.6 Hz, CH2 glycerol), 4.23 - 4.26 (m, 2H, CH2 glycerol, H-6), 4.58 
(s, 2H, CH2 Bn), 4.79 (s, 2H, CH2 Bn), 5.10 (d, 1H, J = 3.7 Hz, H-1), 5.61 (s, 1H, CH benzylidene), 
6.84 (d, 4H, J = 8.9 Hz, Harom), 7.14 - 7.50 (m, 24H, Harom); 13C NMR (100 MHz, CD3CN): δ = 9.5 (3 
x CH3 Et3N), 30.9 (CH2 succinyl), 31.7 (CH2 succinyl), 45.9 (3 x CH2 Et3N), 55.9 (2 x OMe), 63.7 
(CH2 glycerol), 63.7 (C-5), 65.0 (CH2 glycerol), 69.5 (C-6), 73.4 (CH2 Bn), 75.3 (CH2 Bn), 75.7 (CH 
glycerol), 79.0 (C-3), 80.3 (C-2), 82.6 (C-4), 87.3 (Cq DMT), 114.1 (CHarom), 127.2 - 131.0 
(CHarom), 136.7, 136.8, 138.9, 139.4, 140.1, 146.0, 159.6 (2 x Cq Bn, 4 x Cq DMT, Cq benzylidene), 
174.0, 176.8 (2 x CO succinate); HRMS (as free acid): C55H56O13 + Na+ requires 947.3613, found 
947.3627. 
Hexaglycerolphosphate (16) 
Synthesis on 10 µmol scale (100 mg glycerol-CPG). 
Average coupling efficiency: 98.3% (5 couplings). 
Purification method A gave the semiprotected 
hexamer (10) as white amorphous solid (3.4 mg, 1.8 
µmol, 18%). Method B (synthesis on 15 µmol scale) gave 10 as white amorphous solid (2.7 mg, 
1.5 µmol, 10%). LC-MS (gradient: 10 mM NH4OAc in H2O/acetonitrile 1/0  1/9 in 13.5 min): 
r.t. 5.85 min, C74H99NO33P6 + H+ requires 1716.5 found 1716.6.; 31P-NMR (162 MHz, D2O): δ = 1.0 
(4P), 1.1 (1P), 1.2 (1P); 1H-NMR (600 MHz, D2O): δ = 1.12 (m, 4H, 2 x CH2 hexylspacer), 1.26 (m, 
2H, CH2 hexylspacer), 1.42 (m, 2H, CH2 hexylspacer), 2.92 (t, 2H, J = 6.9 Hz, CH2-N hexylspacer), 
3.50 - 3.61 (m, 3H, CH glycerol, CH2 glycerol), 3.68 - 3.93 (m, 29H, CH2-O hexylspacer, 11 x CH2 
glycerol, 5 x CH glycerol), 4.41 - 4.54 (m, 12H, 6 x CH2 Bn), 4.92 (s, 2H, CH2 benzylcarbamate), 
7.16 - 7.32 (m, 35H, Harom); 13C NMR (150 MHz, D2O): δ = 25.6, 26.5, 29.7, 30.7 (4 x CH2 
hexylspacer), 41.3 (CH2-N hexylspacer), 61.4 (CH2 glycerol), 65.1, 65.4, 65.5 - 65.7, 67.2, 67.6 
(CH2-O hexylspacer, 11 x CH2 glycerol, CH2 benzylcarbamate), 72.7, 73.0 (6 x CH2 Bn), 78.0 - 
78.1 (5 x CH glycerol), 79.2 (CH glycerol), 128.6 - 129.7 (CHarom), 137.5, 138.4 - 138.5 (6 x Cq Bn, 
Cq benzylcarbamate), 159.2 (Cq benzylcarbamate); HRMS: [C74H99NO33P6 + 2H]2+ requires 
858.7335, found 858.7340; Deprotection: The semiprotected hexamer (10, 4.7 mg, 2.5 µmol) 
was deprotected using the standard procedure yielding hexamer 16 (1.9 mg, 1.6 µmol, 65%) as 
an amorphous off-white solid. 31P-NMR (162 MHz, D2O): δ = 1.2 (1P), 1.2 (3P), 1.3 (2P); 1H-NMR 
(600 MHz): δ = 1.36 - 1.38 (m, 4H, 2 x CH2 hexylspacer), 1.58 - 1.64 (m, 4H, 2 x CH2 hexylspacer), 
2.94 (at, 2H, J = 7.5 Hz, CH2-N hexylspacer), 3.54 (dd, 1H, J = 6.1 Hz, 11.8 Hz, CHH glycerol), 3.62 
(dd, 1H, J = 4.2 Hz, 11.8 Hz, CHH glycerol), 3.78 - 3.91 (m, 25H, CH2-O hexylspacer, 11 x CH2 
glycerol, CH glycerol), 3.96 - 4.01 (m, 5H, 5 x CH glycerol); 13C NMR (150 MHz, D2O): δ = 25.4, 
26.1, 27.6, 30.3 (4 x CH2 hexylspacer), 40.4 (CH2-N hexylspacer), 63.0 (CH2 glycerol), 66.9 - 67.3 
(CH2-O hexylspacer, 11 x CH2 glycerol), 70.4 - 70.6, 71.7 (6 x CH glycerol); HRMS: C24H57NO31P6 
+ H+ requires 1042.1413, found 1042.1425. 
10-mer (17) 
Synthesis on 10 µmol scale (100 mg glycerol-CPG). 
Average coupling efficiency: 98.0% (9 couplings). 
Purification method A gave the semiprotected 
decamer (11) as white amorphous solid (8.5 mg, 2.9 
µmol, 29%). Method B (synthesis on 15 µmol scale) 
gave the semiprotected decamer (11) as white amorphous solid (7.1 mg, 2.4 µmol, 16%). LC-MS 
(gradient: 10 mM NH4OAc in H2O/acetonitrile 1/0  1/9 in 13.5 min): r.t. 6.15 min, 
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[C114H151NO53P10 + 2H]2+ requires 1346.8 found 1346.8.; 31P-NMR (162 MHz, D2O): δ = 1.0 (8P), 
1.1 (1P), 1.2 (1P); 1H-NMR (600 MHz, D2O): δ = 1.03 (m, 2H, CH2 hexylspacer), 1.08 (m, 2H, CH2 
hexylspacer), 1.20 (m, 2H, CH2 hexylspacer), 1.38 (m, 2H, CH2 hexylspacer), 2.86 (m, 2H, CH2-N 
hexylspacer), 3.49 - 3.59 (m, 3H, CH glycerol, CH2 glycerol), 3.64 - 3.92 (m, 49H, CH2-O 
hexylspacer, 19 x CH2 glycerol, 9 x CH glycerol), 4.33 - 4.47 (m, 20H, 10 x CH2 Bn), 4.82 (bs, 2H, 
CH2 benzylcarbamate), 7.00 - 7.22 (m, 55H, Harom); 13C NMR (150 MHz, D2O): δ = 25.7, 26.6, 29.8, 
30.7 (4 x CH2 hexylspacer), 41.2 (CH2-N hexylspacer), 61.3 (CH2 glycerol), 65.1, 65.5 - 65.6, 67.1, 
67.5 (CH2-O hexylspacer, 19 x CH2 glycerol, CH2 benzylcarbamate), 72.6, 72.8 - 72.9 (10 x CH2 
Bn), 78.0 - 78.1 (9 x CH glycerol), 79.2 (CH glycerol), 128.6 - 129.6 (CHarom), 138.4 - 138.5 (10 x 
Cq Bn, Cq benzylcarbamate) 158.9 (Cq benzylcarbamate); HRMS: [C114H151NO53P10 + 2Na]2+ 
requires 1369.3173, found 1369.3181; Deprotection: The partially protected decamer (11, 7.10 
mg, 2.44 µmol) was deprotected using the standard procedure yielding decameric GTA 17 (3.6 
mg, 1.9 µmol, 78%) as an amorphous off-white solid. 31P-NMR (162 MHz, D2O): δ = 1.2 (1P), 1.3 
(7P), 1.3 (2P); 1H-NMR (600 MHz, D2O): δ = 1.36 - 1.39 (m, 4H, 2 x CH2 hexylspacer), 1.58 - 1.65 
(m, 4H, 2 x CH2 hexylspacer), 2.95 (at, 2H, J = 7.5 Hz, CH2-N hexylspacer), 3.55 (dd, 1H, J = 6.1 Hz, 
11.8 Hz, CHH glycerol), 3.62 (dd, 1H, J = 4.2 Hz, 11.8 Hz, CHH glycerol), 3.72 (m, 1H, CHH 
glycerol), 3.80 - 4.02 (m, 49H, CH2-O hexylspacer, 18 x CH2 glycerol, 1 x CHH glycerol, 10 x CH 
glycerol); 13C NMR (150 MHz, D2O): δ = 25.4, 26.0, 27.5, 30.3 (4 x CH2 hexylspacer), 40.3 (CH2-N 
hexylspacer), 63.0 (CH2 glycerol), 66.9 - 67.3 (CH2-O hexylspacer, 19 x CH2 glycerol), 70.4 - 70.5, 
71.3, 71.6, 71.7 (10 x CH glycerol); HRMS: C36H85NO51P10 + H+ requires 1658.1537, found 
1658.1553. 
14-mer (18) 
Synthesis on 10 µmol scale (100 mg glycerol-CPG). 
Average coupling efficiency: 98.1% (13 couplings). 
Purification method A gave the semiprotected 14-mer 
(12) as white amorphous solid (3.0 mg, 0.75 µmol, 
8%). Method B gave the semiprotected 14-mer (12) as 
white amorphous solid (8.2 mg, 2.1 µmol, 21%). LC-MS (gradient: 10 mM NH4OAc in 
H2O/acetonitrile 1/0  1/9 in 13.5 min): r.t. 5.84 min, [C154H203NO73P14 + 3H]3+ requires 1224.0 
found 1224.4.; 31P-NMR (162 MHz, D2O): δ = 0.7 - 1.1 (14P); 1H-NMR (600 MHz, D2O): δ = 0.99 
(m, 2H, CH2 hexylspacer), 1.05 (m, 2H, CH2 hexylspacer), 1.15 (m, 2H, CH2 hexylspacer), 1.35 (m, 
2H, CH2 hexylspacer), 2.83 (m, 2H, CH2-N hexylspacer), 3.47 - 3.58 (m, 3H, CH glycerol, CH2 
glycerol), 3.60 - 3.92 (m, 69H, CH2-O hexylspacer, 27 x CH2 glycerol, 13 x CH glycerol), 4.29 - 
4.44 (m, 28H, 14 x CH2 Bn), 4.72 (bs, 2H, CH2 benzylcarbamate), 6.91 - 7.15 (m, 75H, Harom); 13C 
NMR (150 MHz, D2O): δ = 24.7, 25.6, 28.9, 29.8 (4 x CH2 hexylspacer), 40.3 (CH2-N hexylspacer), 
60.2 (CH2 glycerol), 64.1, 64.4 - 64.6, 66.1, 66.4 (CH2-O hexylspacer, 27 x CH2 glycerol, CH2 
benzylcarbamate), 71.6, 71.8 (14 x CH2 Bn), 77.0 - 77.1 (13 x CH glycerol), 78.2 (CH glycerol), 
127.6 - 128.6 (CHarom), 137.5 - 137.6 (14 x Cq Bn, Cq benzylcarbamate); HRMS: [C154H203NO73P14 
+ 2Na]2+ requires 1857.4174 found 1857.4167; Deprotection: The semiprotected 14-mer (12, 
5.5 mg, 1.4 µmol) was deprotected using the standard procedure yielding 14-mer glycerol TA 
18 (3.0 mg, 1.2 µmol, 84%) as an amorphous off-white solid. 31P-NMR (162 MHz, D2O): δ = 1.1 - 
1.3 (14P); 1H-NMR (600 MHz, D2O): δ =1.37 - 1.41 (m, 4H, 2 x CH2 hexylspacer), 1.60 - 1.67 (m, 
4H, 2 x CH2 hexylspacer), 2.97 (at, 2H, J = 7.5 Hz, CH2-N hexylspacer), 3.57 (dd, 1H, J = 6.1 Hz, 
11.8 Hz, CHH glycerol), 3.64 (dd, 1H, J = 4.1 Hz, 11.8 Hz, CHH glycerol), 3.71 - 3.76 (m, 1H, CHH 
glycerol), 3.78 - 4.04 (m, 69H, CH2-O hexylspacer, 26 x CH2 glycerol, CHH glycerol, 14 x CH 
glycerol); 13C NMR (150 MHz, D2O): δ = 25.4, 26.1, 27.6, 30.4 (4 x CH2 hexylspacer), 40.4 (CH2-N 
hexylspacer), 63.1 (CH2 glycerol), 65.8 (CH2 glycerol), 67.3 - 67.7 (CH2-O hexylspacer, 26 x CH2 
glycerol), 70.5 - 70.6, 71.3, 71.7 (14 x CH glycerol); HRMS: C48H112NO71P14 + H+ requires 
2273.1584, found 2273.1562. 
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20-mer (19) 
Synthesis on 15 µmol scale (150 mg glycerol-CPG). 
Average coupling efficiency: 98.5% (19 couplings). 
Purification method B gave the semiprotected 20-mer 
(13) as white amorphous solid (20.2 mg, 3.62 µmol, 
24%). LC-MS (gradient: 10 mM NH4OAc in 
H2O/acetonitrile 9/1  1/9 in 13.5 min): r.t. 5.23 min, [C214H281NO103P20 + 4H]4+ requires 
1284.6 found 1284.8.; 31P-NMR (162 MHz, D2O): δ = 0.8 (1P), 1.0 (18P), 1.1 (1P); 1H-NMR (600 
MHz, D2O): δ = 0.96 (m, 2H, CH2 hexylspacer), 1.03 (m, 2H, CH2 hexylspacer), 1.13 (m, 2H, CH2 
hexylspacer), 1.33 (m, 2H, CH2 hexylspacer), 2.82 (m, 2H, CH2-N hexylspacer), 3.43 - 3.55 (m, 
3H, CH glycerol, CH2 glycerol), 3.57 - 4.08 (m, 99H, CH2-O hexylspacer, 39 x CH2 glycerol, 19 x 
CH glycerol), 4.17 - 4.44 (m, 40H, 20 x CH2 Bn), 4.69 (bs, 2H, CH2 benzylcarbamate), 6.85 - 7.13 
(m, 105H, Harom), 7.68 (s, 1H, NH); 13C NMR (150 MHz, D2O): δ = 25.7, 26.6, 30.0, 30.7 (4 x CH2 
hexylspacer), 41.3 (CH2-N hexylspacer), 61.1 (CH2 glycerol), 64.9 - 65.6, 67.1, 67.2, 67.6 (CH2-O 
hexylspacer, 39 x CH2 glycerol, CH2 benzylcarbamate), 72.5 - 72.8 (20 x CH2 Bn), 77.7 - 78.1 (19 
x CH glycerol), 79.1 (CH glycerol), 128.6 - 129.6 (CHarom), 137.5, 138.4 - 138.7 (20 x Cq Bn, Cq 
benzylcarbamate), 158.4 (Cq benzylcarbamate); HRMS: [C214H296N6O103P20 + 3H]3+ (mass + 5 x 
NH3) requires 1740.7715, found 1740.7691; Deprotection: The partially protected 20-mer (13, 
6.2 mg, 1.1 µmol) was deprotected using the standard procedure yielding 20-mer glycerol TA 
19 (3.8 mg, 1.1 µmol, 95%) as an amorphous off-white solid. 31P-NMR (162 MHz, D2O): δ = 1.2 - 
1.4 (20P); 1H-NMR (600 MHz, D2O): δ = 1.36 - 1.40 (m, 4H, 2 x CH2 hexylspacer), 1.59 - 1.71 (m, 
4H, 2 x CH2 hexylspacer), 2.95 (at, 2H, J = 7.5 Hz, CH2-N hexylspacer), 3.56 (dd, 1H, J = 6.2 Hz, 
11.8 Hz, CHH glycerol), 3.63 (dd, 1H, J = 4.3 Hz, 11.9 Hz, CHH glycerol), 3.72 (m, 1H, CHH 
glycerol), 3.81 - 4.04 (m, 99H, CH2-O hexylspacer, 38 x CH2 glycerol, CHH glycerol, 20 x CH 
glycerol); 13C NMR (150 MHz, D2O): δ = 25.4, 26.0, 27.6, 30.4 (4 x CH2 hexylspacer), 40.4 (CH2-N 
hexylspacer), 63.0 (CH2 glycerol), 65.7 (CH2 glycerol), 66.9 - 67.5 (CH2-O hexylspacer, 37 x CH2 
glycerol), 67.7 (CH2 glycerol), 70.4 - 70.7, 71.3, 71.7 (20 x CH glycerol); HRMS: [C66H155NO101P20 
+ 2H]2+ requires 1599.5961, found 1599.5971. 
glucosylated hexamer (20) 
Synthesis on 15 µmol scale (150 mg glycerol-CPG). 
Average coupling efficiency: 98.2% (5 couplings). 
Purification method B gave the semiprotected 
hexamer (14) as white amorphous solid (10.5 mg, 4.86 
µmol, 32%). LC-MS (gradient: 10 mM NH4OAc in 
H2O/acetonitrile 9/1  1/1 in 25 min): r.t. 13.80 min, 
[C94H119NO38P6 + 2H]2+ requires 1029.3 found 1029.2.; 
31P-NMR (162 MHz, D2O): δ = 1.0 (1P), 1.1 (3P), 1.1 (1P), 1.2 (1P); 1H-NMR (600 MHz, D2O): δ = 
0.85 - 1.17 (m, 6H, 3 x CH2 hexylspacer), 1.37 (m, 2H, CH2 hexylspacer), 2.84 (m, 2H, CH2-N 
hexylspacer), 3.34 - 4.11 (m, 38H, CH2-O hexylspacer, 12 x CH2 glycerol, 6 x CH glycerol, H-2, H-
3, H-4, H-5, 2 x H-6), 4.29 - 4.71 (m, 16H, 7 x CH2 Bn, CH2 benzylcarbamate), 5.22 (bs, 1H, H-1), 
5.28 (bs, 1H, CH benzylidene), 6.86 - 7.43 (m, 45H, Harom); HRMS: [C94H119NO38P6 + NH4 + H]2+ 
requires 1037.3123, found 1037.3120; Deprotection: The partially protected hexamer (14, 10.5 
mg, 4.86 µmol) was deprotected using the standard procedure yielding hexamer 
monoglucosylglycerol TA 20 (4.4 mg, 3.3 µmol, 68%) as an amorphous off-white solid. 31P-NMR 
(162 MHz, D2O): δ = 0.9 (1P), 1.2 (3P), 1.3 (1P), 1.3 (1P); 1H-NMR (600 MHz, D2O): δ =1.36 - 1.40 
(m, 4H, 2 x CH2 hexylspacer), 1.58 - 1.65 (m, 4H, 2 x CH2 hexylspacer), 2.94 (at, 2H, J = 7.5 Hz, 
CH2-N hexylspacer), 3.34 (at, 1H, J  = 9.6 Hz, H-4), 3.46 (dd, 1H, J = 3.7 Hz, 9.9 Hz, H-2), 3.55 (dd, 
1H, J = 6.1 Hz, 11.8 Hz, CHH glycerol), 3.62 (dd, 1H, J = 4.2 Hz, 11.8 Hz, CHH glycerol), 3.69 - 3.72 
(m, 3H, H-3, H-5, H-6), 3.79 - 4.00 (m, 30H, CH2-O hexylspacer, 11 x CH2 glycerol, 5 x CH glycerol, 
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H-6), 4.05 (m, 1H, CH glycerol), 5.11 (d, 1H, J = 3.7 Hz, H-1); 13C NMR (150 MHz, D2O): δ = 25.4, 
26.1, 27.6, 30.4 (4 x CH2 hexylspacer), 40.4 (CH2-N hexylspacer), 61.5 (C-6), 63.0 (CH2 glycerol), 
65.2 (CH2 glycerol), 66.1 (CH2 glycerol) 67.0 - 67.4 (CH2-O hexylspacer, 9 x CH2 glycerol), 70.4 - 
70.6 (4 x CH glycerol, C-4), 71.7 (CH glycerol), 72.5 (C-2), 72.8 (C-5), 73.9 (C-3), 76.3 (CH 
glycerol), 98.7 (C-1); HRMS: C30H67NO36P6 + H+ requires 1204.1941, found 1204.1957. 
glucosylated hexamer (21) 
Synthesis on 15 µmol scale (150 mg glucosylglycerol-
CPG). Average coupling efficiency: 96.9% (5 couplings). 
Purification method B gave the semiprotected hexamer 
(15) as white amorphous solid (11.6 mg, 5.37 µmol, 
36%). LC-MS (gradient: 10 mM NH4OAc in 
H2O/acetonitrile 9/1  1/1 in 25 min): r.t. 13.55 min, 
C94H119NO38P6 + H+ requires 2057.6 found 2058.0.; 31P-
NMR (162 MHz, D2O): δ = 1.0 - 1.3 (6P); 1H-NMR (600 MHz, D2O): δ = 0.90 - 1.15 (m, 6H, 3 x CH2 
hexylspacer), 1.33 (m, 2H, CH2 hexylspacer), 2.80 (m, 2H, CH2-N hexylspacer), 3.22 - 4.18 (m, 
38H, CH2-O hexylspacer, 12 x CH2 glycerol, 6 x CH glycerol, H-2, H-3, H-4, H-5, 2 x H-6), 4.30 - 
4.69 (m, 16H, 7 x CH2 Bn, CH2 benzylcarbamate), 5.12 - 5.20 (m, 2H, H-1, CH benzylidene), 6.86 - 
7.26 (m, 45H, Harom); HRMS: [C94H119NO38P6 + 2H]2+ requires 1028.7991, found 1028.7996; 
Deprotection: The partially protected hexamer (15, 2.2 mg, 0.99 µmol) was deprotected using 
the standard procedure yielding hexamer monoglucosyl TA 21 (1.1 mg, 0.85 µmol, 86%) as an 
amorphous off-white solid. 31P-NMR (162 MHz, D2O): δ = 1.2 (1P), 1.2 (3P), 1.3 (1P), 1.3 (1P); 
1H-NMR (600 MHz, D2O): δ = 1.36 - 1.40 (m, 4H, 2 x CH2 hexylspacer), 1.59 - 1.65 (m, 4H, 2 x CH2 
hexylspacer), 2.94 (at, 2H, J = 7.5 Hz, CH2-N hexylspacer), 3.36 (at, 1H, J  = 9.7 Hz, H-4), 3.48 (dd, 
1H, J = 3.8 Hz, 9.9 Hz, H-2), 3.68 - 3.73 (m, 4H, H-3, 2 x H-6, CHH glycerol), 3.77 - 4.02 (m, 32H, 
CH2-O hexylspacer, 11 x CH2 glycerol, CHH glycerol, 6 x CH glycerol, H-5), 5.12 (d, 1H, J = 3.7 Hz, 
H-1); 13C NMR (150 MHz, D2O): δ = 25.4, 26.0, 27.6, 30.3 (4 x CH2 hexylspacer), 40.4 (CH2-N 
hexylspacer), 61.5 (CH2 glycerol), 62.2 (C-6), 65.2 (CH2 glycerol), 66.9 - 67.2 (CH2-O 
hexylspacer, 11 x CH2 glycerol), 70.4 - 70.6 (5 x CH glycerol, C-4), 72.4 (C-2), 72.9 (C-5), 73.8 (C-
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Chapter two and chapter three describe the generation of teichoic acids (TAs) via 
solution phase and automated solid phase approaches, both of which have advantages 
and disadvantages. The solution phase protocol is relatively labor and time consuming 
due to the intermediate isolation and purification steps. However, the approach bears 
some important advantages: It can be executed on both small and large scale and it 
can be performed employing a stoichiometric amount or small excess of reagents.1 
The automated solid phase synthesis strategy is time and labor efficient by postponing 
product purification to the final stage of the synthesis, which makes it suitable for the 
generation of a small library of structures. The main disadvantages are that this 
protocol requires a relatively large excess of expensive building blocks (6-8 eq) and 
can only be executed on a relatively small scale (~15 µmol).2  
Alternative synthetic strategies have recently emerged that are based on the use of 
soluble supports. In an ideal situation, these strategies combine the “best of both 
worlds”: the soluble support allows the application of (a relatively small) excess of 
reagents to drive the reactions to completion; it also enables the rapid isolation and 
purification of intermediates and is readily adapted to different reaction scales. 
Several supports have been recommended over the years, including polyethylene 
glycol polymers (PEG)3, lipophilic tails4 and ionic tags.5 With the advent of fluorous 
solid phase extraction (F-SPE) methodologies, a technique known as light fluorous 
synthesis6-11 has become popular for the construction of biopolymers, especially in the 
area of carbohydrate chemistry.10,12-16 Applications in the assembly of oligopeptides10 
have also been reported, but the use of fluorous chemistry in oligonucleotide 
synthesis has been restricted to tagging techniques, in which a fluorous building block 
is employed at the end of a solid phase oligonucleotide synthesis to discriminate the 
target full length oligomers from unwanted, capped deletion sequences.17-19 
This chapter discusses the light fluorous approach to (aminoglucosylated) TAs. 
With use of perfluorooctylpropylsulfonyl ethyl (F-Pse) as the fluorous phosphate 
protection a dodecamer glycerol TA (19) is built up using phosphoramidite chemistry. 
After each elongation cycle, which comprises 3 steps (coupling, oxidation, 
detritylation), an F-SPE purification is performed. Using this technique a set of 
aminoglucosylated TA fragments is obtained (molecules 32a, 32b and 43).20 The 
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antigenicity of these fragments is determined using an opsonophagocytic inhibition 
assay (OPIA) which measures their binding to rabbit antibodies raised against 
enterococcal LTA. 
Results and Discussion 
The first objective was the selection of a suitable light fluorous phosphate 
protecting group. To date only one such protecting group has been reported, which 
has been applied in the synthesis of a disaccharide.21 In 2003 De Visser et al. and, 
more recently, Ali et al. reported on the use of fluorous sulfonylethyl based groups to 
protect both amino and hydroxyl functions, in the form of a carbamate and carbonate 
respectively (See Figure 1).22,23 This group seemed suitable to protect phosphate 
functions since it can be removed at the end of the synthesis by base catalyzed β-
elimination. The effective use of the 2-(methylsulfonyl) ethyl (MSc) group in solid 
phase oligonucleotide synthesis bodes well for this approach. Whereas the use of the 
fluorous version of the MSc group, the [1H,1H,2H,2H]-perfluorodecylsulfonyl-
ethoxycarbonyl (F-Msc, 1), functioned well as a nitrogen protecting group, it proved to 
be too base labile for use as a hydroxyl protecting group (as in 2). Thus, for the 
fluorous version of the Msc carbonate, an extra methylene moiety between the 
fluorous part and the sulfonyl group was incorporated to provide extra insulation for 
the C8F17 tail, giving the perfluorooctylpropylsulfonylethoxycarbonyl (F-Psc, 3) 
group.23 Based on these considerations F-Pse group 4 was chosen as a fluorous linker 
and phosphate protecting group. With this linker, synthesized as reported previously, 
the first goal was to establish the scope and limitations of fluorous teichoic acid 
synthesis.  
As depicted in Scheme 1, F-Pse alcohol 5 was elongated in a step-wise manner with 
glycerol phosphoramidite 6.1 Each elongation cycle consisted of four steps: 1) reaction 
of the alcohol with phosphoramidite 6 under the agency of dicyanoimidazole (DCI); 2) 
oxidation of the intermediate phosphite with I2; 3) removal of the DMT protecting 
group using dichloroacetic acid (DCA) in the presence of triethylsilane (TES); and 4) F-
SPE purification. The work-up procedure includes an extraction with aqueous MeCN 
and hexane to remove most of the 4,4’-dimethoxytriphenylmethane and excess TES, 
since it was found that these could not be separated from the target compounds by F-
SPE when present in relatively large amounts. Using this protocol, protected 
oligoglycerol phosphates up to the dodecamer level were rapidly generated. Although 
the relative fluorous content in 
compounds 7-18 significantly 
decreases with increasing 
oligomer length (ranging from 
37% fluorine in compound 7 to 
8% fluorine in dodecamer 18), 
this had little or no effect on 
Figure 1. Fluorous versions of the MSc type protecting group. 
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Scheme 1. Light fluorous synthesis of dodecamer 19. 
the purification efficiency and 
a single fluorous silica column 
(2 or 4g) was sufficient to 
purify all oligomers (0.1-0.25 
mmol). However, a larger 
excess of 6 was required to 
push the coupling reactions 
to completion with increasing 
length of the oligomer. Up to 
four equivalents of the 
phosphoramidite were 
required in the final coupling 
step to the dodecamer (see scheme 1). Because at this stage an automated solid phase 
approach becomes competitive, further elongation was abandoned. 
Deprotection of the fully protected dodecamer (18) started with removal of the F-
Pse and cyanoethyl groups using 25% aqueous ammonia solution. In a model 
deprotection experiment (Scheme 2) compound 21 was subjected to the above 
mentioned deprotection conditions at slightly elevated temperatures (40 oC) and it 
was observed that the F-Pse group at the terminal phosphotriester was selectively 
cleaved with respect to the cyanoethyl group (compound 22, see Scheme 2 and Figure 
2). Elimination of the remaining cyanoethyl group on the obtained phosphodiester 
required prolonged reaction times (typically overnight) to ensure complete 
unmasking of the target phosphomonoester (24). Applying this protocol to 
dodecamer 18 (scheme 1) led, after ensuing hydrogenolysis of the partially protected 
oligomer and gel filtration, to 30 mg of fully deprotected dodecamer 19 (86%). 
  
Scheme 2. Monitoring of the deprotection of model compound 21 with 25% NH4OH. 
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Figure 2. LC-MS (C-18, gradient (13.5 min) 10%  90% MeCN, 15mM NH4OAc) analysis of the base 
catalyzed deprotection (25% NH4OH at 40 oC) of compound 21. A) before the reaction. B) after 30 
minutes. C) after overnight reaction.  
Having established that F-Pse alcohol 5 can be used for the efficient assembly of 
glycerol phosphate teichoic acids, the next goal was to investigate the incorporation of 
glycosyl substituents in the TA chains through the assembly of two teichoic acid 
hexamers. TA 32a (Scheme 4) carries a GlcNAc residue, as present in TA chains of 
Staphylococcus aureus,24 whereas a positively charged glucosamine is grafted on 
hexamer 32b, a structural element found in several Streptomyces species.25,26 The 
required glucosaminyl glycerol phosphoramidites were obtained as depicted in 
Scheme 3. Triol 25 was benzylated to give intermediate 2627 from which both building 
blocks 29a and 29b were assembled. Reduction of the azide functionality in 26 and 
subsequent acetylation gave N-acetyl glucosamine derivative 27a, while protection 
with a benzyloxycarboxyl group led to 27b. Both glucosaminyl glycerol building 
blocks were then transformed into the required phosphoramidites 29a and 29b 
following a well-established sequence of reactions, involving deallylation, 
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Scheme 3. Synthesis of glucosamineglycerol phosphoramidites 29a and 29b. 
With building blocks 29a/b the target hexamers 32a/b were assembled starting 
from fluorous pentamer 11 (Scheme 4). Thus, condensation of 11 and 29a/b and 
subsequent oxidation and removal of the DMT-group gave crude 30a/b. Also in this 
case F-SPE purification proceeded uneventfully and hexamers 30a/b were obtained in 
73% and 88% respectively. The hexamers were then equipped with a hexylamino 
spacer using phosphoramidite 20 to give fully protected TA structures 31a/b in pure 
form after F-SPE. Global deprotection using the deprotection protocol described above 
led to both target hexamers 32a/b, the successful assembly of which indicates that the  
Scheme 4. Light fluorous synthesis of glucosamine containing GTA hexamer 32a and 32b. 
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fluorous synthesis strategy can also be applied to substituted 
oligoglycerolphosphates.  
Finally, the assembly of more complex structures was explored, as exemplified by 
the synthesis of teichoic acid fragment 43, which is characterized by the [→6)-
glucosamine-(α-1→2)-sn-glycerol-1-phosphate-] repeating unit and is found in 
Spirilliplanes Yamanashiensis (scheme 5).28 The synthesis of the required GlcNHAc-
glycerol phosphoramidite building block 36 commenced with dimethoxytritylation of 
the primary alcohol in 25. Subsequent desilylation and benzylation of the resulting 
triol gave the fully protected GlcNHAc-glycerol 34, which was transformed into 
required phosphoramidite 36 through azide reduction and acetylation followed by a 
deallylation-phosphitylation reaction sequence. For the assembly of hexamer 43, F- 
Pse linker 5 was elongated in a step-wise manner with 36 using the chemistry 
described above. As can be seen in Scheme 5 all elongation steps proceeded efficiently. 
Although 36 is a more lipophilic building block than the above described glycerol 
phosphates, this did not pose any problems in the purification of the oligomers. 
Notably, the single C8F17-tail sufficed for the easy purification of fully protected 
hexamer 42, having a molecular mass of 4.7 kDa (relative fluorine content: 7%). 
Finally, deprotection of 42 was accomplished by β-elimination of the F-Pse linker and 
cyanoethyl groups and global debenzylation to give target compound 43 in 76% yield. 
 
 
TA fragments 19, 32a 
and 32b were evaluated in 
an OPIA, where the 
binding of the molecules to 
antibodies raised in 
rabbits against 
enterococcal LTA was 
measured. The three TAs 
all partially inhibited the 
killing of E. faecalis by the 
opsonic antibodies when 
added in a concentration of 
100 µg/ml (see Figure 3). 
However, when compared 
to the glucosylated 
hexamers described in 
chapter three the 
inhibition of killing by 
these molecules was 
Scheme 5. Synthesis of complex hexamer 43. 
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considerably less. This indicates that the presence of 
either the (N-acetyl)aminoglucosyl or the terminal 
phosphate moiety (or both) might have a negative 
effect on the potency of the antigen.  
Conclusion 
In conclusion, an efficient fluorous synthesis 
strategy for the assembly of teichoic acid fragments, 
was developed, based on the application of 
perfluorooctylpropylsulfonylethanol as a new 
fluorous phosphate protecting group. The strategy is 
especially useful for the assembly of multi-milligram 
quantities of medium sized TA fragments, featuring 
6-12 repeating units. As displayed by the assembly of 
teichoic acid fragment 43, complex glycerol 
phosphate building blocks can also be used, 
indicating that this strategy might be a valuable asset 
for the construction of various classes of phosphate 
ester containing biomolecules.  
 
Experimental section 
General Procedures and Material: All chemicals (Acros, Fluka, Merck, Schleicher & Schuell, 
Sigma-Aldrich, Genscript, Fluorous Technologies) were used as received and reactions were 
carried out dry, under an argon atmosphere, at ambient temperature, unless stated otherwise. 
Column chromatography was performed on Screening Devices silica gel 60 (0.040-0.063 mm). 
TLC analysis was conducted on HPTLC aluminium sheets (Merck, silica gel 60, F245). 
Compounds were visualized by UV absorption (245 nm), by spraying with 20% H2SO4 in 
ethanol or with a solution of (NH4)6Mo7O24•4 H2O 25 g/l and (NH4)4Ce(SO4)4•2 H2O 10 g/l, in 
10% aqueous H2SO4 followed by charring at +/- 140 oC. Some unsaturated compounds were 
visualized by spraying with a solution of KMnO4 (2%) and K2CO3 (1%) in water. Optical rotation 
measurements ([α]D20) were performed on a Propol automated polarimeter (Sodium D-line, λ = 
589 nm) with a concentration of 10 mg/ml (c = 1), unless stated otherwise. Infrared spectra 
were recorded on a Shimadzu FT-IR 8300. 31P, 1H, and 13C NMR spectra were recorded with a 
Bruker AV 400 (161.7, 400 and 125 MHz respectively) or a Bruker DMX 600 (600 and 150 MHz 
respectively). NMR spectra were recorded in CDCl3 with chemical shift (δ) relative to 
tetramethylsilane, unless stated otherwise. When D2O was used, 1H-NMR spectra were recorded 
with chemical shift relative (δ) to HDO (4.755 ppm), 31P spectra were measured with chemical 
shift relative to 85% H3PO4 (external standard) and 13C-NMR spectra were recorded with 
chemical shift relative to TMS (external standard). High resolution mass spectra (HRMS) were 
recorded by direct injection (2 µl of a 2 µM solution in water/acetonitrile; 50/50; v/v and either 
0.1% formic acid or 10mM ammonium formate for the oligomers) on a mass spectrometer 
(Thermo Finnigan LTQ Orbitrap) equipped with an electrospray ion source in positive mode 
(source voltage 3.5 kV, sheath gas flow 10, capillary temperature 275 oC) with resolution R = 
60000 at m/z 400 (mass range m/z = 150-2000) and dioctylphthalate (m/z = 391.28428) as a 
Figure 3. Results OPIA of 
compounds 19, 32a/b at 100 µg/ml. 
The left bar represents killing by 
the serum without addition of 
inhibitor. The second bar from the 
left (LTA) represents the positive 
control where native LTA is added 
as the inhibitor. 
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lock mass. The high resolution mass spectrometer was calibrated prior to measurements with a 
calibration mixture (Thermo Finnigan). 
General procedure for phosphoramidite coupling, oxidation, detritylation and F-SPE on a 
typical scale (0.1-0.25 mmol): Starting alcohol was dissolved in MeCN (0.1M). DCI (0.25M 
solution in MeCN, 2 eq with respect to phosphoramidite) was added, together with freshly 
activated MS3Å and the mixture was stirred under argon for 15 minutes. Phosphoramidite (0.1-
0.2 M solution in MeCN, 1.3 - 4.0 eq with respect to starting material) was added and the 
reaction was stirred until TLC analysis revealed full conversion of the starting material into a 
higher running spot (~1 hr). Added were H2O (~1 ml) and I2 (0.2 M in THF/pyr 4/1, 1.5 eq with 
respect to phosphoramidite) and the mixture was stirred for an additional 5 min. The mixture 
was diluted with EtOAc (~50 ml) and washed with sat. aq. Na2S2O3 (~20 ml), 0.5 M KHSO4 (~20 
ml) and a 1/1 mixture of sat. aq. NaHCO3 and brine (~20 ml), respectively. The organic layer 
was dried over Na2SO4 (s) and concentrated under reduced pressure. The residue was 
coevaporated once with toluene (10 ml) before it was redissolved in DCM (50 mM). 
Triethylsilane and dichloroacetic acid (20 eq with respect to starting material) were added and 
the mixture was stirred until the bright orange color fully dissapeared (~30 min). DCM (~40 
ml) was added and the organic layer was washed with a 1/1 mixture of sat. aq. NaHCO3 and 
brine (~20 ml, check if pH >7), before it was dried over Na2SO4 and concentrated in vacuo. The 
residue was taken up in 4/1 MeCN/H2O (10 ml) and washed with hexane (50 ml). The hexane 
layer was extracted twice with 4/1 MeCN/H2O (2 x 10 ml) and the combined MeCN/H2O layers 
were concentrated under reduced pressure in a 100 ml pear shaped flask. The residue was 
taken up in 0.5 ml MeCN and applied to a small column containing fluoroflashTM fluorous silica 
(2 or 4g) which was preeluted with 1/1 MeCN/H2O. The column was eluted with 1/1 
MeCN/H2O until all the non-fluorous byproducts (DMT-H, phosphates, DCI) were removed. 
Subsequently the fluorous product was eluted from the column with CH3CN and acetone.  
Global deprotection and purification of oligomers: The fully protected oligomer was treated 
with a 9/1 mixture of 28% NH4OH (aq)/1,4-dioxane at a concentration of 5 mg/ml at 40 - 45 oC 
overnight in a sealed flask or tube. After cooling down to RT the mixture was washed with Et2O 
(equal volume) and the ether layer was extracted twice with H2O (~5.0 ml). The aqueous layer 
was concentrated under reduced pressure after which NMR and HRMS analysis confirmed full 
conversion to the semiprotected intermediate. The intermediate was then treated with Pd 
(0)/H2 (using ~5 mg palladium black per ml reaction medium) in a slightly acidic (pH ~2.7) 
mixture of dioxane/water (1/4, containing ~1% AcOH, or, in the case of hexamer 27b, 
containing aqueous HCl, pH 2.7) at a concentration of ~5 mg of starting material per ml. After 
stirring for three days the mixture was filtered and concentrated in vacuo. The residue was 
purified by size exclusion chromatography (Sephadex HW40, eluent: 0.15 M NH4OAc). After 
repeated lyophilisation, the purified product was eluted through a small column containing 
Dowex Na+ cation-exchange resin (type: 50WX4-200, stored on 0.5 M NaOH in H2O, flushed with 
H2O and MeOH before use). Lyophilization gave the fully deprotected oligomer of which the 
integrity and purity was confirmed by HRMS and NMR (1H, 13C, 31P) analysis. 
1-[(Perfluorooctylpropysulfonylethyl)-(2-cyanoethyl)-
phosphate]-2-O-benzyl-sn-glycerol (7) 
Perfluorooctylpropylsulfonyl ethanol 5 (145 mg, 254 µmol) was 
coupled to glycerol phosphoramidite 6 (0.175 M in MeCN, 2.18 ml, 
381 µmol, 1.5 eq), oxidized, detritylated and purified (F-SPE) using 
the general procedure as described above. Monomer 7 (218 mg, 
251 µmol, 99 %) was obtained as a colorless oil. 31P NMR (161.7 
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MHz): δ = -1.5, -1.5 (1P); 1H NMR (400 MHz): δ = 2.12 - 2.36 (m, 4H, F17C8CH2CH2CH2SO2-, 
F17C8CH2CH2CH2SO2-), 2.52 (bs, 1H, CH2OH), 2.66 - 2.72 (m, 2H, CH2 cyanoethyl), 3.08 - 3.15 (m, 
2H, F17C8CH2CH2CH2SO2-), 3.29 - 3.35 (m, 2H, -OCH2CH2SO2-), 3.68 - 3.77 (m, 3H, CH glycerol, 
CH2 glycerol), 4.19 - 4.27 (m, 3H, CHH glycerol, CH2 cyanoethyl), 4.31 - 4.38 (m, 1H, CHH 
glycerol), 4.47 - 4.52 (m, 2H, -OCH2CH2SO2-,), 4.62 - 4.68 (m, 2H, CH2 Bn), 7.30 - 7.37 (m, 5H, 
Harom); 13C NMR (100 MHz): δ = 13.4 (F17C8CH2CH2CH2SO2-), 19.5 - 19.6 (CH2 cyanoethyl), 29.3 
(t, J = 22 Hz, F17C8CH2CH2CH2SO2-), 53.1 - 53.3 (F17C8CH2CH2CH2SO2-, -OCH2CH2SO2-), 60.5 (CH2 
glycerol), 61.3 - 61.4 (-OCH2CH2SO2-), 62.3 - 62.4 (CH2 cyanoethyl), 66.8 - 66.9 (CH2 glycerol), 
72.0 (CH2 Bn), 77.4 (CH glycerol), 116.6 (Cq cyanoethyl), 127.9 - 128.5 (CHarom), 137.5 (Cq Bn); 
HRMS: C26H27F17NO8PS + H+ requires 868.0996, found 868.0996. 
2-O-Benzyl-glycerol phosphate dimer (8) 
Alcohol 7 (217 mg, 250 µmol) was coupled to glycerol 
phosphoramidite 6 (0.175 M in MeCN, 1.86 ml, 325 µmol, 1.3 eq), 
oxidized, detritylated and purified (F-SPE) using the general 
procedure as described above. dimer 8 (277 mg, 238 µmol, 95 %) was 
obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.9, -1.9, -1.8, -1.8 (1P), -0.8, -0.8, -0.8, -0.8 
(1P); 1H NMR (400 MHz): δ = 2.11 - 2.35 (m, 4H, F17C8CH2CH2CH2SO2-, F17C8CH2CH2CH2SO2-), 
2.56 - 2.70 (m, 5H, 2 x CH2 cyanoethyl, CH2OH), 3.07 - 3.14 (m, 2H, F17C8CH2CH2CH2SO2-), 3.26 - 
3.34 (m, 2H, -OCH2CH2SO2-), 3.65 - 3.78 (m, 3H, CH glycerol, CH2 glycerol), 3.82 - 3.86 (m, 1H, CH 
glycerol), 4.15 - 4.36 (m, 10H, 3 x CH2 glycerol, 2 x CH2 cyanoethyl), 4.45 - 4.51 (m, 2H, -
OCH2CH2SO2-,), 4.59 - 4.67 (m, 4H, 2 x CH2 Bn), 7.28 - 7.37 (m, 10H, Harom); 13C NMR (100 MHz): 
δ = 13.3 (F17C8CH2CH2CH2SO2-), 19.4 - 19.5 (2 x CH2 cyanoethyl), 29.3 (t, J = 22 Hz, 
F17C8CH2CH2CH2SO2-), 53.0 - 53.2 (F17C8CH2CH2CH2SO2-, -OCH2CH2SO2-), 60.4 - 60.5 (CH2 
glycerol), 61.3 - 61.4 (-OCH2CH2SO2-), 62.1 (CH2 cyanoethyl), 62.4 (CH2 cyanoethyl), 65.3 (CH2 
glycerol), 66.0 (CH2 glycerol), 66.5 - 66.6 (CH2 glycerol), 66.8 - 66.9 (CH2 glycerol), 72.0 (CH2 
Bn), 72.2 (CH2 Bn), 75.1 - 75.2 (CH glycerol), 77.4 - 77.5 (CH glycerol), 116.6 (2 x Cq cyanoethyl), 
127.8 - 128.5 (CHarom), 137.0 (Cq Bn), 137.6 (Cq Bn); HRMS: C39H43F17N2O13P2S + H+ requires 
1165.1762, found 1165.1756. 
2-O-Benzyl-glycerol phosphate trimer (9) 
Glycerol phosphate dimer 8 (275 mg, 236 µmol) was coupled to 
glycerol phosphoramidite 6 (0.175 M in MeCN, 2.02 ml, 354 µmol, 1.5 
eq), oxidized, detritylated and purified (F-SPE) using the general 
procedure as described above. trimer 9 (318 mg, 217 µmol, 92 %) 
was obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.9, -1.9, -1.8, (1P), -1.3, -1.3, -1.2, -1.1 
(1P), -0.8, -0.8, -0.8, -0.8 (1P); 1H NMR (400 MHz): δ = 2.10 - 2.36 (m, 4H, F17C8CH2CH2CH2SO2-, 
F17C8CH2CH2CH2SO2-), 2.56 - 2.73 (m, 7H, 3 x CH2 cyanoethyl, CH2OH), 3.06 - 3.13 (m, 2H, 
F17C8CH2CH2CH2SO2-), 3.26 - 3.34 (m, 2H, -OCH2CH2SO2-), 3.64 - 3.73 (m, 3H, CH glycerol, CH2 
glycerol), 3.81 - 3.86 (m, 2H, 2 x CH glycerol), 4.11 - 4.35 (m, 16H, 5 x CH2 glycerol, 3 x CH2 
cyanoethyl), 4.44 - 4.50 (m, 2H, -OCH2CH2SO2-,), 4.58 - 4.67 (m, 6H, 3 x CH2 Bn), 7.27 - 7.37 (m, 
15H, Harom); 13C NMR (100 MHz): δ = 13.3 (F17C8CH2CH2CH2SO2-), 19.3 - 19.4 (3 x CH2 
cyanoethyl), 29.2 (t, J = 22 Hz, F17C8CH2CH2CH2SO2-), 53.0 - 53.2 (F17C8CH2CH2CH2SO2-, -
OCH2CH2SO2-), 60.3 - 60.4 (CH2 glycerol), 61.3 (-OCH2CH2SO2-), 62.0 - 62.4 (3 x CH2 cyanoethyl), 
65.4 - 66.6 (5 x CH2 glycerol), 71.9 (CH2 Bn), 72.1 (2 x CH2 Bn), 75.2 - 75.3 (2 x CH glycerol), 77.4 
- 77.5 (CH glycerol), 116.7 (3 x Cq cyanoethyl), 127.5 - 128.5 (CHarom), 137.1 (2 x Cq Bn), 137.7 
(Cq Bn); HRMS: C52H59F17N3O18P3S + Na+ requires 1484.2348, found 1484.2363. 
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2-O-Benzyl-glycerol phosphate tetramer (10) 
Glycerol phosphate trimer 9 (311 mg, 213 µmol) was coupled to 
glycerol phosphoramidite 6 (0.175 M in MeCN, 1.83 ml, 320 µmol, 1.5 
eq), oxidized, detritylated and purified (F-SPE) using the general 
procedure as described above. tetramer 10 (339 mg, 192 µmol, 91 %) 
was obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.9, -1.9 (1P), -1.4, -1.3 (1P), -1.2, -1.2, 
-1.1 (1P), -0.9, -0.9, -0.8, -0.8 (1P); 1H NMR (400 MHz): δ = 2.10 - 2.36 (m, 4H, 
F17C8CH2CH2CH2SO2-, F17C8CH2CH2CH2SO2-), 2.54 - 2.76 (m, 9H, 4 x CH2 cyanoethyl, CH2OH), 
3.06 - 3.13 (m, 2H, F17C8CH2CH2CH2SO2-), 3.25 - 3.34 (m, 2H, -OCH2CH2SO2-), 3.64 - 3.72 (m, 3H, 
CH glycerol, CH2 glycerol), 3.79 - 3.85 (m, 3H, 3 x CH glycerol), 4.10 - 4.35 (m, 22H, 7 x CH2 
glycerol, 4 x CH2 cyanoethyl), 4.44 - 4.50 (m, 2H, -OCH2CH2SO2-,), 4.58 - 4.67 (m, 8H, 4 x CH2 Bn), 
7.27 - 7.36 (m, 20H, Harom); 13C NMR (100 MHz): δ = 13.3 (F17C8CH2CH2CH2SO2-), 19.3 - 19.4 (4 x 
CH2 cyanoethyl), 29.2 (t, J = 22 Hz, F17C8CH2CH2CH2SO2-), 52.9 - 53.1 (F17C8CH2CH2CH2SO2-, -
OCH2CH2SO2-), 60.3 - 60.4 (CH2 glycerol), 61.3 (-OCH2CH2SO2-), 62.0 - 62.4 (4 x CH2 cyanoethyl), 
65.4 - 66.6 (7 x CH2 glycerol), 71.9 (CH2 Bn), 72.1 (3 x CH2 Bn), 75.1 - 75.4 (3 x CH glycerol), 77.4 
- 77.5 (CH glycerol), 116.6 - 116.7 (4 x Cq cyanoethyl), 127.7 - 128.5 (CHarom), 137.1 - 137.2 (3 x 
Cq Bn), 137.7 (Cq Bn); HRMS: C65H75F17N4O23P4S + Na+ requires 1781.3114, found 1781.3106. 
2-O-Benzyl-glycerol phosphate pentamer (11) 
Glycerol phosphate tetramer 10 (538 mg, 306 µmol) was coupled to 
glycerol phosphoramidite 6 (0.175 M in MeCN, 2.62 ml, 459 µmol, 1.5 
eq), oxidized, detritylated and purified (F-SPE) using the general 
procedure as described above. Pentamer 11 (524 mg, 255 µmol, 83 
%) was obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.9, -1.9 (1P), -1.4 - -1.1 (3P), -0.9, 
-0.9, -0.9 (1P); 1H NMR (400 MHz): δ = 2.11 - 2.34 (m, 4H, F17C8CH2CH2CH2SO2-, 
F17C8CH2CH2CH2SO2-), 2.53 - 2.70 (m, 11H, 5 x CH2 cyanoethyl, CH2OH), 3.06 - 3.13 (m, 2H, 
F17C8CH2CH2CH2SO2-), 3.25 - 3.34 (m, 2H, -OCH2CH2SO2-), 3.63 - 3.72 (m, 3H, CH glycerol, CH2 
glycerol), 3.79 - 3.85 (m, 4H, 4 x CH glycerol), 4.09 - 4.34 (m, 28H, 9 x CH2 glycerol, 5 x CH2 
cyanoethyl), 4.43 - 4.50 (m, 2H, -OCH2CH2SO2-,), 4.58 - 4.66 (m, 10H, 5 x CH2 Bn), 7.26 - 7.36 (m, 
25H, Harom); 13C NMR (100 MHz): δ = 13.3 (F17C8CH2CH2CH2SO2-), 19.2 - 19.4 (5 x CH2 
cyanoethyl), 29.2 (t, J = 21 Hz, F17C8CH2CH2CH2SO2-), 52.9 - 53.1 (F17C8CH2CH2CH2SO2-, -
OCH2CH2SO2-), 60.3 - 60.4 (CH2 glycerol), 61.3 (-OCH2CH2SO2-), 62.0 - 62.4 (5 x CH2 cyanoethyl), 
65.4 - 66.6 (9 x CH2 glycerol), 71.8 (CH2 Bn), 72.1 (4 x CH2 Bn), 75.1 - 75.3 (4 x CH glycerol), 77.4 
- 77.5 (CH glycerol), 116.6 - 116.7 (5 x Cq cyanoethyl), 127.7 - 128.5 (CHarom), 137.1 - 137.2 (4 x 
Cq Bn), 137.7 (Cq Bn); HRMS: [C78H91F17N5O28P5S + 2NH4]2+ requires 1045.7332, found 
1045.7344. 
2-O-Benzyl-glycerol phosphate hexamer (12) 
Glycerol phosphate pentamer 11 (237 mg, 115 µmol) was coupled to 
glycerol phosphoramidite 6 (0.175 M in MeCN, 0.99 ml, 173 µmol, 1.5 
eq), oxidized, detritylated and purified (F-SPE) using the general 
procedure as described above. Hexamer 12 (240 mg, 102 µmol, 89 %) 
was obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.9, -1.9 (1P), -1.4 - -1.1 (4P), -0.9, -
0.9, -0.9 (1P); 1H NMR (400 MHz): δ = 2.09 - 2.36 (m, 4H, F17C8CH2CH2CH2SO2-, 
F17C8CH2CH2CH2SO2-), 2.46 - 2.69 (m, 13H, 6 x CH2 cyanoethyl, CH2OH), 3.06 - 3.13 (m, 2H, 
F17C8CH2CH2CH2SO2-), 3.25 - 3.34 (m, 2H, -OCH2CH2SO2-), 3.63 - 3.72 (m, 3H, CH glycerol, CH2 
glycerol), 3.79 - 3.86 (m, 5H, 5 x CH glycerol), 4.08 - 4.33 (m, 34H, 11 x CH2 glycerol, 6 x CH2 
cyanoethyl), 4.43 - 4.50 (m, 2H, -OCH2CH2SO2-,), 4.58 - 4.66 (m, 12H, 6 x CH2 Bn), 7.26 - 7.36 (m, 
30H, Harom); 13C NMR (100 MHz): δ = 13.3 (F17C8CH2CH2CH2SO2-), 19.2 - 19.4 (6 x CH2 
cyanoethyl), 29.3 (F17C8CH2CH2CH2SO2-), 53.0 - 53.1 (F17C8CH2CH2CH2SO2-, -OCH2CH2SO2-), 60.4 
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- 60.5 (CH2 glycerol), 61.3 (-OCH2CH2SO2-), 62.0 - 62.4 (6 x CH2 cyanoethyl), 65.4 - 66.6 (11 x 
CH2 glycerol), 71.9 (CH2 Bn), 72.1 (5 x CH2 Bn), 75.1 - 75.4 (5 x CH glycerol), 77.5 - 77.6 (CH 
glycerol), 116.7 - 116.8 (6 x Cq cyanoethyl), 127.8 - 128.5 (CHarom), 137.1 - 137.3 (5 x Cq Bn), 
137.7 (Cq Bn); HRMS: [C91H107F17N6O33P6S + 2H]2+ requires 1177.2450, found 1177.2466. 
2-O-Benzyl-glycerol phosphate heptamer (13) 
Glycerol phosphate hexamer 12 (238 mg, 101 µmol) was coupled to 
glycerol phosphoramidite 6 (0.175 M in MeCN, 1.15 ml, 202 µmol, 2 
eq), oxidized, detritylated and purified (F-SPE) using the general 
procedure as described above. Heptamer 13 (225 mg, 84.7 µmol, 84 
%) was obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.9, -1.9 (1P), -1.4 - -1.1 (5P), -0.9, 
-0.9 (1P); 1H NMR (400 MHz): δ = 2.10 - 2.36 (m, 5H, F17C8CH2CH2CH2SO2-, F17C8CH2CH2CH2SO2-, 
CH2OH), 2.52 - 2.69 (m, 14H, 7 x CH2 cyanoethyl), 3.06 - 3.13 (m, 2H, F17C8CH2CH2CH2SO2-), 3.25 
- 3.34 (m, 2H, -OCH2CH2SO2-), 3.64 - 3.71 (m, 3H, CH glycerol, CH2 glycerol), 3.78 - 3.85 (m, 6H, 6 
x CH glycerol), 4.07 - 4.34 (m, 40H, 13 x CH2 glycerol, 7 x CH2 cyanoethyl), 4.43 - 4.50 (m, 2H, -
OCH2CH2SO2-,), 4.58 - 4.67 (m, 14H, 7 x CH2 Bn), 7.26 - 7.36 (m, 35H, Harom); 13C NMR (100 
MHz): δ = 13.4 (F17C8CH2CH2CH2SO2-), 19.3 - 19.5 (7 x CH2 cyanoethyl), 29.3 (t, J = 22 Hz, 
F17C8CH2CH2CH2SO2-), 53.0 - 53.2 (F17C8CH2CH2CH2SO2-, -OCH2CH2SO2-), 60.4 - 60.5 (CH2 
glycerol), 61.3 (-OCH2CH2SO2-), 62.0 - 62.4 (7 x CH2 cyanoethyl), 65.4 - 66.6 (13 x CH2 glycerol), 
71.9 (CH2 Bn), 72.1 (6 x CH2 Bn), 75.2 - 75.5 (6 x CH glycerol), 77.5 - 77.6 (CH glycerol), 116.6 - 
116.8 (7 x Cq cyanoethyl), 127.8 - 128.5 (CHarom), 137.1 - 137.3 (6 x Cq Bn), 137.7 (Cq Bn); HRMS: 
[C104H123F17N7O38P7S + 2Na]2+ requires 1348.2669, found 1348.2666. 
2-O-Benzyl-glycerol phosphate octamer (14) 
Glycerol phosphate heptamer 13 (222 mg, 83.7 µmol) was coupled to 
glycerol phosphoramidite 6 (0.175 M in MeCN, 0.96 ml, 167 µmol, 2 
eq), oxidized, detritylated and purified (F-SPE) using the general 
procedure as described above. Octamer 14 (206 mg, 69.7 µmol, 83 %) 
was obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.9, -1.8 (1P), -1.4 - -1.1 (6P), -0.9 
(1P); 1H NMR (400 MHz): δ = 2.10 - 2.36 (m, 5H, F17C8CH2CH2CH2SO2-, F17C8CH2CH2CH2SO2-, 
CH2OH), 2.51 - 2.68 (m, 16H, 8 x CH2 cyanoethyl), 3.06 - 3.13 (m, 2H, F17C8CH2CH2CH2SO2-), 3.25 
- 3.33 (m, 2H, -OCH2CH2SO2-), 3.64 - 3.72 (m, 3H, CH glycerol, CH2 glycerol), 3.78 - 3.85 (m, 7H, 7 
x CH glycerol), 4.07 - 4.33 (m, 46H, 15 x CH2 glycerol, 8 x CH2 cyanoethyl), 4.43 - 4.50 (m, 2H, -
OCH2CH2SO2-,), 4.57 - 4.66 (m, 16H, 8 x CH2 Bn), 7.26 - 7.37 (m, 40H, Harom); 13C NMR (100 
MHz): δ = 13.3 (F17C8CH2CH2CH2SO2-), 19.3 - 19.4 (8 x CH2 cyanoethyl), 29.3 
(F17C8CH2CH2CH2SO2-), 53.0 - 53.2 (F17C8CH2CH2CH2SO2-, -OCH2CH2SO2-), 60.4 - 60.5 (CH2 
glycerol), 61.3 (-OCH2CH2SO2-), 62.0 - 62.4 (8 x CH2 cyanoethyl), 65.4 - 66.6 (15 x CH2 glycerol), 
71.9 (CH2 Bn), 72.1 (7 x CH2 Bn), 75.2 - 75.5 (7 x CH glycerol), 77.5 - 77.6 (CH glycerol), 116.6 - 
116.7 (8 x Cq cyanoethyl), 127.8 - 128.5 (CHarom), 137.2 - 137.3 (7 x Cq Bn), 137.8 (Cq Bn); HRMS: 
[C117H139F17N8O43P8S + 2Na]2+ requires 1496.8052, found 1496.8054. 
2-O-Benzyl-glycerol phosphate nonamer (15) 
Glycerol phosphate octamer 14 (200 mg, 68.0 µmol) was coupled to 
glycerol phosphoramidite 6 (0.175 M in MeCN, 0.78 ml, 136 µmol, 2 
eq), oxidized, detritylated and purified (F-SPE) using the general 
procedure as described above. Nonamer 15 (182 mg, 56.1 µmol, 83 
%) was obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.9, -1.9 (1P), -1.3 - -1.1 (7P), -0.9 
(1P); 1H NMR (400 MHz): δ = 2.11 - 2.41 (m, 5H, F17C8CH2CH2CH2SO2-, F17C8CH2CH2CH2SO2-, 
CH2OH), 2.51 - 2.70 (m, 18H, 9 x CH2 cyanoethyl), 3.06 - 3.14 (m, 2H, F17C8CH2CH2CH2SO2-), 3.25 
Chapter 4 
~ 80 ~ 
- 3.34 (m, 2H, -OCH2CH2SO2-), 3.64 - 3.71 (m, 3H, CH glycerol, CH2 glycerol), 3.78 - 3.85 (m, 8H, 8 
x CH glycerol), 4.07 - 4.33 (m, 52H, 17 x CH2 glycerol, 9 x CH2 cyanoethyl), 4.43 - 4.50 (m, 2H, -
OCH2CH2SO2-,), 4.58 - 4.66 (m, 18H, 9 x CH2 Bn), 7.26 - 7.37 (m, 45H, Harom); 13C NMR (100 
MHz): δ = 13.3 (F17C8CH2CH2CH2SO2-), 19.3 - 19.4 (9 x CH2 cyanoethyl), 29.3 (t, J = 21 Hz, 
F17C8CH2CH2CH2SO2-), 53.0 - 53.2 (F17C8CH2CH2CH2SO2-, -OCH2CH2SO2-), 60.4 - 60.5 (CH2 
glycerol), 61.3 - 61.4 (-OCH2CH2SO2-), 62.0 - 62.4 (9 x CH2 cyanoethyl), 65.4 - 66.6 (17 x CH2 
glycerol), 71.9 (CH2 Bn), 72.1 (8 x CH2 Bn), 75.2 - 75.5 (8 x CH glycerol), 77.5 - 77.6 (CH 
glycerol), 116.6 - 116.8 (9 x Cq cyanoethyl), 127.8 - 128.5 (CHarom), 137.2 - 137.3 (8 x Cq Bn), 
137.8 (Cq Bn); HRMS: [C130H155F17N9O48P9S + 2Na]2+ requires 1645.3435, found 1645.3433. 
2-O-Benzyl-glycerol phosphate decamer (16) 
Glycerol phosphate nonamer 15 (175 mg, 54.0 µmol) was coupled to 
glycerol phosphoramidite 6 (0.175 M in MeCN, 0.93 ml, 162 µmol, 3 
eq), oxidized, detritylated and purified (F-SPE) using the general 
procedure as described above. Decamer 16 (166 mg, 46.9 µmol, 87 
%) was obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.9, -1.9 (1P), -1.4 - -1.1 (8P), -0.9 
(1P); 1H NMR (400 MHz): δ = 2.10 - 2.40 (m, 5H, F17C8CH2CH2CH2SO2-, F17C8CH2CH2CH2SO2-, 
CH2OH), 2.51 - 2.69 (m, 20H, 10 x CH2 cyanoethyl), 3.06 - 3.14 (m, 2H, F17C8CH2CH2CH2SO2-), 
3.25 - 3.34 (m, 2H, -OCH2CH2SO2-), 3.64 - 3.71 (m, 3H, CH glycerol, CH2 glycerol), 3.78 - 3.86 (m, 
9H, 9 x CH glycerol), 4.06 - 4.34 (m, 58H, 19 x CH2 glycerol, 10 x CH2 cyanoethyl), 4.43 - 4.49 (m, 
2H, -OCH2CH2SO2-,), 4.57 - 4.65 (m, 20H, 10 x CH2 Bn), 7.25 - 7.37 (m, 50H, Harom); 13C NMR (100 
MHz): δ = 13.4 (F17C8CH2CH2CH2SO2-), 19.3 - 19.5 (10 x CH2 cyanoethyl), 29.3 (t, J = 21 Hz, 
F17C8CH2CH2CH2SO2-), 53.0 - 53.2 (F17C8CH2CH2CH2SO2-, -OCH2CH2SO2-), 60.4 - 60.5 (CH2 
glycerol), 61.3 - 61.4 (-OCH2CH2SO2-), 62.0 - 62.4 (10 x CH2 cyanoethyl), 65.4 - 66.6 (19 x CH2 
glycerol), 71.9 (CH2 Bn), 72.1 (9 x CH2 Bn), 75.2 - 75.5 (9 x CH glycerol), 77.5 - 77.6 (CH 
glycerol), 116.7 - 116.8 (10 x Cq cyanoethyl), 127.8 - 128.5 (CHarom), 137.2 - 137.3 (9 x Cq Bn), 
137.7 (Cq Bn); HRMS: [C143H171F17N10O53P10S + 2Na]2+ requires 1793.8818, found 1793.8812. 
2-O-Benzyl-glycerol phosphate undecamer (17) 
Glycerol phosphate decamer 16 (165 mg, 46.6 µmol) was coupled to 
glycerol phosphoramidite 6 (0.175 M in MeCN, 0.80 ml, 140 µmol, 3 
eq), oxidized, detritylated and purified (F-SPE) using the general 
procedure as described above. Undecamer 17 (159 mg, 41.5 µmol, 89 
%) was obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.9, -1.9 (1P), -1.4 - -1.1 (9P), -0.9, 
-0.9 (1P); 1H NMR (400 MHz): δ = 2.10 - 2.37 (m, 4H, F17C8CH2CH2CH2SO2-, F17C8CH2CH2CH2SO2-
), 2.46 - 2.68 (m, 23H, 11 x CH2 cyanoethyl, CH2OH), 3.06 - 3.13 (m, 2H, F17C8CH2CH2CH2SO2-), 
3.25 - 3.34 (m, 2H, -OCH2CH2SO2-), 3.64 - 3.70 (m, 3H, CH glycerol, CH2 glycerol), 3.77 - 3.85 (m, 
10H, 10 x CH glycerol), 4.06 - 4.31 (m, 64H, 21 x CH2 glycerol, 11 x CH2 cyanoethyl), 4.43 - 4.50 
(m, 2H, -OCH2CH2SO2-,), 4.57 - 4.66 (m, 22H, 11 x CH2 Bn), 7.26 - 7.36 (m, 55H, Harom); 13C NMR 
(100 MHz): δ = 13.3 (F17C8CH2CH2CH2SO2-), 19.2 - 19.4 (11 x CH2 cyanoethyl), 29.3 
(F17C8CH2CH2CH2SO2-), 53.0 - 53.1 (F17C8CH2CH2CH2SO2-, -OCH2CH2SO2-), 60.3 - 60.4 (CH2 
glycerol), 61.3 (-OCH2CH2SO2-), 62.0 - 62.4 (11 x CH2 cyanoethyl), 65.4 - 66.6 (21 x CH2 
glycerol), 71.9 (CH2 Bn), 72.1 (10 x CH2 Bn), 75.2 - 75.5 (10 x CH glycerol), 77.5 - 77.6 (CH 
glycerol), 116.6 - 116.8 (11 x Cq cyanoethyl), 127.8 - 128.5 (CHarom), 137.2 - 137.3 (10 x Cq Bn), 
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2-O-Benzyl-glycerol phosphate dodecamer (18) 
Glycerol phosphate undecamer 17 (159 mg, 41.4 µmol) was coupled 
to glycerol phosphoramidite 6 (0.175 M in MeCN, 0.95 ml, 166 µmol, 
4 eq), oxidized, detritylated and purified (F-SPE) using the general 
procedure as described above. Dodecamer 18 (161 mg, 38.8 µmol, 94 
%) was obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.9, -1.9 (1P), -1.4 - -1.1 (10P), -
0.9, -0.9, -0.9 (1P); 1H NMR (400 MHz): δ = 2.11 - 2.40 (m, 5H, F17C8CH2CH2CH2SO2-, 
F17C8CH2CH2CH2SO2-, CH2OH), 2.52 - 2.69 (m, 24H, 12 x CH2 cyanoethyl), 3.06 - 3.13 (m, 2H, 
F17C8CH2CH2CH2SO2-), 3.25 - 3.34 (m, 2H, -OCH2CH2SO2-), 3.64 - 3.71 (m, 3H, CH glycerol, CH2 
glycerol), 3.78 - 3.85 (m, 11H, 11 x CH glycerol), 4.06 - 4.32 (m, 70H, 23 x CH2 glycerol, 12 x CH2 
cyanoethyl), 4.43 - 4.50 (m, 2H, -OCH2CH2SO2-,), 4.57 - 4.65 (m, 24H, 12 x CH2 Bn), 7.26 - 7.37 
(m, 60H, Harom); 13C NMR (100 MHz): δ = 13.3 (F17C8CH2CH2CH2SO2-), 19.2 - 19.5 (12 x CH2 
cyanoethyl), 29.3 (t, J = 21 Hz, F17C8CH2CH2CH2SO2-), 53.0 - 53.2 (F17C8CH2CH2CH2SO2-, -
OCH2CH2SO2-), 60.4 - 60.5 (CH2 glycerol), 61.3 (-OCH2CH2SO2-), 62.0 - 62.4 (12 x CH2 
cyanoethyl), 65.4 - 66.6 (23 x CH2 glycerol), 71.9 (CH2 Bn), 72.1 (11 x CH2 Bn), 75.2 - 75.5 (11 x 
CH glycerol), 77.5 - 77.6 (CH glycerol), 116.6 - 116.8 (12 x Cq cyanoethyl), 127.8 - 128.5 (CHarom), 
137.1 - 137.3 (11 x Cq Bn), 137.7 (Cq Bn); HRMS: [C169H203F17N12O63P12S + 3Na]3+ requires 
1401.6354, found 1401.6361. 
Glycerol phosphate dodecamer (19) 
Protected dodecamer 18 (72.4 mg, 17.5 µmol) was treated with 
aqueous ammonia as described above. The compound was eluted (H2O, 
~5 ml) through a small column containing Dowex Na+ cation-exchange 
resin (type: 50WX4-200, stored on 0.5 M NaOH in H2O, flushed with 
MeOH and H2O until pH neutral before use) and, subsequently, lyophilized, yielding the 
intermediate dodecamer (56.5 mg, 17.5 µmol, 100 %) as an amorphous white solid. Analytical 
data intermediate: 31P NMR (161.7 MHz, D2O): δ = 1.0 - 1.2 (11P), 2.5 (1P, phosphomonoester); 
1H NMR (400 MHz, D2O): δ = 3.46 - 3.71 (m, 14H, 12 x CH glycerol, CH2 glycerol), 3.72 - 4.01 (m, 
46H, 23 x CH2 glycerol), 4.26 - 4.58 (m, 24H, 12 x CH2 Bn), 6.93 - 7.33 (m, 60H, Harom); 13C NMR 
(100 MHz, D2O): δ = 60.2 (CH2 glycerol), 63.2 (CH2 glycerol), 64.3 - 64.6 (22 x CH2 glycerol), 71.6 
(CH2 Bn), 71.8 - 72.0 (11 x CH2 Bn), 76.9 - 77.1 (11 x CH glycerol), 78.1 (CH glycerol), 127.9 - 
128.6 (CHarom), 137.4 - 137.6 (12 x Cq Bn); HRMS: [C120H158O61P12 + 2NH4]2+ requires 1491.8411, 
found 1491.8423. A portion of the intermediate (53.0 mg, 16.4 µmol) was deprotected with Pd 
(0)/H2 using the standard procedure. Dodecaglycerolphosphate 19 (30.3 mg, 14.1 µmol, 86 %) 
was obtained as an amorphous white solid. 31P NMR (161.7 MHz, D2O): δ = 1.2 - 1.3 (11P), 2.8 
(1P, phosphomonoester); 1H NMR (600 MHz, D2O): δ = 3.59 (dd, 1H, J = 6.1 Hz, 11.8 Hz, CHH 
glycerol), 3.67 (dd, 1H, J = 4.3 Hz, 11.8 Hz, CHH glycerol), 3.81 - 3.97 (m, 48H, 2 x CH glycerol, 23 
x CH2 glycerol), 3.99 - 4.06 (m, 10H, 10 x CH glycerol); 13C NMR (150 MHz, D2O): δ = 63.1 (CH2 
glycerol), 66.3 (d, J = 4.9 Hz, CH2 glycerol), 67.1 (d, J = 5.5 Hz, CH2 glycerol), 67.2 (d, J = 5.4 Hz, 
19 x CH2 glycerol), 67.4 (d, J = 5.8 Hz, CH2 glycerol), 67.4 (d, J = 5.7 Hz, CH2 glycerol), 70.5 (t, J = 
8.0 Hz, 10 x CH glycerol), 70.9 (t, J = 7.7 Hz, CH glycerol), 71.7 (d, J = 7.8 Hz, CH glycerol); HRMS: 
C36H86O61P12 + NH4+ requires 1884.0817, found 1884.0826. 
1-[(Perfluorooctylpropysulfonylethyl)-(2-cyanoethyl)-
phosphate]-2-O-benzyl-3-O-[(6-Cbz-aminohexyl)-(2-
cyanoethyl) phosphate]-sn-glycerol (21) 
Monomeric glycerol phosphate alcohol 7 (182 mg, 209 µmol) 
was coupled to spacer phosphoramidite 20 (0.2 M in MeCN, 
2.61 ml, 523 µmol, 2.5 eq), oxidized and purified (F-SPE) as described in the general procedure. 
Construct 21 (243 mg, 197 µmol, 94 %) was obtained as a colorless oil. 31P NMR (161.7 MHz): δ 
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= -1.8, -1.8 (1P), -1.1, -1.0 (1P); 1H NMR (400 MHz): δ =  1.31 - 1.42 (m, 4H, 2 x CH2 hexylspacer), 
1.46 - 1.55 (m, 2H, CH2 hexylspacer), 1.64 - 1.72 (m, 2H, CH2 hexylspacer), 2.12 - 2.37 (m, 4H, 
F17C8CH2CH2CH2SO2-, F17C8CH2CH2CH2SO2-), 2.63 - 2.72 (m, 4H, 2 x CH2 cyanoethyl), 3.07 - 3.21 
(m, 4H, F17C8CH2CH2CH2SO2-, CH2-N hexylspacer), 3.25 - 3.36 (m, 2H, -OCH2CH2SO2-), 3.85 - 3.91 
(m, 1H, CH glycerol), 4.05 - 4.10 (m, 2H, CH2-O hexylspacer), 4.14 - 4.29 (m, 7H, CH2 glycerol, 
CHH glycerol, 2 x CH2 cyanoethyl), 4.32 - 4.39 (m, 1H, CHH glycerol), 4.46 - 4.52 (m, 2H, -
OCH2CH2SO2-,), 4.67 (s, 2H, CH2 Bn), 4.95 (bs, 1H, NH CBz), 5.09 (s, 2H, CH2 CBz), 7.29 - 7.38 (m, 
10H, Harom); 13C NMR (100 MHz): δ = 13.3 (F17C8CH2CH2CH2SO2-), 19.4 - 19.5 (2 x CH2 
cyanoethyl), 24.8, 25.9 (2 x CH2 hexylspacer), 29.2 (t, J = 23 Hz, F17C8CH2CH2CH2SO2-), 29.6 (CH2 
hexylspacer), 29.8 (d, J = 6.6 Hz, CH2 hexylspacer), 40.7 (CH2-N hexylspacer), 53.0 - 53.2 
(F17C8CH2CH2CH2SO2-, -OCH2CH2SO2-), 61.3 (-OCH2CH2SO2-), 61.8 - 61.9 (CH2 cyanoethyl), 62.3 - 
62.4 (CH2 cyanoethyl), 65.2 - 65.3 (CH2 glycerol), 66.1 - 66.2 (CH2 glycerol), 66.4 (CH2 CBz), 68.3 
- 68.5 (CH2-O hexylspacer), 72.2 (CH2 Bn), 75.3 (t, J = 6.8 Hz, CH glycerol), 116.6 (2 x Cq 
cyanoethyl), 127.8 - 128.5 (CHarom), 136.6, 137.1 (Cq Bn, Cq CBz), 156.3 (C=O CBz); HRMS: 
C43H50F17N3O13P2S + H+ requires 1234.2341, found 1234.2342. 
1-O-tert-Butyldiphenylsilyl-2-O-(2-azido-3,4,6-tri-O-benzyl-2-deoxy-
α-D-glucopyranosyl)-3-O-allyl-sn-glycerol (26). 
To a cooled (0 oC) solution of triol 25 (5.09 g, 9.13 mmol) and benzyl 
bromide (10.2 ml, 85.0 mmol) in a 3/2 mixture of DMF/THF (110 ml) was 
added NaH (60 % dispersion in mineral oil, 2.90 g, 72.5 mmol). After 
stirring for 30 h at RT, MeOH (10 ml) was added and the mixture was 
allowed to stir for another 30 min. The volatiles were removed under reduced pressure and the 
residue was taken up in Et2O (500 ml) and washed with H2O (100 ml) and brine (300 ml). The 
organic layer was dried (Na2SO4) and concentrated in vacuo, after which purification of the 
residue by column chromatography (EtOAc/PE) yielded fully protected 26 (4.24 g, 5.12 mmol, 
56%) as a colorless oil. Analytical data were in accordance to literature data.27 
1-O-tert-Butyldiphenylsilyl-2-O-(2-acetamido-3,4,6-tri-O-benzyl-2-
deoxy-α-D-glucopyranosyl)-3-O-allyl-sn-glycerol (27a). 
To a solution of compound 26 (3.38 g, 4.09 mmol) in a 5/1 mixture of 1,4-
dioxane/H2O (24 ml) was added PMe3 (1M in toluene, 8.2 ml, 8.2 mmol). 
After stirring for 4 h, the volatiles were removed under reduced pressure 
and, subsequently, the residue was coevaporated with toluene (3 x 20 
ml). The residue was taken up in pyridine (20 ml) and, after the addition of Ac2O (0.80 ml, 8.5 
mmol), stirred overnight. The mixture was diluted with Et2O (200 ml) and and washed with H2O 
(70 ml), sat. aq. NaHCO3 (70 ml) and brine (70 ml). The organic layer was dried (Na2SO4) and 
concentrated in vacuo after which purification of the residue by column chromatography 
(EtOAc/PE) gave title compound 27a (2.80 g, 3.32 mmol, 81%) as a colourless oil. Analytical 




To a solution of allyl ether 27a (1.92 g, 2.11 mmol) in THF (29 ml) was 
added Ir(COD)(PPh2Me)2PF6 (89 mg, 0.11 mmol). The solution was 
shortly purged with H2 (g) (~10s) and stirred for 45 min under argon 
atmosphere. The mixture was diluted with sat. aq. NaHCO3 (10 ml) and I2 (1.45 g, 5.71 mmol) 
was added. After stirring for 30 m in the mixture was diluted with EtOAc (250 ml) and washed 
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with sat. aq. Na2S2O3 (50 ml) and brine (100 ml), respectively. The organic layer was dried 
(Na2SO4) and the volatiles removed under reduced pressure after which purification of the 
residue by column chromatography (EtOAc/PE) gave the intermediate 1-O-tert-
Butyldiphenylsilyl-2-O-(2-acetamido-3,4,6-tri-O-benzyl-2-deoxy-α-D-glucopyranosyl)-sn-
glycerol as a slightly yellow oil. Analytical data were in accordance to literature data.27 To a 
cooled (0 oC) solution of 1-O-tert-butyldiphenylsilyl-2-O-(2-acetamido-3,4,6-tri-O-benzyl-2-
deoxy-α-D-glucopyranosyl)-sn-glycerol (2.17 g, 2.70 mmol) and Et3N (0.60 ml, 4.33 mmol) in 
DCM (14 ml)  was added DMT-Cl (1.17 g, 3.46 mmol). The mixture was stirred for 2 hrs before 
MeOH (5.0 ml) was added. After stirring for an additional 15 minutes the reaction mixture was 
diluted with DCM (40 ml) and washed with a 1/1 mixture of sat. aq. NaHCO3 and brine (30 ml). 
The aqueous layer was extracted with DCM (2 x 10 ml) and the combined organic layers were 
dried (Na2SO4) and concentrated under reduced pressure. The residual oil was purified by silica 
gel column chromatography (EtOAc/PE, containing ~0.5% Et3N) yielding DMT ether 28a (2.57 
g, 2.32 mmol, 86%) as an off white oil. [α]D20 (CHCl3): +41.0; IR (neat): 1028, 1248, 1508, 1684, 
2906, 2930; 1H NMR (400 MHz): δ = 0.95 (s, 9H, t-Bu TBDPS), 1.53 (s, 3H, NHAc), 3.20 (dd, 1H, J 
= 6.4 Hz, 10.1 Hz, CHH glycerol), 3.36 (d, 1H, J = 10.2 Hz, H-6), 3.40 (dd, 1H, J = 3.5 Hz, 10.2 Hz, 
CHH glycerol), 3.59 (dd, 1H, J = 2.5 Hz, 10.7 Hz, H-6’), 3.63 - 3.67 (m, 2H, H-3, CHH glycerol), 3.72 
- 3.82 (m, 9H, H-4, H-5, CHH glycerol, 2 x OMe), 3.89 - 3.94 (m, 1H, CH glycerol), 4.29 - 4.39 (m, 
2H, H-2, CHH Bn), 4.47 (d, 1H, J = 10.9 Hz, CHH Bn), 4.56 (d, 1H, J = 12.2 Hz, CHH Bn), 4.61 (d, 
1H, J = 11.5 Hz, CHH Bn), 4.77 (d, 1H, J = 10.8 Hz, CHH Bn), 4.79 (d, 1H, J = 11.4 Hz, CHH Bn), 4.96 
(d, 1H, J = 3.7 Hz, H-1), 5.49 (d, 1H, J = 9.7 Hz, NH), 6.78 - 6.82 (m, 4H, Harom), 7.12 - 7.40 (m, 30H, 
Harom), 7.54 - 7.57 (m, 4H, Harom); 13C NMR (100 MHz): δ = 19.1 (Cq t-Bu), 23.3 (CH3 NHAc), 26.7 
(3 x CH3 TBDPS), 52.4 (C-2), 55.2 (2 x OMe), 63.0 (CH2 glycerol), 63.6 (CH2 glycerol), 68.1 (C-6), 
71.1 (C-5), 73.3 (CH2 Bn), 74.8 (CH2 Bn), 74.9 (CH2 Bn), 77.5 (CH glycerol), 78.0 (C-4), 81.0 (C-
3), 86.2 (Cq DMTr), 97.6 (C-1), 113.1 (CHarom), 126.8 - 130.0 (CHarom), 133.1, 133.1 (2 x Cq 
phenyl), 135.4 (CHarom), 135.8, 135.9, 138.0, 138.2, 138.4 (2 x Cq DMTr, 3 x Cq Bn), 144.8 (Cq 





Compound 28a (2.36 g, 2.13 mmol) was dissolved in THF (21 ml) and 
after addition of TBAF (1.00 M in THF, 3.20 ml, 3.20 mmol) stirred 
overnight. After evaporation of the solvents under reduced pressure 
the resulting oil was purified by column chromatography (EtOAc/PE, 
containing ~0.5% Et3N) giving the intermediate alcohol (1.74 g, 2.00 
mmol, 94%) as a colourless oil. Analytical data 2-O-(2-acetamido-3,4,6-tri-O-benzyl-2-deoxy-
α-D-glucopyranosyl)-3-O-(4,4’-dimethoxytrityl)-sn-glycerol: [α]D20 (CHCl3):  +45.5; IR 
(neat): 906, 1373, 1541, 1663, 2900; 1H NMR (400 MHz): δ = 1.59 (s, 3H, NHAc), 3.18 (dd, 1H, J 
= 3.7 Hz, 10.2 Hz, CHH glycerol), 3.29 (dd, 1H, J = 6.7 Hz, 10.1 Hz, CHH glycerol), 3.54 - 3.59 (m, 
3H, H-4, H-6, CHH glycerol), 3.67 - 3.78 (m, 10H, H-3, H-6’, CH glycerol, CHH glycerol, 2 x OMe), 
4.03 - 4.07 (m, 1H, H-5), 4.33 (td, 1H, J = 3.8 Hz, 10.0 Hz, 10.0 Hz, H-2), 4.47 - 4.57 (m, 3H, 3 x 
CHH Bn), 4.65 (d, 1H, J = 11.4 Hz, CHH Bn), 4.80 (d, 1H, J = 10.9 Hz, CHH Bn), 4.83 (d, 1H, J = 11.4 
Hz, CHH Bn), 4.90 (d, 1H, J = 3.8 Hz, H-1), 5.53 (d, 1H, J = 9.5 Hz, NH), 6.80 - 6.83 (m, 4H, Harom), 
7.15 - 7.41 (m, 24H, Harom) ; 13C NMR (100 MHz): δ = 23.2 (CH3 NHAc), 52.5 (C-2), 55.1 (2 x 
OMe), 63.4 (CH2 glycerol), 63.6 (CH2 glycerol), 68.7 (C-6), 71.4 (C-5), 73.4 (CH2 Bn), 75.0 (CH2 
Bn), 75.1 (CH2 Bn), 78.4 (C-4), 81.0, 81.4 (C-3, CH glycerol), 86.3 (Cq DMTr), 98.2 (C-1), 113.1 
(CHarom), 126.9 - 129.9 (CHarom), 135.7, 137.5, 137.7, 138.2 (2 x Cq DMTr, 3 x Cq Bn), 144.6 (Cq 
DMTr), 158.5 (Cq DMTr), 169.8 (C=O NHAc); HRMS: C53H57NO10 + Na+ requires 890.3875, found 
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890.3882. To a cooled (0 oC) solution of the intermediate alcohol (828 mg, 0.950 mmol) and 
Et3N (200 µl, 1.44 mmol) in freshly distilled DCM (10 ml) was added 2-cyanoethyl-N,N-
diisopropylchlorophosphoramidite (250 µl, 1.12 mmol). After stirring overnight, the reaction 
was quenched by the addition of H2O (2.0 ml), diluted with DCM (40 ml) and washed with H2O 
(20 ml) and brine (20 ml), respectively. The organic layer was dried over Na2SO4 and 
concentrated in vacuo. Purification of the residue by column chromatography (EtOAc/PE, 
containing ~0.5% Et3N) gave phosphoramidite 29a (760 mg, 0.710 mmol, 75%, mixture of 
diastereomers) as a white foam. IR (neat): 1248, 1508, 1607, 1676, 2870, 2928, 3279; 31P NMR 
(161.7 MHz, CD3CN): δ = 148.9, 149.2 (diastereoisomers); 1H NMR (400 MHz, CD3CN): δ = 1.09 - 
1.16 (m, 12H, 4 x CH3 isopropylamino), 1.67, 1.68 (2s, 3H, NHAc, diastereoisomers), 2.48 - 2.54 
(m, 2H, CH2 cyanoethyl), 3.14 - 3.24 (m, 1H, CHH glycerol), 3.30 - 3.36 (m, 1H, CHH glycerol), 
3.50 - 3.90 (m, 16H, H-3, H-4, H-6, H-6’, CH2 glycerol, 2 x OMe, CH2 cyanoethyl, 2 x CH 
isopropylamino), 3.92 - 4.00 (m, 1H, CH glycerol), 4.02 - 4.16 (m, 2H, H-2, H-5), 4.52 - 4.61 (m, 
3H, 3 x CHH Bn), 4.69 (d, 1H, J = 11.2 Hz, CHH Bn), 4.79 - 4.82 (m, 2H, 2 x CHH Bn), 4.91, 4.93 
(2d, 1H, J = 3.5 Hz, H-1, diastereoisomers), 6.33, 6.36 (2d, 1H, J = 9.7 Hz, NH), 6.87 (d, 4H, J = 8.8 
Hz, Harom), 7.21 - 7.47 (m, 24H, Harom); 13C NMR (100 MHz, CD3CN): δ = 20.9, 20.9 (CH2 
cyanoethyl), 23.4 (CH3 NHAc) 24.9 - 25.2 (4 x CH3 isopropylamino), 43.7, 43.8 (2 x CH 
isopropylamino), 53.7 (C-2), 55.9 (2 x OMe), 59.3, 59.5 (CH2 cyanoethyl), 63.4 (CH2 glycerol), 
64.4 - 64.6 (CH2 glycerol), 69.9, 69.9 (C-6), 71.9, 72.0 (C-5), 73.8, 73.9 (CH2 Bn), 75.4, 75.5 (CH2 
Bn), 75.7 (CH2 Bn), 76.7, 77.1 (2d, J = 8 Hz, CH glycerol, diastereoisomers), 79.5, 79.6 (C-4), 81.6 
(C-3), 87.0 (Cq DMTr), 97.7, 98.0 (C-1), 114.1 (CHarom), 118.2 (Cq cyanoethyl), 127.7 - 130.9 
(CHarom), 136.9, 139.5 - 139.9 (2 x Cq DMTr, 3 x Cq Bn), 146.2 (Cq DMTr), 159.6 (Cq DMTr), 170.4 
(C=O NHAc); HRMS: C62H74N3O11P + Na+ requires 1090.4953, found 1090.4953. 
GlcNAc-2-O-benzylglycerol phosphate hexamer (30a) 
Glycerol phosphate pentamer 11 (74.1 mg, 36.0 µmol) 
and N-acetylglucosamineglycerol phosphoramidite 29a 
(77.0 mg, 72.1 µmol, 2 eq) were dissolved in CH3CN (1.0 
ml) together with freshly activated MS3Å and stirred for 
15 min under argon. Subsequently, DCI (0.25M solution 
in CH3CN, 0.72 ml, 0.18 mmol) was added and the 
mixture stirred for 1 hr before water (0.50 ml) was added. The oxidation, detritylation and F-
SPE steps were performed according to the general procedure. Hexamer 30a (71.6 mg, 26.2 
µmol, 73 %) was obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.9, -1.8 (1P), -1.6 - -1.0 
(5P); 1H NMR (400 MHz): δ = 1.87 - 1.92 (bs, 3H, NHAc), 2.10 - 2.34 (m, 5H, CH2OH, 
F17C8CH2CH2CH2SO2-, F17C8CH2CH2CH2SO2-), 2.42 - 2.70 (m, 12H, 6 x CH2 cyanoethyl), 3.06 - 3.13 
(m, 2H, F17C8CH2CH2CH2SO2-), 3.24 - 3.33 (m, 2H, -OCH2CH2SO2-), 3.54 - 3.98 (m, 13H, H-3, H-4, 
H-5, H-6, H-6’, 6 x CH glycerol, CH2 glycerol), 4.03 - 4.34 (m, 35H, H-2, 11 x CH2 glycerol, 6 x CH2 
cyanoethyl), 4.43 - 4.51 (m, 2H, -OCH2CH2SO2-), 4.56 - 4.69 (m, 14H, 7 x CH2 Bn), 4.75 - 4.80 (m, 
2H, CH2 Bn), 4.96 (m, 1H, H-1), 6.55 - 6.76 (m, 1H, NHAc), 7.11 - 7.17 (m, 2H, Harom), 7.22 - 7.36 
(m, 38H, Harom); HRMS: [C113H132F17N7O38P6S + 2NH4]2+ requires 1386.3598, found 1386.3608. 
GlcNAc-2-O-benzylglycerol phosphate 
hexamer-aminohexyl spacer (31a) 
Hexamer 30a (68.9 mg, 25.2 µmol) was 
coupled to phosphoramidite 20 (0.2 M in 
MeCN, 0.50 ml, 101 µmol, 4 eq), oxidized and 
purified (F-SPE) using the general procedure as 
described above. Oligomer 31a (62.5 mg, 20.1 
µmol, 80 %) was obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.9, -1.8 (1P), -1.4 - -0.9  
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(5P), -0.8, -0.7 (1P); 1H NMR (400 MHz): δ = 1.15 - 1.54 (m, 6H, 3 x CH2 hexylspacer), 1.63 - 1.69 
(m, 2H, CH2 hexylspacer), 1.96 - 2.00 (bs, 3H, NHAc), 2.06 - 2.36 (m, 4H, F17C8CH2CH2CH2SO2-, 
F17C8CH2CH2CH2SO2-), 2.42 - 2.73 (m, 14H, 7 x CH2 cyanoethyl), 3.05 - 3.20 (m, 4H, 
F17C8CH2CH2CH2SO2-, CH2-N hexylspacer), 3.23 - 3.34 (m, 2H, -OCH2CH2SO2-), 3.64 - 3.97 (m, 
11H, H-3, H-4, H-5, H-6, H-6’, 6 x CH glycerol), 4.03 - 4.38 (m, 41H, H-2, 12 x CH2 glycerol, 7 x 
CH2 cyanoethyl, CH2-O hexylspacer), 4.42 - 4.51 (m, 4H, -OCH2CH2SO2-, CH2 Bn), 4.56 - 4.65 (m, 
11H, 5 x CH2 Bn, CHH Bn), 4.68 - 4.80 (m, 3H, CH2 Bn, CHH Bn), 4.90 - 4.93 (m, 1H, H-1), 5.00 - 
5.15 (m, 3H, NH CBz, CH2 CBz),  7.09 - 7.20 (m, 3H, NHAc, Harom), 7.22 - 7.38 (m, 43H, Harom); 
HRMS: [C130H155F17N9O43P7S + 2NH4]2+ requires 1569.4271, found 1569.4276. 
GlcNAc glycerol phosphate hexamer-
aminohexyl spacer (32a) 
Protected hexamer 31a (59.7 mg, 19.2 µmol) was 
treated with aqueous ammonia as described 
above. The compound was eluted through a small 
column containing Dowex Na+ cation-exchange 
resin (type: 50WX4-200, stored on 0.5 M NaOH in 
H2O, flushed with H2O and MeOH before use) and, subsequently, lyophilized, yielding the 
intermediate semi-protected hexamer (43.6 mg, 18.6 µmol, 97 %) as an amorphous white solid. 
Analytical data intermediate: 31P NMR (161.7 MHz, D2O): δ = 1.0 - 1.3 (6P), 2.5 (1P, 
phosphomonoester); 1H NMR (400 MHz, D2O): δ = 0.90 - 1.30 (m, 6H, 3 x CH2 hexylspacer), 1.39 
- 1.52 (m, 2H, CH2 hexylspacer), 1.96 (bs, 3H, NHAc), 2.82 - 2.93 (m, 2H, CH2-N hexylspacer), 
3.43 - 4.17 (m, 40H, H-2, H-3, H-4, H-5, H-6, H-6’, 12 x CH2 glycerol, 6 x CH glycerol, CH2-O 
hexylspacer, 2 x CHH Bn), 4.28 - 4.55 (m, 14H, 6 x CH2 Bn, 2 x CHH Bn), 4.78 - 4.85 (m, 3H, NH 
CBz, CH2 CBz), 4.96 - 4.98 (m, 1H, H-1), 6.76 - 6.82 (m, 3H, NHAc, Harom), 6.96 - 7.29 (m, 43H, 
Harom); HRMS: [C96H125N2O41P7 + 2H]2+ requires 1090.3033, found 1090.3043. A portion of the 
intermediate (43.0 mg, 18.4 µmol) was deprotected with Pd (0)/H2 using the standard 
procedure. monoGlcNAc hexamer 32a (23.6 mg, 16.1 µmol, 88 %) was obtained as an 
amorphous white solid. 31P NMR (161.7 MHz, D2O): δ = 1.0 (1P), 1.1 (1P), 1.3 (3P), 1.4 (1P), 3.2 
(1P, phosphomonoester); 1H NMR (600 MHz, D2O): δ = 1.33 - 1.37 (m, 4H, 2 x CH2 hexylspacer), 
1.55 - 1.62 (m, 4H, 2 x CH2 hexylspacer), 1.99 (s, 3H, NHAc), 2.92 (t, 2H, J = 7.5 Hz, CH2-N 
hexylspacer), 3.39 (at, 1H, J = 9.6 Hz, H-3), 3.69 - 3.99 (m, 37H, H-2, H-4, H-5, H-6, H-6’, 6 x CH 
glycerol, 12 x CH2 glycerol, CH2-O hexylspacer), 5.00 (d, 1H, J = 3.5 Hz, H-1); 13C NMR (150 MHz, 
D2O): δ = 23.0 (CH3 NHAc), 25.4, 26.1, 27.5 (3 x CH2 hexylspacer), 30.4 (d, J = 6.9 Hz, CH2 
hexylspacer), 40.3 (CH2-N hexylspacer), 54.6 (C-2), 61.4 (C-6), 65.2 (d, J = 5.1 Hz, CH2 glycerol), 
66.0 - 66.1 (CH2 glycerol, CH2-O hexylspacer), 67.0 - 67.4 (10 x CH2 glycerol), 70.4 (t, J = 7.9 Hz, 4 
x CH glycerol), 70.9 - 71.0 (C-3, CH glycerol), 71.9 (C-4), 73.0 (C-5), 76.7 (t, J = 7.8 Hz, CH 




To a solution of compound 26 (787 mg, 0.950 mmol) in dioxane/water 
(5/1, 6.0 ml) was added PMe3 (1.00 M in toluene, 2.00 ml, 2.00 mmol). 
This mixture was allowed to stir at rt for 4h after which the volatiles were 
removed in vacuo. The crude intermediate was, after coevaporation with 
toluene, redissolved in MeOH (7.0 ml) and CHCl3 (14 ml). To this mixture were added NaHCO3 
(500 mg, 5.95 mmol) and benzylchloroformate (0.160 ml, 1.14 mmol). After stirring for 1.5 h, 
the solvents were removed under reduced pressure and the residue was taken up in EtOAc, 
filtrated and concentrated in vacuo. Purification by silica gel column chromatography 
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(EtOAc/PE) afforded carbamate 27b (738 mg, 0.788 mmol, 83%) as a colorless oil. [α]D20 
(CHCl3): +46.0; IR (neat): 908, 1024, 1045, 1508, 1719, 2858, 3030; 1H NMR (400 MHz): δ = 1.03 
(s, 9H, t-Bu TBDPS), 3.38 (ad, 1H, J = 10.7 Hz, H-6), 3.49 (m, 1H, CHH glycerol), 3.56 - 3.81 (m, 
7H, H-4, H-5, H-6’, CH glycerol, CHH glycerol, CH2 glycerol), 3.86 - 4.04 (m, 4H, H-2, H-3, CH2 
allyl), 4.37 (d, 1H, J = 12.2 Hz, CHH Bn), 4.46 (d, 1H, J = 10.9 Hz, CHH Bn), 4.55 (d, 1H, J = 12.2 Hz, 
CHH Bn), 4.64 (d, 1H, J = 11.2 Hz, CHH Bn), 4.74 (d, 1H, J = 11.2 Hz, CHH Bn), 4.77 (d, 1H, J = 10.9 
Hz, CHH Bn), 4.99 (d, 1H, J = 3.5 Hz, H-1), 5.02 - 5.08 (m, 2H, CHH Cbz, CHH allyl), 5.14 - 5.19 (m, 
2H, CHH Cbz, CHH allyl), 5.31 (d, 1H, J = 9.7 Hz, NH), 5.79 (ddd, 1H, J = 5.6 Hz, 10.8 Hz, 16.2 Hz, 
CH allyl), 7.11 - 7.13 (m, 2H, Harom), 7.22 - 7.40 (m, 24H, Harom), 7.61 - 7.63 (m, 4H, Harom); 13C 
NMR (100 MHz): δ = 19.2 (Cq t-Bu), 26.8 (3 x CH3 TBDPS), 55.0 (C-2), 63.6 (CH2 glycerol), 66.7 
(CH2 Cbz), 68.1 (C-6), 69.5 (CH2 glycerol), 71.2 (C-5), 72.2 (CH2 allyl), 73.3 (CH2 Bn), 74.7 (CH2 
Bn), 75.2 (CH2 Bn), 77.8 (C-3, CH glycerol), 81.3 (C-4), 98.4 (C-1), 117.2 (CH2 allyl), 127.4 - 128.4 
(CHarom), 129.7 (CHarom), 133.1, (Cq phenyl), 134.4 (CH allyl), 135.5 (CHarom), 136.5, 138.0, 138.3, 





A solution of glycoside 27b (1.08 g, 1.15 mmol) in freshly distilled THF 
(10 ml) was stirred under argon for 30 min. After the addition of 
Ir(COD)(Ph2MeP)2PF6 (48 mg, 0.060 mmol) the solution was purged 
with H2 (g) for ~15s. After stirring under argon for 1.5 hrs, the mixture was diluted with THF 
(10 ml) and sat. aq. NaHCO3 (10 ml). Upon addition of I2 (0.58 g, 2.3 mmol), the mixture was 
allowed to stir for 30 mins at room temperature. The mixture was then diluted with EtOAc (100 
ml) and washed with sat. aq. Na2S2O3 (30 ml) and brine (40 ml), respectively. The organic layer 
was dried over Na2SO4 and concentrated in vacuo. Column chromatography (EtOAc/PE) 
afforded the intermediate alcohol (963 mg, 1.09 mmol, 95%) as a pale yellow oil. Analytical data 
1-O-tert-butyldiphenylsilyl-2-O-(2-benzylcarbamate-3,4,6-tri-O-benzyl-2-deoxy-α-D-
glucopyranosyl)-sn-glycerol: [α]D20 (CHCl3): +57.0; IR (neat): 816, 1036, 1452, 1549, 1670, 
1697, 2924, 3065, 3306; 1H NMR (400 MHz):δ = 1.03 (s, 9H, t-Bu TBDPS), 2.27 (bs, 1H, OH), 
3.37 (ad, 1H, J = 10.2 Hz, H-6), 3.56 (ad, 1H, J = 10.0 Hz, H-6’), 3.64 - 3.84 (m, 8H, H-3, H-4, H-5, 
CH glycerol, 2 x CH2 glycerol), 3.94 - 4.00 (m, 1H, H-2), 4.38 (d, 1H, J = 12.2 Hz, CHH Bn), 4.46 (d, 
1H, J = 10.8 Hz, CHH Bn), 4.53 (d, 1H, J = 12.2 Hz, CHH Bn), 4.62 (d, 1H, J = 10.9 Hz, CHH Bn), 4.73 
- 4.78 (m, 2H, 2 x CHH Bn), 4.99 - 5.05 (m, 2H, H-1, CHH Cbz), 5.14 (d, 1H, J = 12.2 Hz, CHH Cbz), 
5.21 (d, 1H, J = 8.0 Hz, NH), 7.06 - 7.41 (m, 26H, Harom), 7.61 - 7.65 (m, 4H, Harom); 13C NMR (100 
MHz): δ = 19.1 (Cq t-Bu), 26.8 (3 x CH3 TBDPS), 55.0 (C-2), 62.2 (CH2 glycerol), 64.2 (CH2 
glycerol), 66.8 (CH2 Cbz), 68.1 (C-6), 71.1 (C-5), 73.3 (CH2 Bn), 74.7 (CH2 Bn), 75.1 (CH2 Bn), 
77.9, 78.1, (C-3, CH glycerol), 80.7 (C-4), 97.4 (C-1), 127.6 - 128.4 (CHarom), 129.8 (CHarom), 132.8 
(Cq phenyl), 135.5 (CHarom), 136.4, 137.8, 138.2 (4 x Cq Bn), 156.1 (C=O, Cbz); HRMS: 
C54H61NO9Si + Na+ requires 918.4009, found 918.4008. To a cooled (0 oC) solution of the 
intermediate alcohol (755 mg, 0.858 mmol) and Et3N (0.19 ml, 1.3 mmol) in DCM (4.3 ml) was 
added DMTr-Cl (349 mg, 1.02 mmol). The mixture was stirred for 2 hrs before MeOH (1.0 ml) 
was added. After stirring for an additional 15 minutes the reaction mixture was diluted with 
DCM (40 ml) and washed with a 1/1 mixture of sat. aq. NaHCO3 and brine (30 ml). The aqueous 
layer was extracted with DCM (2 x 10 ml) and the combined organic layers were dried (Na2SO4) 
and concentrated under reduced pressure. The residual oil was purified by silica gel column 
chromatography (EtOAc/PE, containing ~0.5% Et3N) yielding DMTr-ether 28b (962 mg, 0.803 
mmol, 94%) as an off white oil. [α]D20 (CHCl3): +52.0; IR (neat): 1028, 1248, 2951, 1508, 1726, 
2857, 2901, 2930; 1H NMR (400 MHz): δ = 0.93 (s, 9H, t-Bu TBDPS), 3.10 (dd, 1H, J = 7.0 Hz, 10.3 
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Hz, CHH glycerol), 3.37 (ad, 1H, J = 10.6 Hz, H-6), 3.44 (dd, 1H, J = 2.1 Hz, 9.8 Hz, CHH glycerol), 
3.55 - 3.63 (m, 3H, H-3, H-6’, CHH glycerol), 3.71 - 3.78 (m, 9H, H-4, H-5, CHH glycerol, 2 x OMe), 
3.96 - 4.01 (m, 1H, CH glycerol), 4.05 - 4.11 (m, 1H, H-2), 4.39 (d, 1H, J = 12.2 Hz, CHH Bn), 4.45 
(d, 1H, J = 10.9 Hz, CHH Bn), 4.57 (d, 1H, J = 12.2 Hz, CHH Bn), 4.60 (d, 1H, J = 11.9 Hz, CHH Bn), 
4.63 (d, 1H, J = 12.5 Hz, CHH Cbz), 4.72 (d, 1H, J = 11.2 Hz, CHH Bn), 4.76 (d, 1H, J = 10.9 Hz, CHH 
Bn), 4.93 (d, 1H, J = 9.9 Hz, NH), 5.09 (d, 1H, J = 12.0 Hz, CHH Cbz), 5.15 (d, 1H, J = 3.3 Hz, H-1), 
6.70 - 6.83 (m, 4H, Harom), 7.11 - 7.41 (m, 35H, Harom), 7.51 - 7.56 (m, 4H, Harom); 13C NMR (100 
MHz): δ = 19.1 (Cq t-Bu), 26.7 (3 x CH3 TBDPS), 54.8 (C-2), 55.1 (2 x OMe), 63.6 (CH2 glycerol), 
63.8 (CH2 glycerol), 66.7 (CH2 Cbz), 68.1 (C-6), 71.1 (C-5), 73.3 (CH2 Bn), 74.8 (CH2 Bn), 75.2 
(CH2 Bn), 77.4 (CH glycerol), 77.8 (C-4), 81.4 (C-3), 86.2 (Cq DMTr), 98.1 (C-1), 113.1 (CHarom), 
126.6 - 130.0 (CHarom), 133.0, 133.1 (2 x Cq phenyl), 135.4 (CHarom), 135.6, 136.0, 136.3, 137.9, 
138.2, 138.3 (2 x Cq DMTr, 4 x Cq Bn), 144.9 (Cq DMTr), 155.8 (C=O, Cbz), 158.3 (Cq DMTr); 




Compound 28b (900 mg, 0.751 mmol) was dissolved in THF (7.50 ml) 
and after addition of TBAF (1.00 M in THF, 1.20 ml, 1.20 mmol) stirred 
overnight. After evaporation of the solvents under reduced pressure 
the resulting oil was purified by column chromatography (EtOAc/PE, 
containing ~0.5% Et3N), giving the intermediate alcohol (711 mg, 
0.741 mmol, 99%) as a colourless oil. Analytical data 2-O-(2-Benzylcarbamate-3,4,6-tri-O-
benzyl-2-deoxy-α-D-glucopyranosyl)-3-O-(4,4’-dimethoxytrityl)-sn-glycerol: [α]D20 
(CHCl3): +59.4; IR (neat): 906, 1209, 1714, 2249; 1H NMR (400 MHz): δ = 2.79 (bs, 1H, OH), 3.20 
- 3.23 (m, 2H, CH2 glycerol), 3.51 - 3.60 (m, 3H, H-4, H-6, CHH glycerol), 3.65 - 3.78 (m, 10H, H-3, 
H-6’, CH glycerol, CHH glycerol, 2 x OMe), 4.00 - 4.11 (m, 2H, H-2, H-5), 4.47 (d, 1H, J = 10.9 Hz, 
CHH Bn), 4.51 (d, 1H, J = 12.3 Hz, CHH Bn), 4.57 (d, 1H, J = 12.3 Hz, CHH Bn), 4.65 (d, 1H, J = 11.1 
Hz, CHH Bn), 4.75 - 4.81 (m, 3H, 2 x CHH Bn, CHH Cbz), 4.96 (d, 1H, J = 9.9 Hz, NH), 5.01 (d, 1H, J 
= 3.5 Hz, H-1), 5.12 (d, 1H, J = 12.2 Hz), CHH Cbz), 6.75 - 6.78 (m, 4H, Harom), 7.12 - 7.41 (m, 29H, 
Harom); 13C NMR (100 MHz): δ = 54.9 (C-2), 55.1 (2 x OMe), 63.5 (2 x CH2 glycerol), 66.8 (CH2 
Cbz), 68.7 (C-6), 71.4 (C-5), 73.4 (CH2 Bn), 75.0 (CH2 Bn), 75.4 (CH2 Bn), 78.3 (C-4), 81.1 (CH 
glycerol), 81.5 (C-3), 86.3 (Cq DMTr), 98.5 (C-1), 113.1 (CHarom), 126.7 - 130.0 (CHarom), 135.7, 
135.8, 136.3, 137.5, 137.8, 138.1 (2 x Cq DMTr, 4 x Cq Bn), 144.7 (Cq DMTr), 155.9 (C=O, Cbz), 
158.4 (Cq DMTr); HRMS: C59H61NO11 + Na+ requires 982.4137, found 982.4142. To a cooled (0 
oC) solution of the intermediate alcohol (969 mg, 1.01 mmol) and Et3N (220 µl, 1.52 mmol) in 
freshly distilled DCM (10 ml) was added 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite 
(267 µl, 1.20 mmol). After stirring overnight, the reaction was quenched by the addition of H2O 
(2.0 ml), diluted with DCM (40 ml) and washed with, respectively, H2O (20 ml) and brine (20 
ml). The organic layer was dried over Na2SO4 and concentrated in vacuo. Purification of the 
residue by column chromatography (EtOAc/PE, containing ~0.5% Et3N) gave phosphoramidite 
29b (939 mg, 0.810 mmol, 80%) as a white foam. IR (neat): 1248, 1508, 1606, 1724, 2837, 
2870, 2930, 2965, 3063; 31P NMR (161.7 MHz, CD3CN): δ = 149.1, 149.2 (diastereoisomers); 1H 
NMR (400 MHz, CD3CN): δ = 1.03 - 1.12 (m, 12H, 4 x CH3 isopropylamino), 2.40 - 2.47 (m, 2H, 
CH2 cyanoethyl), 3.07 - 3.18 (m, 1H, CHH glycerol), 3.27 - 3.33 (m, 1H, CHH glycerol), 3.44 - 4.04 
(m, 19H, H-2, H-3, H-4, H-5, H-6, H-6’, CH glycerol, CH2 glycerol, 2 x OMe, CH2 cyanoethyl, 2 x CH 
isopropylamino), 4.50 - 4.80 (m, 7H, 3 x CH2 Bn, CHH Cbz), 4.99 - 5.07 (m, 2H, H-1, CHH Cbz), 
5.43 - 5.49 (m, 1H, NH), 6.77 - 6.82 (m, 4H, Harom), 7.16 - 7.45 (m, 29H, Harom); 13C NMR (100 
MHz, CD3CN): δ = 20.9, 20.9 (CH2 cyanoethyl), 24.8 - 25.1 (4 x CH3 isopropylamino), 43.7, 43.8 
(2 x CH isopropylamino), 55.9 (2 x OMe), 56.2 (C-2), 59.3, 59.5 (CH2 cyanoethyl), 64.0 - 64.4 (2 x 
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CH2 glycerol), 67.1 (CH2 Cbz), 69.8, 69.9 (C-6), 72.0 (C-5), 73.8, 73.9 (CH2 Bn), 75.4, 75.4 (CH2 
Bn), 76.0 (CH2 Bn), 77.3 - 77.5 (CH glycerol), 79.4 (C-4), 82.1 (C-3), 87.1 (Cq DMTr), 98.6, 98.7 
(C-1), 114.0 (CHarom), 118.3 (Cq cyanoethyl), 127.7 - 131.0 (CHarom), 136.8, 137.0, 137.9, 139.5 - 
139.7 (2 x Cq DMTr, 4 x Cq Bn), 146.2 (Cq DMTr), 156.9 (C=O, Cbz), 159.5 (Cq DMTr); HRMS: 
C68H78N3O12P + H+ requires 1160.5396, found 1160.5392. 
Cbz-glucosamine-2-O-benzylglycerol phosphate 
hexamer (30b) 
Glycerol phosphate pentamer 11 (76.3 mg, 37.1 µmol) 
and N-CBz-glucosamineglycerol phosphoramidite 29b 
(86.1 mg, 74.2 µmol) were dissolved in CH3CN (1.0 ml) 
together with freshly activated MS3Å and stirred for 15 
min under argon. Subsequently, DCI (0.25M solution in 
CH3CN, 0.4 ml, 0.19 mmol) was added and the mixture stirred for 1 hr before water (0.50 ml) 
was added. The oxidation, detritylation and F-SPE steps were performed according to the 
general procedure. Hexamer 30b (91.4 mg, 32.5 µmol, 88 %) was obtained as a colorless oil. 31P 
NMR (161.7 MHz): δ = -1.9, -1.9 (1P), -1.4 - -1.0 (5P); 1H NMR (400 MHz): δ = 2.09 - 2.69 (m, 
17H, CH2OH, F17C8CH2CH2CH2SO2-, F17C8CH2CH2CH2SO2-, 6 x CH2 cyanoethyl), 3.05 - 3.13 (m, 2H, 
F17C8CH2CH2CH2SO2-), 3.24 - 3.33 (m, 2H, -OCH2CH2SO2-), 3.54 - 4.34 (m, 48H, H-2, H-3, H-4, H-5, 
H-6, H-6’, 6 x CH glycerol, 12 x CH2 glycerol, 6 x CH2 cyanoethyl), 4.40 - 4.81 (m, 18H, -
OCH2CH2SO2-, 8 x CH2 Bn), 4.95 - 5.04 (m, 2H, H-1, CHH CBz), 5.12 - 5.19 (m, 1H, CHH CBz), 5.78 
- 5.98 (m, 1H, NH CBz), 7.10 - 7.15 (m, 2H, Harom), 7.22 - 7.38 (m, 43H, Harom); HRMS: 
[C119H136F17N7O39P6S + 2Na]2+ requires 1437.3283, found 1437.3288. 
Cbz-glucosamine-2-O-benzylglycerol 
phosphate hexamer aminohexyl spacer 
(31b) 
Hexamer 30b (88.6 mg, 31.5 µmol) was 
coupled to spacer phosphoramidite 20 (0.2M in 
MeCN, 0.63 ml, 126 µmol, 4 eq), oxidized and 
purified (F-SPE) using the general procedure as 
described above. Hexamer 31b (89.3 mg, 28.1 µmol, 89 %) was obtained as a colorless oil. 31P 
NMR (161.7 MHz): δ = -1.9, -1.8 (1P), -1.4 - -0.8  (6P); 1H NMR (400 MHz): δ = 1.23 - 1.68 (m, 8H, 
4 x CH2 hexylspacer), 2.06 - 2.71 (m, 18H, F17C8CH2CH2CH2SO2-, F17C8CH2CH2CH2SO2-, 7 x CH2 
cyanoethyl), 3.05 - 3.18 (m, 4H, F17C8CH2CH2CH2SO2-, CH2-N hexylspacer), 3.23 - 3.34 (m, 2H, -
OCH2CH2SO2-), 3.67 - 3.88 (m, 11H, H-3, H-4, H-5, H-6, H-6’, 6 x CH glycerol), 3.94 - 4.34 (m, 41H, 
H-2, 12 x CH2 glycerol, 7 x CH2 cyanoethyl, CH2-O hexylspacer), 4.42 - 4.51 (m, 4H, -
OCH2CH2SO2-, CH2 Bn), 4.55 - 4.66 (m, 11H, 5 x CH2 Bn, CHH Bn), 4.69 - 4.79 (m, 3H, CH2 Bn, 
CHH Bn), 4.96 - 5.16 (m, 6H, H-1, NH CBz, 2 x CH2 CBz), 5.93 - 6.23 (m, 1H, NH CBz), 7.09 - 7.13 
(m, 2H, Harom), 7.24 - 7.37 (m, 48H, Harom); HRMS: [C136H159F17N9O44P7S + 2Na]2+ requires 
1620.3956, found 1620.3957. 
Glucosamine glycerol phosphate hexamer-
aminohexyl spacer (32b) 
Protected hexamer 31b (87.3 mg, 27.5 µmol) was 
treated with aqueous ammonia as described 
above. The compound was eluted through a small 
column containing Dowex Na+ cation-exchange 
resin (type: 50WX4-200, stored on 0.5 M NaOH in 
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H2O, flushed with H2O and MeOH before use) and, subsequently, lyophilized, yielding the 
intermediate hexamer (66.3 mg, 27.5 µmol, 100 %) as an amorphous white solid. Analytical 
data intermediate: 31P NMR (161.7 MHz, D2O): δ = 0.9 - 1.4 (6P), 3.4 (1P, phosphomonoester); 
1H NMR (400 MHz, D2O): δ = 0.86 - 1.49 (m, 8H, 4 x CH2 hexylspacer), 2.72 - 2.88 (m, 2H, CH2-N 
hexylspacer), 3.34 - 4.07 (m, 40H, H-2, H-3, H-4, H-5, H-6, H-6’, 12 x CH2 glycerol, 6 x CH 
glycerol, CH2-O hexylspacer, 2 x CHH Bn), 4.15 - 4.55 (m, 14H, 6 x CH2 Bn, 2 x CHH Bn), 4.80 - 
5.17 (m, 5H, H-1, 2 x CH2 CBz), 6.64 - 6.69 (m, 2H, Harom), 6.75 - 7.29 (m, 48H, Harom); HRMS: 
[C102H129N2O42P7 + 2NH4]2+ requires 1153.8447, found 1153.8455. A portion of the intermediate 
(24.7 mg, 10.2 µmol) was deprotected with Pd (0)/H2 using the standard procedure. 
Glucosaminylated hexamer 32b (11.7 mg, 8.33 µmol, 81 %) was obtained as an amorphous 
white solid. 31P NMR (161.7 MHz, D2O): δ = 0.9 (1P), 1.2 (1P), 1.3 (2P), 1.4 (1P), 1.5 (1P), 2.6 (1P, 
phosphomonoester); 1H NMR (600 MHz, D2O): δ = 1.39 - 1.42 (m, 4H, 2 x CH2 hexylspacer), 1.61 
- 1.69 (m, 4H, 2 x CH2 hexylspacer), 2.98 (t, 2H, J = 7.5 Hz, CH2-N hexylspacer), 3.32 (dd, 1H, J = 
3.5 Hz, 10.6 Hz, H-2), 3.47 (at, 1H, J = 9.6 Hz, H-4), 3.75 - 4.08 (m, 35H, H-3, H-5, H-6, H-6’, 5 x CH 
glycerol, 12 x CH2 glycerol, CH2-O hexylspacer), 4.14 - 4.17 (m, 1H, CH glycerol), 5.40 (d, 1H, J = 
3.5 Hz, H-1); 13C NMR (150 MHz, D2O): δ = 25.5, 26.1, 27.6 (3 x CH2 hexylspacer), 30.4 (d, J = 6.7 
Hz, CH2 hexylspacer), 40.4 (CH2-N hexylspacer), 55.0 (C-2), 61.2 (C-6), 65.5 (d, J = 5.5 Hz, CH2 
glycerol), 65.9 (d, J = 5.3 Hz, CH2 glycerol), 66.3 (d, J = 4.9 Hz, CH2-O hexylspacer), 67.1 - 67.5 (10 
x CH2 glycerol), 70.5 - 70.9 (C-4, C-5, 5 x CH glycerol), 73.3 (C-3), 76.5 (t, J = 7.7 Hz, CH glycerol), 
95.7 (C-1); HRMS: C30H69N2O38P7 + H+ requires 1283.1764, found 1283.1769.  
3-O-Allyl-2-O-(2-azido-2-deoxy-6-O-[4,4’-dimethoxytrityl]-α-D-
glucopyranosyl)-sn-glycerol (33) 
To a solution of glycoside 25 (1.26 g, 2.26 mmol) in DCM/1,4-dioxane 
(1/1, 60 ml) were added Et3N (0.490 ml, 3.39 mmol) and DMTr-Cl (0.920 
g, 2.72 mmol), respectively. After stirring for 24h MeOH (10 ml) was 
added and the mixture stirred for 30 minutes after which the solution 
was further diluted with DCM (50 ml) and washed with water (10 ml) and brine (20 ml). The 
combined waterlayers were extracted with DCM (20 ml) and the organic layer was washed with 
brine. The combined organic layers were dried (Na2SO4) and concentrated in vacuo, after which 
purification with column chromatography (EtOAc/PE, containing ~0.5% Et3N) gave the 
intermediate diol as a pale yellow oil (1.51 g, 1.76 mmol, 78 %). Analytical data 3-O-allyl-2-O-
(2-azido-2-deoxy-6-O-[4,4’-dimethoxytrityl]-α-D-glucopyranosyl)-1-O-tert-
butyldiphenylsilyl-sn-glycerol: [α]D20 (CHCl3): +30.6; IR (neat): 1028, 1248, 1508, 1607, 2106, 
2932; 1H NMR (400 MHz): δ = 1.01 (s, 9H, t-Bu TBDPS), 3.16 (dd, 1H, J = 3.6 Hz, 10.4 Hz, H-2), 
3.18 - 3.24 (m, 2H, H-6, H-6’), 3.59 - 3.65 (m, 2H, H-4, CHH glycerol), 3.69 - 3.84 (m, 10H, H-5, 
CH2 glycerol, CHH glycerol, 2 x OMe), 3.95 - 4.02 (m, 4H, H-3, CH glycerol, CH2 allyl), 5.18 (dd, 
1H, J = 1.6 Hz, 10.4 Hz, CHH allyl), 5.25 - 5.30 (m, 2H, H-1, CHH allyl), 5.90 (ddd, 1H, J = 5.6 Hz, 
10.6 Hz, 17.1 Hz, CH allyl), 6.78 - 6.81 (m, 4H, Harom), 7.17 - 7.40 (m, 15H, Harom), 7.60 - 7.65 (m, 
4H, Harom); 13C NMR (100 Mhz): δ = 19.2 (Cq t-Bu), 26.8 (3 x CH3 TBDPS), 55.2 (2 x OMe), 62.5 (C-
2), 63.2 (C-6), 63.9 (CH2 glycerol), 69.8 (C-5), 70.0 (CH2 glycerol), 71.0 (C-3), 72.4 (CH2 allyl), 
72.6 (C-4), 77.3 (CH glycerol), 86.4 (Cq DMTr), 97.2 (C-1), 113.2 (CHarom), 117.0 (CH2 allyl), 126.9 
- 129.9 (CHarom), 133.1, 133.2 (2 x Cq TBDPS), 134.6 (CH allyl), 135.6 (CHarom), 135.6, 144.4, 
158.5 (5 x Cq DMTr); HRMS: C49H57N3O9Si+Na+ requires 882.3756, found 882.3764. To a 
solution of the intermediate diol (840 mg, 0.977 mmol) in THF (10 ml) was added TBAF (1.00 M 
in THF, 1.50 ml). This mixture was stirred overnight and concentrated in vacuo. Purification 
with column chromatography (EtOAc/PE, containing ~0.5% Et3N) furnished triol 33 (508 mg, 
0.817 mmol, 84 %) as a colourless oil. [α]D20 (CHCl3): +38.0; IR (neat): 1038, 1074, 1105, 1497, 
2104, 2857, 2901, 2928, 3067; 1H NMR (400 MHz): δ = 3.12 (dd, 1H, J = 3.6 Hz, 10.4 Hz, H-2), 
3.31 (dd, 1H, J = 5.1 Hz, 10.1 Hz, H-6), 3.38 (dd, 1H, J = 3.5 Hz, 10.1 Hz, H-6’), 3.49 - 3.78 (m, 11H, 
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H-4, 2 x OMe, 2 x CH2 glycerol), 3.90 - 4.01 (m, 5H, H-3, H-5, CH2 allyl, CH glycerol), 5.16 - 5.20 
(m, 2H, H-1, CHH allyl), 5.27 (dd, 1H, J = 1.6 Hz, 17.2 Hz, CHH allyl), 5.89 (ddd, 1H, J = 5.6 Hz, 
11.0 Hz, 17.3 Hz, CH allyl), 6.82 (d, 4H, J = 8.9 Hz, Harom), 7.15 - 7.33 (m, 7H, Harom), 7.43 (d, 2H, J 
= 7.4 Hz, Harom); 13C NMR (100 MHz): δ = 55.2 (2 x OMe), 62.7 (C-2), 63.4 (C-6), 63.6 (CH2 
glycerol), 69.8 (CH2 glycerol), 70.6 (C-5), 71.1 (C-4), 72.3 (C-3), 72.4 (CH2 allyl), 78.1 (CH 
glycerol), 86.5 (Cq DMTr), 97.5 (C-1), 113.1 (CHarom), 117.3 (CH2 allyl), 126.9 - 130.0 (CHarom), 
134.2 (CH allyl), 135.7, 135.8, 144.5, 158.5, 158.5 (5 x Cq DMTr); HRMS: C33H39N3O9+Na+ 
requires 644.2580, found 644.2579. 
3-O-Allyl-2-O-(2-azido-3,4-di-O-benzyl-2-deoxy-6-O-[4,4’-
dimethoxytrityl]-α-D-glucopyranosyl)-1-O-benzyl-sn-glycerol (34)  
To a cooled (0 ̊ C) solution of triol 33 (4.08 g, 6.56 mmol) in DMF (35 ml) 
were added sodium hydride (60% in mineral oil, 944 mg, 23.7 mmol) and 
benzyl bromide (2.83 ml, 23.7 mmol). This reaction mixture was allowed 
to stir overnight at rt before MeOH was added (10 ml). After strring for 30 
min the reaction mixture was diluted with Et2O (250 ml) and washed with water (2 x 50 ml) 
and brine (100 ml). The organic layer was dried (Na2SO4) and concentrated in vacuo, after 
which the residue was purified by column chromatography (EtOAc/PE, containing ~0.5% Et3N) 
yielding fully protected construct 34 (5.45 g, 6.11 mmol, 93%) as a colourless oil. [α]D20 (CHCl3): 
+48.6; IR (neat): 1034, 1250, 1508, 1607, 2106, 2851, 2922; 1H NMR (400 MHz): δ = 3.10 (dd, 
1H, J = 3.4 Hz, 10.3 Hz, H-6), 3.40 (dd, 1H, J = 1.4 Hz, 10.3 Hz, H-6’), 3.45 (dd, 1H, J = 3.6 Hz, 10.3 
Hz, H-2), 3.56 - 3.68 (m, 4H, 2 x CH2 glycerol), 3.73 - 3.75 (m, 6H, 2 x OMe), 3.83 (at, 1H, J = 9.5 
Hz, H-4), 3.98 (at, 1H, J = 10.0 Hz, H-3), 4.02 - 4.09 (m, 3H, H-5, CH2 allyl), 4.10 - 4.16 (m, 1H, CH 
glycerol), 4.29 (d, 1H, J = 10.4 Hz, CHH Bn), 4.43 (s, 2H, CH2 Bn), 4.65 (d, 1H, J = 10.4 Hz, CHH 
Bn), 4.86 (s, 2H, CH2 Bn), 5.21 (dd, 1H, J = 1.3 Hz, 10.4 Hz, CHH allyl), 5.29 - 5.34 (m, 2H, H-1, 
CHH allyl), 5.94 (ddd, 1H, J = 5.6 Hz, 10.7 Hz, 17.4 Hz, CH allyl), 6.74 - 6.78 (m, 4H, Harom), 6.82 - 
6.86 (m, 2H, Harom), 7.14 - 7.47 (m, 22H, Harom); 13C NMR (100 MHz): δ = 55.1 (2 x OMe), 61.5 (C-
6), 63.6 (C-2), 70.3, 70.4 (2 x CH2 glycerol), 70.8 (C-5), 72.4 (CH2 allyl), 73.1, 74.8 (2 x CH2 Bn), 
75.3 (CH glycerol), 75.6 (CH2 Bn), 78.6 (C-4), 80.1 (C-3), 85.6 (Cq DMTr), 97.4 (C-1), 113.0 
(CHarom), 117.1 (CH2 allyl), 126.6 - 129.1 (CHarom), 130.1, 130.2 (CHarom), 134.6 (CH allyl), 135.7, 
136.2, 137.8, 138.0, 144.9, (3 x Cq Bn, 5 x Cq DMTr), 158.3, 158.4 (2 x Cq DMTr); HRMS: 
C54H57N3O9+Na+ requires 914.3987, found 914.3995. 
3-O-Allyl-2-O-(2-acetamido-3,4-di-O-benzyl-2-deoxy-6-O-[4,4’-
dimethoxytrityl]-α-D-glucopyranosyl)-1-O-benzyl-sn-glycerol (35) 
To a solution of compound 34 (5.45 g, 6.11 mmol) in a mixture of 1,4-
dioxane/water (36 ml, 5:1) was added PMe3 (1.0 M in toluene, 12.2 ml, 
12.2 mmol). After stirring for 4 h the mixture was concentrated in vacuo 
and coevaporated with toluene (3 x 50 ml). The crude intermediate was 
taken up in pyridine (30 ml) and Ac2O (1.13 ml, 12.0 mmol) was added. After stirring overnight, 
the mixture was diluted with EtOAc (300 ml) and washed with water (50 ml), saturated 
aqueous NaHCO3 solution (50 ml) and brine (50 ml). The organic layer was dried (Na2SO4) and 
concentrated in vacuo, after which purification by column chromatography (EtOAc/PE, 
containing ~0.5% Et3N) yielded acetamide 35 (4.77 g, 5.25 mmol, 86%) as a slightly yellow oil. 
[α]D20 (CHCl3): +30.0; IR (neat): 1090, 1250, 1454, 1508, 2853, 2924, 3063; 1H NMR (400 MHz): 
δ = 1.87 (s, 3H, HNAc). 3.17 - 3.23 (m, 1H, H-6), 3.41 - 3.65 (m, 12H, H-3, H-6’, 2 x CH2 glycerol, 2 
x OMe), 3.71 - 3.78 (m, 1H, H-4), 3.86 - 4.09 (m, 4H, H-5, CH glycerol, CH2 allyl), 4.30 - 4.46 (m, 
4H, H-2, CH2Bn, CHH Bn), 4.65 - 4.72 (m, 2H, 2 x CHH Bn), 4.85 (d, 1H, J = 11.5 Hz, CHH Bn), 5.08 
- 5.25 (m, 3H, H-1, CH2 allyl), 5.82 (ddd, 1H, J = 5.4 Hz, 10.5 Hz, 16.1 Hz, CH allyl), 6.09 (d, 1H, J = 
9.0 Hz, HNAc), 6.73 - 6.77 (m, 4H, Harom), 6.86 - 6.89 (m, 2H, Harom), 7.09 - 7.40 (m, 20H, Harom), 
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7.52 (d, 2H, J = 7.5 Hz, Harom); 13C NMR (100 MHz): δ = 22.8 (HNAc), 52.6 (C-2), 54.4 (2 x OMe), 
61.3 (C-6), 69.6, 69.7 (2 x CH2 glycerol), 70.8 (C-5), 71.6 (CH2 allyl), 72.5, 74.2, 74.5 (3 x CH2 Bn), 
76.0 (CH glycerol), 78.0 (C-4), 80.3 (C-3), 85.1 (Cq DMTr), 97.8 (C-1), 112.5 (CHarom), 116.6 (CH2 
allyl), 126.0 - 127.8 (CHarom), 129.6, 129.7 (CHarom) 133.8 (CH allyl), 135.2, 135.6, 137.3, 137.4, 
138.1, 144.6, 157.8 (3 x Cq Bn, 5 x Cq DMTr), 169.3 (C=O NHAc); HRMS: C56H61NO10+Na+ 




A solution of compound 35 (6.36 g, 7.00 mmol) in THF (100 
ml) was stirred under argon for 30 min after which 
Ir(COD)(PPhMe)2PF6 (177 mg, 0.209 mmol) was added. The 
solution was purged with H2 (g) (20s) before it was stirred 
under argon for 1 h. After the addition of, respectively, saturated aqueous NaHCO3 solution (25 
ml) and I2 (4.80 g, 18.9 mmol) the mixture was stirred for 30 min before it was diluted with 
EtOAc (400 ml) and washed with saturated Na2S2O3 solution (100 ml) and brine (200 ml). The 
organic layer was dried (Na2SO4) and concentrated in vacuo, after which purification by column 
chromatography (EtOAc/PE, containing ~0.5% Et3N) yielded the intermediate alcohol (5.63 g, 
6.49 mmol, 93%) as a yellow foam. Analytical data 1-O-benzyl-2-O-(2-acetamido-3,4-di-O-
benzyl-2-deoxy-6-O-[4,4’-dimethoxytrityl]-α-D-glucopyranosyl)-sn-glycerol: [α]D20 
(CHCl3): +49.8; IR (neat): 1028, 1091, 1246, 1660, 2945; 1H NMR (400 MHz): δ = 1.86 (s, 3H, 
HNAc), 2.70 (bs, 1H, OH), 3.19 (dd, 1H, J = 4.0, 10.2 Hz, H-6), 3.42 (dd, 1H, J = 1.3, 10.0 Hz, H-6’), 
3.59 (dd, 1H, J = 5.3 Hz, 10.0 Hz, CHH glycerol), 3.64 - 3.79 (m, 10H, H-3, CH2 glycerol, CHH 
glycerol, 2 x OMe), 3.79 - 3.90 (m, 2H, H-4, CH glycerol), 3.95 (dd, 1H, J = 2.2 Hz, 9.9 Hz, H-5), 
4.26 - 4.33 (m, 2H, H-2, CHH Bn), 4.43 (s, 2H, CH2 Bn), 4.61 - 4.67 (m, 2H, CH2 Bn), 4.84 (d, 1H, J 
= 11.6 Hz, CHH Bn), 5.09 (d, 1H, J = 3.6 Hz, H-1), 6.16 (d, 1H, J = 8.8 Hz, HNAc), 6.76 - 6.81 (m, 
4H, Harom), 6.84 - 6.88 (m, 2H, Harom), 7.15 - 7.37 (m, 20H, Harom), 7.46 - 7.49 (m, 2H, Harom); 13C 
NMR (100 MHz): δ = 23.2 (NHAc), 53.1 (C-2), 55.1 (2 x OMe), 61.9 (C-6), 62.6, 70.5 (2 x CH2 
glycerol), 71.4 (C-5), 73.4, 74.9, 75.0 (3 x CH2 Bn), 77.2 (CH glycerol), 78.4 (C-4), 80.3 (C-3), 85.7 
(Cq DMTr), 97.5 (C-1), 113.0 (CHarom), 126.6 - 130.2 (CHarom), 135.8, 136.1, 137.5, 137.7, 138.4, 
144.9, 158.4 (3 x Cq Bn, 5 x Cq DMTr), 170.5 (C=O); HRMS: C53H57NO10+Na+ requires 890.3875, 
found 890.3880. To a solution of the intermediate alcohol (694 mg, 0.800 mmol) and Et3N (166 
μl, 1.20 mmol) in DCM (8.0 ml) was added (N,N-diisopropylamino)-2-cyanoethyl-
chlorophosphoramidite (214 μl, 0.959 mmol). This mixture was allowed to stir for 2 h, after 
which H2O (2.0 ml) was added. The mixture was diluted with DCM (20 ml) and washed was 
washed with brine (15 ml). The organic layer was dried (Na2SO4) and concentrated in vacuo, 
after which the residue was purified by column chromatography (EtOAc/PE, containing ~0.5% 
Et3N) yielding phosphoramidite 36 (786 mg, 0.736 mmol, 92%, mixture of diastereoisomers) as 
a white foam. IR (neat): 1248, 1454, 1508, 1653, 2837, 2870, 2928, 2965, 3021, 3055, 3221; 31P 
NMR (162 MHz): δ = 147.3, 147.8 (diastereoisomers); 1H NMR (400 MHz): δ = 1.21 - 1.24 (m, 12 
H, 4 x CH3 isopropylamino), 1.95 - 1.97 (m, 3H, J = 1.6 Hz, HNAc), 2.64 - 2.68 (m, 2H, CH2 
cyanoethyl), 3.07 (dd, 1H, J = 4.7, 10.1 Hz, H-6), 3.38 (ad, 1H, J = 9.9 Hz, H-6’), 3.61 - 3.90 (m, 
16H, H-3, H-4, 2 x CH isopropylamino, 2 x CH2 glycerol, CH2 cyanoethyl, 2 x OMe), 4.09 - 4.15 (m, 
2H, H-5, CH glycerol), 4.17 - 4.26 (m, 1H, H-2), 4.30 (d, 1H, J = 10.7 Hz, CHH Bn), 4.47 - 4.54 (m, 
2H, CH2 Bn), 4.66 - 4.73 (m, 2H, CH2 Bn), 4.79 - 4.84 (m, 1H, CHH Bn), 5.10 (d, 0.5H, J = 3.6 Hz, H-
1 diastereoisomer 1), 5.12 (d, 0.5H, J = 3.6 Hz, H-1 diastereoisomer 2), 6.47 (d, 0.5H, J = 9.5 Hz, 
HNAc diastereoisomer 1), 6.53 (d, 0.5H, J = 9.6 Hz, HNAc diastereoisomer 2), 6.82 - 6.87 (m, 4H, 
Harom), 6.92 - 6.96 (m, 2H, Harom), 7.20 - 7.38 (m, 20H, Harom), 7.52 (d, 2H, J = 7.5 Hz, Harom); 13C 
NMR (100 MHz): δ = 21.0, 21.1 (CH2 cyanoethyl), 23.5 (HNAc), 24.9 - 25.1 (4 x CH3 
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isopropylamino), 43.8, 43.9 (2 x CH isopropylamino), 53.9, 53.9 (C-2), 55.8 (2 x OMe), 59.3 - 
59.6 (CH2 cyanoethyl), 63.3 (C-6), 63.8, 63.9 (CH2 glycerol) 71.1 (CH2 glycerol), 71.9 (C-5), 73.6, 
75.2, 75.8 (3 x CH2 Bn), 76.7 - 76.9 (CH glycerol), 79.6 (C-4), 81.7, 81.8 (C-3), 86.5 (Cq DMTr), 
98.0, 98.2 (C-1), 114.0 (CHarom), 118.3 (Cq cyanoethyl), 127.6 - 129.2 (CHarom), 131.0, 131.1 
(CHarom), 136.8, 137.1, 139.2, 139.5, 139.9, 146.3, 159.5 (3 x Cq Bn, 5 x Cq DMTr), 170.5 (C=O 
NHAc); HRMS: C62H74N3O11P+H+ requires 1068.5134, found 1068.5146. 
GlcNAc-glycerol phosphate monomer (37) 
Fluorous alcohol 5 (254 mg, 445 µmol) was coupled to 
phosphoramidite 36 (0.2 M in MeCN, 3.34 ml, 668 µmol, 1.5 eq), 
oxidized, detritylated and purified (F-SPE) using the general 
procedure as described above. Monomer 37 (501 mg, 400 µmol, 
90 %) was obtained as a white foam. 31P NMR (161.7 MHz): δ = -
1.8, -1.6 (1P); 1H NMR (400 MHz): δ = 1.95 (s, 3H, NHAc), 2.00 - 2.39 (m, 5H, 
F17C8CH2CH2CH2SO2-, F17C8CH2CH2CH2SO2-, CH2OH), 2.58 - 2.76 (m, 2H, cyanoethyl), 3.00 (t, 1H, 
J = 7.4 Hz, F17C8CH2CH2CHHSO2-), 3.14 (t, 1H, J = 7.4 Hz, F17C8CH2CH2CHHSO2-), 3.25 - 3.40 (m, 
2H, -OCH2CH2SO2-), 3.52 - 3.79 (m, 7H, H-3, H-4, H-5, H-6, H-6’, CH2 glycerol), 3.88 - 3.92 (m, 1H, 
CH glycerol), 4.13 - 4.37 (m, 5H, H-2, CH2 cyanoethyl, CH2 glycerol), 4.43 - 4.52 (m, 4H, CH2 Bn, -
OCH2CH2SO2-), 4.63 (d, 1H, J = 10.8 Hz, CHH Bn), 4.71 (d, 1H, J = 11.4 Hz, CHH Bn), 4.79 - 4.86 
(m, 2H, 2 x CHH Bn), 4.91 (m, 1H, H-1), 6.87 (d, 0.5 H, J = 9.6 Hz, NHAc), 6.91 (d, 0.5 H, J = 9.5 Hz, 
NHAc), 7.24 - 7.37 (m, 15H, Harom ); 13C NMR (100 MHz): δ = 13.4 (F17C8CH2CH2CH2SO2-), 19.4 - 
19.6 (CH2 cyanoethyl), 23.0 (NHAc), 29.1 - 29.6 (F17C8CH2CH2CH2SO2-), 52.7 (C-2), 52.9 - 53.4 
(F17C8CH2CH2CH2SO2-, -OCH2CH2SO2-), 61.1 (-OCH2CH2SO2-), 61.6 (C-6), 62.4 - 62.6 (CH2 
cyanoethyl), 68.3 - 68.7 (2 x CH2 glycerol), 72.1 (C-5), 73.5 (CH2 Bn), 74.8 - 75.1 (2 x CH2 Bn), 
76.8 (CH glycerol), 77.7, 77.8 (C-4), 80.3 (C-3), 99.6 (C-1), 116.5 (Cq cyanoethyl), 127.6 - 128.5 
(CHarom), 137.4, 137.9, 138.4 (3 x Cq Bn), 170.7 (Cq acetyl); HRMS: C48H52F17N2O13PS+H+ requires 
1252.2763, found 1252.2764. 
GlcNAc-glycerol phosphate dimer (38) 
Monomer 37 (250 mg, 200 µmol) was coupled to 
phosphoramidite building-block 36 (0.2M in MeCN, 1.50 ml, 
300 µmol, 1.5 eq), oxidized, detritylated and purified (F-SPE) 
using the general procedure as described above. Dimer 38 (321 
mg, 166 µmol, 83 %) was obtained as a white foam. 31P NMR 
(161.7 MHz): δ = -1.9, -1.9 (0.5P), -1.7, -1.7 (0.5P), -1.1, -1.1 (0.5P), -0.9, -0.9 (0.5P); 1H NMR 
(400 MHz): δ = 1.94 - 1.99 (m, 6H, 2 x NHAc), 2.03 - 2.37 (m, 5H, CH2OH, F17C8CH2CH2CH2SO2-, 
F17C8CH2CH2CH2SO2-), 2.54 - 2.76 (m, 4H, 2 x CH2 cyanoethyl), 2.93 (t, 0.5H, J = 7.5 Hz, 
F17C8CH2CH2CHHSO2-), 3.02 (t, 0.5H, J = 7.4 Hz, F17C8CH2CH2CHHSO2-), 3.13 (t, 1H, J = 7.1 Hz, 
F17C8CH2CH2CHHSO2-), 3.23 - 3.41 (m, 2H, -OCH2CH2SO2-), 3.46 - 3.85 (m, 12H, 2 x H-3, 2 x H-4, 
2 x H-5, H-6, H-6’, 2 x CH2 glycerol), 3.89 - 3.96 (m, 2H, 2 x CH glycerol), 4.00 - 4.33 (m, 12H, 2 x 
H-2, H-6, H-6’, 2 x CH2 glycerol, 2 x CH2 cyanoethyl), 4.39 - 4.52 (m, 6H, -OCH2CH2SO2-, 2 x CH2 
Bn), 4.58 - 4.93 (m, 10H, 2 x H-1, 4 x CH2 Bn), 6.81 - 7.15 (m, 2H, 2 x NH), 7.22 - 7.37 (m, 30H, 
Harom); 13C NMR (100 MHz): δ = 13.2 - 13.4 (F17C8CH2CH2CH2SO2-), 19.2 - 19.5 (2 x CH2 
cyanoethyl), 22.9 (2 x NHAc), 28.9 - 29.4 (F17C8CH2CH2CH2SO2-), 52.5, 52.6 (2 x C-2), 52.9 - 53.2 
(F17C8CH2CH2CH2SO2-, -OCH2CH2SO2-), 61.0 - 61.1 (-OCH2CH2SO2-), 61.4 - 62.5 (C-6, 2 x CH2 
cyanoethyl), 66.3 -  66.6 (C-6), 67.9 - 68.6 (4 x CH2 glycerol), 70.2 (CH glycerol), 72.1, 72.5 (2 x 
C-5), 73.3 (2 x CH2 Bn), 74.9 - 75.1 (4 x CH2 Bn), 76.3 - 76.6 (CH glycerol), 77.6, 78.3 (2 x C-4), 
80.1 - 80.5 (2 x C-3), 99.0 - 99.7 (2 x C-1), 116.5 (2 x Cq cyanoethyl), 127.4 - 128.4 (CHarom), 
137.3 - 138.3 (6 x Cq Bn), 170.7 - 170.8 (2 x Cq acetyl); HRMS C83H93F17N4O23P2S+H+, requires 
1931.5228, found 1931.5237. 
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GlcNAc-glycerol phosphate trimer (39) 
Dimer 38 (312 mg, 162 µmol) was coupled to phosphoramidite 
building-block 36 (0.2 M in MeCN, 1.22 ml, 243 µmol, 1.5 eq), 
oxidized, detritylated and purified (F-SPE) using the general 
procedure as described above. Trimer 39 (336 mg, 129 µmol, 
80 %) was obtained as a white foam. 31P NMR (161.7 MHz): δ = 
-1.9, -1.9 (0.5P), -1.7, -1.7 (0.5P), -1.3, -1.2, -1.2, -1.1 (1P), -0.9, -0.9 (1P); 1H NMR (400 MHz): δ = 
1.93 - 2.02 (m, 9H, 3 x NHAc), 2.06 - 2.33 (m, 4H, F17C8CH2CH2CH2SO2-, F17C8CH2CH2CH2SO2-), 
2.47 - 2.73 (m, 7H, 3 x CH2 cyanoethyl, CH2OH), 2.94 - 3.05 (m, 1H, F17C8CH2CH2CHHSO2-), 3.12 
(t, 1H, 7.0 Hz, F17C8CH2CH2CHHSO2-), 3.21 - 3.38 (m, 2H, -OCH2CH2SO2-), 3.45 - 3.86 (m, 17H, 3 x 
H-3, 3 x H-4, 3 x H-5, H-6, H-6’, 3 x CH2 glycerol), 3.88 - 3.99 (m, 3H, 3 x CH glycerol), 4.00 - 4.35 
(m, 19H, 3 x H-2, 2 x H-6, 2 x H-6’, 3 x CH2 glycerol, 3 x CH2 cyanoethyl), 4.38 - 4.51 (m, 8H, -
OCH2CH2SO2-, 3 x CH2 Bn), 4.55 - 4.93 (m, 15H, 3 x H-1, 6 x CH2 Bn), 6.95 - 7.60 (m, 48H, 3 x 
NHAc, Harom); 13C NMR (100 MHz); δ = 13.2 - 13.4 (F17C8CH2CH2CH2SO2-), 19.2 - 19.6 (3 x CH2 
cyanoethyl), 22.9 (NHAc), 29.2 (F17C8CH2CH2CH2SO2-), 52.5 - 52.6 (3 x C-2), 53.0 - 53.2 
(F17C8CH2CH2CH2SO2-, -OCH2CH2SO2-), 61.0 - 61.1 (-OCH2CH2SO2-), 61.4 - 62.5 (C-6, 3 x CH2 
cyanoethyl), 66.3 - 66.9 (2 x C-6), 67.9 - 68.6 (6 x CH2 glycerol), 70.1 - 70.2 (2 x CH glycerol) , 
72.0 - 72.5 (3 x C-5), 73.2 - 73.4 (3 x CH2 Bn), 74.8 - 75.2 (6 x CH2 Bn), 76.9 (CH glycerol), 77.1, 
77.6, 78.5 (3 x C-4), 80.3 - 80.6 (3 x C-3), 99.1 - 99.8 (3 x C-1), 116.4 - 116.5 (3 x Cq cyanoethyl), 
127.4 - 128.5 (CHarom), 137.3 - 138.4 (9 x Cq Bn), 170.7 - 170.8 (3 x Cq acetyl); HRMS: 
[C118H134F17N6O33P3S+2NH4]2+ requires 1323.9182, found 1323.9186. 
GlcNAc-glycerol phosphate tetramer (40) 
Trimer 39 (252 mg, 96.4 µmol) was coupled to 
phosphoramidite building-block 36 (0.2 M in MeCN, 0.72 ml, 
144 µmol, 1.5 eq), oxidized, detritylated and purified (F-SPE) 
using the general procedure as described above. Tetramer 40 
(225 mg, 68.2 µmol, 71 %) was obtained as a white foam. 31P 
NMR (161.7 MHz): δ = -1.9, -1.9 (0.5P), -1.7, -1.7 (0.5P), -1.3 - -1.1 (1.5P), -0.9 - -0.9 (1.5 P); 1H 
NMR (400 MHz): δ = 1.93 - 2.01 (m, 12H, 4 x NHAc), 2.08 - 2.37 (m, 5H, CH2OH, 
F17C8CH2CH2CH2SO2-, F17C8CH2CH2CH2SO2-), 2.52 - 2.74 (m, 8H, 4 x CH2 cyanoethyl), 2.94 - 3.15 
(m, 2H, F17C8CH2CH2CH2SO2), 3.23 - 3.38 (m, 2H, -OCH2CH2SO2-), 3.45 - 3.89 (m, 22H, 4 x H-3, 4 x 
H-4, 4 x H-5, H-6, H-6’, 4 x CH2 glycerol), 3.90 - 3.98 (m, 4H, 4 x CH glycerol), 3.99 - 4.35 (m, 26H, 
4 x H-2, 3 x H-6, 3 x H-6’, 4 x CH2 glycerol, 4 x CH2 cyanoethyl), 4.37 - 4.51 (m, 10H, -
OCH2CH2SO2-, 4 x CH2 Bn), 4.55 - 4.93 (m, 20H, 4 x H-1, 8 x CH2 Bn), 6.94 - 7.62 (m, 64H, 4 x 
NHAc, Harom); HRMS: [C153H175F17N8O43P4S+2H]2+ requires 1647.0166, found 1647.0176. 
GlcNAc-glycerol phosphate pentamer (41) 
Tetramer 40 (218 mg, 66.1 µmol) was coupled to 
phosphoramidite building-block 36 (0.2 M in MeCN, 0.59 ml, 
119 µmol, 1.8 eq), oxidized, detritylated and purified (F-SPE) 
using the general procedure as described above. Pentamer 41 
(199 mg, 50.0 µmol, 76 %) was obtained as a white foam. 31P 
NMR (161.7 MHz): δ = -1.9, -1.9 (0.5P), -1.7, -1.7 (0.5P), -1.2 - -1.1 (2P), -1.0 - -0.9 (2P); 1H NMR 
(400 MHz): δ = 1.94 - 2.02 (m, 15H, 5 x NHAc), 2.08 - 2.36 (m, 5H, CH2OH, F17C8CH2CH2CH2SO2-, 
F17C8CH2CH2CH2SO2-), 2.49 - 2.74 (m, 10H, 5 x CH2 cyanoethyl), 2.94 - 3.15 (m, 2H, 
F17C8CH2CH2CH2SO2), 3.23 - 3.38 (m, 2H, -OCH2CH2SO2-), 3.44 - 3.87 (m, 27H, 5 x H-3, 5 x H-4, 5 
x H-5, H-6, H-6’, 5 x CH2 glycerol), 3.88 - 3.98 (m, 5H, 5 x CH glycerol), 3.99 - 4.36 (m, 33H, 5 x H-
2, 4 x H-6, 4 x H-6’, 5 x CH2 glycerol, 5 x CH2 cyanoethyl), 4.37 - 4.52 (m, 12H, -OCH2CH2SO2-, 5 x 
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CH2 Bn), 4.55 - 4.93 (m, 25H, 5 x H-1, 10 x CH2 Bn), 6.95 - 7.65 (m, 80H, 5 x NHAc, Harom); HRMS: 
[C188H216F17N10O53P5S+2H]2+ requires 1987.6432, found 1987.6437. 
GlcNAc-glycerol phosphate hexamer (42) 
Pentamer 41 (186 mg, 46.9 µmol) was coupled to 
phosphoramidite building-block 36 (0.2 M in MeCN, 0.47 ml, 
93.8 µmol, 2.0 eq), oxidized, detritylated and purified (F-SPE) 
using the general procedure as described above. Hexamer 42 
(183 mg, 39.3 µmol, 84 %) was obtained as a white foam. 31P 
NMR (161.7 MHz): δ = -1.9, -1.9, (0.5P), -1.7, -1.7 (0.5P), -1.3 - -1.1 (2.5P), -1.0 - -0.9 (2.5P); 1H 
NMR (400 MHz): δ = 1.93 - 2.02 (m, 18H, 6 x NHAc), 2.09 - 2.37 (m, 5H, CH2OH, 
F17C8CH2CH2CH2SO2-, F17C8CH2CH2CH2SO2-), 2.49 - 2.74 (m, 12H, 6 x CH2 cyanoethyl), 2.94 - 3.16 
(m, 2H, F17C8CH2CH2CH2SO2), 3.22 - 3.38 (m, 2H, -OCH2CH2SO2-), 3.44 - 3.87 (m, 32H, 6 x H-3, 6 x 
H-4, 6 x H-5, H-6, H-6’, 6 x CH2 glycerol), 3.89 - 3.98 (m, 6H, 6 x CH glycerol), 3.98 - 4.35 (m, 40H, 
6 x H-2, 5 x H-6, 5 x H-6’, 6 x CH2 glycerol, 6 x CH2 cyanoethyl), 4.37 - 4.52 (m, 14H, -
OCH2CH2SO2-, 6 x CH2 Bn), 4.54 - 4.93 (m, 30H, 6 x H-1, 12 x CH2 Bn), 6.90 - 7.61 (m, 96H, 6 x 
NHAc, Harom); HRMS: [C223H257F17N12O63P6S+2H]2+ requires 2327.7681, found 2327.7673. 
GlcNAc-glycerol phosphate hexamer (43) 
Protected hexamer 42 (85.7 mg, 18.4 µmol) was treated with 
aqueous ammonia as described above affording the intermediate 
hexamer (71.6 mg, 18.3 µmol, 100%). Analytical data 
intermediate: 31P NMR (161.7 MHz): δ = 0.5 - 0.9 (6P); 1H NMR 
(400 MHz): δ = 1.72 - 1.98 (m, 18H, 6 x NHAc), 2.89, 3.35 (2 x t, 2 x 
12H, J = 6.8 Hz, 6 x NH4), 3.35 - 4.65 (m, 102H, 6 x H-2, 6 x H-3, 6 x H-4, 6 x H-5, 6 x H-6, 6 x H-6’, 
6 x CH glycerol, 12 x CH2 glycerol, 18 x CH2 Bn), 4.86 - 5.02 (m, 6H, 6 x H-1), 6.67 - 7.22 (m, 90H, 
Harom); HRMS: [C192H230N6O61P6+H+NH4]2+ requires 1901.1991, found 1901.2015. A portion of 
the semiprotected hexamer (69.6 mg, 17.8 µmol) was deprotected with Pd (0)/H2 using the 
standard procedure. Hexamer 43 (31.5 mg, 13.6 µmol, 76%) was obtained as an amorphous 
white solid. 31P NMR (161.7 MHz): δ = 1.2 - 1.3 (5P), 3.0 (1P, phosphomonoester); 1H NMR (600 
MHz): δ = 2.06 - 2.08 (m, 18H, 6 x NHAc), 3.48 (t, 1H, J = 9.4 Hz, H-3), 3.53 - 3.57 (m, 5H, 5 x H-
3), 3.72 - 3.80 (m, 19H, 6 x H-4, H-6, 6 x CH2 glycerol), 3.82 - 3.91 (m, 10H, H-5, H-6’, 6 x CH 
glycerol, CH2 glycerol), 3.92 - 4.03 (m, 21H, 6 x H-2, 6 x H-5, 5 x H-6, 5 x H-6’), 4.06 - 4.10 (m, 
10H, 5 x CH2 glycerol), 5.03 (d, 1H, J = 3.8 Hz, H-1), 5.04 (d, 4H, J = 3.6 Hz, H-1), 5.07 (d, 1H, J = 
3.7 Hz, H-1); 13C NMR (150 MHz): δ = 23.0 - 23.1 (6 x NHAc), 54.5 (6 x C-2), 61.4 (C-6), 62.1 - 
62.2 (6 x CH2 glycerol), 63.9 (CH2 glycerol), 65.1 - 65.4 (5 x C-6, 5 x CH2 glycerol), 70.5 (5 x C-3), 
70.9 (C-3), 71.9 - 72.1 (6 x C-4, 5 x C-5), 73.1 (C-5), 78.3 (d, J = 7.4 Hz, CH glycerol), 78.9 - 79.1 (4 
x CH glycerol), 79.3 (d, J = 7.4 Hz, CH glycerol), 97.9 (C-1), 98.2 - 98.4 (5 x C-1), 175.4 (5 x Cq 
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The automated solid phase strategy described in chapter three, led to the 
generation of a small library of teichoic acid (TA) fragments. The antigenicity of these 
molecules was evaluated by means of an opsonophagocytic inhibition assay (OPIA). In 
this assay the inhibition of killing Enterococcus faecalis by rabbit antibodies raised 
against a biological preparation of native enterococcal LTA by the synthetic antigens 
was quantified. It was found that two glucosylated TA fragments showed the highest 
inhibitory potency (1 and 2, 
figure 1) when tested in such an 
assay (see figures 2 and 3, 
chapter three).1 A next step in 
the immunological evaluation 
of 1 and 2 comprises the 
coupling of these molecules to 
carrier proteins and test the 
potential of the resulting 
conjugates as a vaccine against 
Enterococcus faecalis.2-4 In 
order to achieve this, sufficient 
quantities of 1 and 2 are 
required which cannot easily be 
generated using an automated 
solid phase synthesis approach. 
In chapter four, a light 
fluorous5-10 approach is 
described, which allowed the 
rapid production of 
multimilligram amounts of TAs. 
With this method, starting from 
Figure 1. Glucosylated hexamers 1-4. 
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the perfluorooctylpropylsulfonyl ethanol linker (F-Pse), it was possible to perform a 
quick purification of the intermediates using fluorous solid phase extraction (F-SPE) 
after each elongation cycle. At the end of the synthesis, the fluorous linker is cleaved 
and the molecules undergo a final hydrogenolysis step, giving multimilligram 
quantities of the target TAs bearing a terminal phosphomonoester.11  
This chapter first discusses the synthesis of TA fragment 3, a phosphorylated 
version of hexamer 1, which is attained using the earlier described light fluorous 
approach. To enable the light fluorous synthesis of TAs without terminal phosphate an 
alternative fluorous linker is required. The perfluorooctylpropyl succinyl linker 
proved suitable for this, as is illustrated by the synthesis of lead TA 2 and TA 4 in 
which a second glucosyl moiety is incorporated.12 Finally, the antigenic properties of 
the prepared TAs (2,3,4) are probed in an OPIA, as described earlier, whereby the 
influence of a terminal phosphate and a second glucosyl moiety on the immunological 
activity could be established. 
Results and Discussion 
As described in chapter four perfluorooctylpropylsulfonylethanol (F-Pse) can be 
used effectively as a phosphate protecting group and concomitantly serve as a 
fluorous linker in the solution phase synthesis of TA fragments.11 First the synthesis of 
hexamer 3, a phosphorylated analogue of TA fragment 1, was explored, using this 
 
Scheme 1. Assembly of TA-fragment 3. 
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linker-system. Thus, F-Pse 513 was elongated in a stepwise manner (Scheme 1) with 
glycerol phosphoramidite 614 in an elongation process, which comprises coupling, 
oxidation, detritylation and, finally, a F-SPE7 purification step. Before the F-SPE 
purification the crude reaction mixture was partitioned between acetonitrile/water 
(80/20) and hexane to remove the bulk of TES and DMT-H that are released during 
the detritylation step in order to simplify the F-SPE purification. Repeating this 
process four times led to pentamer 7 which was then subjected to an adapted 
elongation process. Coupling with benzylidene protected glucosylglycerol 
phosphoramidite 81 under agency of DCI and standard oxidation was followed by 
detritylation using the milder PPTS/MeOH cocktail as the 4,6-O-benzylidene moiety is 
unstable towards DCA/TES.14,15 The presence of the lipophilic protected carbohydrate 
moiety did not influence the F-SPE purification and the target compound was obtained 
uneventfully in 74% yield. At this stage an aminospacer was introduced to allow the 
conjugation of the target structure to, for instance, a carrier protein. Condensation of 
hexamer 9 and phosphoramidite 10 was followed by oxidation and F-SPE to give the 
fully protected construct 11 in 86% yield. Deprotection of hexamer 11 started by 
removal of the cyanoethyl (CE) and F-Pse groups by overnight treatment with 
aqueous ammonia at 40 oC. The semi-protected intermediate was separated from the 
released fluorous linker (perfluorooctylpropylsulfonylethyl amine) using a Et2O/H2O 
extraction. Subsequently, the benzylidene acetal, benzyl ethers and benzyl carbamate 
were removed by means of hydrogenolysis (Pd/H2), leading to the target hexamer 3 in 
98% yield.  
To attain the light fluorous assembly of TA fragments without a terminal phosphate 
moiety the next objective was to find a suitable fluorous hydroxyl protecting group. 
Inspired by contemporary DNA synthesis methods, a succinyl type linker was deemed 
suitable because of its stability towards phosphoramidite chemistry, oxidation and 
detritylation conditions.16,17 The base lability of a fluorous succinyl linker allows the 
same deprotection strategy as employed in the synthesis of hexamer 3. Moreover, 
attention was paid to the development of a more acid-stable glucosyl glycerol synthon 
that allows the incorporation of a glucosyl moiety at any stage of the elongation 
sequence. As described earlier, the benzylidene acetal does not withstand the 
standard detritylation conditions, necessitating the use of a carefully controlled 
procedure for the removal of the temporary DMT group. Therefore, the synthesis of 
the more acid stable tetra-O-benzyl glucosyl synthon 19 was undertaken (Scheme 2). 
A crucial step en route to synthon 19 is the stereoselective introduction of the α-
glucosidic linkage. First the use of per-benzylated glucosyl imidate 12a18 for the 
construction of this linkage was explored. Condensation of this donor with glycerol 
acceptor 13 in DCM led to formation of product 14a with poor selectivity (α/β = 2/1). 
The use of ether as co-solvent19 improved the α/β-ratio (4/1), but the anomeric 
mixture proved to be inseparable. Next, a glucosyl donor bearing an Fmoc protecting 
group on the C6 hydroxyl known to favor the formation of the α-product was 
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Scheme 2. Synthesis of phosphoramidite 19 and F-Pse linked glucosyl glycerol 21. 
explored.20-22 Coupling 6-O-Fmoc glucosyl imidate 12b with glycerol 13 using Et2O as 
a solvent, led to the formation of 14b in high selectivity (α/β ~10/1). Purification by 
column chromatography, afforded α-glucoside 14b in 91% yield (containing < 3% β-
adduct, based on 1H-NMR analysis). Compound 14b was then treated with DBU in 
DCM, and benzylation of the intermediate alcohol 15 led to tetrabenzylglucosyl 
derivative 16 in 87% yield. In the next step the allyl ether was removed by iridium 
catalyzed isomerisation, followed by oxidative cleavage of the intermediate enol ether, 
giving alcohol 17 in 87% yield. Installation of the DMT ether and desilylation led to 
building block 18, which was transformed into the phosphoramidite synthon 19 using 
N,N-diisopropyl-2-cyanoethylchlorophosphoramidite and Et3N. Alternatively, 18 was 
reacted with succinic anhydride and Et3N in DCM, giving succinyl ester 20 in 96% 
yield (scheme 2). Coupling of 20 with perfluorooctylpropylamine, using BOP as a 
condensing agent, was followed by detritylation to give the crude fluorous glucosyl 
glycerol 21, which was purified by F-SPE to give the pure target compound in 90% 
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Scheme 3. Light fluorous assembly of 2. 
yield. This molecule was 
elongated in a step-wise 
manner with glycerol 
phosphoramidite 6 using a 
five-fold repetition of the 4-
step elongation process 
described above leading to 
hexamer 26 (scheme 3). The 
aminohexyl-spacer was then 
introduced to give the fully 
protected hexamer 27. 
Deprotection by 25% 
aqueous ammonia (1 hr, RT), 
was followed by 
hydrogenolysis to give 40 
mg of target compound 2 
(92%).  
To broaden the palette of TA 
fragments, and further 
explore the effectiveness of 
the light fluorous chemistry, 
the synthesis was continued 
with the assembly of 
hexamer 4, containing two 
glucosyl moieties (Scheme 
4). Pentamer 25 was 
coupled to glucosylglycerol 
phosphoramidite 19, 
resulting in bis glucosylated hexamer 28 in 87%. Also this compound was 
uneventfully purified by F-SPE. After introduction of the spacer, the resulting hexamer 
29 was deprotected using the aforementioned conditions, to yield the bis-glucosyl TA 
fragment 4 in 96% yield.  
Hexameric TAs 3 and 4 were compared with TAs 1 and 2 on their ability to bind to 
rabbit antibodies raised against enterococcal LTA in an OPIA, that was performed as 
described before.1-4 Surprisingly, TA 3 bearing an extra phosphate moiety compared 
to one of the lead fragments (1) showed no inhibitory activity at all, even when 
administered at a concentration of 400 µg/ml. This indicates that the terminal 
phosphate moiety is at least disadvantageous to the immunogenicity of the TA. 
Compound 4, which bears a second glucose moiety but lacks the terminal phosphate, 
showed some inhibitory potency. However, when compared to lead TA 2 the 
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antibody binding was 
considerably reduced, 
indicating that an extra 
glucosyl moiety has a 
detrimental effect on 
antigenicity (see figure 2). 
Conclusion 
In summary, this chapter 
describes the development 
of two complementary 
fluorous linker systems for 
the assembly of 
glucosylated TA fragments. 
The first linker, 
perfluorooctylpropyl-
sulfonylethyl, is used as a 
phosphate protecting 
group and allows the 
assembly of TA fragments 
featuring a terminal 
phosphate monoester 
(hexamer 3). The second 
linker, a perfluorooctyl-
propyl succinyl system, is 
used as a hydroxyl 
protecting functionality 
and leads to the formation 
of TA structures terminating in an alcohol 
functionality (structures 2 and 4). Acid stable 
tetra-O-benzyl glucosyl building block 19, 
allowing the incorporation of a glucosyl 
substitution at any position of the TA chain was  
Figure 2. Hexamers 3,4 showing dimished inhibitory activity 
in the OPIA compared to previously made hexamers 1 and 
2. The left bar represents killing by the serum without 
addition of inhibitor. The second bar from the left (LTA) 
represents the positive control where native LTA is added as 
the inhibitor. 
Scheme 4. Light fluorous assembly of 29. 
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prepared and applied in the assembly of TAs 1 and 2. The presence of two lipophilic 
tetrabenzylglucosyl moieties in the fully protected precursor (29) of 4 did not have a 
negative effect on the F-SPE purifications. Fluorous chemistry is an efficient means for 
the assembly of (glycosylated) TA fragments and allows the construction of pure TA 
oligomers in multi milligram quantities, sufficient for most initial biochemical studies.  
Experimental section 
General Procedures and Material: All chemicals (Acros, Fluka, Merck, Schleicher & Schuell, 
Sigma-Aldrich, Genscript, Fluorous Technologies) were used as received and reactions were 
carried out dry, under an argon atmosphere, at ambient temperature, unless stated otherwise. 
Column chromatography was performed on Screening Devices silica gel 60 (0.040-0.063 mm). 
TLC analysis was conducted on HPTLC aluminium sheets (Merck, silica gel 60, F245). 
Compounds were visualized by UV absorption (245 nm), by spraying with 20% H2SO4 in 
ethanol or with a solution of (NH4)6Mo7O24•4 H2O 25 g/l and (NH4)4Ce(SO4)4•2 H2O 10 g/l, in 
10% aqueous H2SO4 followed by charring at +/- 140 oC. Some unsaturated compounds were 
visualized by spraying with a solution of KMnO4 (2%) and K2CO3 (1%) in water. Optical rotation 
measurements ([α]D20) were performed on a Propol automated polarimeter (Sodium D-line, λ = 
589 nm) with a concentration of 10 mg/ml (c = 1), unless stated otherwise. Infrared spectra 
were recorded on a Shimadzu FT-IR 8300. 31P, 1H, and 13C NMR spectra were recorded with a 
Bruker AV 400 (161.7, 400 and 125 MHz respectively) or a Bruker DMX 600 (600 and 150 MHz 
respectively). NMR spectra were recorded in CDCl3 with chemical shift (δ) relative to 
tetramethylsilane, unless stated otherwise. When D2O was used, 1H-NMR spectra were recorded 
with chemical shift relative (δ) to HDO (4.755 ppm), 31P spectra were measured with chemical 
shift relative to 85% H3PO4 (external standard) and 13C-NMR spectra were recorded with 
chemical shift relative to TMS (external standard). High resolution mass spectra (HRMS) were 
recorded by direct injection (2 µl of a 2 µM solution in water/acetonitrile; 50/50; v/v and either 
0.1% formic acid or 10mM ammonium formate for the oligomers) on a mass spectrometer 
(Thermo Finnigan LTQ Orbitrap) equipped with an electrospray ion source in positive mode 
(source voltage 3.5 kV, sheath gas flow 10, capillary temperature 275 oC) with resolution R = 
60000 at m/z 400 (mass range m/z = 150-2000) and dioctylphthalate (m/z = 391.28428) as a 
lock mass. The high resolution mass spectrometer was calibrated prior to measurements with a 
calibration mixture (Thermo Finnigan). 
General procedure for phosphoramidite coupling, oxidation, detritylation and FSPE on a 
typical scale (0.1-0.25 mmol): Starting alcohol was dissolved in ACN (0.1M). DCI (0.25M 
solution in CH3CN, 2 eq compared to phosphoramidite) was added, together with freshly 
activated MS3Å and the mixture was stirred under argon for 15 minutes. Phosphoramidite 
(0.175M in ACN, 1.3 - 4.0 eq) was added and the reaction was stirred until TLC analysis revealed 
full conversion of the starting material into a higher running spot (~1 hr). Added were, 
respectively, H2O (~1 ml) and I2 (0.2 M in THF/pyr 4/1), and the mixture was stirred for an 
additional 5 min. The mixture was diluted with EtOAc (~50 ml) and washed with, respectively, 
sat. aq. Na2S2O3 (~20 ml), 0.5 M KHSO4 (~20 ml) and a 1/1 mixture of sat. aq. NaHCO3 and brine 
(~20 ml). The organic layer was dried over Na2SO4 (s) and concentrated under reduced 
pressure. The residue was coevaporated once with toluene (10 ml) before it was redissolved in 
DCM. Triethylsilane and dichloroacetic acid were added and the mixture was stirred until the 
bright orange color fully dissapeared (~30 min). DCM (~40 ml) was added and the organic 
layer was washed with a 1/1 mixture of sat. aq. NaHCO3 and brine (~20 ml, check if pH >7), 
before it was dried over Na2SO4 and concentrated in vacuo. The residue was taken up in 4/1 
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ACN/H2O (10 ml) and washed with hexane (50 ml). The hexane layer was extracted twice with 
4/1 ACN/H2O (2 x 10 ml) and the combined ACN/H2O layers were concentrated under reduced 
pressure in a 100 ml pear shaped flask. The residue was taken up in 0.5 ml ACN and applied to a 
small column containing fluoroflashTM fluorous silica (4g) which was preeluted with 1/1 ACN 
H2O. The column was eluted with 1/1 ACN/H2O until all the non-fluorous byproducts (DMT-H, 
phosphates, DCI) were removed. Subsequently the fluorous product was eluted from the 
column with, respectively, CH3CN and acetone.  
Global deprotection and purification of oligomers: The fully protected oligomer was treated 
with a 9/1 mixture of 28% NH4OH (aq)/1,4-dioxane at a concentration of 5 mg/ml at 40 - 45 oC 
overnight in a sealed flask or tube in case of of 11. In the synthesis of oligomers 2 and 4, the 
corresponding protected hexamers (27 and 29, respectively) were treated with a 9/1 mixture 
of 28% NH4OH (aq)/1,4-dioxane at a concentration of 5 mg/ml at room temperature for 1h. 
Next, in all cases, the mixture was washed with Et2O (equal volume) and the ether layer was 
extracted twice with H2O. The aqueous layer was concentrated under reduced pressure after 
which NMR and HRMS analysis confirmed full conversion to the semiprotected intermediate. 
The intermediate was then treated with Pd (0)/H2 in a slightly acidic (pH ~2.7) mixture of 
dioxane/water (1/4, containing ~1% AcOH). After stirring for three days the mixture was 
filtered and concentrated in vacuo. The residue was purified by size exclusion chromatography 
(Sephadex HW40, eluent: 0.15 M NH4OAc). After repeated lyophilisation, the purified product 
was eluted through a small column containing Dowex Na+ cation-exchange resin (type: 50WX4-
200, stored on 0.5 M NaOH in H2O, flushed with H2O and MeOH before use). Lyophilization gave 
the fully deprotected oligomer of which the integrity and purity was confirmed by HRMS and 
NMR (1H, 13C, 31P) analysis. 
Glucosyl-2-O-benzylglycerol phosphate hexamer (9) 
Glycerol phosphate pentamer 7 (286 mg, 139 µmol) and 
DCI (0.25M solution in CH3CN, 2.22 ml, 556 µmol) were 
dissolved in CH3CN (2.0 ml) together with freshly 
activated MS3Å and stirred for 15 min under argon. 
Subsequently, glucosyl-glycerol phosphoramidite 8 (0.1M 
in CH3CN, 2.30 ml, 230 µmol) was added and the mixture 
stirred for 30 min at RT. H2O (1.0 ml) was added after which the oxidation step was performed 
according to the general procedure. The crude intermediate was redissolved in a 1/1 mixture of 
DCM and MeOH (40 ml) and treated with PPTS (40 mg, 0.16 mmol) for 8 hrs under gentle 
stirring. The mixture was diluted with DCM (80 ml) and washed with a 1/1 mixture of sat. aq. 
NaHCO3 and brine (50 ml). The organic layer was dried (Na2SO4) and concentrated in vacuo, 
after which the crude product was purified with FSPE, according to the general procedure. 
Glucosylated hexamer 9 (277 mg, 103 µmol, 74%) was obtained as a colorless oil. 31P NMR 
(161.7 MHz): δ = -1.9, -1.8 (1P), -1.3 (2P), -1.1 - -0.9 (3P); 1H NMR (400 MHz): δ = 2.09 - 2.35 (m, 
4H, F17C8CH2CH2CH2SO2-, F17C8CH2CH2CH2SO2-), 2.47 - 2.77 (m, 13H, 6 x CH2 cyanoethyl, CH2-
OH), 3.05 - 3.13 (m, 2H, F17C8CH2CH2CH2SO2-), 3.24 - 3.34 (m, 2H, -OCH2CH2SO2-), 3.51 - 3.72 (m, 
5H, H-2, H-4, H-6, CH2 glycerol), 3.77 - 3.88 (m, 6H, 6 x CH glycerol), 3.98 - 4.34 (m, 37H, H-3, H-
5, H-6’, 11 x CH2 glycerol, 6 x CH2 cyanoethyl), 4.42 - 4.50 (m, 2H, -OCH2CH2SO2-), 4.56 - 4.65 (m, 
10H, 5 x CH2 Bn), 4.70 (d, 1H, J = 11.6 Hz, CHH Bn), 4.80 (d, 1H, J = 11.3 Hz, CHH Bn), 4.87 (d, 1H, 
J = 11.6 Hz, CHH Bn), 4.91 (d, 1H, J = 3.7 Hz, H-1), 4.95 (d, 1H, J = 11.3 Hz, CHH Bn), 5.55 (s, 1H, 
CH benzylidene), 7.25 - 7.40 (m, 38H, Harom), 7.44 - 7.48 (m, 2H, Harom); 13C NMR (100 MHz): δ = 
13.3 (F17C8CH2CH2CH2SO2-), 19.2 - 19.5 (12 x CH2 cyanoethyl), 29.2 (t, J = 22 Hz, 
F17C8CH2CH2CH2SO2-), 53.0, 53.1 (F17C8CH2CH2CH2SO2-, -OCH2CH2SO2-), 60.9 (CH2 glycerol), 
61.3 (-OCH2CH2SO2-), 62.0 - 62.4 (6 x CH2 cyanoethyl), 62.8 (C-5), 65.4 - 66.0 (10 x CH2 glycerol), 
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67.2 (CH2 glycerol), 68.7 (C-6), 72.0 - 72.1 (5 x CH2 Bn), 74.3 (CH2 Bn), 75.0 (CH2 Bn), 75.2 - 75.4 
(5 x CH glycerol), 78.6 - 78.8 (C-2, C-3, CH glycerol), 82.0 (C-4), 98.6, 98.9 (C-1), 100.9 (CH 
benzylidene), 116.6 - 116.7 (6 x Cq cyanoethyl), 125.7 (CHarom), 127.6 - 128.9 (CHarom), 137.1 - 
137.4 (7 x Cq Bn), 138.4 (Cq benzylidene); HRMS: C111H127F17N6O38P6S + NH4+ requires 
2710.6403, found 2710.6393. 
Glucosyl-2-O-benzylglycerol phosphate 
hexamer aminohexyl spacer (11) 
Hexamer 9 (272 mg, 101 µmol) was coupled to 
spacer phosphoramidite 10 (4 eq), oxidized 
and purified (FSPE) using the general 
procedure as described above. Fully protected 
hexamer 11 (267 mg, 87.2 µmol, 86%) was 
obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.9, -1.8 (1P), -1.3 - -1.0 (6P); 1H NMR 
(400 MHz): δ = 1.27 - 1.37 (m, 4H, 2 x CH2 hexylspacer), 1.42 - 1.51 (m, 2H, CH2 hexylspacer), 
1.60 - 1.68 (m, 2H, CH2 hexylspacer), 2.09 - 2.34 (m, 4H, F17C8CH2CH2CH2SO2-, 
F17C8CH2CH2CH2SO2-), 2.39 - 2.69 (m, 14H, 7 x CH2 cyanoethyl), 3.05 - 3.17 (m, 4H, 
F17C8CH2CH2CH2SO2-, CH2-N hexylspacer), 3.24 - 3.33 (m, 2H, -OCH2CH2SO2-), 3.57 - 3.72 (m, 3H, 
H-2, H-4, H-6), 3.75 - 3.85 (m, 5H, 5 x CH glycerol), 3.94 - 4.33 (m, 44H, H-3, H-5, H-6’, CH 
glycerol, 12 x CH2 glycerol, 7 x CH2 cyanoethyl, CH2-O hexylspacer), 4.43 - 4.50 (m, 4H, -
OCH2CH2SO2-, CH2 Bn), 4.53 - 4.64 (m, 10H, 5 x CH2 Bn), 4.71 - 4.77 (m, 2H, CH2 Bn), 4.81, (d, 1H, 
J = 11.6 Hz, CHH Bn), 4.92, (d, 1H, J = 11.6 Hz, CHH Bn), 4.99 - 5.12 (m, 4H, H-1, NH CBz, CH2 
CBz), 5.55 (s, 1H, CH benzylidene), 7.26 - 7.38 (m, 43H, Harom), 7.44 - 7.48 (m, 2H, Harom); 13C 
NMR (100 MHz): δ = 13.3 (F17C8CH2CH2CH2SO2-), 19.2 - 19.5 (7 x CH2 cyanoethyl), 24.8, 25.9 (2 
x CH2 hexylspacer), 29.3 - 29.9 (2 x CH2 hexylspacer, F17C8CH2CH2CH2SO2-), 40.7 (CH2-N 
hexylspacer), 53.0, 53.1 (F17C8CH2CH2CH2SO2-, -OCH2CH2SO2-), 61.3 (-OCH2CH2SO2-), 61.8 - 62.4 
(7 x CH2 cyanoethyl), 62.8 (C-5), 65.3 - 66.0 (11 x CH2 glycerol), 66.3 (CH2 CBz), 68.4 - 68.6 (C-6, 
CH2 glycerol), 72.0 - 72.2 (5 x CH2 Bn), 73.4 - 73.5 (CH2 Bn), 75.0 (CH2 Bn), 75.2 - 75.5 (6 x CH 
glycerol), 78.0 - 78.1 (C-3), 78.9 (C-2), 81.7 - 81.8 (C-4), 97.4 - 97.7 (C-1), 100.8 (CH 
benzylidene), 116.6 - 116.7 (7 x Cq cyanoethyl), 125.7 (CHarom), 127.5 - 128.9 (CHarom), 136.6 (Cq 
Bn), 137.1 - 137.3 (6 x Cq Bn), 137.9 (Cq Bn), 138.5 (Cq benzylidene), 156.3 (Cq CBz); HRMS: 
C128H150F17N8O43P7S + NH4+ requires 3076.7748, found 3076.7789. 
Glucosyl-glycerolphosphate hexamer (3) 
Protected hexamer 11 (99.5 mg, 32.5 µmol) 
was treated with aqueous ammonia as 
described above. Additionally, the compound 
was eluted through a small column containing 
Dowex Na+ cation-exchange resin (type: 
50WX4-200, stored on 0.5 M NaOH in H2O, 
flushed with H2O and MeOH before use) and, 
subsequently, lyophilized, yielding the intermediate semiprotected hexamer (75.2 mg, 32.5 
µmol, 100%) as an amorphous white solid. Analytical data intermediate: 31P NMR (161.7 MHz, 
D2O): δ = 0.9 - 1.1 (6P), 2.9 (1P, phosphomonoester); 1H NMR (400 MHz, D2O): δ = 0.95 - 1.24 
(m, 6H, 3 x CH2 hexylspacer), 1.34 - 1.44 (m, 2H, CH2 hexylspacer), 2.85 - 2.94 (m, 2H, CH2-N 
hexylspacer), 3.51 - 4.15 (m, 38H, H-2, H-3, H-4, H-5, H-6, H-6’, CH2-O hexylspacer, 6 x CH 
glycerol, 12 x CH2 glycerol), 4.29 - 4.41 (m, 10H, 5 x CH2 Bn), 4.47 - 4.58 (m, 4H, 2 x CH2 Bn), 
4.89 (s, 2H, CH2 CBz), 5.29 (d, 1H, J = 3.6 Hz, H-1), 5.47 (s, 1H, CH benzylidene), 6.98 - 7.37 (m, 
45H, Harom); HRMS: [C94H120NO41P7 + 2H]2+ requires 1068.7822, found 1068.7828. A portion of 
the intermediate (75.1 mg, 32.5 µmol) was deprotected with Pd (0)/H2 using the standard 
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procedure. Monoglucosylated hexamer 3 (45.5 mg, 31.7 µmol, 98%) was obtained as an 
amorphous white solid. 31P NMR (161.7 MHz, D2O): δ = 0.9 (1P), 1.2 - 1.3 (4P), 1.4 (1P), 4.7 (1P, 
phosphomonoester); 1H NMR (600 MHz, D2O): δ = 1.38 - 1.43 (m, 4H, 2 x CH2 hexylspacer), 1.60 
- 1.68 (m, 4H, 2 x CH2 hexylspacer), 2.97 (t, 2H, J = 7.5 Hz, CH2-N hexylspacer), 3.37 (at, 1H, J = 
9.6 Hz, H-4), 3.49 (dd, 1H, J = 3.8 Hz, 9.9 Hz, H-2), 3.71 - 3.77 (m, 3H, H-3, H-6, CHH glycerol), 
3.79 - 4.04 (m, 32H, H-5, H-6’, 5 x CH glycerol, 11 x CH2 glycerol, CHH glycerol, CH2-O 
hexylspacer), 4.06 - 4.09 (m, 1H, CH glycerol), 5.14 (d, 1H, J = 3.7 Hz, H-1); 13C NMR (150 MHz, 
D2O): δ = 25.4, 26.1, 27.6 (3 x CH2 hexylspacer), 30.4 (d, J = 6.8 Hz, CH2 hexylspacer), 40.4 (CH2-
N hexylspacer), 61.5 (C-6), 65.2 (d, J = 6.0 Hz, CH2 glycerol), 65.7 (d, J = 4.5 Hz, CH2 glycerol), 
66.1 (d, J = 5.2 Hz, CH2 glycerol), 67.1 - 67.3 (8 x CH2 glycerol, CH2-O hexylspacer), 67.7 (d, J = 
5.5 Hz, CH2 glycerol), 70.5 (t, J = 7.7 Hz, 4 x CH glycerol), 70.7 (C-4), 71,3 (t, J = 7.3 Hz, CH 
glycerol), 72.5 (C-2), 72.8 (C-5), 73.9 (C-3), 76.4 (t, J = 8.0 Hz, CH glycerol), 98.7 (C-1); HRMS: 
C30H68NO39P7 + H+ requires 1284.1605, found 1284.1610. 
3-O-Allyl-2-O-(2,3,4,6-tetra-O-benzyl-α,β-D-glucopyranosyl)-1-
O-(tert-butyldiphenylsilyl)-sn-glycerol (14a) 
To a cooled (0 oC) solution of donor 12a (171 mg, 0.250 mmol) and 
semiprotected glycerol 13 (111 mg, 0.300 mmol) in a 4/1 mixture of 
Et2O/DCM (5.0 ml) was added TMSOTf (2.25 µl, 12.4 µmol). After 
stirring 40 min, Et3N (3 drops) was added and the mixture diluted 
with DCM (10 ml). After washing once with a 1/1 mixture of sat. aq. NaHCO3 and brine (10 ml), 
the organic layer was dried (Na2SO4) and concentrated in vacuo. Purification of the residue by 
silica gel column chromatography (EtOAc/PE) gave pseudodisaccharide 14a (168 mg, 0.188 
mmol, 75%) as an inseparable mixture of anomers (α/β ratio of ~4/1, based on 1H-NMR 
analysis. This was ~2/1 when the reaction was performed in pure DCM). For analytical data of 




To a cooled (0 oC) solution of donor 12b (7.51 g, 8.90 mmol) and 
semiprotected glycerol 13 (3.96 g, 10.7 mmol) in Et2O (180 ml) was 
added TfOH (157 µl, 1.78 mmol). After stirring 25 min, sat. aq. 
NaHCO3 (75 ml) was added and the layers separated. The ether layer was washed once with 
brine (50 ml) before it was dried (Na2SO4) and concentrated in vacuo. Purification of the residue 
by silica gel column chromatography (EtOAc/PE) gave pseudodisaccharide 14b (8.30 g, 8.09 
mmol, 91%) as a colourless oil containing a minor amount (< 3%, based on 1H-NMR analysis) of 
the β-product. [α]D20 (CHCl3): +32.0; IR: 1007, 1072, 1254, 1450, 1748, 2859; 1H NMR (400 
MHz): δ = 1.05 (s, 9H, t-Bu TBDPS), 3.58 - 3.63 (m, 3H, H-2, H-4, CHH glycerol), 3.69 - 3.80 (m, 
3H, CHH glycerol, CH2 glycerol), 3.94 - 4.14 (m, 6H, H-3, H-5, CH glycerol, CHH FMOc, CH2 allyl), 
4.20 - 4.26 (m, 2H, CHH FMOc, CH FMOc), 4.31 - 4.40 (m, 2H, H-6, H-6’), 4.55 (d, 1H, J = 10.8 Hz, 
CHH Bn), 4.69 (d, 1H, J = 11.6 Hz, CHH Bn), 4.76 - 4.79 (m, 3H, 1 x CH2 Bn, CHH Bn), 4.88 (d, 1H, J 
= 10.8 Hz, CHH Bn), 5.00 (d, 1H, J = 10.8 Hz, CHH Bn), 5.16 (ad, 1H, J = 10.8 Hz, CHH allyl), 5.25 
(dd, 1H, J = 1.4 Hz, 17.4 Hz, CHH allyl), 5.32 (d, 1H, J = 3.6 Hz, H-1), 5.87 (ddd, 1H, J = 5.5 Hz, 10.7 
Hz, 22.6 Hz, CH allyl), 7.22 - 7.40 (m, 25H, Harom), 7.58 (d, 1H, J = 7.5 Hz, Harom), 7.61 (d, 1H, J = 
7.5 Hz, Harom), 7.66 (d, 4H, J = 7.1 Hz, Harom), 7.75 (d, 2H, J = 7.6 Hz, Harom);  13C NMR (100 MHz): δ 
= 19.2 (Cq t-Bu), 26.8 (3 x CH3 TBDPS), 46.6 (CH FMOc), 63.8 (CH2 glycerol), 66.2 (CH2 FMOc), 
68.5 (C-5), 69.9 (C-6), 70.6 (CH2 glycerol), 72.2 (CH2 allyl), 72.3 (CH2 Bn), 75.0 (CH2 Bn), 75.7 
(CH2 Bn), 75.8 (CH glycerol), 77.1 (C-4), 79.5 (C-2), 81.7 (C-3), 95.7 (C-1), 116.9 (CH2 allyl), 
125.1, 125.2 (CHarom), 127.1 - 128.6 (CHarom), 129.7 (CHarom), 133.1, 133.2 (Cq phenyl), 134.6 (CH 
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allyl), 135.5 (CHarom), 138.1, 138.2, 138.7, 138.8 (3 x Cq Bn), 141.2, 141.2 (2 x Cq FMOc), 143.2, 




To a solution of compound 14b (3.40 g, 3.32 mmol) in DCM (65 ml) 
was added DBU (165 µl, 1.10 mmol). After stirring for 15 min the 
solvent was removed under reduced pressure and the residue 
purified by silica gel column chromatography (EtOAc/PE) giving 
alcohol 15 (2.50 g, 3.11 mmol, 94%) as a colourless oil. [α]D20 (CHCl3): +33.6; IR: 737, 1026, 
1072, 1454, 2928; 1H NMR (400 MHz): δ = 1.03 (s, 9H, t-Bu TBDPS), 3.48 - 3.80 (m, 9H, H-2, H-4, 
H-5, H-6, H-6’, 2 x CH2 glycerol), 3.97 - 4.04 (m, 4H, H-3, CH glycerol, CH2 allyl), 4.61 (d, 1H, J = 
10.8 Hz, CHH Bn), 4.68 (d, 1H, J = 12.0 Hz, CHH Bn), 4.76 (d, 1H, J = 12.0 Hz, CHH Bn), 4.78 (d, 
1H, J = 10.4 Hz, CHH Bn), 4.86 (d, 1H, J = 11.2 Hz, CHH Bn), 4.97 (d, 1H, J = 10.8 Hz, CHH Bn), 5.16 
(dd, 1H, J = 1.6 Hz, 10.4 Hz, CHH allyl), 5,24 - 5.28 (m, 2H, H-1, CHH allyl), 5.88 (ddd, 1H, J = 5.5 
Hz, 10.7 Hz, 22.6 Hz, CH allyl), 7.24 - 7.42 (m, 21H, Harom), 7.64 - 7.67 (m, 4H, Harom); 13C NMR 
(100 MHz): δ = 19.1 (Cq t-Bu), 26.8 (3 x CH3 TBDPS), 61.4 (C-6), 63.8 (CH2 glycerol), 70.7 (C-5), 
70.9 (CH2 glycerol), 72.2 (CH2 allyl), 72.3 (CH2 Bn), 74.9 (CH2 Bn), 75.6 (CH2 Bn), 76.0 (CH 
glycerol), 77.1 (C-4), 79.6 (C-2), 81.6 (C-3), 96.0 (C-1), 116.9 (CH2 allyl), 127.5 - 128.4 (CHarom), 
129.7 (CHarom), 133.1, 133.2 (Cq phenyl), 134.6 (CH allyl), 135.5 (CHarom), 138.2, 138.3, 138.8 (3 
x Cq Bn); HRMS: C49H58O8Si + Na+ requires 825.3793, found 825.3784. 
3-O-Allyl-2-O-(2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl)-1-O-
(tert-butyldiphenylsilyl)-sn-glycerol (16) 
A solution of alcohol 15 (2.521 g, 3.14 mmol) together with BnBr 
(0.94 ml, 7.85 mmol) in DMF (20 ml) was stirred for 5 minutes at 0 oC, 
after which NaH (60% dispersion in mineral oil, 0.314 g, 7.85 mmol) 
was added. The resulting mixture was stirred for 75 min and allowed 
to slowly warm up to RT, before MeOH (5.0 ml) was added. After stirring for 15 min, H2O (30 
ml) was added and the mixture extracted with Et2O (50 ml). The organic layer was washed 
twice with H2O (20 ml) and once with brine (20 ml) before it was dried (Na2SO4) and 
concentrated in vacuo. Purification of the residual oil by silica gel column chromatography 
(EtOAc/PE) furnished perbenzylglucosyl glycerol derivative 16 (2.429 g, 2.72 mmol, 87%) as a 
colourless oil. [α]D20 (CHCl3): +31.8; IR: 737, 1026, 1069, 1454, 2928; 1H NMR (400 MHz): δ = 
1.05 (s, 9H, t-Bu TBDPS), 3.36 (dd, 1H, J = 1.7 Hz, 10.6 Hz, H-6), 3.54 - 3.84 (m, 8H, H-2, H-4, H-5, 
H-6’, 2 x CH2 glyc), 3.95 - 4.00 (m, 3H, CH2 allyl, H-3), 4.06 (m, 1H, CH glycerol), 4.36 (d, 1H, J = 
12.4 Hz, CHH Bn), 4.43 (d, 1H, J = 10.8 Hz, CHH Bn), 4.55 (d, 1H, J = 12.0 Hz, CHH Bn), 4.69 (d, 
1H, J = 12.0 Hz, CHH Bn), 4.74 - 4.82 (m, 3H, CH2 Bn, CHH Bn), 4.97 (d, 1H, J = 10.8 Hz, CHH Bn), 
5.15 (dd, 1H, J = 1.4 Hz, 10.6 Hz, CHH allyl), 5.24 - 5.29 (m, 2H, CHH allyl, H-1), 5.88 (ddd, 1H, J = 
5.5 Hz, 10.7 Hz, 22.7 Hz, CH allyl), 7.08 - 7.11 (m, 2H, Harom), 7.20 - 7.38 (m, 24H, Harom), 7.64 - 
7.67 (m, 4H, Harom); 13C NMR (100 MHz): δ = 19.1 (Cq t-Bu), 26.8 (3 x CH3 TBDPS), 63.8 (CH2 
glycerol), 68.0 (C-6), 70.1 (C-5), 70.5 (CH2 glycerol), 72.2 (CH2 allyl), 72.2 (CH2 Bn), 73.3 (CH2 
Bn), 74.8 (CH2 Bn), 75.5 (CH2 Bn), 76.0 (CH glycerol), 77.4 (C-4), 79.5 (C-2), 81.8 (C-3), 96.1 (C-
1), 116.7 (CH2 allyl), 127.4 - 128.2 (CHarom), 129.6 (CHarom), 133.1, 133.3 (Cq phenyl), 134.6 (CH 
allyl), 135.5 (CHarom), 137.9, 138.3, 138.4, 138.8 (4 x Cq Bn); HRMS: C56H64O8Si + NH4+ requires 
910.4709, found 910.4718. 
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2-O-(2,3,4,6-tetra-O-Benzyl-α-D-glucopyranosyl)-1-O-(tert-
butyldiphenylsilyl)-sn-glycerol (17) 
A solution of glycoside 16 (2.37 g, 2.65 mmol) in freshly distilled THF 
(18 ml) was stirred under argon for 30 min. After the addition of 
Ir(COD)(Ph2MeP)2PF6 (112 mg, 0.133 mmol) the solution was purged 
with H2 (g) for ~15s. After stirring under argon for 2 hrs, the mixture 
was diluted with THF (20 ml) and sat. aq. NaHCO3 (20 ml). Upon addition of I2 (1.01 g, 3.98 
mmol), the mixture was allowed to stir for 1.5 hrs at room temperature. The mixture was then 
diluted with EtOAc (100 ml) and washed with, respectively, sat. aq. NaS2O3 (30 ml) and brine 
(40 ml). The organic layer was dried over Na2SO4 and concentrated in vacuo. Column 
chromatography (EtOAc/PE) afforded 17 (1.97 g, 2.31 mmol, 87%) as a colourless oil. [α]D20 
(CHCl3): +21.4; IR: 737, 1026, 1069, 1454, 1724, 2928, 3449; 1H NMR (400 MHz): δ = 1.05 (s, 
9H, t-Bu TBDPS), 3.11 (bs, 1H, CH2OH), 3.32 (dd, 1H, J = 1.5 Hz, 10.6 Hz, H-6), 3.54 - 3.57 (m, 2H, 
H-2, H-6’), 3.62 - 3.70 (m, 3H, H-4, 2 x CHH glycerol), 3.77 - 3.86 (m, 4H, H-5, CH glycerol, 2 x 
CHH glycerol), 3.97 (t, 1H, J = 9.3 Hz, H-3), 4.33 (d, 1H, J = 12.2 Hz, CHH Bn), 4.44 (d, 1H, J = 10.9 
Hz, CHH Bn), 4.52 (d, 1H, J = 12.2 Hz, CHH Bn), 4.66 (d, 1H, J = 11.6 Hz, CHH Bn), 4.77 - 4.85 (m, 
3H, CH2 Bn, CHH Bn), 4.90 - 4.93 (m, 2H, H-1, CHH Bn), 7.08 - 7.12 (m, 2H, Harom), 7.20 - 7.39 (m, 
24H, Harom), 7.62 - 7.64 (m, 4H, Harom); 13C NMR (100 MHz): δ = 19.0 (Cq t-Bu), 26.7 (3 x CH3 
TBDPS), 62.6 (CH2 glycerol), 63.7 (CH2 glycerol), 67.8 (C-6), 70.4 (C-5), 73.3, 73.8, 74.7, 75.5 (4 x 
CH2 Bn), 77.4 (C-4), 79.4 (C-2), 80.8 (CH glycerol), 82.0 (C-3), 98.4 (C-1), 127.4 - 128.4 (CHarom), 
129.6 (CHarom), 132.9, 133.0 (Cq phenyl), 135.4 (CHarom), 137.4, 137.6, 138.1, 138.5 (Cq Bn); 
HRMS: C53H60O8Si + Na+ requires 875.3950, found 875.3946. 
2-O-(2,3,4,6-tetra-O-Benzyl-α-D-glucopyranosyl)-3-O-(4,4’-
dimethoxytrityl)-sn-glycerol (18) 
To a cooled (0 oC) solution of alcohol 17 (1.85 g, 2.17 mmol) and Et3N 
(0.45 ml, 3.3 mmol) in DCM (11 ml) was added DMTr-Cl (881 mg, 2.60 
mmol). The mixture was stirred for 2.5 hrs before MeOH (1.0 ml) was 
added. After stirring for an additional 15 minutes the reaction mixture 
was diluted with DCM (40 ml) and washed with a 1/1 mixture of sat. aq. NaHCO3 and brine (30 
ml). The aqueous layer was extracted with DCM (2 x 10 ml) and the combined organic layers 
were dried (Na2SO4) and concentrated under reduced pressure. The residual oil was 
redissolved in THF (15ml) and, subsequently, TBAF (1M solution in THF, 7.8 ml) was added. 
The mixture was stirred for 3 hrs after which the volatiles were removed in vacuo and the 
residual oil was purified by silica gel column chromatography (EtOAc/PE/Et3N) yielding mono-
alcohol 18 (1.77 g, 1.93 mmol, 89%) as a colourless oil. [α]D20 (CHCl3): +40.6; IR: 737, 1030, 
1065, 1250, 1508, 1609, 2927, 3487; 1H NMR (400 MHz): δ = 2.85 (at, 1H, J = 5.0 Hz, CH2OH), 
3.21 (dd, 1H, J = 6.1 Hz, 9.6 Hz, CHH glycerol), 3.35 (dd, 1H, J = 5.5 Hz, 9.6 Hz, CHH glycerol), 3.53 
- 3.57 (m, 2H, H-2, H-4), 3.61 - 3.67 (m, 3H, H-6, H-6’, CHH glycerol), 3.71 (s, 6H, 2 x OMe), 3.76 - 
3.82 (m, 1H, CHH glycerol), 3.86 (m, 1H, CH glycerol), 3.96 - 4.04 (m, 2H, H-3, H-5), 4.46 (d, 1H, J 
= 10.8 Hz, CHH Bn), 4.47 (d, 1H, J = 12.4 Hz, CHH Bn), 4.58 (d, 1H, J = 11.6 Hz, CHH Bn), 4.63 (d, 
1H, J = 12.0 Hz, CHH Bn), 4.80 (d, 1H, J = 10.4 Hz, CHH Bn), 4.82 (d, 1H, J = 10.4 Hz, CHH Bn), 4.96 
(d, 1H, J = 10.8 Hz, CHH Bn), 4.99 (d, 1H, J = 3.6 Hz, H-1), 6.78 - 6.81 (m, 4H, Harom), 7.11 - 7.13 
(m, 2H, Harom), 7.18 - 7.36 (m, 25H, Harom), 7.46 (d, 2H, J = 7.4 Hz, Harom); 13C NMR (100 MHz): δ = 
55.0 (2 x OMe), 63.4 (CH2 glycerol), 63.9 (CH2 glycerol), 68.5 (C-6), 70.5 (C-5), 72.6, 73.4, 75.0, 
75.6 (4 x CH2 Bn), 77.7 (C-4), 79.5 (C-2), 80.0 (CH glycerol), 81.8 (C-3), 86.3 (Cq DMTr), 96.8 (C-
1), 113.0 (CHarom), 126.7 - 129.0 (CHarom), 130.0 (CHarom), 135.8, 137.5, 137.9, 138.0, 138.6, 
144.7, 158.4 (4 x Cq Bn, 5 x Cq DMTr ); HRMS: C58H60O10 + Na+ requires 939.4079, found 
939.4090. 
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To a cooled (0 oC) solution of alcohol 18 (801 mg, 0.873 mmol) 
and Et3N (0.19 ml, 1.4 mmol) in DCM (6.0 ml) was added 2-
cyanoethyl-N,N-diisopropylchlorophosphoramidite (258 mg, 1.09 
mmol). After stirring 30 min, the reaction was quenched by the 
addition of H2O (1.0 ml), diluted with DCM (20 ml) and washed 
with a 1/1 mixture of sat. aq. NaHCO3 and brine (20 ml). The aqueous layer was extracted with 
DCM (2 x 10 ml) and the combined organic layers were dried over Na2SO4 and concentrated in 
vacuo. Purification of the residue by column chromatography (EtOAc/PE/Et3N) gave 
phosphoramidite 19 (722 mg, 0.646 mmol, 74%) as a colourless oil. IR: 1030, 1250, 1508, 1605, 
2928; 31P NMR (161.7 MHz, CD3CN): δ = 149.0, 149.4 (diastereoisomers); 1H NMR (400 MHz, 
CD3CN, mixture of diastereoisomers): δ = 1.04 - 1.12 (m, 12H, 4 x CH3 isopropylamino), 2.40 - 
2.42 (m, 2H, CH2 cyanoethyl), 3.16 - 3.25 (m, 2H, CH2 glycerol), 3.44 - 3.55 (m, 4H, H-2, H-4, 2 x 
CH isopropylamino), 3.60 - 3.88 (m, 13H, H-3, H-6, H-6’, 2 x OMe, CH2 glycerol, CH2 cyanoethyl), 
3.91 - 4.02 (m, 2H, H-5, CH glycerol), 4.48 - 4.61 (m, 5H, CH2 Bn), 4.72 - 4.80 (m, 2H, C2 Bn), 4.86 
- 4.90 (m, 1H, CHH Bn), 5.15 - 5.18 (m, 1H, H-1), 6.80 (d, 4H, J = 8.9 Hz, Harom), 7.12 - 7.36 (m, 
27H, Harom), 7.44 - 7.47 (m, 2H, Harom); 13C NMR (100 MHz): δ = 24.9 - 25.1 (4 x CH3 
isopropylamino), 43.7 - 43.8 (2 x CH isopropylamino), 55.8 (2 x OMe), 59.3 - 59.6 (CH2 glycerol), 
64.3 - 64.4 (CH2 glycerol, CH2 cyanoethyl), 69.9 (C-6), 71.4 - 71.5 (C-5), 72.8 - 72.9, 73.9, 75.4 - 
75.5, 76.0 (4 x CH2 Bn), 77.5 - 77.7 (CH glycerol), 78.8 (C-4), 81.0 (C-2), 82.5 (C-3), 87.2 (Cq 
DMTr), 97.1 - 97.3 (C-1), 114.0 (CHarom), 127.7 - 129.3 (CHarom), 131.0 (CHarom), 136.9, 139.5, 
139.5, 139.7, 139.8, 140.1, 146.1, 159.6 (4 x Cq Bn, 5 x Cq DMTr, Cq cyanoethyl); HRMS: 
C67H77N2O11P + H+ requires 1117.5338, found 1117.5337. 
2-O-(2,3,4,6-tetra-O-Benzyl-α-D-glucopyranosyl)-3-O-(4,4’-
dimethoxytrityl)-1-O-succinyl-sn-glycerol (20) 
To a cooled (0 oC) solution of alcohol 18 (914 mg, 0.997 mmol) and 
Et3N (1.52 ml, 11.0 mmol) in DCM (10 ml) was added succinic 
anhydride (498 mg, 4.98 mmol). After stirring for 1 h the mixture was 
concentrated under reduced pressure, after which column 
chromatography (EtOAc/PE/Et3N) gave succinyl ester 20 (966 mg, 
0.963 mmol, 96%) as a pale yellow oil. [α]D20 (CHCl3): +36.6; IR: 1030, 
1153, 1246, 1508, 1609, 1713, 1736, 2928; 1H NMR (400 MHz, 
CD3CN): δ = 2.49 (s, 4H, 2 x CH2 succinyl), 3.22 - 3.31 (m, 2H, CH2 glycerol), 3.50 (dd, 1H, J = 3.5 
Hz, 9.7 Hz, H-2), 3.57 (at, 1H, J = 9.5 Hz, H-4), 3.68 - 3.77 (m, 8H, H-6, H-6’, 2 x OMe), 3.90 (at, 1H, 
J = 9.3 Hz, H-3), 3.93 - 3.98 (m, 1H, H-5), 4.01 - 4.08 (m, 1H, CH glycerol), 4.23 - 4.32 (m, 2H, CH2 
glycerol), 4.49 - 4.61 (m, 5H, CHH Bn, 2 x CH2 Bn), 4.78 (d, 1H, J = 11.1 Hz, CHH Bn), 4.83 (d, 1H, J 
= 11.1 Hz, CHH Bn), 4.91 (d, 1H, J = 11.1 Hz, CHH Bn), 5.12 (d, 1H, J = 3.5 Hz, H-1), 6.84 (d, 4H, J = 
8.9 Hz, Harom), 7.16 - 7.39 (m, 27H, Harom), 7.48 (d, 2H, J = 7.4 Hz, Harom); 13C NMR (100 MHz, 
CD3CN): δ = 29.8, 30.3 (2 x CH2 succinyl), 56.5 (2 x OMe), 64.1 (CH2 glycerol), 65.9 (CH2 
glycerol), 70.5 (C-6), 72.2 (C-5), 73.7, 74.5, 76.1 (3 x CH2 Bn), 76.2 (CH glycerol), 76.6 (CH2 Bn), 
79.4 (C-4), 81.5 (C-2), 82.9 (C-3), 87.9 (Cq DMTr), 97.6 (C-1), 114.7 (CHarom), 128.4 - 129.9 
(CHarom), 131.6 (CHarom), 137.3, 137.4, 139.9, 140.0, 140.2, 140.7, 146.6, 160.2 (5 x Cq DMTr, 4 x 
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2-O-(2,3,4,6-tetra-O-Benzyl-α-D-glucopyranosyl)-1-O-(N-[3-
perfluorooctylpropyl]-succinamidyl-sn-glycerol (21) 
To a solution of compound 20 (351 mg, 0.350 mmol), 
perfluorooctylpropylamine (119 mg, 0.250 mmol) and N,N-
diisopropylethylamine (0.366 ml, 2.10 mmol) in a 2/1 mixture 
of DCM/DMF (5.0 ml) was added BOP (310 mg, 0.700 mmol). 
The mixture was stirred for 1.5 h before it was diluted with 
EtOAc (100 ml) and, subsequently, washed with sat. aq. NaHCO3 
(2 x 50 ml), H2O (2 x 50 ml) and brine (50 ml). The organic 
layer was dried (Na2SO4) and concentrated under reduced 
pressure, after which the residue was taken up in DCM (5.0 ml). 
After the addition of, respectively, triethylsilane (0.605 ml, 3.75 
mmol) and dichloroacetic acid (0.308 ml, 3.75 mmol) the mixture was stirred 30 min and, 
subsequently, diluted with DCM (40 ml) and washed with a 1/1 mixture of sat. aq. NaHCO3 and 
brine (20 ml). The organic layer was dried (Na2SO4) and concentrated in vacuo, after which the 
residue was partitioned between 80/20 acetonitrile/water and hexane and purified by FSPE as 
described in the general procedure. Fluorous compound 21 (263 mg, 0.224 mmol, 90%) was 
isolated as an amorphous solid. [α]D20 (CHCl3): +23.8; IR: 1026, 1065, 1146, 1200, 1547, 1644, 
1736, 2924; 1H NMR (400 MHz): δ = 1.71 - 1.79 (m, 2H, F17C8CH2CH2CH2N), 1.99 - 2.13 (m, 2H, 
F17C8CH2CH2CH2N), 2.38 (t, 2H, J = 6.7 Hz, CH2 succinyl), 2.63 (t, 2H, J = 6.7 Hz, CH2 succinyl), 
3.24 (dd, 2H, J = 6.8 Hz, 13.3 Hz, F17C8CH2CH2CH2N), 3.54 - 3.75 (m, 6H, H-2, H-4, H-6, H-6’, CH2 
glycerol), 3.83 - 3.89 (m, 1H, CH glycerol), 3.91 - 3.96 (m, 1H, H-5), 4.00 (at, 1H, J = 9.4 Hz, H-3), 
4.13 - 4.16 (m, 2H, CH2 glycerol), 4.46 - 4.50 (m, 2H, 2 x CHH Bn), 4.59 (d, 1H, J = 12.1 Hz, CHH 
Bn), 4.67 (d, 1H, J = 11.6 Hz, CHH Bn), 4.80 - 4.90 (m, 4H, H-1, 3 x CHH Bn), 4.95 (d, 1H, J = 11.0 
Hz, CHH Bn), 5.85 (t, 1H, J = 5.9 Hz, NH), 7.12 - 7.15 (m, 2H, Harom), 7.24 - 7.37 (m, 18H, Harom); 
13C NMR (100 MHz): δ = 20.8 (F17C8CH2CH2CH2N), 28.3 (t, J = 22 Hz, F17C8CH2CH2CH2N), 29.3, 
30.7 (2 x CH2 succinyl), 38.5 (F17C8CH2CH2CH2N), 61.8 (CH2 glycerol), 64.1 (CH2 glycerol), 68.4 
(C-6), 70.9 (C-5), 73.5, 74.2, 75.1, 75.6 (4 x CH2 Bn), 77.7 (C-4), 78.8 (CH glycerol), 79.5 (C-2), 
82.1 (C-3), 98.6 (C-1), 127.6 - 128.6 (CHarom), 137.4, 137.7, 138.0, 138.5 (4 x Cq Bn), 171.5, 172.6 
(2 x C=O succinyl); HRMS: C52H52F17NO10 + Na+ requires 1196.3212, found 1196.3210. 
Glucosyl glycerol phosphate dimer (22) 
Monomer 21 (133 mg, 113 µmol) was 
coupled to glycerol phosphoramidite 6 (1.5 
eq), oxidized, detritylated and purified 
(FSPE) using the general procedure as 
described above. Dimer 22 (153 mg, 104 
µmol, 92%) was obtained as a colorless oil. 
31P NMR (161.7 MHz): δ = -0.9, -0.9 (1P); 1H NMR (400 MHz): δ = 1.70 - 1.78 (m, 2H, 
F17C8CH2CH2CH2N), 1.99 - 2.12 (m, 2H, F17C8CH2CH2CH2N), 2.26 - 2.67 (m, 7H, 2 x CH2 succinyl, 
CH2 cyanoethyl, CH2OH), 3.22 (dd, 2H, J = 6.7 Hz, 13.0 Hz, F17C8CH2CH2CH2N), 3.54 - 3.60 (m, 1H, 
H-2), 3.61 - 3.73 (m, 6H, H-4, H-6, H-6’, CH glycerol, CH2 glycerol), 3.84 - 3.95 (m, 2H, H-3, H-5), 
4.01 - 4.31 (m, 9H, CH glycerol, 3 x CH2 glycerol, CH2 cyanoethyl), 4.44 - 4.49 (m, 2H, 2 x CHH 
Bn), 4.56 - 4.73 (m, 5H, CHH Bn, 2 x CH2 Bn), 4.78 - 4.83 (m, 2H, 2 x CHH Bn), 4.92 - 4.96 (m, 1H, 
CHH Bn), 5.01 - 5.03 (m, 1H, H-1), 6.01 - 6.05 (m,1H, NH), 7.12 - 7.14 (m, 2H, Harom), 7.25 - 7.37 
(m, 23H, Harom); 13C NMR (100 MHz): δ = 19.3 - 19.4 (CH2 cyanoethyl), 20.7 (F17C8CH2CH2CH2N), 
28.3 (t, J = 22 Hz, F17C8CH2CH2CH2N), 29.4, 30.7 (2 x CH2 succinyl), 38.5 (F17C8CH2CH2CH2N), 
60.5 (d, J = 5 Hz, CH2 glycerol), 62.0 (d, J = 5 Hz, CH2 cyanoethyl), 63.0 (CH2 glycerol), 66.1 - 66.6 
(2 x CH2 glycerol), 68.3 (C-6), 70.9 (C-5), 72.0, 72.0 (CH2 Bn), 73.1, 73.2 (CH2 Bn), 73.5 (CH2 Bn), 
73.9 - 74.1 (CH glycerol), 75.1, 75.5 (2 x CH2 Bn), 77.4 - 77.6 (C-4, CH glycerol), 79.6, 79.7 (C-2), 
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81.5 (C-3), 96.9, 97.1 (C-1), 116.4, 116.5 (Cq cyanoethyl), 127.6 - 128.5 (CHarom), 137.6 - 137.7, 
137.9, 138.6 (5 x Cq Bn), 171.5, 172.3 (2 x C=O succinyl); HRMS: C65H68F17N2O15P + Na+ requires 
1493.3978, found 1493.3978. 
Glucosyl glycerol phosphate trimer (23) 
Dimer 22 (149 mg, 101 µmol) was coupled 
to glycerol phosphoramidite 6 (1.5 eq), 
oxidized, detritylated and purified (FSPE) 
using the general procedure as described 
above. Trimer 23 (161 mg, 91.0 µmol, 90%) 
was obtained as a colorless oil. 31P NMR 
(161.7 MHz): δ = -1.4, -1.3, -1.3, -1.3 (1P), -1.0, -0.9 (1P); 1H NMR (400 MHz): δ = 1.69 - 1.77 (m, 
2H, F17C8CH2CH2CH2N), 1.98 - 2.12 (m, 2H, F17C8CH2CH2CH2N), 2.17 - 2.69 (m, 9H, 2 x CH2 
succinyl, 2 x CH2 cyanoethyl, CH2OH), 3.18 - 3.26 (m, 2H, F17C8CH2CH2CH2N), 3.55 - 3.60 (m, 1H, 
H-2), 3.61 - 3.74 (m, 6H, H-4, H-6, H-6’, CH glycerol, CH2 glycerol), 3.76 - 3.82 (m, 1H, CH 
glycerol), 3.86 - 3.95 (m, 2H, H-3, H-5), 4.01 - 4.31 (m, 15H, CH glycerol, 5 x CH2 glycerol, 2 x CH2 
cyanoethyl), 4.44 - 4.49 (m, 2H, 2 x CHH Bn), 4.56 - 4.65 (m, 5H, CHH Bn, 2 x CH2 Bn), 4.69 - 4.72 
(m, 2H, 2 x CHH Bn), 4.77 - 4.83 (m, 2H, 2 x CHH Bn), 4.91 - 4.95 (m, 1H, CHH Bn), 5.01 - 5.04 (m, 
1H, H-1), 6.16 - 6.22 (m,1H, NH), 7.12 - 7.15 (m, 2H, Harom), 7.25 - 7.37 (m, 28H, Harom); 13C NMR 
(100 MHz): δ = 19.2 - 19.4 (2 x CH2 cyanoethyl), 20.6 (F17C8CH2CH2CH2N), 28.2 (t, J = 22 Hz, 
F17C8CH2CH2CH2N), 29.3, 30.6 (2 x CH2 succinyl), 38.4 (F17C8CH2CH2CH2N), 60.4, 60.5 (CH2 
glycerol), 62.0 - 62.2 (2 x CH2 cyanoethyl), 63.0 (CH2 glycerol), 65.5 - 66.7 (4 x CH2 glycerol), 
68.3 (C-6), 70.8 (C-5), 72.0 (CH2 Bn), 72.1, 72.2 (CH2 Bn), 73.0, 73.1 (CH2 Bn), 73.4 (CH2 Bn), 
73.8 - 74.1 (CH glycerol), 75.1 (CH2 Bn), 75.2 - 75.4 (CH glycerol), 75.5 (CH2 Bn), 77.4 - 77.5 (C-4, 
CH glycerol), 79.6 (C-2), 81.5 (C-3), 96.9, 97.0 (C-1), 116.5 - 116.6 (2 x Cq cyanoethyl), 127.5 - 
128.5 (CHarom), 137.1, 137.7 - 138.0, 138.5 (6 x Cq Bn), 171.5, 172.3 (2 x C=O succinyl); HRMS: 
C78H84F17N3O20P2 + Na+ requires 1790.4744, found 1790.4744. 
Glucosyl glycerol phosphate tetramer 
(24) 
Trimer 23 (157 mg, 88.7 µmol) was coupled 
to glycerol phosphoramidite 6 (1.5 eq), 
oxidized, detritylated and purified (FSPE) 
using the general procedure as described 
above. Tetramer 23 (169 mg, 82.0 µmol, 
92%) was obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.4 - -1.2 (2P), -0.9, -0.9, -0.9 
(1P); 1H NMR (400 MHz): δ = 1.68 - 1.76 (m, 2H, F17C8CH2CH2CH2N), 1.98 - 2.19 (m, 3H, 
F17C8CH2CH2CH2N, CH2OH), 2.35 - 2.67 (m, 10H, 2 x CH2 succinyl, 3 x CH2 cyanoethyl), 3.18 - 
3.25 (m, 2H, F17C8CH2CH2CH2N), 3.54 - 3.60 (m, 1H, H-2), 3.61 - 3.75 (m, 6H, H-4, H-6, H-6’, CH 
glycerol, CH2 glycerol), 3.76 - 3.83 (m, 2H, 2 x CH glycerol), 3.85 - 3.95 (m, 2H, H-3, H-5), 4.01 - 
4.30 (m, 21H, CH glycerol, 7 x CH2 glycerol, 3 x CH2 cyanoethyl), 4.44 - 4.49 (m, 2H, 2 x CHH Bn), 
4.56 - 4.66 (m, 7H, CHH Bn, 3 x CH2 Bn), 4.69 - 4.72 (m, 2H, 2 x CHH Bn), 4.76 - 4.83 (m, 2H, 2 x 
CHH Bn), 4.91 - 4.95 (m, 1H, CHH Bn), 5.01 - 5.04 (m, 1H, H-1), 6.12 - 6.19 (m,1H, NH), 7.10 - 
7.15 (m, 2H, Harom), 7.23 - 7.38 (m, 33H, Harom); 13C NMR (100 MHz): δ = 19.2 - 19.5 (3 x CH2 
cyanoethyl), 20.6 (F17C8CH2CH2CH2N), 28.2 (t, J = 22 Hz, F17C8CH2CH2CH2N), 29.3, 30.6 (2 x CH2 
succinyl), 38.4 (F17C8CH2CH2CH2N), 60.4, 60.5 (CH2 glycerol), 62.0 - 62.2 (3 x CH2 cyanoethyl), 
63.1 (CH2 glycerol), 65.5 - 66.6 (6 x CH2 glycerol), 68.3 (C-6), 70.8 (C-5), 72.0 (CH2 Bn), 72.1 - 
72.2 (2 x CH2 Bn), 73.0, 73.1 (CH2 Bn), 73.4 (CH2 Bn), 73.7 - 74.2 (CH glycerol), 75.1 (CH2 Bn), 
75.2 - 75.4 (2 x CH glycerol), 75.5 (CH2 Bn), 77.4 - 77.5 (C-4, CH glycerol), 79.6 (C-2), 81.6 (C-3), 
96.8, 97.0 (C-1), 116.6 - 116.7 (3 x Cq cyanoethyl), 127.6 - 128.5 (CHarom), 137.2, 137.7 - 138.0, 
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138.5 (7 x Cq Bn), 171.4, 172.3 (2 x C=O succinyl); HRMS: [C91H100F17N4O25P3 + 2Na]2+ requires 
1055.2701, found 1055.2705. 
Glucosyl glycerol phosphate pentamer 
(25) 
Tetramer 24 (165 mg, 79.9 µmol) was 
coupled to glycerol phosphoramidite 6 (1.8 
eq), oxidized, detritylated and purified 
(FSPE) using the general procedure as 
described above. Pentamer 25 (176 mg, 
74.3 µmol, 93%) was obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.4 - -1.1 (3P), -0.9, -
0.9, -0.9 (1P); 1H NMR (400 MHz): δ = 1.68 - 1.76 (m, 2H, F17C8CH2CH2CH2N), 1.98 - 2.12 (m, 2H, 
F17C8CH2CH2CH2N), 2.26 - 2.67 (m, 13H, 2 x CH2 succinyl, 4 x CH2 cyanoethyl, CH2OH), 3.18 - 
3.26 (m, 2H, F17C8CH2CH2CH2N), 3.54 - 3.60 (m, 1H, H-2), 3.61 - 3.75 (m, 6H, H-4, H-6, H-6’, CH 
glycerol, CH2 glycerol), 3.76 - 3.83 (m, 3H, 3 x CH glycerol), 3.86 - 3.95 (m, 2H, H-3, H-5), 4.00 - 
4.30 (m, 27H, CH glycerol, 9 x CH2 glycerol, 4 x CH2 cyanoethyl), 4.43 - 4.49 (m, 2H, 2 x CHH Bn), 
4.56 - 4.67 (m, 9H, CHH Bn, 4 x CH2 Bn), 4.69 - 4.71 (m, 2H, 2 x CHH Bn), 4.76 - 4.83 (m, 2H, 2 x 
CHH Bn), 4.91 - 4.95 (m, 1H, CHH Bn), 5.01 - 5.04 (m, 1H, H-1), 6.14 - 6.20 (m,1H, NH), 7.10 - 
7.15 (m, 2H, Harom), 7.23 - 7.39 (m, 38H, Harom); 13C NMR (100 MHz): δ = 19.3 - 19.4 (4 x CH2 
cyanoethyl), 20.6 (F17C8CH2CH2CH2N), 28.2 (t, J = 23 Hz, F17C8CH2CH2CH2N), 29.3, 30.6 (2 x CH2 
succinyl), 38.4 (F17C8CH2CH2CH2N), 60.4, 60.5 (CH2 glycerol), 62.0 - 62.2 (4 x CH2 cyanoethyl), 
63.0 (CH2 glycerol), 65.5 - 66.6 (8 x CH2 glycerol), 68.3 (C-6), 70.8 (C-5), 71.9 (CH2 Bn), 72.1 - 
72.2 (3 x CH2 Bn), 73.0, 73.1 (CH2 Bn), 73.4 (CH2 Bn), 73.7 - 74.0 (CH glycerol), 75.1 (CH2 Bn), 
75.1 - 75.4 (3 x CH glycerol), 75.5 (CH2 Bn), 77.4 - 77.5 (C-4, CH glycerol), 79.6 (C-2), 81.5 (C-3), 
96.8, 96.9 (C-1), 116.6 - 116.7 (4 x Cq cyanoethyl), 127.5 - 128.4 (CHarom), 137.2, 137.7 - 138.0, 
138.5 (8 x Cq Bn), 171.4, 172.3 (2 x C=O succinyl); HRMS: [C104H116F17N5O30P4 + 2Na]2+ requires 
1204.3101, found 1204.3100. 
Glucosyl glycerol phosphate hexamer 
(26) 
Pentamer 25 (149 mg, 63.1 µmol) was 
coupled to glycerol phosphoramidite 6 (2.0 
eq), oxidized, detritylated and purified 
(FSPE) using the general procedure as 
described above. Hexamer 26 (151 mg, 56.8 
µmol, 90%) was obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.4 - -1.1 (4P), -0.9, -0.9, -
0.9 (1P); 1H NMR (400 MHz): δ = 1.68 - 1.76 (m, 2H, F17C8CH2CH2CH2N), 1.98 - 2.12 (m, 2H, 
F17C8CH2CH2CH2N), 2.31 - 2.67 (m, 15H, 2 x CH2 succinyl, 5 x CH2 cyanoethyl, CH2OH), 3.17 - 
3.25 (m, 2H, F17C8CH2CH2CH2N), 3.54 - 3.59 (m, 1H, H-2), 3.61 - 3.74 (m, 6H, H-4, H-6, H-6’, CH 
glycerol, CH2 glycerol), 3.76 - 3.84 (m, 4H, 4 x CH glycerol), 3.85 - 3.94 (m, 2H, H-3, H-5), 4.00 - 
4.31 (m, 33H, CH glycerol, 11 x CH2 glycerol, 5 x CH2 cyanoethyl), 4.44 - 4.48 (m, 2H, 2 x CHH 
Bn), 4.57 - 4.66 (m, 11H, CHH Bn, 5 x CH2 Bn), 4.68 - 4.71 (m, 2H, 2 x CHH Bn), 4.77 - 4.82 (m, 
2H, 2 x CHH Bn), 4.90 - 4.95 (m, 1H, CHH Bn), 5.01 - 5.04 (m, 1H, H-1), 6.17 - 6.23 (m,1H, NH), 
7.11 - 7.14 (m, 2H, Harom), 7.23 - 7.38 (m, 43H, Harom); 13C NMR (100 MHz): δ = 19.2 - 19.4 (5 x 
CH2 cyanoethyl), 20.6 (F17C8CH2CH2CH2N), 28.2 (t, J = 22 Hz, F17C8CH2CH2CH2N), 29.3, 30.5 (2 x 
CH2 succinyl), 38.4 (F17C8CH2CH2CH2N), 60.4, 60.5 (CH2 glycerol), 62.0 - 62.2 (5 x CH2 
cyanoethyl), 63.1 (CH2 glycerol), 65.5 - 66.6 (10 x CH2 glycerol), 68.3 (C-6), 70.8 (C-5), 71.9 (CH2 
Bn), 72.1 - 72.2 (4 x CH2 Bn), 73.0, 73.0 (CH2 Bn), 73.4 (CH2 Bn), 73.8 - 74.0 (CH glycerol), 75.1 
(CH2 Bn), 75.2 - 75.5 (4 x CH glycerol), 75.5 (CH2 Bn), 77.4 - 77.6 (C-4, CH glycerol), 79.6 (C-2), 
81.5 (C-3), 96.8, 96.9 (C-1), 116.6 - 116.8 (5 x Cq cyanoethyl), 127.5 - 128.5 (CHarom), 137.2, 
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137.7 - 138.0, 138.5 (9 x Cq Bn), 171.4, 172.3 (2 x C=O succinyl); HRMS: [C117H132F17N6O35P5 + 
2Na]2+ requires 1352.8484, found 1352.8479. 
Glucosyl glycerol phosphate 
hexamer spacer (27) 
Hexamer 26 (145 mg, 54.6 
µmol) was coupled to spacer 
phosphoramidite 10 (2.5 eq), 
oxidized and purified (FSPE) 
using the general procedure as 
described above. Hexamer 27 
(147 mg, 48.7 µmol, 89%) was obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.4 - -1.1 
(6P); 1H NMR (400 MHz): δ = 1.25 - 1.40 (m, 4H, 2 x CH2 hexylspacer), 1.44 - 1.52 (m, 2H, CH2 
hexylspacer), 1.60 - 1.68 (m, 2H, CH2 hexylspacer), 1.68 - 1.76 (m, 2H, F17C8CH2CH2CH2N), 1.98 - 
2.12 (m, 2H, F17C8CH2CH2CH2N), 2.35 - 2.67 (m, 16H, 2 x CH2 succinyl, 6 x CH2 cyanoethyl), 3.12 - 
3.25 (m, 4H, CH2-N hexylspacer, F17C8CH2CH2CH2N), 3.54 - 3.59 (m, 1H, H-2), 3.61 - 3.68 (m, 2H, 
H-4, H-6), 3.70 - 3.75 (m, 1H, H-6’), 3.76 - 3.84 (m, 5H, 5 x CH glycerol), 3.85 - 3.94 (m, 2H, H-3, 
H-5), 4.00 - 4.31 (m, 39H, CH glycerol, 12 x CH2 glycerol, 6 x CH2 cyanoethyl, CH2-O hexylspacer), 
4.44 - 4.48 (m, 2H, 2 x CHH Bn), 4.57 - 4.65 (m, 11H, CHH Bn, 5 x CH2 Bn), 4.68 - 4.71 (m, 2H, 2 x 
CHH Bn), 4.76 - 4.83 (m, 2H, 2 x CHH Bn), 4.90 - 4.95 (m, 1H, CHH Bn), 5.01 - 5.13 (m, 4H, H-1, 
CH2 Cbz, NH Cbz ), 6.11 - 6.18 (m,1H, NH), 7.11 - 7.14 (m, 2H, Harom), 7.22 - 7.39 (m, 48H, Harom); 
13C NMR (100 MHz): δ = 19.2 - 19.5 (6 x CH2 cyanoethyl), 20.6 (F17C8CH2CH2CH2N), 24.8 (CH2 
hexylspacer), 25.9 (CH2 hexylspacer), 28.2 (t, J = 22 Hz, F17C8CH2CH2CH2N), 29.3 (CH2 succinyl), 
29.6 (CH2 hexylspacer), 29.9 (d, J = 7 Hz, CH2 hexylspacer), 30.5 (CH2 succinyl), 38.3 
(F17C8CH2CH2CH2N), 40.7 (CH2-N hexylspacer), 61.8 - 62.1 (6 x CH2 cyanoethyl), 63.0 (CH2 
glycerol), 65.5 - 66.4 (11 x CH2 glycerol, CH2 Cbz), 68.3 - 68.4 (C-6, CH2-O hexylspacer), 70.8 (C-
5), 72.1 - 72.2 (6 x CH2 Bn), 72.9, 73.0 (CH2 Bn), 73.4 (CH2 Bn), 73.7 - 74.0 (CH glycerol), 75.0 
(CH2 Bn), 75.3 - 75.5 (5 x CH glycerol), 77.4 (C-4), 79.6 (C-2), 81.5 (C-3), 96.8, 96.9 (C-1), 116.5 - 
116.7 (6 x Cq cyanoethyl), 127.5 - 128.5 (CHarom), 136.6, 137.2, 137.7 - 138.0, 138.5 (9 x Cq Bn, Cq 
Cbz), 156.3 (C=O Cbz), 171.3, 172.2 (2 x C=O succinyl); HRMS: [C134H155F17N8O40P6 + 2Na]2+ 
requires 1535.9156, found 1535.9153. 
Glucosyl glycerol phosphate hexamer (2) 
Protected hexamer 27 (139 mg, 46.3 µmol) was 
treated with aqueous ammonia as described 
above. The intermediate hexamer (98.5 mg, 44.1 
µmol, 95%) was obtained as an amorphous white 
solid. Analytical data intermediate: 31P NMR 
(161.7 MHz, D2O): δ = 0.9 - 1.1 (5P), 1.2 (1P); 1H 
NMR (400 MHz, D2O): δ = 0.80 - 1.10 (m, 6H, 3 x 
CH2 hexylspacer), 1.21 - 1.36 (m, 2H, CH2 hexylspacer), 2.59 - 2.78 (m, 2H, CH2-N hexylspacer), 
3.24 - 4.05 (m, 38H, H-2, H-3, H-4, H-5, H-6, H-6’, 12 x CH2 glycerol, 6 x CH glycerol, CH2-O 
hexylspacer), 4.16 - 5.02 (m, 22H, H-1, 9 x CH2 Bn, CH2 Cbz, NH Cbz), 6.66 - 7.14 (m, 50H, Harom); 
HRMS: [C101H127NO38P6 + 2NH4]2+ requires 1092.3586, found 1092.3590. A portion of the 
intermediate (34.5 mg, 15.4 µmol) was deprotected with Pd (0)/H2 using the standard 
procedure. Glucosylated hexamer 2 (19.7 mg, 15.0 µmol, 97%) was obtained as an amorphous 
white solid. 31P NMR (161.7 MHz, D2O): δ = 1.2 (1P), 1.2 - 1.3 (4P), 1.3 (1P); 1H NMR (600 MHz, 
D2O): δ = 1.39 - 1.44 (m, 4H, 2 x CH2 hexylspacer), 1.61 - 1.70 (m, 4H, 2 x CH2 hexylspacer), 2.99 
(t, 2H, J = 7.5 Hz, CH2-N hexylspacer), 3.39 (at, 1H, J = 9.6 Hz, H-4), 3.52 (dd, 1H, J = 3.9 Hz, 9.9 
Hz, H-2), 3.71 - 3.76 (m, 4H, H-3, H-6, CH2 glycerol), 3.80 - 4.05 (m, 32H, H-5, H-6’, 6 x CH 
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glycerol, 11 x CH2 glycerol, CH2-O hexylspacer), 4.14 - 4.17 (m, 1H, CH glycerol), 5.15 (d, 1H, J = 
3.8 Hz, H-1); 13C NMR (150 MHz, D2O): δ = 25.3, 26.0, 27.5, 30.3 (4 x CH2 hexylspacer), 40.3 
(CH2-N hexylspacer), 61.4 (C-6), 62.2 (CH2 glycerol), 65.2 (d, J = 6 Hz, CH2 glycerol), 66.9 - 67.1 
(CH2-O hexylspacer, 11 x CH2 glycerol), 70.3 - 70.5 (5 x CH glycerol,C-4), 72.4 (C-2), 72.9 (C-5), 
73.8 (C-3), 77.7 (d, J = 8 Hz, CH glycerol), 98.7 (C-1); HRMS: C30H67NO36P6 + H+ requires 
1204.1941, found 1204.1948.  
bis-Glucosyl glycerol phosphate hexamer 
(28) 
Pentamer 25 (22.5 mg, 9.52 µmol) was 
coupled to glucosyl-glycerol phosphoramidite 
19 (3.0 eq), oxidized, detritylated and purified 
(FSPE) using the general procedure as 
described above. Bis-glucosylated hexamer 28 
(25.7 mg, 8.31 µmol, 87%) was obtained as a 
colorless oil. 31P NMR (161.7 MHz): δ = -1.4 - -
1.3 (2P), -1.2 , -1.0 (3P); 1H NMR (400 MHz): δ 
= 1.66 - 1.82 (m, 2H, F17C8CH2CH2CH2N), 1.97 - 2.12 (m, 2H, F17C8CH2CH2CH2N), 2.28 - 2.68 (m, 
15H, 2 x CH2 succinyl, 5 x CH2 cyanoethyl, CH2OH), 3.17 - 3.28 (m, 2H, F17C8CH2CH2CH2N), 3.51 - 
3.98 (m, 19H, 2 x H-2, 2 x H-3, 2 x H-4, 2 x H-5, 2 x H-6, 2 x H-6’, 5 x CH glycerol, CH2 glycerol), 
4.00 - 4.31 (m, 33H, CH glycerol, 11 x CH2 glycerol, 5 x CH2 cyanoethyl), 4.42 - 4.48 (m, 4H, 4 x 
CHH Bn), 4.56 - 4.64 (m, 10H, 2 x CHH Bn, 4 x CH2 Bn), 4.67 - 4.71 (m, 3H, 3 x CHH Bn), 4.76 - 
4.84 (m, 5H, 5 x CHH Bn), 4.90 - 4.95 (m, 3H, H-1, 2 x CHH Bn), 5.01 - 5.03 (m, 1H, H-1), 6.02 - 
6.09 (m, 1H, NH), 7.09 - 7.16 (m, 4H, Harom), 7.22 - 7.38 (m, 56H, Harom); HRMS: 
[C144H160F17N6O40P5 + 2Na]2+ requires 1568.9452, found 1568.9454. 
bis-Glucosylglycerol 
phosphate hexamer spacer 
(29) 
Hexamer 28 (24.5 mg, 7.92 
µmol) was coupled to spacer 
phosphoramidite 10 (5 eq), 
oxidized and purified (FSPE) 
using the general procedure as 
described above. Hexamer 29 
(24.3 mg, 7.06 µmol, 89%) was 
obtained as a colorless oil. 31P NMR (161.7 MHz): δ = -1.4 - -1.0 (6P); 1H NMR (400 MHz): δ = 
1.26 - 1.37 (m, 4H, 2 x CH2 hexylspacer), 1.41 - 1.49 (m, 2H, CH2 hexylspacer), 1.59 - 1.68 (m, 2H, 
CH2 hexylspacer), 1.68 - 1.77 (m, 2H, F17C8CH2CH2CH2N), 1.97 - 2.11 (m, 2H, F17C8CH2CH2CH2N), 
2.30 - 2.66 (m, 16H, 2 x CH2 succinyl, 6 x CH2 cyanoethyl), 3.10 - 3.25 (m, 4H, CH2-N hexylspacer, 
F17C8CH2CH2CH2N), 3.54 - 3.94 (m, 18H, 2 x H-2, 2 x H-3, 2 x H-4, 2 x H-5, 2 x H-6, 2 x H-6’, 4 x CH 
glycerol), 4.00 - 4.30 (m, 40H, 2 x CH glycerol, 12 x CH2 glycerol, 6 x CH2 cyanoethyl, CH2-O 
hexylspacer), 4.40 - 4.48 (m, 4H, 4 x CHH Bn), 4.55 - 4.64 (m, 10H, 2 x CHH Bn, 4 x CH2 Bn), 4.68 
- 4.71 (m, 4H, 4 x CHH Bn), 4.76 - 4.83 (m, 4H, 4 x CHH Bn), 4.90 - 4.95 (m, 2H, 2 x CHH Bn), 5.01 
- 5.13 (m, 5H, 2 x H-1, CH2 Cbz, NH Cbz ), 6.04 - 6.11 (m,1H, NH), 7.08 - 7.15 (m, 4H, Harom), 7.22 - 
7.38 (m, 61H, Harom); HRMS: [C161H183F17N8O45P6 + 2H]2+ requires 1730.0305, found 1730.0312. 
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bis-Glucosyl glycerol phosphate 
hexamer (4) 
Protected hexamer 29 (22.5 mg, 
6.54 µmol) was treated with 
aqueous ammonia as described 
above. The intermediate hexamer 
(17.1 mg, 6.42 µmol, 98%) was 
obtained as an amorphous white 
solid. Analytical data intermediate: 31P NMR (161.7 MHz, D2O): δ = 0.9 - 1.2 (6P); 1H NMR (400 
MHz, D2O): δ = 0.76 - 1.10 (m, 6H, 3 x CH2 hexylspacer), 1.21 - 1.34 (m, 2H, CH2 hexylspacer), 
2.55 - 2.76 (m, 2H, CH2-N hexylspacer), 3.11 - 4.14 (m, 44H, 2 x H-2, 2 x H-3, 2 x H-4, 2 x H-5, 2 x 
H-6, 2 x H-6’, 12 x CH2 glycerol, 6 x CH glycerol, CH2-O hexylspacer), 4.15 - 4.84 (m, 28H, 2 x H-1, 
12 x CH2 Bn, CH2 Cbz), 4.96 - 5.04 (m, 1H, NH Cbz), 6.61 - 7.17 (m, 65H, Harom); HRMS: 
[C128H155NO43P6 + 2NH4]2+ requires 1308.4554, found 1308.4563. A portion of the intermediate 
(15.6 mg, 5.85 µmol) was deprotected with Pd (0)/H2 using the standard procedure. Bis-
glucosylated hexamer 4 (8.43 mg, 5.71 µmol, 98%) was obtained as an amorphous white solid. 
31P NMR (161.7 MHz, D2O): δ = 0.9 (1P), 1.2 - 1.3 (5P); 1H NMR (600 MHz, D2O): δ = 1.40 - 1.44 
(m, 4H, 2 x CH2 hexylspacer), 1.62 - 1.70 (m, 4H, 2 x CH2 hexylspacer), 2.99 (t, 2H, J = 7.5 Hz, 
CH2-N hexylspacer), 3.36 - 3.41 (m, 2H, 2 x H-4), 3.48 - 3.53 (m, 2H, 2 x H-2), 3.71 - 3.77 (m, 6H, 
2 x H-3, 2 x H-6, CH2 glycerol), 3.80 - 4.05 (m, 33H, 2 x H-5, 2 x H-6’, 5 x CH glycerol, 11 x CH2 
glycerol, CH2-O hexylspacer), 4.07 - 4.10 (m, 1H, CH glycerol), 5.15 (d, 2H, J = 3.4 Hz, 2 x H-1); 
13C NMR (150 MHz, D2O): δ = 25.5, 26.1, 27.6, 30.5 (4 x CH2 hexylspacer), 40.4 (CH2-N 
hexylspacer), 61.2 (2 x C-6), 61.7 (CH2 glycerol), 65.3 (d, J = 5 Hz, CH2 glycerol), 66.1 (d, J = 5 Hz, 
CH2 glycerol), 67.1 - 67.3 (CH2-O hexylspacer, 10 x CH2 glycerol), 70.4 - 70.7 (4 x CH glycerol,2 x 
C-4), 72.5, 72.5 (2 x C-2), 72.9, 73.0 (2 x C-5), 73.9, 74.0 (2 x C-3), 76.4 (t, J = 8 Hz, CH glycerol), 
77.8 (d, J = 8 Hz, CH glycerol), 98.7, 98.8 (2 x C-1); HRMS: C36H77NO41P6 + H+ requires 
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Chapter 6 





Many Gram positive bacteria, such as Staphylococcus aureus, Enterococcus faecalis, 
Streptococcus pneumonia and Clostridium difficile, pose an emerging risk in healthcare 
due to the increasing resistance against antibiotics.1 E. faecalis has become second in 
line of most common nosocomial infections and this normally harmless commensal 
poses a considerable threat to immunocompromized and critically ill patients as the 
source of infections such as bacteremia, peritonitis, endocarditis, urinary tract and 
wound infections.2 As a result there is a growing interest in the development of 
alternative treatments and preventive strategies to combat these bacteria. With the 
identification of several virulence factors of E. faecalis, the possibility for the 
development of prophylactic and therapeutic vaccine strategies becomes an attractive 
option.3 
Several virulence factors involved in the pathogenesis of enterococcal infections 
have been identified, including cell surface exposed proteins, involved in the 
adherence of the bacteria to extracellular structures, biofilm formation and 
colonization events, and cell-wall carbohydrate antigens, such as capsular 
polysaccharides (CPs) and lipoteichoic acids (LTAs).4 In 2006, Theilacker et al. 
demonstrated that non-encapsulated strains of E. faecalis, which account for about 
half of the clinical isolates, are opsonized by rabbit antibodies raised against purified 
LTA derived from these bacteria.5 Passive immunization of infected mice with this 
antiserum led to clearance of E. faecalis and S. epidermis in the bloodstream. 
Additionally, it was revealed that the rabbit antiserum raised against E. faecalis LTA 
opsonized a selection of clinically relevant enterococcal, streptococcal and 
staphylococcal strains in an opsonophagocytic killing assay (OPA). These results 
indicate that the opsonic antibodies were raised against the common non-substituted 
1,3-glycerol phosphate LTA-backbone. With the aid of synthetic TA oligomers, 
described in chapter 3 and chapter 5 of this thesis, it was shown that relatively short 
non-substituted oligoglycerol phosphates were capable of inhibiting killing by opsonic 
antibodies raised against native E. faecalis LTA.6 Using the same opsonophagocytic 
killing inhibition assay (OPIA) it was revealed that the incorporation of a single α-
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glucosyl substituent in a TA hexamer fragments led to a significantly improved 
inhibitor, indicating that the glucosylated oligomers could function as potent 
antigens.7 Notably, this type of substitution does not occur in E. faecalis LTA. The 
identification of TA hexamer 1 (Figure 1) as a possible synthetic antigen invites the 
use of this compound in a model vaccine for passive and/or active immunization 
strategies. This chapter describes the development of a semi-synthetic TA-carrier 
protein conjugate as a possible vaccine candidate.  
Figure 1. Active 1 and inactive 2 and their conjugates with BSA (3,4). 
Results and Discussion 
Small (carbohydrate) antigens, such as fragment 1, are generally poorly 
immunogenic and only induce a T-cell independent immune response. A well-
established approach to improve this low immune response comprises the 
conjugation of the antigen to an immunogenic carrier protein. This leads to T-cell 
dependent immune response, invoking immunological memory, affinity maturation, 
and IgM to IgG isotype switching.8-10 Conjugate vaccines11-17 are capable of eliciting an 
immune response in infants below the age of two years and this type of vaccines is 
now commonly used in broad national vaccination programs worldwide. A notable 
example of a semi-synthetic glycoconjugate vaccine that is currently used in Cuba and 
Vietnam and other countries is represented by Quimihib®, a vaccine developed 
against Haemophilus influenza Type b by Verez-Bencomo et al. comprising a fully 
synthetic antigen covalently linked to a tetanus toxoid (TTd) carrier protein.17 Various 
(semi)-synthetic conjugate vaccines against important pathogens and specific cancer 
types are currently under development.8,9,18 
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For the development of conjugate vaccines several proteins can be used as 
immunogenic carrier, such as the tetanus toxoid mentioned above, diphteria toxoid 
(DTd), CRM197 (a non-toxic recombinant form of DTd), keyhole limpet hemocyanin 
(KLH) and bovine serum albumin (BSA). Because of its stability, ease of handling and 
modification possibilities, the latter protein was selected as a carrier in the first 
experimental vaccine. Its favorable molecular weight (~67 kD) as well as its non-
glycosylated nature allows the use of several analytical techniques to characterize the 
conjugate.10  
Two synthetic antigens were selected for conjugation to BSA: TA hexamer 1, 
featuring a glycosyl substituent on the terminal glycerol phosphate moiety and 
kojibiosyl-containing fragment 2 (Figure 1). The former was selected because it 
represent the most active synthetic fragment from the assembled TA-oligomer library, 
as indicated by the OPIA described in chapter 3. The latter structure was used, 
because this structure, although it includes the natural glycosyl substituent found in E. 
faecalis LTA, showed a relatively poor inhibitory activity and therefore the projected 
conjugate serves as a relevant control compound. The conjugation of haptens to 
carrier proteins such as BSA can be accomplished with the aid of various chemical 
strategies and the aminohexyl functionality present on TA fragments 1 and 2 allows 
the installment of a conjugation handle of choice. It was decided to adapt the 
conjugation strategy used by Verez-Bencomo et al. in the development of the 
Quimihib®-vaccine, because of the structural similarities between the Hib capsular 
polysaccharide and the TA-oligomers. In this procedure the phosphodiester glycan  
fragments are equipped with a maleimide functionality and the lysine side chain 
amino functions in the protein are decorated with thiopropionyl moieties to allow for 
a robust and reliable conjugation reaction through a Michael type addition.17,19 
As depicted in Scheme 1, treatment of 1 and 2 with the hydroxysuccinimide ester of 
3-maleimidopropionic acid (5) in a basic mixture of DMF and H2O gave, after size 
exclusion chromatography, the maleimides 6 and 7 in 67 and 86% yield, respectively. 
BSA (8) was treated with the homodisulfide of 3-thiopropionic acid 
hydroxysuccinimide ester (9) in a mixture of DMF and phosphate buffer saline (PBS, 
pH 8.0). After reduction of the disulfide bonds with dithiothreitol (DTT) and dialysis 
under inert atmosphere, the thiolated BSA (10) was obtained.19 Quantification of the 
thiols present on the protein was performed by reaction of 10 with Ellman’s reagent 
followed by UV412 analysis, indicating the presence of an additional ~26 thiol 
functionalities (total amount of thiol groups ~43) compared to DTT treated BSA (8, 
~17 thiols per protein). Maleimides 6 and 7 were conjugated with thiolated-BSA 10 
(1.2 eq of maleimide with respect to the total amount of thiol groups were used) to 
give conjugates 3 and 4, which were purified by dialysis and analyzed on protein and 
sugar content. Based on UV280 spectrometry and phenol/H2SO4 colorimetric assays a 
sugar:protein ratio of ~1.5:1 was established for both conjugates. SDS-PAGE analysis 
of the conjugates showed broad bands around ~95 kDa and ~100 kDa, respectively,  
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Scheme 1. Synthesis of conjugates 3 and 4. 
 
Figure 2. SDS-PAGE followed by Coomassie Brilliant Blue staining of conjugates 3 (A) and 4 (B). A: 
BSA (lane 1,3), 10 (lane 3-6), conjugate 3 (lane 8,9), DC-marker (lane 2,7; top to bottom: 250, 150, 100, 
75, 50, 37 kDa). B: BSA (lane 1,2), 10 (lane 2-5), conjugate 4 (lane 5-7), DC-marker (lane 8). 
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indicating protein:sugar ratio’s of ~2.4:1 and 2.0:1 for 3 and 4, respectively. These 
data suggest a substitution rate of around 20 (+/- 5) TA-fragments per BSA (see 
Figure 2). 
To evaluate the immunological activity, rabbits were repeatedly immunized s.c. and 
subsequently i.v. with conjugate 3, 4 or native BSA. After five weeks, serum was 
obtained and tested regarding the presence of opsonic antibodies against E. faecalis in 
an opsonophagocytic killing assay (OPA). In this assay appropriate serum dilutions 
(100 µl) were added to a mixture of human leukocytes (100 µl, 2 x 107 cells/ml), 
complement proteins (preadsorped baby rabbit serum, 100 µl) and E. faecalis (100 µl, 
2 x 107 CFU/ml). After incubating 90 minutes at 37 
oC on a rotor rack, the remaining number of viable 
enterococcal colony forming units (CFUs) was 
quantified. The results of this OPA are depicted in 
Figure 3, where it can be seen that only the serum 
raised against conjugate 3 was able to significantly 
kill E. faecalis. Anti-4 serum gave rise to a low 
amount of opsonic antibodies and the anti-BSA 
serum showed no opsonic killing at all. These 
results show that fragment 1 not only effectively 
binds to opsonic antibodies raised against native 
enterococcal LTA, as revealed in chapter 3, but 
that it can also be used as an immunogen when 
present as a BSA conjugate in vivo. As a control 
experiment an opsonophagocytic inhibition assay 
(OPIA) was performed with anti-3 serum on E. 
faecalis and E. faecium 
using conjugate 3 as an 
inhibitor. Figure 4 
demonstrates the 
specificity of the opsonic 
killing observed. While 
serum dilutions of 
1:1,000 were effectively 
able to kill E. faecalis and 
E. faecium, this killing 
activity could be 
removed by absorbtion 
with conjugate 3 in a 
dose-dependent fashion. 
As described above, Theilacker et al. observed that serum raised against native 
enterococcal LTA showed cross-reactivity towards a selection of Gram-positive 
species.6 Therefore, it was explored whether the anti-3 rabbit serum was able to 
Figure 3. Opsonic killing of E. faecalis 
by rabbit antiserum raised to 
conjugates 3 and 4. Anti-BSA is used 
as a control (left). 
Figure 4. OPIA assay of different amounts of construct 3 using anti-3 
serum against E. faecium and E. faecalis. The black bars on the left 
represent the killing of the bacterium by anti-3 in the OPA when no 
inhibitor is present (negative control). 
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opsonize some of these bacteria. To this end, the previously mentioned OPA was 
performed using strains of Enterococcus faecalis, Enterococcus faecium and 
Staphylococcus aureus. As revealed in Figure 5, E. faecalis is readily opsonized by the 
serum. The closely related E. faecium was effectively killed in the OPA and also S. 
aureus was opsonized by anti-3 serum to a significant extent (i.e. about 70% killing at 
a serum dilution of 1:1,000). Because the OPA showed that the serum raised against 
conjugate 3 could be diluted 5000-fold with minimal loss of activity against E. faecalis 
and E. faecium the serum was investigated at higher dilutions (Figure 6). This revealed 
that E. faecalis is significantly opsonized by this serum up to a 20.000-fold dilution 
(~70 % killing). Notably, the serum proved even more potent against E. faecium and 
could be diluted 160.000 fold before a significant drop in activity was observed. 
Figure 5. Crossreactivity of the serum: Opsonic killing of E.Faecalis, E. Faecium and S. Aureus by 
rabbit serum (dilutions 1:10  1:5000) raised against conjugate 3. 
Figure 6. Opsonic killing of E. Faecalis (left) and E.Faecium (right) by rabbit anti-3 at dilutions up to 
1:200.000. 
The next step of the immunological evaluation of conjugate 3 comprised an in vivo 
passive immunization experiment using the serum raised against this conjugate. To 
this end, a modification of a rat endocarditis model, described originally by Lee et al. 
to measure the protective properties of antiserum raised against S. aureus type 5 
capsular polysaccharide, was used.20 Rats were treated with normal rabbit serum 
(NRS) or anti-3 serum 48 and 24h before they were challenged intravenously with E. 
faecalis. Four days after the infection, rats were euthanized and the total weight of 
bacterial vegetation on the aortic valve determined. In addition, the amount of colony 
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forming units (CFUs) per mg of the harvested vegetation was determined. It was 
found that the weight of endocarditic vegetation present on the aortic valves of the 
rats receiving NRS was between 1 and 3 mg (see Figure 7A). The total weight of 
vegetations found on 
the valves of rats 
immunized with the 
anti-3 serum was 
significantly less (~0.5 
mg). The potency of 
the serum was also 
revealed by the 
significant reduction 
of CFUs present in the 
bacterial vegetation: 
104-107 CFUs per mg 
vegetation were 
present in rats receiving 
NRS, whereas bacterial 
vegetations in the anti-3 
immunized rats contained 
101-104 CFUs per mg on 
average (see Figure 7B).21 
Conclusion 
Carbohydrate substituted glycerol TA hexamers 1 and 2 were successfully attached 
to BSA (8) using thiol-maleimide chemistry resulting in conjugates 3 and 4, 
respectively. Conjugate 3 showed promising results in initial immunological 
evaluation experiments and it was shown subsequently that rabbit serum raised 
against conjugate 3 was able to kill E. faecalis in an OPA. In addition, the serum was 
able to opsonize individual bacterial strains of two other Gram-positive species (S. 
aureus and E. faecium). Notably, the activity of the serum against E. faecium was 
especially high and it was shown that the serum could be diluted 160.000-fold before 
a significant drop in activity resulted. Passive immunization with the rabbit anti-3 
serum protected rats against E. faecalis in an endocarditis model. The initial 
immunological evaluation of conjugate 3 indicates that it is a promising lead candidate 
for a semi-synthetic vaccine against E. faecalis and possibly also as a broad-spectrum 
vaccine directed against several other Gram-positive species. Notably, the results 
described here show that a relatively small hexameric fragment 1 can be used to elicit 
an immune response against native LTA. This bodes well for the future development 
and large scale production of a semi-synthetic synthetic TA vaccine. The next step in 
the evaluation of conjugate 3 will comprise its evaluation in an active immunization 
setting. 
Figure 7. Effects of anti-3 serum in a rat endocarditis model. A: 
Bacterial matter (in mg) found on the murine aortic valves 
immunized with either NRS or anti-3 serum. B: CFUs found in the 
corresponding vegetation (CFUs/mg). 
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Experimental section 
General procedures: 31P, 1H, and 13C NMR spectra were recorded with a Bruker AV 400 (161.7, 
400 and 125 MHz respectively) or a Bruker DMX 600 (600 and 150 MHz respectively). 1H-NMR 
spectra were recorded in D2O with chemical shift (δ) relative to HDO (4.755 ppm) at room 
temperature. 31P spectra were measured with chemical shift relative to 85% H3PO4 (external 
standard) and 13C-NMR spectra were recorded with chemical shift relative to TMS (external 
standard). High resolution mass spectra (HRMS) were recorded by direct injection (2 µl of a 2 
µM solution in water/acetonitrile; 50/50; v/v and 10mM ammonium formate) on a mass 
spectrometer (Thermo Finnigan LTQ Orbitrap) equipped with an electrospray ion source in 
positive mode (source voltage 3.5 kV, sheath gas flow 10, capillary temperature 275 oC) with 
resolution R = 60000 at m/z 400 (mass range m/z = 150-2000) and dioctylphthalate (m/z = 
391.28428) as a lock mass. The high resolution mass spectrometer was calibrated prior to 
measurements with a calibration mixture (Thermo Finnigan). Analysis of the conjugates (3, 4) 
comprised of sugar quantification22 (phenol/sulfuric acid assay, using TAs 1 and 2, respectively, 
as external standards), protein quantification (UV280 absorption, using BSA as an external 
standard) and SDS-PAGE analysis. SDS-PAGE was performed using 7.5% polyacrylamide gels on 
which BSA (8, 300 and 600ng), thiolated BSA (10, 500 and 1000 ng), the conjugate (3 or 4, 500-
2500ng) and Dual Color Marker mixture (containing 37, 50, 75, 100, 150 and 250 kDa markers) 
were applied after boiling in sample buffer for 5 minutes. Stacking onto the running gel was 
performed in 30 minutes at 90V. Run time 90-120 minutes at 120V. Visualization of proteins 
and conjugates was achieved after staining overnight with Coomassie Brilliant Blue followed by 
washing three or four times with milliQ over a period of 24 hrs. 
Glucosylated glycerol phosphate 
hexamer maleimide (6)  
To a solution of TA 1 (7.0 mg, 5.3 µmol) in 
a mixture of saturated aqueous NaHCO3 
(100 µl) and H2O (300 µl) was added N-
succinimidyl-3-maleimido propionate 5 
(28.4 mg, 107 µmol, dissolved in 800 µl 
3/2 MeCN/1,4-dioxane). After stirring 
overnight at RT, the mixture was diluted with H2O (~5 ml) and washed with EtOAc (20 ml). The 
organic layer was extracted once with 5 ml of H2O and the combined aqueous layers 
concentrated under reduced pressure until ~1 ml was left. This solution was applied to a size 
exclusion column (Sephadex HW40, eluent: 0.05 M Et3NHOAc) after which the fractions 
corresponding to the TA fragment were evaporated and, subsequently, lyophilized three times. 
The crude product (in ~0.5 ml H2O) was then eluted through a small column containing Dowex 
Na+ cation-exchange resin (type: 50WX4-200, stored on 0.5 M NaOH in H2O, flushed with H2O 
and MeOH before use). After concentration in vacuo the purified product was coevaporated 
three times with 1% AcOH (~5 ml) in order to regain the maleimide in the non-hydrolyzed 
form. Finally, after lyophilization TA maleimide 6 (5.3 mg, 3.6 µmol, 67%) was obtained as an 
amorphous off-white solid. 31P NMR (161.7 MHz, D2O, hydrolyzed maleimide): δ = 1.2 - 1.3 (5P), 
1.4 (1P); 1H NMR (600 MHz, D2O, hydrolyzed maleimide): δ = 1.23 - 1.33 (m, 4H, 2 x CH2 
hexylspacer), 1.39 - 1.45 (m, 2H, CH2 hexylspacer), 1.52 - 1.58 (m, 2H, CH2 hexylspacer), 2.38 (t, 
2H, J = 6.6 Hz, CH2 maleimidopropionyl), 3.09 (t, 2H, J = 6.9 Hz, CH2-N hexylspacer), 3.33 (at, 1H, 
J = 9.5 Hz, H-4), 3.39 (t, 2H, J = 6.6 Hz, CH2-N maleimidopropionyl), 3.46 (dd, 1H, J = 3.9 Hz, 9.9 
Hz, H-2), 3.65 - 4.00 (m, 36H, H-3, H-5, H-6, H-6’, CH2-O hexylspacer, 6 x CH glycerol, 12 x CH2 
glycerol), 5.10 (d, 1H, J = 3.8 Hz, H-1), 5.83 (d, 1H, J = 12.2 Hz, CH maleimide), 6.24 (d, 1H, J = 
12.3 Hz, CH maleimide); HRMS: C37H72N2O39P6 + H+ requires 1355.2211, found 1355.2225. 
Synthesis of TA-Protein Conjugates and Their Immunological Evaluation 
~ 125 ~ 
Kojibiosylated glycerol phosphate 
hexamer maleimide (7)  
To a solution of kojibiosyl TA 2 (10.0 mg, 
6.42 µmol) in a mixture of saturated aqueous 
NaHCO3 (300 µl) and H2O (300 µl) was added 
N-succinimidyl-3-maleimido propionate 5 
(23.3 mg, 87.4 µmol, dissolved in 1.0 ml 3/2 
MeCN/1,4-dioxane). After stirring overnight 
at RT, the mixture was diluted with H2O (~5 
ml) and washed with EtOAc (20 ml). The 
organic layer was extracted once with 5 ml of H2O and the combined aqueous layers 
concentrated under reduced pressure until ~1 ml was left. This solution was applied to a size 
exclusion column (Sephadex HW40, eluent: 0.05 M Et3NHOAc) after which the fractions 
corresponding to the TA fragment were evaporated and, subsequently, lyophilized three times. 
The crude product (in ~0.5 ml H2O) was then eluted through a small column containing Dowex 
Na+ cation-exchange resin (type: 50WX4-200, stored on 0.5 M NaOH in H2O, flushed with H2O 
and MeOH before use). After concentration in vacuo the purified product was coevaporated 
three times with 1% AcOH (~5 ml) in order to regain the maleimide in the non-hydrolyzed 
form. Finally, after lyophilization TA maleimide 7 (9.11 mg, 5.52 µmol, 86%) was obtained as an 
amorphous off-white solid. 31P NMR (161.7 MHz, D2O, hydrolyzed maleimide): δ = 0.9 (1P), 1.1 
(1P), 1.2 - 1.3 (3P), 1.3 (1P); 1H NMR (600 MHz, D2O, hydrolyzed maleimide): δ = 1.25 - 1.33 (m, 
4H, 2 x CH2 hexylspacer), 1.41 - 1.47 (m, 2H, CH2 hexylspacer), 1.54 - 1.59 (m, 2H, CH2 
hexylspacer), 2.39 (t, 2H, J = 6.6 Hz, CH2 maleimidopropionyl), 3.10 (t, 2H, J = 6.9 Hz, CH2-N 
hexylspacer), 3.34 - 3.42 (m, 4H, 2 x H-4, CH2-N maleimidopropionyl), 3.49 - 3.56 (m, 2H, CHH 
glycerol, H-2), 3.59 - 3.63 (m, 2H, CHH glycerol, H-2), 3.67 - 4.01 (m, 37H, 5 x CH glycerol, 11 x 
CH2 glycerol, CH2-O hexylspacer, 2 x H-3, 2 x H-5, 4 x H-6), 4.10 - 4.15 (m, 1H, CH glycerol), 5.10 
(d, 1H, J = 3.7 Hz, H-1), 5.39 (d, 1H, J = 3.5 Hz, H-1), 5.84 (d, 1H, J = 12.3 Hz, CH maleimide), 6.25 
(d, 1H, J = 12.3 Hz, CH maleimide); HRMS (hydrolyzed form): C43H84N2O45P6 + Na+ requires 
1557.2664, found 1557.2677. 
Glucosyl TA-BSA conjugate(3)  
To a solution of freshly prepared18 
thiolated BSA (10, 68 nmol protein, 
max 2.9 µmol thiol, ~4.7 mg) in 
phosphate buffer saline (PBS, pH 7.2, 
1.65 ml) was added TA 6 (5.2 mg, 3.5 
µmol, in 400 µl PBS). After stirring 
for 20 hrs at RT, 3-
maleimidopropionic acid (0.65 mg, 
3.8 µmol, in 150 µl PBS) was added. 
After overnight reaction the solution 
was transferred to a Slide-A-Lyzer 
dialysis cassette (20 kDa MW cut off, 
capacity 3 ml) and dialyzed overnight 
versus PBS (3l) and milliQ (2 x 3l, overnight). The resulting solution was lyophilized giving the 
target glucosylated hexaglycerol phosphate-BSA conjugate 3 (~8 mg) as an amorphous white 
solid. The protein:sugar ratio was found ~1.5:1 and was determined by UV280 and a 
phenol/H2SO4 assay as described above. SDS-PAGE analysis was performed as described in the 
general procedures and shows a broad band around 95 kDa (see Figure 2, gel A, lane 8,9). These 
combined results indicate the presence of ~20 TA fragments per molecule of BSA. Details SDS-
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PAGE (see also figure 2, gel A); lane 1: BSA (600ng), lane 2: dual color mix (37, 50, 75, 100, 150, 
250 kDa markers), lane 3: BSA (300 ng) and 10 (500 ng), lane 4: 10 (500 ng), lane 5: 10 (1000 
ng), lane 6: 10 (500 ng), lane 7: dual color mix, lane 8: 3 (1200 ng), lane 9: 3 (2400 ng). 
Kojibiosyl TA-BSA conjugate(4)  
To kojibiosyl TA 7 (3.4 mg, 2.0 
µmol) was added a solution of 
freshly prepared18 thiolated BSA 
(10, 46 nmol protein, max 2.0 
µmol thiol, ~3.1 mg) in phosphate 
buffer saline (PBS, pH 7.2, 1.39 
ml). After stirring for 20 hrs at RT, 
3-maleimidopropionic acid (0.34 
mg, 2.0 µmol, in 100 µl PBS) was 
added. After overnight reaction 
the solution was transferred to a 
Slide-A-Lyzer dialysis cassette (20 
kDa MW cut off, capacity 3 ml) and 
dialyzed overnight versus PBS (3l) 
and milliQ (2 x 3l, overnight). The resulting solution was lyophilized giving the target 
kojibiosylated hexaglycerol phosphate-BSA conjugate 4 (~5 mg) as an amorphous white solid. 
The protein:sugar ratio was found ~1.5:1 and was determined by UV280 and a phenol/H2SO4 
assay as described above. SDS-PAGE analysis was performed as described in the general 
procedures and shows a broad band around 100 kDa (see Figure 2, gel B, lane 5-7). These 
combined results indicate the presence of ~20 kojibiosyl TA fragments per molecule of BSA. 
Details SDS-PAGE (see also figure 2, gel B); lane 1: BSA (600ng), lane 2: BSA (300 ng) and 10 
(500 ng), lane 3: 10 (600 ng), lane 4: 10 (1000 ng), lane 5: 10 (600 ng) and 4 (600 ng), lane 6: 4 
(600 ng), lane 7: 4 (1200 ng), lane 8: dual color mix (37, 50, 75, 100, 150, 250 kDa markers). 
Rabbit immunization6: Rabbits were immunized according to literature precedents using 2 
injections of 100 µg s.c. of either BSA or conjugate 3 or 4. in incomplete Freund adjuvant, 
followed by 9 i.v. injections over 3 weeks. All serum samples were heat-inactivated to remove 
complement activity. For all experiments, serum from the final bleed of the rabbit was used. 
Opsonophagocytic assays6: These assays were performed as described by Theilacker et al. 
White blood cells (WBCs) were collected by dextran sedimentation from fresh human blood 
collected from healthy adult volunteers. Baby rabbit serum (Cedarlane Laboratories, Hornby, 
Ontario, Canada) diluted 1:15 in Roswell Park Memorial Institute medium (RPMI)–fetal bovine 
serum was used as the complement source. Unless stated otherwise, bacteria (E. faecalis 12030, 
E. faecium E1162, S. aureus MW2) grown overnight on tryptic soy agar were adjusted to an 
optical density at 650 nm (OD650) of 0.1 with fresh TSB and allowed to grow to an OD650 of 0.4. 
For comparison of opsonophagocytosis of S. aureus strains in different growth phases, an 
additional culture was grown overnight to late stationary phase, and the bacterial concentration 
was adjusted to an OD of 0.4 before the assay. Equal volumes of bacterial suspension (2.5 x 107 
per mL), leukocytes (2.5 x 107 per mL), complement source (1.7% final concentration), and 
immune rabbit serum (anti-BSA, anti-3 or anti-4) at the dilutions indicated in figures 3-6 were 
combined and incubated on a rotor rack at 37 oC for 90 minutes. After incubation, live bacteria 
were quantified by agar culture of serial dilutions. Controls included tubes lacking serum, tubes 
containing complement but lacking serum and WBCs, and tubes containing serum and WBCs 
but lacking complement. For all bacterial strains tested in the study, no significant killing (<5%) 
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was observed in the presence of complement alone. The percentage of killing was calculated by 
determining the mean number of colony-forming units (CFUs) in tubes without WBCs to the 
number of CFUs in tubes with serum samples, leukocytes, complement, and bacteria. 
Opsonophagocytic inhibition assays: anti-3 serum was diluted to a concentration of 1:1000 
(final concentration) giving ~90% killing in the OPA. This antiserum was incubated at 4 oC for 
60 minutes with 0.8-100 µg/mL of inhibitor. After this incubation step, the OPA was continued 
as described above. The percentage of inhibition of killing was calculated by determining the 
ratio of the CFUs surviving in the tubes with inhibitor to the CFUs surviving in the tubes without 
inhibitor. 
Rat endocarditis experiments: The experiments were performed following a procedure 
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Chapter 7 
Summary and Future Prospects 
 
 
This thesis describes the development of synthetic methodologies to acquire 
structurally defined fragments of teichoic acids (TAs). TAs are an important class of 
phosphodiester containing biopolymers that occur in the cell wall of Gram-positive 
bacteria.1-5 The structure of TAs mostly consists of linear polymers of alditol (glycerol, 
ribitol) phosphates, non-stoichiometrically substituted with D-alanyl and 
carbohydrate moieties. The TA structure is related to the type of bacteria and is 
dependent on the conditions these encounter. TAs not only take part in vital functions 
of the bacteria but also are immunologically active. In the introductory chapter the 
discovery, the structural classification, as well as physiological and immunological 
aspects of TAs is briefly discussed. In addition, selected examples of reported 
syntheses to TA fragments, with a focus on phosphor chemistry are presented. The 
synthetic efforts described in this thesis are mainly directed to TAs originating from 
Enterococcus faecalis. This normally harmless commensal has become a considerable 
threat in hospitals as growing antibiotic resistance makes this species difficult to 
treat.6-10 In collaboration with the group of Huebner, specialists on the pathogenesis, 
treatment, and prevention of enterococcal infections, the prepared TAs are 
immunologically evaluated. 
Chapter two describes the solution phase synthesis of a spacer containing 
(kojibiosyl) glycerol hexamer, a striking fragment of a TA from Enterococcus faecalis.9 
Benefit was taken from knowledge on oligonucleotide synthesis, indicating that 
phosphoramidite chemistry is the most efficient procedure for the formation of 
phosphodiesters and the dimethoxytrityl group is most appropriate as temporary 
protective group. Suitably protected glycerol and kojibiosyl glycerol phosphoramidite 
building blocks and an aminohexylphosphoramidite were prepared and implemented 
in the stepwise elongation of dibenzylglycerol to the target hexamer. Each elongation 
cycle comprised three reactions: 1) Phosphitylation using a phosphoramidite. 2) 
Oxidation of the intermediate phosphite triester. 3) Cleavage of the dimethoxytrityl 
group. Deprotection and purification of the target hexamer proceeded uneventful. The 
synthetic approach proved efficient and could be performed at a relatively large scale 
using only a small excess of phosphoramidite reagents.11 
The phosphoramidite chemistry described in chapter two could be applied for the 
development of a solid phase approach, executed with the aid of a DNA synthesizer. 
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Chapter three deals with the construction of a small library of TA fragments using an 
automated solid phase synthesis approach. The library consists of linear 1,3-glycerol 
phosphate TAs comprising six, ten, fourteen and twenty residues and two α-
glucosylated hexaglycerol phosphate TAs. The approach proved to be a fast and 
efficient means to obtain small quantities of a library of TA fragments.12 
The automated solid phase synthesis protocol described in chapter three can 
potentially give access to all kinds of TAs. Intrinsically base-labile structural entities 
such as diacyl glycerol, which is the core structure of the glycolipid anchor of all LTAs 
and alanylated TAs can potentially be made using this approach. However, this 
excludes the 2-cyanoethyl as a phosphate protecting group and the succinyl linker to 
the solid-support since these require base treatment in the final stage of the synthesis. 
The protective group pattern should be adjusted and an example of a retro-synthesis 
to a fragment of the LTA of S. aureus using benzyl protection for the phosphate 
moieties and a photo-cleavable linker to the solid support is outlined in Scheme 1. 
The lability of D-alanyl esters present on TAs makes it difficult to get a clear 
understanding of the immunomodulatory functions that these moieties possess.13 
Even synthetic TAs, the structure of which is spectroscopically ascertained, can 
spontaneously degrade when dissolved in the buffer belonging to in vitro or in vivo 
 
Scheme 1. Retrosynthesis of staphylococcal LTA, no significant base is used during the synthesis. 
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immunological evaluation assays. This problem can possibly be circumvented by the 
synthesis of TA fragments that are equipped with “stabilized” alanines. Schmidt and 
co-workers have reported on the use of alanyl amides as replacement of alanyl esters 
in the synthesis of an analogue of staphylococcal LTA.14 This structural change, 
although adding extra potential hydrogen bond donors, minimally affects important 
properties of teichoic acids such as the overall charge. It is proposed to investigate the 
optically pure α-amino ketone as another example of a stabilized D-alanyl ester 
analogue. In this case the molecules lose a hydrogen bond acceptor for every 
replacement. A third option would be to omit the carbonyl moiety and incorporate the 
stereochemically pure 1-(2-amino)-propyl ether as an alanine mimetic. In this case the 
molecule loses an H-bond acceptor but gains more flexibility. In Scheme 2, a 
retrosynthetic approach to these TA mimetics is presented. In order to avoid potential 
epimerization of the alanyl C-2, it is recommended to use a linker to the solid support 
that is sufficiently base labile. Alternatively, the photo-cleavable linker, the structure 
of which is depicted in Scheme 1, can be amended for this purpose.  
Scheme 2. Retrosynthesis of stabilized D-alanylated TA mimetics 12-14. 
Chapter four informs on a new light fluorous approach to the synthesis of a small 
library of TA fragments, having a terminal phosphate monoester. Glycerol TAs up to a 
length of a dodecamer and several hexamers containing (amino)glucosyl moieties, as 
present in TAs of several strains of bacteria, were efficiently obtained via this 
technique. The molecules were built up from a base labile perfuorooctylpropyl 
sulfonyl ethyl (F-Pse) scaffold, which concomitantly served as a phosphate protecting 
group. This method bears the advantages of the solution phase method (chapter 
two), such as the scale of the reaction allowing the production of multimilligram 
amounts of target TAs and the small excess of expensive phosphoramidite building 
blocks. In addition, the highly efficient fluorous solid phase extraction (F-SPE) 
purification step, which is performed after each elongation cycle ensures a 
significantly reduced purification time.15 
Chapter five reports on an alternative light fluorous approach to three 
glucosylated TA hexamers. In order to obtain TAs provided with a terminal hydroxyl 
function instead of a phosphate monoester, a base labile fluorous succinyl linker was 
developed. In addition, the synthesis towards a more acid stable tetrabenzylglucosyl 
glycerol phosphoramidite is described. This building block provided with acid stabile 
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protecting groups allowed the introduction of the (glucosyl)glycerol moiety into the 
TA backbone at an earlier stage of the synthesis.16 
The chemical research described in chapters two, three, four and five can be 
summarized as the development of three distinctive synthetic approaches to TA 
fragments. These three synthetic approaches: solution phase (chapter two), 
automated solid phase (chapter three) and fluorous phase (chapters four/five) all 
have their advantages and disadvantages, which are summarized in Table 1. From the 
summary drafted in this Table one can envisage that for the development and 
optimization of the applied chemistry the solution phase approach suits best. For a 
small-scale synthesis of a library of TA fragments to screen the initial biological 
properties such as their antigenic potency, the automated solid phase approach is the 
most suitable method. If screening experiments make available a lead compound 
provided with an interesting immunological profile, larger quantities of this TA 
fragment are required for additional immunological experiments. The TA fragment 
can in that case be obtained on a larger scale using one of the light fluorous 
approaches (chapter four/five), which allows a more rapid and efficient synthesis 
compared to regular solution phase chemistry (chapter two). 
Table 1. Relative valuation of the three approaches on several practical elements.               
(+ = good, +/- = reasonable, - = poor) 
 Solution phase Automated solid phase Light fluorous 







Equivalent of phosphoramidite 































It was envisioned that the automated solid phase TA synthesis could be improved 
by amending the purification method with a fluorous tagging procedure.17-19 This 
procedure comprises the installation of a suitable fluorous tag in the final elongation 
step of the automated synthesis to TAs. Because deletion sequences have been capped 
(acetylated) throughout the assembly process, only the target fragment will be 
equipped with the fluorous tag. Cleavage from the solid support and removal of the 
base-labile protecting groups provides a crude mixture, in which the semi-protected 
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target TA is the sole fluorous compound, allowing an efficient purification by F-SPE or 
F-HPLC. To test the viability of this purification procedure in TA synthesis, fluorous 
benzyl carbamate20 protected aminohexyl phosphoramidite (17) was prepared from 
fluorous benzyl alcohol (15) in three steps (see Scheme 3). A small library of TA 
fragments, in which this fluorous tag was appended, was made. The library consisted 
of glycerol phosphates hexamer 20, 20-mer 21, 30-mer 22, and two 15-mers, bearing 
three α-glucosyl or α-N-acetyl glucosamine residues (23, 24). F-SPE proved to be an 
efficient purification method for hexamer 20, although it was observed that the 
difference in affinity for the F-SPE column of 20 with respect to its by-products was 
small. Semi-protected hexamer 20 could be obtained in 51% yield. In case of 20-mer 
21, the F-SPE purification of the crude product was significantly less effective, as 20-
mer 21 partially co-eluted with non-fluorous by-products. A second F-SPE purification 
step of the mixed fractions was required to afford the pure target 21 in 25% yield. In 
the case of 30-mer glycerol phosphate 22, no separation between the fluorous and 
non-fluorous products was obtained with F-SPE, indicating the limit of the F-SPE 
purification method. To effect the purification of 22 the potency of a fluorous HPLC 
purification was explored. Interestingly, with this technique no significant 
improvement in separation of the fluorous 30-mer (22) from the by-products was 
 
Scheme 3. Automated solid phase synthesis of TA fragments using a fluorous tagging strategy. 
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observed compared to a normal RP-HPLC (C18) purification. Apparently, the 
lipophilicity of the fluorous tag in these charged, semi-protected, glycerol phosphates 
has a larger effect on the separation than the fluorous affinity. Purification of the 30-
mer with regular preparative RP-HPLC (C18) gave pure 22 in 11% yield. The 
glycosylated 15-mers 23 and 24 were also purified with preparative RP-HPLC. The 
relatively lipophilic benzylated carbohydrate residues in 15-mers 23 and 24, led to 
significant peak broadening during RP-HPLC analysis using a C18 column. When the 
RP-HPLC purification was performed with a preparative C4 column the two semi-
protected TA 15-mers were isolated in adequate yields: 21% for 23, and 24% for 24, 
respectively. These results indicate that the fluorous tagging strategy is viable for the 
synthesis of TA fragments. For the smaller fragments, the target compounds can be 
purified by exploiting the fluorous character of the TAs, where purification of the 
longer fragments hinges on the extra lipophilicity of the fluorous benzyl group 
attached to the targets, as a RP-HPLC-purification handle.  
The TA fragments described in chapters two, three, four and five were tested on 
their antigenicity in an opsonophagocytic inhibition assay (OPIA). The antigenicity of 
the compounds depended on their length, and the non-substituted 20-mer inhibited 
the killing of E. faecalis more efficiently than the shorter non-substituted glycerol 
phosphates. Surprisingly, the fragments containing an α-glucosyl moiety, which is a 
substitution not found in native enterococcal LTA, showed even better inhibitory 
activity in the OPIA (see chapter three) than the 20-mer. Surprisingly, the TA 
fragments containing a phosphate monoester functionality (chapter four) all showed 
low activity and the bis-glucosylated hexaglycerol phosphate (chapter five) was less 
active than its monoglucosylated counterpart (structure 25, Figure 1). The outcome of 
these studies indicate that the activity of the TA fragments critically depends on the 
substitution pattern and that more structure activity studies are warranted to arrive 
at a TA fragment with an optimal immunological profile.10,12 
Chapter six describes the synthesis and immunological evaluation of a conjugate of 
fragment 25 with bovine serum albumin (BSA), an immunogenic carrier protein. 
Conjugate 26 was obtained via thiol maleimide chemistry and the conjugate contained 
~20 TAs per protein (see Figure 1).21 Serum obtained from rabbits, immunized with 
this conjugate, showed high opsonic activity against E. faecalis. Notably, two strains of 
different Gram-positive pathogens (Enterococcus faecium and Staphylococcus aureus) 
were also opsonized this rabbit anti-26 serum. The opsonic activity against E. faecium 
was surprisingly high, as the antiserum could be diluted ~160.000 fold before the 
killing was reduced. In an in vivo endocarditis model it was shown that rats could 
successfully be passively immunized against E. faecalis using the rabbit antiserum 
raised against conjugate 26.22 A next step in the evaluation of conjugate 26 as an 
experimental vaccine modality would be to test the possibility of active immunization.  
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Figure 1. Hexamer 25, the TA fragment with the highest inhibitory activity, and its BSA conjugate (26). 
 
Scheme 4. Synthesis of TA-TTd conjugate 30. 
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When TA-BSA conjugate 26 proves successful in the additional immunological 
evaluation, it is needed to replace BSA by a protein carrier that is more suitable for 
clinical studies. One of these carrier proteins is tetanus toxoid (TTd), which is used in 
several conjugate vaccines. A notable example is the Quimihib®-vaccine, a TTd-
conjugate of the (synthetic) capsular polysaccharide of Haemophilus influenza.21 In 
anticipation, TA fragment 25 was equipped with a (2-thioacetyl)acetyl moiety using 
the corresponding hydroxysuccinimide ester (27) to give modified TA 28 in 96% yield 
(see Scheme 4). The thiol functionality in 28 was liberated in a buffer containing 
hydroxylamine, and coupled in situ to bromoacetylated-TTd (29) as described earlier 
by Hoogerhout and co-workers.23,24 An H2SO4/phenol colorimetric assay25 of the 
resulting conjugate (30) indicated the presence of carbohydrates on the protein and a 
protein/sugar ratio of ~1.25/1 (~80 TAs per TTd). The immunological evaluation of 
this conjugate is currently in progress.  
In conclusion, this thesis describes the development of three distinctive synthetic 
methodologies to well defined TA fragments. The solution phase, automated solid 
phase and light fluorous approaches all have their specific merits and can be amended 
for different purposes. The synthetic TA fragments have been evaluated on their 
antigenicity and the most potent compound has been conjugated to a protein carrier. 
The TA-protein conjugate shows promising results in initial in vitro and in vivo 
immunological assays and can be used to passively immunize rats against E. faecalis 
an increasingly important Gram-positive threat in healthcare. Further biological 
studies will indicate whether the conjugate is a suitable candidate for clinical trials. 
Experimental section 
General Procedures and Material: All chemicals (Acros, Fluka, Merck, Schleicher & Schuell, 
Sigma-Aldrich, Genscript, Fluorous Technologies) were used as received and reactions were 
carried out dry, under an argon atmosphere, at ambient temperature, unless stated otherwise. 
Column chromatography was performed on Screening Devices silica gel 60 (0.040-0.063 mm). 
TLC analysis was conducted on HPTLC aluminium sheets (Merck, silica gel 60, F245). 
Compounds were visualized by UV absorption (245 nm), by spraying with 20% H2SO4 in 
ethanol or with a solution of (NH4)6Mo7O24•4 H2O 25 g/l and (NH4)4Ce(SO4)4•2 H2O 10 g/l, in 
10% aqueous H2SO4 followed by charring at +/- 140 oC. 31P, 1H, and 13C NMR spectra were 
recorded with a Bruker AV 400 (161.7, 400 and 125 MHz respectively) or a Bruker DMX 600 
(600 and 150 MHz respectively). NMR spectra were recorded in CDCl3 with chemical shift (δ) 
relative to tetramethylsilane, unless stated otherwise. When D2O was used, 1H-NMR spectra 
were recorded with chemical shift relative (δ) to HDO (4.755 ppm), 31P spectra were measured 
with chemical shift relative to 85% H3PO4 (external standard) and 13C-NMR spectra were 
recorded with chemical shift relative to TMS (external standard). High resolution mass spectra 
(HRMS) were recorded by direct injection (2 µl of a 2 µM solution in water/acetonitrile; 50/50; 
v/v and either 0.1% formic acid or 10mM ammonium formate for the oligomers) on a mass 
spectrometer (Thermo Finnigan LTQ Orbitrap) equipped with an electrospray ion source in 
positive mode (source voltage 3.5 kV, sheath gas flow 10, capillary temperature 275 oC) with 
resolution R = 60000 at m/z 400 (mass range m/z = 150-2000) and dioctylphthalate (m/z = 
391.28428) as a lock mass. The high resolution mass spectrometer was calibrated prior to 
measurements with a calibration mixture (Thermo Finnigan). 
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Procedure for automated solid-phase synthesis, purification and global deprotection of 
TA oligomers: Modified polystyrene support (amino PS, Fluka) was loaded with glycerol 
succinates and the loading was determined (loading: 100 µmol/g CPG) using the method 
described by Pon.ref The automated syntheses were performed on a synthesizer (ӒKTA 
oligopilot plus, GE Healthcare) on a scale of 100-150 mg immobilized 19 (10-15 µmol glycerol 
derivative) and started off with acidolysis of the dimethoxytrityl ether using 3% dichloroacetic 
acid in toluene (15 ml, 3 min). After flushing with acetonitrile (5ml, 1 min), the resulting alcohol 
was reacted with phosphoramidites 18a (0.2 M in MeCN, 5 eq) and 5-benzylthiotetrazole (BTT, 
0.3M in MeCN, 22.5 eq) for 5 min using a cycled flow. After flushing with MeCN (5ml, 1 min), 
oxidation of the intermediate phosphite was performed using I2 (0.05 M in pyridine/H2O 9/1, 
2ml, 1 min). A flushing step with MeCN (5ml, 1 min) was followed by a capping step (1 ml of a 
1/1 mixture of capping solution A (20 v/v% N-methylimidazole in MeCN) and capping solution 
B (20 v/v% Ac2O, 15 v/v% 2,6-lutidine in MeCN for 12s). After flushing with MeCN (5ml, 1 min), 
a detritylation step was performed using the before mentioned cocktail and the molecule was 
elongated using phosphoramidites 18a,b or c using the same set of reactions (coupling, 
oxidation, capping, detritylation). The average coupling efficiency was measured by quantitative 
UV-detection (400 nm) of the dimethoxytrityl cation during each detritylation step. When the 
desired length was obtained, spacer phosphoramidite 17 (0.2 M in ACN, 2 x 5 eq, 2 x 5 min) was 
coupled to the PS-TA-oligomer using BTT (0.3M in MeCN, 2 x 22.5 eq) and, subsequently treated 
with I2 (0.05 M in pyridine/H2O 9/1, 2ml, 1 min), before it was released from the solid support 
using 25% NH4OH (10ml, 1h, the cyanoethyl groups are concomitantly released at this stage). 
The solvents were then removed in vacuo before the crude oligomer was purified using F-SPE 
or RP-HPLC. 
F-SPE: The crude product was taken up in 0.5 ml H2O and applied to a small column containing 
fluoroflashTM fluorous silica (4g) which was preeluted with H2O. The column was eluted with 
H2O and 10% CH3CN in H2O until all the non-fluorous by-products were removed. The fluorous 
product was then eluted from the column with a 2/2/1 mixture of acetony/CH3CN/H2O. 
Lyophilization gave the partially protected oligomer of which the integrity and purity was 
confirmed by LC-MS, HRMS and NMR (1H, 13C, 31P) analysis. 
RP-HPLC: Gilson preparative HPLC system; column: Alltima C18 or C4, particle size: 5 µm, 
dimensions: 10/250 mm; eluent: (10 mM NH4OAc in H2O for C18 or 25mM TEAA for in H2O for 
C4)/MeCN, 9/1 → 1/9, detection: UV (215 and 254 nm), the fractions containing product were 
collected and the solvents were removed under reduced pressure. Repeated lyophilization 
(trice) of the residue gave the partially protected oligomer of which the integrity and purity was 
confirmed by LC-MS, HRMS and NMR (1H, 13C, 31P) analysis. 
4-(2-perfluorooctylethyl)benzyl N-(6-hydroxyhexyl)carbamate (16) 
To a cooled (0 oC) solution of fluorous benzyl alcohol 15 (1.11 g, 2.00 
mmol) in THF (20 ml) was added phosgene (2M in toluene, 2.50 ml, 5 
mmol). After stirring for 90 minutes the volatiles were removed under 
reduced pressure and the residue coevaporated with THF (10 ml). The 
crude chloroformate was dissolved in a mixture of THF (30 ml) and sat. 
aq. NaHCO3 (12 ml) after which 1-amino-6-hexanol (2.34 g, 20 mmol) 
was added. After stirring overnight the mixture was diluted with Et2O 
(300 ml) and washed with brine (2 x 150 ml). The organic layer was 
dried (Na2SO4) and concentrated in vacuo. Crystallization (EtOAc/PE) of the residue afforded 
the title carbamate (16, 1.21 g, 1.74 mmol, 87%) as an amorphous off-white solid. 1H NMR (300 
MHz): δ = 1.30 - 1.41 (m, 4H, 2 x CH2 hexylspacer), 1.47 - 1.60 (m, 4H, 2 x CH2 hexylspacer), 2.27 
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- 2.48 (m, 2H, F17C8CH2CH2-), 2.86 - 2.98 (m, 2H, F17C8CH2CH2-), 3.11 - 3.21 (m, 2H, CH2-N 
hexylspacer), 3.58 (t, 2H, J = 6.5 Hz, CH2-O hexylspacer), 5.06 (s, 2H, CH2 F-Bn), 5.41 (bs, 1H, 
NH), 7.22 (d, 2H, J = 7.8 Hz, Harom), 7.32 (d, 2H, J = 7.9 Hz, Harom); 13C NMR (75 MHz): δ = 25.1, 
25.9, 26.2 (2 x CH2 hexylspacer, F17C8CH2CH2-), 29.6, 32.1 (2 x CH2 hexylspacer), 32.7 (t, J = 22 
Hz, F17C8CH2CH2-), 40.7 (CH2-N hexylspacer), 61.9 (CH2-O hexylspacer), 66.1 (CH2 F-Bn), 128.3 - 
128.4 (CHarom), 134.9 (Cq F-Bn), 138.9 (Cq F-Bn). 
4-(2-perfluorooctylethyl)benzyl N-(6-O-[{N,N-diisopropyl}-2-
cyanoethyl phosphoramidite]-hexyl)-carbamate (17) 
To a solution of fluorous alcohol 16 (1.13 g, 1.62 mmol) and DiPEA 
(0.43 ml, 2.47 mmol) in DCM (32 ml) was added (N,N-diisopropyl)-
2-cyanoethyl-chlorophosphoramidite (0.452 ml, 2.03 mmol). After 
stirring 90 min H2O (10 ml) was added and the layers separated. 
The organic layer was washed with H2O (10 ml) and brine (10 ml) 
after which it was dried (Na2SO4) and concentrated in vacuo. 
Purification of the residue by column chromatography 
(EtOAc/PE/Et3N) gave phosphoramidite 17 (692 mg, 771 µmol, 
48%) as an oily substance. 31P NMR (161.7 MHz, CD3CN): δ = 148.2; 1H NMR (400 MHz, CD3CN): 
δ = 1.16 - 1.20 (m, 12H, 4 x CH3 isopropylamino), 1.30 - 1.41 (m, 4H, 2 x CH2 hexylspacer), 1.44 - 
1.51 (m, 2H, CH2 hexylspacer), 1.56 - 1.62 (m, 2H, CH2 hexylspacer), 2.35 - 2.49 (m, 2H, 
F17C8CH2CH2-), 2.63 (t, 2H, J = 6.0 Hz, CH2 cyanoethyl), 2.84 - 2.90 (m, 2H, F17C8CH2CH2-), 3.09 
(dd, 2H, J = 6.6 Hz, 13.0 Hz, CH2-N hexylspacer), 3.55 - 3.68 (m, 4H, CH2-O hexylspacer, 2 x CH 
isopropylamino), 3.71 - 3.82 (m, 2H, CH2 cyanoethyl), 5.00 (s, 2H, CH2 F-Bn), 5.74 (t, 1H, J = 5.5 
Hz, NH), 7.20 (d, 2H, J = 7.9 Hz, Harom), 7.27 (d, 2H, J = 7.9 Hz, Harom); 13C NMR (100 MHz, CD3CN): 
δ = 21.1 (d, J = 7 Hz, CH2 cyanoethyl), 25.0 (d, J = 7 Hz, 4 x CH3 isopropylamino), 26.5 (CH2 
hexylspacer), 26.7 (F17C8CH2CH2-), 27.2 (CH2 hexylspacer), 30.7 (CH2 hexylspacer), 31.9 (d, J = 7 
Hz, CH2 hexylspacer), 33.1 (t, J = 22 Hz, F17C8CH2CH2-), 41.6 (CH2-N hexylspacer), 43.8 (d, J = 12 
Hz, 2 x CH isopropylamino), 59.3 (d, J = 19 Hz, CH2 cyanoethyl), 64.3 (d, J = 17 Hz, CH2-O 
hexylspacer), 66.4 (CH2 F-Bn), 119.5 (Cq cyanoethyl), 129.1, 129.4 (CHarom), 136.9 (Cq F-Bn), 
139.9 (Cq F-Bn), 157.4 (C=O carbamate). 
Fluorous hexa(2-benzyl)glycerol phosphate (20) 
Automated solid phase TA synthesis was performed 
as described above using 15 µmol of immobilized 
glycerol (19). After five consecutive elongation cycles 
using phosphoramidite 18a a capping step with 
fluorous phosphoramidite 17 was performed. After 
ammonia treatment the crude product was purified 
with F-SPE affording hexamer 20 (17.2 mg, 7.6 µmol, 
51%) as an amorphous white solid. 31P NMR (161.7 
MHz, 3/2 D2O/CD3OD): δ = -0.2 (4P), 0.0 (2P); 1H 
NMR (600 MHz, 3/2 D2O/CD3OD, T = 328K): δ = 1.16 - 
1.29 (m, 4H, 2 x CH2 hexylspacer), 1.34 - 1.39 (m, 2H, CH2 hexylspacer), 1.45 - 1.51 (m, 2H, CH2 
hexylspacer), 2.29 - 2.39 (m, 2H, F17C8CH2CH2-), 2.82 (t, 2H, J = 7.9 Hz, F17C8CH2CH2-), 2.99 - 3.05 
(m, 2H, CH2-N hexylspacer), 3.57 - 3.68 (m, 3H, CH glycerol, CH2 glycerol), 3.72 - 3.99 (m, 29H, 5 
x CH glycerol, 11 x CH2 glycerol, CH2-O hexylspacer), 4.51 - 4.63 (m, 12H, 6 x CH2 Bn), 5.01 (s, 
2H, CH2 F-Bn), 7.11 - 7.33 (m, 34H, Harom); HRMS: C84H102F17NO33P6 + NH4+ requires 2179.4827, 
found 2179.4840. 
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Fluorous (2-benzyl)glycerol phosphate 20-mer 
(21) 
Automated solid phase TA synthesis was performed 
as described above using 15 µmol of immobilized 
glycerol (19). After nineteen consecutive elongation 
cycles using phosphoramidite 18a a capping step 
with fluorous phosphoramidite 17 was performed. 
After ammonia treatment the crude product was 
purified with F-SPE. In addition, the purified oligomer 
was eluted through a small column containing Dowex 
Na+ cation-exchange resin (type: 50WX4-200, stored 
on 0.5 M NaOH in H2O, flushed with H2O and MeOH before use). Lyophilization afforded 20-mer 
21 (22.2 mg, 3.69 µmol, 25%) as an amorphous white solid. 31P NMR (161.7 MHz, 3/2 
D2O/CD3OD): δ = 1.2 (18P), 1.3 (2P); 1H NMR (400 MHz, 3/2 D2O/CD3OD, T = 328K): δ = 1.10 - 
1.34 (m, 6H, 3 x CH2 hexylspacer), 1.39 - 1.49 (m, 2H, CH2 hexylspacer), 2.11 - 2.26 (m, 2H, 
F17C8CH2CH2-), 2.65 - 2.71 (m 2H, F17C8CH2CH2-), 2.92 – 2.98 (m, 2H, CH2-N hexylspacer), 3.53 - 
3.99 (m, 102H, 20 x CH glycerol, 40 x CH2 glycerol, CH2-O hexylspacer), 4.47 - 4.59 (m, 40H, 20 x 
CH2 Bn), 4.94 (bs, 2H, CH2 F-Bn), 7.00 - 7.30 (m, 104H, Harom); HRMS: [C224H284F17NO103P20 + 
2NH4]2+ requires 2808.1120, found 2808.1094. 
Fluorous (2-benzyl)glycerol phosphate 30-mer 
(22) 
Automated solid phase TA synthesis was performed 
as described above using 15 µmol of immobilized 
glycerol (19). After 29 consecutive elongation cycles 
using phosphoramidite 18a a capping step with 
fluorous phosphoramidite 17 was performed. After 
ammonia treatment the crude product was purified 
with RP-HPLC (C18). In addition, the purified 
oligomer was eluted through a small column 
containing Dowex Na+ cation-exchange resin (type: 
50WX4-200, stored on 0.5 M NaOH in H2O, flushed with H2O and MeOH before use). 
Lyophilization afforded 30-mer 22 (14.6 mg, 1.68 µmol, 11%) as an amorphous white solid. 31P 
NMR (161.7 MHz, 7/3 D2O/CD3OD): δ = 1.0 (28P), 1.1 (2P); 1H NMR (400 MHz, 7/3 D2O/CD3OD, 
T = 328K): δ = 1.01 - 1.29 (m, 6H, 3 x CH2 hexylspacer), 1.34 - 1.41 (m, 2H, CH2 hexylspacer), 
1.85 - 2.01 (m, 2H, F17C8CH2CH2-), 2.43 - 2.51 (m 2H, F17C8CH2CH2-), 2.86 - 2.95 (m, 2H, CH2-N 
hexylspacer), 3.52 - 4.03 (m, 152H, 30 x CH glycerol, 60 x CH2 glycerol, CH2-O hexylspacer), 4.47 
- 4.59 (m, 60H, 30 x CH2 Bn), 4.90 (bs, 2H, CH2 F-Bn), 6.92 - 7.29 (m, 154H, Harom); HRMS: 
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Fluorous tri(2,3,4,6-tetra-O-benzyl-α-D-glucosyl)glycerol phosphate 15-mer (23) 
Automated solid phase TA synthesis was performed as described above using 9 µmol of 
immobilized glycerol (19). After 3 consecutive elongation cycles using phosphoramidite 18a 
one elongation cycle was performed using glucosylglycerol phosphoramidite 18b. This was 
followed by 4 elongations using glycerol amidite 18a and one using glucosylglycerol amidite 
18b. The latter five-step elongation cycle was repeated once, which was followed by capping 
with fluorous phosphoramidite 17. After ammonia treatment the crude product was purified 
with RP-HPLC (C4). Lyophilization afforded 15-mer 23 (13.5 mg, 1.88 µmol, 21%, Et3NH+-form) 
as an amorphous white solid. 31P NMR (161.7 MHz, 1/1 D2O/CD3OD, T = 328K): δ = 1.8 - 2.4 
(15P); 1H NMR (400 MHz, 1/1 D2O/CD3OD, T = 328K): δ = 1.05 - 1.31 (m, 141H, 3 x CH2 
hexylspacer, 45 x CH3 Et3NH+), 1.40 - 1.47 (m, 2H, CH2 hexylspacer), 1.83 - 1.95 (m, 2H, 
F17C8CH2CH2-), 2.38 - 2.47 (m 2H, F17C8CH2CH2-), 2.91 - 3.00 (m, 2H, CH2-N hexylspacer), 3.09 
(q, 90H, J = 7.3 Hz, 45 x CH2 Et3NH+), 3.34 - 4.25 (m, 95H, 15 x CH glycerol, 30 x CH2 glycerol, 
CH2-O hexylspacer, 3 x H-2, 3 x H-3, 3 x H-4, 3 x H-5, 3 x H-6, 3 x H-6’), 4.51 - 4.67 (m, 48H, 24 x 
CH2 Bn), 4.81 (bs, 2H, CH2 F-Bn), 5.09 - 5.17 (m, 3H, 3 x H-1), 6.79 - 7.26 (m, 124H, Harom); LC-
MS: [C255H303F17NO93P15 + 2H]2+ requires 2830.8, found 2830.6. 
Fluorous tri(2-acetamido-3,4,6-tri-O-benzyl-2-deoxy-α-D-glucosyl)glycerol phosphate 
15-mer (24) 
Automated solid phase TA synthesis was performed as described above using 9 µmol of 
immobilized glycerol (19). After 3 consecutive elongation cycles using phosphoramidite 18a 
one elongation cycle was performed using N-acetylglucosaminylglycerol phosphoramidite 18c. 
This was followed by 4 elongations using glycerol amidite 18a and one using N-
acetylglucosaminylglycerol amidite 18c. The latter five-step elongation cycle was repeated 
once, which was followed by capping with fluorous phosphoramidite 17. After ammonia 
treatment the crude product was purified with RP-HPLC (C4). Lyophilization afforded 15-mer 
24 (15.0 mg, 2.13 µmol, 24%, Et3NH+-form) as an amorphous white solid. 31P NMR (161.7 MHz, 
1/1 D2O/CD3OD, T = 328K): δ = 0.3 - 0.7 (13P), 0.8 (1P), 1.0 (1P); 1H NMR (400 MHz, 1/1 
D2O/CD3OD, T = 328K): δ = 1.17 - 1.41 (m, 141H, 3 x CH2 hexylspacer, 45 x CH3 Et3NH+), 1.48 - 
1.56 (m, 2H, CH2 hexylspacer), 1.92 - 2.01 (3 x s, 9H, 3 x NHAc), 2.11 - 2.26 (m, 2H, F17C8CH2CH2-
), 2.67 - 2.73 (m 2H, F17C8CH2CH2-), 2.94 - 3.02 (m, 2H, CH2-N hexylspacer), 3.09 (q, 90H, J = 7.3 
Hz, 45 x CH2 Et3NH+), 3.50 - 4.13 (m, 95H, 15 x CH glycerol, 30 x CH2 glycerol, CH2-O 
hexylspacer, 3 x H-2, 3 x H-3, 3 x H-4, 3 x H-5, 3 x H-6, 3 x H-6’), 4.20 - 4.58 (m, 42H, 21 x CH2 
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Bn), 4.92 (bs, 2H, CH2 F-Bn), 4.94 - 4.97 (m, 3H, 3 x H-1), 6.92 - 7.30 (m, 109H, Harom); LC-MS: 
[C240H294F17N4O93P15 + 3H]3+ requires 1838.5, found 1838.4. 
(2-thioacetyl)acetyl glucosyl hexaglycerol 
phosphate (28) 
To a solution of 25 (8.7 mg, 6.6 µmol) in 0.5 
ml freshly prepared tetraborate buffer (0.1 
M, pH 8.5) was added SATA (27, 30 mg, 0.13 
mmol, dissolved in 300 µl DMF). The mixture 
was allowed to stir overnight after which it 
was filtered and the target compound 
isolated by size exclusion chromatography 
(HW40, 50 mM Et3NHOAc). The purified 
product was lyophilized trice before it was dissolved in H2O (~0.5 ml) and eluted to a small 
column containing Dowex Na+ cation-exchange resin (type: 50WX4-200, stored on 0.5 M NaOH 
in H2O, flushed with H2O and MeOH before use). Lyophilization afforded the target oligomer 
(28, 9.2 mg, ~6.4 mmol, 96%) as a 1:1 mixture of acetate and free thiol. 31P NMR (161.7 MHz, 
D2O): δ = 1.2 - 1.3 (5P), 1.3 - 1.4 (1P); 1H NMR (400 MHz, D2O): δ = 1.23 - 1.34 (m, 4H, 2 x CH2 
hexylspacer), 1.40 - 1.51 (m, 2H, CH2 hexylspacer), 1.52 - 1.60 (m, 2H, CH2 hexylspacer), 2.33 (s, 
~1.5H, CH3 SAc, ~50% on), 3.08 - 3.19 (m, 2H, CH2-N hexylspacer), 3.34 (t, 1H, J = 9.4 Hz, H-4), 
3.37 (s, ~1H, CH2SH), 3.46 (dd, 1H, J = 3.6 Hz, 9.8 Hz, H-2), 3.56 (s, ~1H, CH2SAc), 3.64 - 4.01 (m, 
36H, 6 x CH glycerol, 12 x CH2 glycerol, CH2-O hexylspacer, H-3, H-5, H-6, H-6’), 5.10 (d, 1H, J = 
3.5 Hz, H-1). 
TA-TTd conjugate (30) 
To a solution of modified TA 
28 (9.0 mg, 6.2 µmol) in H2O 
(250 µl) were added 
bromoacetylated TTd (29, 
7.0 mg, 47 nmol, in 2.0 ml 
PBS buffer pH 6.0, 
containing 5 MM EDTA, 
freshly prepared as 
described by van der Ley et 
al.)ref hoogerhout and hydroxylamine hydrochloride (2.0 M in PBS, 25 µl, 50 µmol). The mixture was 
mixed gently and allowed to stand overnight at room temperature after which 2-
aminoethanethiol hydrochloride (18 mM in PBS pH 6.0, 225 µl, 4.0 µmol) was added. After 
stirring overnight, the crude modified TTd (30, in a total volume of 2.5 ml) was equally divided 
over two PD-10 columns, which were pre-equilibrated with PBS buffer (pH 7.2). The columns 
were eluted with PBS (pH 7.2, 3.5 ml) and the fractions containing the modified protein 
combined. The purified conjugate 30 was analyzed on sugar content by a phenol/sulfuric acid 
assayref (using TA 25 as external standard, protein/sugar ratio: ~1.2/1) and stored in solution 
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Synthetische methodologiën naar glycerol teichoïnezuren 
 
Teichoïnezuren kunnen in het algemeen worden gekarakteriseerd als polymeren 
opgebouwd uit repeterende gesubstitueerde glycerol of ribitol eenheden, die door 
middel van fosfodiesters verbonden zijn. Het substitutiepatroon kan per repeterende 
eenheid verschillen en kan bestaan uit verschillende koolhydraatstructuren en/of D-
alanine esters. Teichoïnezuren komen voor in de celwand van Gram-positieve 
bacteriën en zijn kenmerkend voor een bacteriesoort. Teichoïnezuren vervullen een 
scala van functies die voor een bacterie van levensbelang zijn en spelen een rol bij de 
interactie van de bacterie met de omgeving. Zo kunnen teichoïnezuren worden 
herkend door het menselijk immuunsysteem. 
Door de toenemende resistentie van bacteriën tegen antibiotica wordt er veel 
aandacht besteed aan de ontwikkeling van andere geneeswijzen zoals nieuwe soorten 
van (synthetische) vaccins. Teichoïnezuren kunnen vanwege hun antigene 
eigenschappen wellicht een rol spelen bij de ontwikkeling van dergelijke vaccins. Op 
grond van de mogelijke antigene eigenschappen van teichoïnezuren is een onderzoek 
gestart om deze verbindingen synthetisch toegankelijk te maken en om de 
immunologische eigenschappen van deze gedefinieerde, synthetische teichoïnezuren 
vast te stellen.  
Dit proefschrift beschrijft de ontwikkeling van drie methoden voor de synthese van 
glycerol teichoïnezuur fragmenten van verschillende lengte en met verschillende 
glycosylerings patronen. In samenwerking met de groep van Professor Huebner 
(Freiburg Universitair Medisch Centrum) werden de gesynthetiseerde teichoïnezuur 
fragmenten geëvalueerd op hun immunologische eigenschappen. 
In het inleidende hoofdstuk 1 wordt aandacht besteed aan de ontdekking, de 
structurele classificatie en de fysiologische en immunologische aspecten van 
teichoïnezuren. Tevens wordt een overzicht gegeven van bestaande synthesewegen 
naar fragmenten van teichoïnezuren van verschillende bacteriële oorsprong. 
De synthese van een 2’-α-kojibiosyl (een α-1→2 verknoopt glucosyl disaccharide) 
bevattend fragment van het teichoïnezuur van Enterococcus faecalis is het onderwerp 
van hoofdstuk 2. In oplossing werd met behulp van fosforamidiet chemie een glycerol 
fosfaat hexameer met één 2’-α-kojibiosyl eenheid gesynthetiseerd. Het eerste stadium 
van de synthese route omvat de bereiding van de orthogonaal beschermde glycerol 
fosforamidieten, zoals die voorzien van de 2’-α-kojibiosyl eenheid. Vanuit 
dibenzylglycerol wordt het hexameer vervolgens stap voor stap opgebouwd 
doormiddel van de volgende verlengingsprocedure: 1) vorming van een fosfiettriester 
door koppeling van een fosforamidiet met het vrije alcohol. 2) Oxidatie van het fosfiet 
triester intermediair. 3) Het ontschermen van de 4,4’-dimethoxytrityl groep, met als 
resultaat het verkrijgen van een nieuw vrij alcohol. Deze 3-staps verlengings-
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procedure vormt de basis van alle oligoglycerol fosfaat syntheses beschreven in dit 
proefschrift. 
De fosforamidietchemie beschreven in hoofdstuk 2 kon worden toegepast in 
onderzoek naar een geautomatiseerde vaste drager synthese van teichoïnezuur 
fragmenten. In hoofdstuk 3 wordt beschreven hoe een aangepaste DNA synthesizer 
kan worden gebruikt om enkele milligrammen van de teichoïnezuur fragmenten 
efficiënt en snel te produceren. Met deze techniek werd een kleine bibliotheek aan 
verbindingen verkregen bestaande uit 6-, 10-, 14- en 20-meren glycerol-1,3-fosfaat en 
twee geglucosyleerde hexaglycerol fosfaat teichoïnezuur fragmenten. De verkregen 
fragmenten werden getest op hun affiniteit voor antilichamen in immuunserum 
opgewekt in konijnen tegen geïsoleerd lipoteichoïnezuur van E. faecalis. Hieruit bleek 
dat het 20-meer glycerol fosfaat en de twee geglucosyleerde fragmenten het meest 
effectief aan de antilichamen binden. 
Hoofdstuk 4 doet verslag van een nieuwe syntheseprocedure waarbij 
teichoïnezuur fragmenten worden gesynthetiseerd en geisoleerd met behulp van een 
fluorous (perfluoroalkyl) beschermende groep. De perfluorooctylpropylsulfonylethyl 
(F-Pse) groep werd onderzocht als fosfaat beschermende groep. Het hoge gehalte aan 
fluoratomen in deze groep zorgt er voor dat een beschermd teichoïnezuur oligomeer 
voorzien van de F-Pse groep uitstekend bindt aan ge(per)fluoreerde materialen zoals 
fluorous silica, zodat zuivering na iedere elongatie sequentie kan plaatsvinden op basis 
van deze eigenschap. Met deze techniek werden enkele tientallen milligrammen van 
een 12-meer glycerol fosfaat, twee hexaglycerolfosfaten met (N-acetyl)glucosaminyl 
substituties en een hexameer van (N-acetyl)glucosaminylglycerol fosfaat verkregen. 
Een belangrijk verschil met de fragmenten beschreven in hoofdstuk 2 en 3 is dat de 
teichoïnezuren beschreven in hoofdstuk 4 een terminale fosfaat bevatten. De 
fragmenten bleken in de immunologische evaluatie niet actief te zijn.  
Om door middel van zuivering met behulp van fluorous silica, teichoïnezuur 
fragmenten zonder terminale fosfaat toegankelijk te maken werd een alternatieve 
hydroxyl fluorous beschermende groep ontwikkeld. Hoofdstuk 5 behandelt de 
synthese van enkele geglucosyleerde teichoïnezuur fragmenten met behulp van een 
fluorous beschermende groep welke is gebaseerd op een succinyl ester. Tevens wordt 
uitgelegd hoe een “zuur-stabiel” 2’-(tetra-O-benzyl-α-glucosyl)glycerol fosforamidiet 
kan worden verkregen. Deze glucosyl substitutie is stabiel tijdens de standaard 
detrityleringscondities en kan daardoor op een iedere positie in een teichoïnezuur 
fragment worden ingebouwd. 
In hoofdstuk 6 wordt beschreven hoe het immunologisch meest interessante 
teichoïnezuur fragment (geglucosyleerd hexaglycerol fosfaat) wordt geconjugeerd aan 
BSA, een immunogeen drager-eiwit. Met dit experimentele vaccin werden konijnen 
geïmmunizeerd en met behulp van opsonofagocytische testen werd aangetoond dat 
het serum verkregen van deze konijnen antilichamen bevat welke efficiënt aan 
teichoïnezuren van E. faecalis bindt. Het bleek dat het konijnen antiserum zelfs in zeer 
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verdunde toestand in staat was E. faecalis te opsonizeren en dus potentieel als 
therapeutisch vaccin zou kunnen functioneren. Verrassend genoeg werden door dit 
serum ook E. faecium (in meerdere mate) en Staphylococcus aureus (in mindere mate) 
geopsonizeerd. Uit een endocarditis model experiment in ratten bleek dat het eerder 
genoemde antiserum gebruikt kan worden om passief te immunizeren en zo 
bescherming te bieden tegen infecties veroorzaakt door E. faecalis. 
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